

Revised Response Criteria for Malignant Lymphoma

Journal of Clinical Oncology

25, 579-586

DOI: [10.1200/jco.2006.09.2403](https://doi.org/10.1200/jco.2006.09.2403)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2014, 8, 429.	0.6	4
2	Lymphome de Hodgkin de l'adulte. EMC - Hematologie, 2004, 1, 115-134.	0.1	6
3	PET for follicular lymphoma: A work in progress!. Leukemia and Lymphoma, 2007, 48, 1463-1464.	0.6	5
4	Clinical Features, Prognosis and Treatment of Follicular Lymphoma. Hematology American Society of Hematology Education Program, 2007, 2007, 216-225.	0.9	61
5	The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas. Expert Opinion on Biological Therapy, 2007, 7, 1749-1762.	1.4	8
6	Peripheral T-cell lymphomas: Variably or routinely fluorodeoxyglucose-avid?. Leukemia and Lymphoma, 2007, 48, 1465-1467.	0.6	1
7	Hodgkin's Disease " From Pathology Specimen to Cure. New England Journal of Medicine, 2007, 357, 1968-1971.	13.9	43
8	Valproic acid monotherapy leads to CR in a patient with refractory diffuse large B cell lymphoma. Leukemia and Lymphoma, 2007, 48, 1216-1218.	0.6	9
9	Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: A randomized study caveat. Leukemia and Lymphoma, 2007, 48, 1667-1669.	0.6	9
10	Interferon and Low Dose Methotrexate Improve Outcome in Refractory Mycosis Fungoides/Sézary Syndrome. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 836-840.	0.7	33
11	Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leukemia and Lymphoma, 2007, 48, 1548-1555.	0.6	57
12	Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma. JAMA - Journal of the American Medical Association, 2007, 298, 2289.	3.8	260
13	FDG-PET in T-cell and NK-cell neoplasms. Annals of Oncology, 2007, 18, 1685-1690.	0.6	116
14	18F-FDG PET in Non-Hodgkin's Lymphoma: Qualitative or Quantitative?. Journal of Nuclear Medicine, 2007, 48, 1580-1582.	2.8	46
15	Early Interim 2-[¹⁸ F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. Journal of Clinical Oncology, 2007, 25, 3746-3752.	0.8	799
16	Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis. Journal of Nuclear Medicine, 2007, 48, 1626-1632.	2.8	357
17	Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2007, 25, 1741-1746.	0.8	235
18	Is Bone Marrow Biopsy Obligatory in All Patients with Non-Hodgkin's Lymphoma?. Acta Haematologica, 2007, 118, 61-64.	0.7	11

#	ARTICLE	IF	CITATIONS
19	Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1767-1776.	2.8	81
20	How I treat indolent lymphoma. <i>Blood</i> , 2007, 109, 4617-4626.	0.6	100
21	The role of FDG-PET scans in patients with lymphoma. <i>Blood</i> , 2007, 110, 3507-3516.	0.6	285
22	Routine Use of PET Scans After Completion of Therapy in Pediatric Hodgkin Disease Results in a High False Positive Rate. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 667.	0.3	2
23	AML1 Mutation and FLT3-internal Tandem Duplication in Leukemia Transformed From Myelodysplastic Syndrome. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 666-667.	0.3	1
24	The Accuracy of PET(CT) in Evaluating Pediatric Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 667-668.	0.3	2
25	A single unit lymphoma experience " Outcome in a Cape Town academic centre. <i>Transfusion and Apheresis Science</i> , 2007, 37, 93-102.	0.5	5
26	Lymphomas. <i>Update on Cancer Therapeutics</i> , 2007, 2, 101-110.	0.9	1
27	La TEP-TDM dans la maladie de Hodgkin: exp�rience clermontoise. <i>Medecine Nucleaire</i> , 2007, 31, 562-567.	0.2	2
28	FDG-PET scan and treatment planning for early stage Hodgkin lymphoma. <i>Radiotherapy and Oncology</i> , 2007, 85, 176-177.	0.3	8
29	Hodgkin lymphoma: Response assessment by Revised International Workshop Criteria. <i>Leukemia and Lymphoma</i> , 2007, 48, 1539-1547.	0.6	68
30	Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by Integrated International Workshop Criteria. <i>Leukemia and Lymphoma</i> , 2007, 48, 1522-1530.	0.6	43
31	The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era. <i>Leukemia and Lymphoma</i> , 2007, 48, 2121-2136.	0.6	28
32	High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2444-2446.	0.6	0
33	The International Harmonization Project for Response Criteria in Lymphoma Clinical Trials. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 841-854.	0.9	115
34	Do We Need an Early Unfavorable (Intermediate) Stage of Hodgkin's Lymphoma?. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 881-896.	0.9	4
35	New Strategies for the Treatment of Advanced-Stage Hodgkin's Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 897-914.	0.9	25
36	Is [18F]fluorodeoxyglucose Positron Emission Tomography the Ultimate Tool for Response and Prognosis Assessment?. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 855-869.	0.9	9

#	ARTICLE	IF	CITATIONS
37	Relapsed and Refractory Hodgkin's Lymphoma: New Avenues?. Hematology/Oncology Clinics of North America, 2007, 21, 929-941.	0.9	5
38	Whole body MRI and PET/CT in haematological malignancies. Cancer Imaging, 2007, 7, S88-S93.	1.2	20
40	The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-pet with 67gallium scintigraphy in the evaluation of lymphoma. Cancer, 2007, 110, 652-659.	2.0	190
41	The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer, 2007, 110, 1361-1369.	2.0	77
42	2-[18F]Fluoro-2-Deoxyglucose Positron-Emission Tomography in Staging, Response Evaluation, and Treatment Planning of Lymphomas. Seminars in Radiation Oncology, 2007, 17, 190-197.	1.0	48
43	Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Annals of Hematology, 2007, 86, 493-498.	0.8	137
44	Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Annals of Hematology, 2007, 86, 897-903.	0.8	98
45	Is BEACOPP better than ABVD?. Current Hematologic Malignancy Reports, 2007, 2, 161-166.	1.2	8
46	CHOP plus Alemtuzumab can Induce Metabolic Response by FDG-PET but has Minimal Long-term Benefits: A Case Report and Literature Review. Journal of Gastrointestinal Cancer, 2007, 38, 19-23.	0.6	2
47	CHOP Plus Alemtuzumab can Induce Metabolic Response by FDG-PET but has Minimal Long-term benefits: A Case Report and Literature Review. Journal of Gastrointestinal Cancer, 2007, 38, 59-62.	0.6	5
48	Breast Cancer After Treatment of Hodgkin's Lymphoma: General Review. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1291-1297.	0.4	31
49	Imaging of tumor glucose utilization with positron emission tomography. Cancer and Metastasis Reviews, 2008, 27, 545-554.	2.7	65
51	Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1413-1420.	3.3	11
52	Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Annals of Hematology, 2008, 87, 613-621.	0.8	114
55	FDG-PET scans in patients with lymphoma. Current Hematologic Malignancy Reports, 2008, 3, 197-203.	1.2	1
56	Management of relapsed diffuse large B-cell lymphoma. Current Oncology Reports, 2008, 10, 393-403.	1.8	10
57	Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified. Medical Oncology, 2008, 25, 360-364.	1.2	12
58	Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation. Annals of Nuclear Medicine, 2008, 22, 251-260.	1.2	1

#	ARTICLE	IF	CITATIONS
59	Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma. <i>Annals of Nuclear Medicine</i> , 2008, 22, 719-722.	1.2	22
60	18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence. <i>Annals of Nuclear Medicine</i> , 2008, 22, 795-802.	1.2	15
61	Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography. <i>International Journal of Hematology</i> , 2008, 88, 149-153.	0.7	39
62	The impact of functional imaging on radiation medicine. <i>Radiation Oncology</i> , 2008, 3, 25.	1.2	19
63	Fine-needle aspiration cytology in the follow-up of Hodgkin lymphoma. <i>Diagnostic Cytopathology</i> , 2008, 36, 467-472.	0.5	5
64	Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. <i>American Journal of Hematology</i> , 2008, 83, 477-481.	2.0	17
65	Bone marrow necrosis complicating post-transplant lymphoproliferative disorder: Resolution with rituximab. <i>Leukemia Research</i> , 2008, 32, 829-834.	0.4	9
66	Subcutaneous alemtuzumab for S�azary Syndrome in the very elderly. <i>Leukemia Research</i> , 2008, 32, 1299-1303.	0.4	40
67	Tumor Response and Survival Predicted by Post-Therapy FDG-PET/CT in Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 180-186.	0.4	121
68	Impact of [18F] Fluorodeoxyglucose Positron Emission Tomography on Staging and Management of Early-Stage Follicular Non-Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 213-219.	0.4	120
69	Imaging Guiding Therapy Development in Lymphoma. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 443-445.	2.3	1
70	Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2008, 42, 529-534.	1.3	16
71	Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 2008, 99, 253-258.	2.9	11
72	Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. <i>Bone Marrow Transplantation</i> , 2008, 41, 39-43.	1.3	32
73	British HIV Association guidelines for HIV-associated malignancies 2008. <i>HIV Medicine</i> , 2008, 9, 336-388.	1.0	158
74	Phase I study of dexamethasone, methotrexate, ifosfamide, asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. <i>Cancer Science</i> , 2008, 99, 1016-1020.	1.7	193
75	IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosfamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma. <i>British Journal of Haematology</i> , 2008, 141, 244-248.	1.2	14
76	Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. <i>British Journal of Haematology</i> , 2008, 142, 52-56.	1.2	68

#	ARTICLE	IF	CITATIONS
77	Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2008, 142, 786-792.	1.2	25
78	Allogeneic transplantation for Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2008, 143, 468-480.	1.2	20
79	Aiming at a Curative Strategy for Follicular Lymphoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2008, 58, 305-317.	157.7	35
80	PET/CT in the management of haematological malignancies. <i>European Journal of Haematology</i> , 2008, 80, 369-380.	1.1	41
81	[18F]Fluorodeoxyglucose Positron Emission Tomography Scanning for Staging, Response Assessment, and Disease Surveillance in Patients with Mantle Cell Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 159-165.	1.4	38
83	[18F]Fluorodeoxyglucose Positron Emission Tomography in the Management of Lymphomas. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 273-276.	1.4	4
84	Value of [18F]Fluorodeoxyglucose Positron Emission Tomography in the Management of Follicular Lymphoma: The End of a Dilemma?. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 287-293.	1.4	60
85	FDG PET and PET/CT in the Management of Pediatric Lymphoma Patients. <i>PET Clinics</i> , 2008, 3, 621-634.	1.5	12
87	FDG-PET Evaluation of Response to Treatment. <i>PET Clinics</i> , 2008, 3, 37-75.	1.5	3
88	Staging and Evaluation of the Patient with Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 825-837.	0.9	25
89	Imaging of Abdominal Lymphoma. <i>Radiologic Clinics of North America</i> , 2008, 46, 265-285.	0.9	41
90	Imaging of Pediatric Lymphomas. <i>Radiologic Clinics of North America</i> , 2008, 46, 313-338.	0.9	51
91	Quelques perspectives concernant le traitement des lymphomes par Zevalin® À partir de l'évaluation de l'expérience niçoise. <i>Medecine Nucleaire</i> , 2008, 32, 85-95.	0.2	0
94	How to assess anti-tumour efficacy by imaging techniques. <i>European Journal of Cancer</i> , 2008, 44, 39-45.	1.3	38
95	Response assessment in lymphoma. <i>Clinical Radiology</i> , 2008, 63, 125-135.	0.5	30
96	Indeterminate lesions in cancer imaging. <i>Clinical Radiology</i> , 2008, 63, 843-852.	0.5	9
97	Mantle cell lymphoma: an overview of diagnostic and therapeutic advances. <i>Community Oncology</i> , 2008, 5, 465-472.	0.2	1
98	Meeting Highlights. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 210-218.	1.4	0

#	ARTICLE	IF	CITATIONS
99	Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute's Working Group 1996 guidelines. <i>Blood</i> , 2008, 111, 5446-5456.	0.6	2,887
100	The conundrum of hodgkin lymphoma nodes: To be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. <i>Radiotherapy and Oncology</i> , 2008, 88, 202-210.	0.3	113
101	Imaging of Lymphoma of the Musculoskeletal System. <i>Radiologic Clinics of North America</i> , 2008, 46, 379-396.	0.9	35
102	Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. <i>Lancet Oncology</i> , 2008, 9, 766-776.	5.1	150
103	New Staging and Response Criteria for Non-Hodgkin Lymphoma and Hodgkin Lymphoma. <i>Radiologic Clinics of North America</i> , 2008, 46, 213-223.	0.9	30
104	The Impact of Fluorodeoxyglucose-Positron Emission Tomography in Primary Staging and Patient Management in Lymphoma Patients. <i>Radiologic Clinics of North America</i> , 2008, 46, 199-211.	0.9	48
105	Therapy of Mantle Cell Lymphoma: Current Standards and Future Strategies. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 953-963.	0.9	27
106	Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. <i>Blood</i> , 2008, 112, 3989-3994.	0.6	206
107	Non-Hodgkin lymphoma of the Waldeyer's ring: clinicopathologic and therapeutic issues. <i>Leukemia and Lymphoma</i> , 2008, 49, 2263-2271.	0.6	34
108	PET Imaging for Response Assessment in Lymphoma: Potential and Limitations. <i>Radiologic Clinics of North America</i> , 2008, 46, 225-241.	0.9	39
109	Analysis of Competing Risks of Causes of Death and their Variation Over Different Time Periods in Hodgkin's Disease. <i>Clinical Cancer Research</i> , 2008, 14, 5300-5305.	3.2	11
110	Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study. <i>Annals of Oncology</i> , 2008, 19, 951-957.	0.6	2
111	Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. <i>Annals of Oncology</i> , 2008, 19, 1331-1335.	0.6	40
112	New response criteria for lymphomas in clinical trials. <i>Annals of Oncology</i> , 2008, 19, iv35-iv38.	0.6	25
113	Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab. <i>Annals of Oncology</i> , 2008, 19, 1629-1633.	0.6	12
114	High-Dose Yttrium-90 Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 5175-5182.	0.8	68
115	Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. <i>Annals of Oncology</i> , 2008, 19, 964-969.	0.6	165
116	¹⁸ F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review. <i>Journal of Nuclear Medicine</i> , 2008, 49, 13-21.	2.8	142

#	ARTICLE	IF	CITATIONS
117	Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. <i>Journal of Clinical Oncology</i> , 2008, 26, 2717-2724.	0.8	267
118	Tumor Cell Metabolism Imaging. <i>Journal of Nuclear Medicine</i> , 2008, 49, 43S-63S.	2.8	270
119	Primary Mediastinal B-Cell Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 349-358.	0.9	65
120	Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1745-1751.	0.6	96
121	Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 7088-7094.	3.2	88
122	Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. <i>Annals of Oncology</i> , 2008, 19, 1770-1773.	0.6	106
123	Positron emission tomography and CT in the management of lymphoma. <i>Imaging</i> , 2008, 20, 169-175.	0.0	1
124	Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii65-ii66.	0.6	14
125	FDG-PET Staging of Head and Neck Cancer--Can Improved Imaging Lead to Improved Treatment?. <i>Journal of the National Cancer Institute</i> , 2008, 100, 688-689.	3.0	10
126	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii77-ii78.	0.6	6
127	¹⁸ F-FDG PET as a Routine Test for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: Where Is the Evidence?: TABLE 1. <i>Journal of Nuclear Medicine</i> , 2008, 49, 9-12.	2.8	30
128	Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 43-48.	0.6	2
129	Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii67-ii69.	0.6	15
130	Early interim PET scan in Hodgkin lymphoma: Where do we stand?. <i>Leukemia and Lymphoma</i> , 2008, 49, 659-662.	0.6	34
131	Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: A single centre experience. <i>Leukemia and Lymphoma</i> , 2008, 49, 1321-1328.	0.6	21
132	Positron emission tomography in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1693-1701.	0.6	55
133	Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review. <i>Leukemia and Lymphoma</i> , 2008, 49, 1762-1768.	0.6	8
134	What is the role of ¹⁸ F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?. <i>Leukemia and Lymphoma</i> , 2008, 49, 1653-1656.	0.6	5

#	ARTICLE	IF	CITATIONS
135	The mysteries of mantle cell lymphoma—do PET scans provide a clue?. <i>Leukemia and Lymphoma</i> , 2008, 49, 1662-1663.	0.6	2
136	Pulmonary marginal zone lymphoma: A single centre experience and review of the SEER database. <i>Leukemia and Lymphoma</i> , 2008, 49, 1311-1320.	0.6	43
138	Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 160-170.	4.3	119
139	Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 234-238.	4.3	10
140	B-Cell Non-Hodgkin Lymphoma: PET/CT Evaluation after ⁹⁰ Y- ¹²⁵ I-rituximab Radioimmunotherapy—Initial Experience. <i>Radiology</i> , 2008, 246, 895-902.	3.6	28
141	Synchronous presentation of systemic and brain non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 2370-2373.	0.6	3
142	Evaluation of response to fractionated radioimmunotherapy with ⁹⁰ Y- ¹²⁵ I-rituximab in non-Hodgkin's lymphoma by ¹⁸ F-fluorodeoxyglucose positron emission tomography. <i>Haematologica</i> , 2008, 93, 390-397.	1.7	45
143	Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2008, 93, 1364-1371.	1.7	66
144	Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. <i>Haematologica</i> , 2008, 93, 471-472.	1.7	130
147	FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. <i>Current Opinion in Oncology</i> , 2008, 20, 206-219.	1.1	60
149	PET scanning and prognosis in Hodgkin's lymphoma. <i>Current Opinion in Oncology</i> , 2008, 20, 509-516.	1.1	9
150	Clinical Usefulness of FDG-PET/CT Scan Imaging in the Management of Posttransplant Lymphoproliferative Disease. <i>Transplantation</i> , 2008, 85, 707-712.	0.5	75
151	Predictive and prognostic value of FDG-PET. <i>Cancer Imaging</i> , 2008, 8, 70-80.	1.2	52
152	Role of PET/CT Scanning in Initial and Post-Treatment Assessment of Hodgkin Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 623-632.	2.3	4
153	The prognostic value of PET and PET/CT in cervical cancer. <i>Cancer Imaging</i> , 2008, 8, 146-155.	1.2	61
154	Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. <i>OncoTargets and Therapy</i> , 2009, 2, 229.	1.0	4
156	Anti-CD3 Recombinant Diphtheria Immunotoxin Therapy of Cutaneous T Cell Lymphoma. <i>Current Drug Targets</i> , 2009, 10, 104-109.	1.0	47
157	La place de l'ATP au FDG dans l'évaluation des lymphomes. <i>Hematologie</i> , 2009, 15, 305-312.	0.0	0

#	ARTICLE	IF	CITATIONS
158	Role of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1781-1787.	0.8	160
159	Rituximab and Chemotherapy in Primary Gastric Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 25-28.	0.7	30
160	A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. <i>Blood</i> , 2009, 114, 2051-2059.	0.6	183
161	A Phase I Clinical Trial of CHT-25 a ¹³¹ I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 7701-7710.	3.2	40
162	Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating ¹⁸ F-fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. <i>Annals of Oncology</i> , 2009, 20, 503-507.	0.6	73
163	Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2009, 27, 453-459.	0.8	485
164	¹⁸ F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 8-17.	2.8	66
165	Lymphomatous Meningitis Diagnosed with [¹⁸ F]-Fluorodeoxyglucose-Positron-Emission Tomography/CT. <i>American Journal of Neuroradiology</i> , 2009, 30, E150-E151.	1.2	0
166	The Case Against Heavy PETing. <i>Journal of Clinical Oncology</i> , 2009, 27, 1742-1743.	0.8	43
167	p63 Protein expression in high risk diffuse large B-cell lymphoma. <i>Journal of Clinical Pathology</i> , 2009, 62, 77-79.	1.0	27
168	PET imaging in lymphoma. <i>Expert Review of Hematology</i> , 2009, 2, 261-276.	1.0	3
169	Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility. <i>Acta Radiologica</i> , 2009, 50, 201-204.	0.5	28
170	Follicular lymphoma: the case for timely intervention. <i>Expert Review of Hematology</i> , 2009, 2, 277-284.	1.0	0
171	Standards for PET Image Acquisition and Quantitative Data Analysis. <i>Journal of Nuclear Medicine</i> , 2009, 50, 11S-20S.	2.8	720
172	Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 5109-5114.	0.8	50
173	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv119-iv120.	0.6	18
174	Measuring Response with FDG-PET: Methodological Aspects. <i>Oncologist</i> , 2009, 14, 369-377.	1.9	63
175	Long-term outcome following <i>Helicobacter pylori</i> eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. <i>Annals of Oncology</i> , 2009, 20, 1086-1093.	0.6	130

#	ARTICLE	IF	CITATIONS
176	¹⁸ F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response. <i>Journal of Nuclear Medicine</i> , 2009, 50, 88-99.	2.8	287
177	Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 426-432.	0.8	152
178	CT and ¹⁸ F-FDG PET for Noninvasive Detection of Splenic Involvement in Patients with Malignant Lymphoma. <i>American Journal of Roentgenology</i> , 2009, 192, 745-753.	1.0	79
179	Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?. <i>Leukemia and Lymphoma</i> , 2009, 50, 1931-1936.	0.6	30
180	Rituximab in Lymphocyte-Predominant Hodgkin Disease. <i>Oncology</i> , 2009, 76, 26-29.	0.9	14
181	Mantle cell lymphoma in the orbital and adnexal region. <i>British Journal of Ophthalmology</i> , 2009, 93, 1047-1051.	2.1	58
182	Assessment of Interobserver Reproducibility in Quantitative ¹⁸ F-FDG PET and CT Measurements of Tumor Response to Therapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1760-1769.	2.8	65
183	The recent decline in mortality from Hodgkin lymphomas in central and eastern Europe. <i>Annals of Oncology</i> , 2009, 20, 767-774.	0.6	22
184	Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. <i>Haematologica</i> , 2009, 94, 550-565.	1.7	66
185	Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. <i>Annals of Oncology</i> , 2009, 20, 709-714.	0.6	76
186	¹⁸ F-FDG PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. <i>Annals of Oncology</i> , 2009, 20, 1270-1274.	0.6	51
187	Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2009, 20, 1985-1992.	0.6	64
188	Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv110-iv112.	0.6	39
189	Assessment of GS-9219 in a Pet Dog Model of Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 3503-3510.	3.2	58
190	Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2009, 101, 248-255.	3.0	227
191	Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma. <i>Oncologist</i> , 2009, 14, 30-40.	1.9	51
192	Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. <i>Blood</i> , 2009, 114, 2945-2951.	0.6	157
193	Summary. <i>Oncologist</i> , 2009, 14, 52-54.	1.9	0

#	ARTICLE	IF	CITATIONS
194	PET/CT for Therapy Response Assessment in Lymphoma. <i>Journal of Nuclear Medicine</i> , 2009, 50, 21S-30S.	2.8	193
195	Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. <i>Journal of Clinical Oncology</i> , 2009, 27, 4555-4562.	0.8	613
196	Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. <i>European Respiratory Journal</i> , 2009, 34, 1408-1416.	3.1	167
197	Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies. <i>European Journal of Haematology</i> , 2009, 82, 184-193.	1.1	26
198	Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2010, 85, 81-83.	2.0	22
199	Endogenous thrombin potential (ETP) in the assessment of hypercoagulability in systemic lupus erythematosus. <i>American Journal of Hematology</i> , 2009, 85, NA-NA.	2.0	7
200	HIV-negative, HHV-8-unrelated primary effusion lymphoma-like lymphoma: report of two cases. <i>American Journal of Hematology</i> , 2010, 85, 85-87.	2.0	23
201	The number of people with sickle cell disease in the United States: national and state estimates. <i>American Journal of Hematology</i> , 2010, 85, 77-78.	2.0	280
202	Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2010, 85, 87-90.	2.0	26
203	Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacement. <i>American Journal of Hematology</i> , 2010, 85, 79-81.	2.0	11
204	Involved field radiotherapy for limited stage Hodgkin lymphoma: balancing treatment efficacy against long-term toxicities. <i>Hematological Oncology</i> , 2009, 27, 115-122.	0.8	4
205	Diffuse large B-cell lymphoma. <i>Cancer</i> , 2009, 115, 4980-4989.	2.0	23
206	Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin lymphoma: comparison with serum soluble interleukin-2 receptor values. <i>International Journal of Clinical Oncology</i> , 2009, 14, 150-158.	1.0	4
208	NEC Density and Liver ROI S/N Ratio for Image Quality Control of Whole-Body FDG-PET Scans: Comparison with Visual Assessment. <i>Molecular Imaging and Biology</i> , 2009, 11, 480-486.	1.3	25
209	What is the best treatment for children with limited-stage Hodgkin lymphoma?. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 129-135.	1.2	8
210	Prognostic factors in low-grade non-Hodgkin lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 202-210.	1.2	13
211	Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 745-750.	3.3	63
212	Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting: a new standard of care in relapsed or refractory Hodgkin lymphoma?. <i>Annals of Hematology</i> , 2009, 88, 1107-1112.	0.8	5

#	ARTICLE	IF	CITATIONS
213	Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2009, 88, 1229-1236.	0.8	38
214	Primary Nasopharyngeal non-Hodgkin lymphomas: a retrospective review of 26 Moroccan patients. <i>BMC Ear, Nose and Throat Disorders</i> , 2009, 9, 11.	2.6	13
215	High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. <i>British Journal of Haematology</i> , 2009, 144, 524-530.	1.2	61
216	Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. <i>British Journal of Haematology</i> , 2009, 145, 369-372.	1.2	51
218	Bcl-xL Gene Expression Correlated with Lower Apoptotic Cell Numbers and Shorter Progression-Free Survival in PCFCL. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1703-1709.	0.3	13
219	Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. <i>Leukemia</i> , 2009, 23, 777-783.	3.3	210
220	Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2009, 43, 37-42.	1.3	15
221	Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3/6 HLA matched donors. <i>Bone Marrow Transplantation</i> , 2009, 43, 327-333.	1.3	15
222	Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT. <i>Bone Marrow Transplantation</i> , 2009, 43, 323-325.	1.3	6
223	The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2009, 43, 941-948.	1.3	49
224	Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs. <i>Bone Marrow Transplantation</i> , 2009, 44, 19-25.	1.3	4
225	Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2009, 44, 287-293.	1.3	6
226	Idiotypic vaccines for lymphoma: proof-of-principles and clinical trial failures. <i>Nature Reviews Cancer</i> , 2009, 9, 675-681.	12.8	93
227	Clinicopathological comparison of the World Health Organization/Wotherspoon score to the Groupe d'Etude des Lymphomes de l'Adulte grade for the post-treatment evaluation of gastric mucosa-associated lymphoid tissue lymphoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 307-315.	1.4	12
228	Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. <i>Transfusion</i> , 2009, 49, 1890-1900.	0.8	38
229	Positron Emission Tomography in oncology: Present and future of PET and PET/CT. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 239-254.	2.0	42
230	Molecular Imaging with Bioconjugates in Mouse Models of Cancer. <i>Bioconjugate Chemistry</i> , 2009, 20, 631-643.	1.8	30
231	L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. <i>Annals of Oncology</i> , 2009, 20, 110-116.	0.6	111

#	ARTICLE	IF	CITATIONS
232	Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 1456-1461.	0.8	56
233	Assessing Tumor Response to Therapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1S-10S.	2.8	226
234	New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). <i>European Journal of Cancer</i> , 2009, 45, 228-247.	1.3	21,739
235	Evaluation of lymph nodes with RECIST 1.1. <i>European Journal of Cancer</i> , 2009, 45, 261-267.	1.3	233
236	Busulfan and Cyclophosphamide (Bu/Cy) as a Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma: A Single-Institution Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1447-1454.	2.0	35
237	Medical management update: Non-Hodgkin lymphoma. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2009, 107, e19-e33.	1.6	41
238	Le radiopharmaceutique: situation et perspectives depuis la 8e Conférence internationale de l'ACOMEN (Bordeaux, 11-13 mai 2005). <i>Medecine Nucleaire</i> , 2009, 33, 115-121.	0.2	3
240	Injection de produit de contraste? Arguments d'un médecin nucléaire en faveur des injections. <i>Medecine Nucleaire</i> , 2009, 33, 290-293.	0.2	0
241	Les essais cliniques en médecine nucléaire: État et perspectives. <i>Medecine Nucleaire</i> , 2009, 33, 296-304.	0.2	1
243	From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2009, 50, 122S-150S.	2.8	3,047
244	94 Patient-reported outcomes in cancer research. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 24-25.	2.2	0
245	95 New PET-Tracers for imaging pathophysiology and response. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 25.	2.2	0
247	¹⁸ F-fluorodeoxyglucose positron emission tomography in the evaluation of therapy response assessment in lymphomas. Systematic literature review and meta-analysis. <i>Revista Española De Medicina Nuclear</i> , 2009, 28, 48-55.	0.3	1
248	Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?. <i>Leukemia and Lymphoma</i> , 2009, 50, 1992-1998.	0.6	8
249	Rituximab and Dose-Dense Chemotherapy in Primary Testicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 386-389.	1.4	24
250	Rituximab as maintenance therapy for patients with follicular lymphoma. <i>The Cochrane Library</i> , 2009, , CD006552.	1.5	21
251	Non-Hodgkin lymphoma response evaluation with MRI texture classification. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 87.	3.5	42
252	High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. <i>Annals of Oncology</i> , 2009, 20, 309-318.	0.6	137

#	ARTICLE	IF	CITATIONS
253	Clinicopathologic features and treatment outcome of non-Hodgkin lymphoma of the breast – a review of 42 primary and secondary cases in Taiwanese patients. <i>Leukemia and Lymphoma</i> , 2009, 50, 918-924.	0.6	29
254	Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes. <i>Leukemia and Lymphoma</i> , 2009, 50, 1750-1752.	0.6	8
255	Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomycin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index ≤ 1) diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1824-1829.	0.6	5
256	Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas – the PETAL trial. <i>Leukemia and Lymphoma</i> , 2009, 50, 1757-1760.	0.6	42
257	MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. <i>Journal of Clinical Pathology</i> , 2009, 62, 715-723.	1.0	18
258	Monitoring Response to Therapeutic Interventions in Patients With Cancer. <i>Seminars in Nuclear Medicine</i> , 2009, 39, 210-232.	2.5	35
259	Presentation and management of intravascular large B-cell lymphoma. <i>Lancet Oncology</i> , The, 2009, 10, 895-902.	5.1	267
261	Standardised tumour, node and metastasis reporting of oncology CT scans. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2009, 53, 345-352.	0.9	4
262	Comparison of the Accuracy of CT Volume Calculated by Circumscription to Prolate Ellipsoid Volume (Bidimensional Measurement Multiplied by Coronal Long Axis). <i>Academic Radiology</i> , 2009, 16, 181-186.	1.3	20
263	Utility of Positron Emission Tomography in the Mediastinum: Moving Beyond Lung and Esophageal Cancer Staging. <i>Thoracic Surgery Clinics</i> , 2009, 19, 7-15.	0.4	15
264	L'Évaluation en oncologie: comment je fais en imagerie?. <i>Feuillets De Radiologie</i> , 2009, 49, 392-406.	0.0	0
265	Localized large cell lymphoma: is there any need for radiation therapy?. <i>Current Opinion in Oncology</i> , 2009, 21, 401-406.	1.1	18
266	Splenic Follicular Lymphoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 730-738.	2.1	41
267	Salvage Therapy for Hodgkin's Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 161-163.	1.0	37
268	Better infrastructure for critical care trials: Nomenclature, etymology, and informatics. <i>Critical Care Medicine</i> , 2009, 37, S173-S177.	0.4	10
269	The Utility of FDG-PET for Managing Patients with Malignant Lymphoma: Analysis of Data from a Single Cancer Center. <i>Internal Medicine</i> , 2009, 48, 1509-1513.	0.3	6
271	TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. <i>Blood</i> , 2009, 114, 1099-1109.	0.6	150
272	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. <i>Blood</i> , 2009, 113, 18-27.	0.6	99

#	ARTICLE	IF	CITATIONS
274	Tumor Shrinkage and Objective Response Rates. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 354-360.	1.0	14
275	Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective. <i>Current Pharmaceutical Design</i> , 2009, 15, 957-965.	0.9	15
276	Low Stage Follicular Lymphoma: Biologic and Clinical Characterization According to Nodal or Extranodal Primary Origin. <i>American Journal of Surgical Pathology</i> , 2009, 33, 591-598.	2.1	31
278	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , 2010, 95, 1792-1796.	1.7	91
279	False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt's lymphoma. <i>Nuclear Medicine Communications</i> , 2010, 31, 232-238.	0.5	44
280	Unsuspected Synchronous Thyroid Carcinoma Revealed on a Post-Therapy F-18 FDG PET/CT, in a Patient With Follicular Lymphoma. <i>Clinical Nuclear Medicine</i> , 2010, 35, 879-881.	0.7	9
281	Role of early PET in the management of diffuse large B-cell lymphoma. <i>Current Opinion in Oncology</i> , 2010, 22, 414-418.	1.1	17
283	9. Current Treatment and Future Prospects of Malignant Lymphoma.. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2010, 99, 542-547.	0.0	0
284	Non-Hodgkin's Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 288-334.	2.3	233
285	A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma. <i>Haematologica</i> , 2010, 95, 1198-1206.	1.7	26
286	Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma. <i>Haematologica</i> , 2010, 95, 1046-1048.	1.7	39
287	18F-FDG PET/CT Evaluation of Lymphoma with Renal Involvement: Comparison with Renal Carcinoma. <i>Southern Medical Journal</i> , 2010, 103, 642-649.	0.3	31
289	Assessing Cancer Drugs for Reimbursement: Methodology, Relationship between Effect Size and Medical Need. <i>Therapie</i> , 2010, 65, 373-377.	0.6	3
290	PET positive, PET negative, or PET peeve?. <i>Blood</i> , 2010, 115, 752-753.	0.6	4
291	Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. <i>Blood</i> , 2010, 116, 1795-1802.	0.6	69
292	Rosai's Dorfman Disease. <i>Clinical Nuclear Medicine</i> , 2010, 35, 576-578.	0.7	10
293	An Update on the Role of Interim Restaging FDG-PET in Patients With Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 347-352.	2.3	24
294	Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. <i>Haematologica</i> , 2010, 95, 1350-1357.	1.7	36

#	ARTICLE	IF	CITATIONS
295	RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. <i>European Radiology</i> , 2010, 20, 1456-1467.	2.3	168
296	Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. <i>European Radiology</i> , 2010, 20, 2027-2038.	2.3	145
297	In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4324-4332.	0.8	450
298	Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 494-504.	3.3	78
299	18F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1095-1105.	3.3	129
300	Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1633-1642.	3.3	76
301	Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2307-2314.	3.3	121
302	18F-FDG PET/CT in primary non-Hodgkin's lymphoma of the sinonasal tract. <i>Annals of Hematology</i> , 2010, 89, 635-637.	0.8	7
303	A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2010, 89, 1107-1113.	0.8	28
305	Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 883-889.	1.2	80
307	Qualitative and quantitative assessment of endpoints in clinical trials. <i>Memo - Magazine of European Medical Oncology</i> , 2010, 3, 33-36.	0.3	1
308	SEOM clinical guidelines for the treatment of Hodgkin's lymphoma. <i>Clinical and Translational Oncology</i> , 2010, 12, 753-759.	1.2	2
309	F-18 FDG PET/CT evaluation of radiotherapy response in rare case of mucosa-associated lymphoid tissue lymphoma. <i>Annals of Nuclear Medicine</i> , 2010, 24, 115-119.	1.2	2
310	Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience. <i>International Journal of Hematology</i> , 2010, 91, 78-86.	0.7	18
311	Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?. <i>International Journal of Hematology</i> , 2010, 92, 246-254.	0.7	32
312	Incidental carcinomas detected by PET/CT scans in patients with malignant lymphoma. <i>International Journal of Hematology</i> , 2010, 92, 647-650.	0.7	15
313	Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. <i>International Journal of Hematology</i> , 2010, 92, 732-743.	0.7	37
314	CHOP-like regimen in combination with rituximab and peginterferon alpha-2b in newly-diagnosed diffuse large B-cell Non-Hodgkin's lymphoma: Experience in a Chinese center. <i>Clinical Oncology and Cancer Research</i> , 2010, 7, 103-109.	0.1	0

#	ARTICLE	IF	CITATIONS
315	Clinical analysis of 13 cases with Burkitt lymphoma or Burkitt-like lymphoma. <i>Clinical Oncology and Cancer Research</i> , 2010, 7, 110-115.	0.1	0
316	On the Added Value of Baseline FDG-PET in Malignant Lymphoma. <i>Molecular Imaging and Biology</i> , 2010, 12, 225-232.	1.3	33
318	Improving Outcomes for Patients With Diffuse Large B-Cell Lymphoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 393-408.	157.7	143
319	If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. <i>BMC Cancer</i> , 2010, 10, 644.	1.1	20
320	Ki67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. <i>European Journal of Haematology</i> , 2010, 85, 149-157.	1.1	34
321	Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. <i>European Journal of Haematology</i> , 2010, 85, 405-415.	1.1	30
322	PET/CT in cancer research: from preclinical to clinical applications. <i>Contrast Media and Molecular Imaging</i> , 2010, 5, 190-200.	0.4	13
323	Surveillance imaging of Hodgkin lymphoma patients in first remission. <i>Cancer</i> , 2010, 116, 3835-3842.	2.0	71
324	Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. <i>Cancer</i> , 2010, 116, 5667-5675.	2.0	14
325	Multicentre phase II study of CycloBEP plus rituximab in patients with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2010, 28, 68-74.	0.8	11
326	Endothelial cells (EC) and endothelial precursor cells (EPC) kinetics in hematological patients undergoing chemotherapy or autologous stem cell transplantation (ASCT). <i>Hematological Oncology</i> , 2010, 28, 192-201.	0.8	7
327	Consensus conference on the use of 90Yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology. <i>American Journal of Hematology</i> , 2010, 85, 147-155.	2.0	5
328	Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: A prospective, parallel-group, randomized, controlled study with 36-month follow-up. <i>American Journal of Hematology</i> , 2010, 85, 894-896.	2.0	177
329	Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. <i>American Journal of Hematology</i> , 2010, 85, 896-899.	2.0	100
330	Allogeneic hematopoietic cell transplantation for myelofibrosis: A 10-year experience at single institution. <i>American Journal of Hematology</i> , 2010, 85, 904-907.	2.0	3
331	Comparison of real-time microvascular abnormalities in pediatric and adult sickle cell anemia patients. <i>American Journal of Hematology</i> , 2010, 85, 899-901.	2.0	32
332	Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis. <i>American Journal of Hematology</i> , 2010, 85, 902-904.	2.0	14
333	2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. <i>Leukemia Research</i> , 2010, 34, 184-189.	0.4	28

#	ARTICLE	IF	CITATIONS
334	Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. <i>Leukemia Research</i> , 2010, 34, 454-457.	0.4	12
335	Synthesis and in vitro evaluation of ¹⁸ F labeled tyrosine derivatives as potential positron emission tomography (PET) imaging agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3482-3485.	1.0	7
336	Diagnosis and staging in gastrointestinal lymphoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 3-12.	1.0	30
337	Quantification of Local Tumor Response to Fractionated Radiation Therapy for Non-Hodgkin Lymphoma Using Weekly ¹⁸ F-FDG PET/CT Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 850-858.	0.4	8
338	Comparison of Favorable Early-Stage Hodgkin's Lymphoma Treatments: A Single-Institution Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1166-1170.	0.4	2
339	Involved-Lesion Radiation Therapy After Chemotherapy in Limited-Stage Head-and-Neck Diffuse Large B Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 507-512.	0.4	20
340	Standard versus high dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization. <i>Transfusion</i> , 2010, 50, 2432-2446.	0.8	14
341	Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a veterinary cooperative oncology group (VCOG) consensus document. <i>Veterinary and Comparative Oncology</i> , 2010, 8, 28-37.	0.8	210
342	Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. <i>Cancer Science</i> , 2010, 101, 2059-2064.	1.7	61
343	Fludarabine, Bortezomib, Myocet [®] and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010, 148, 810-812.	1.2	12
344	High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. <i>British Journal of Haematology</i> , 2010, 148, 890-897.	1.2	90
345	Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. <i>British Journal of Haematology</i> , 2010, 149, 455-457.	1.2	36
346	Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. <i>British Journal of Haematology</i> , 2010, 150, 39-45.	1.2	72
347	Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP ²¹ . <i>British Journal of Haematology</i> , 2010, 151, 221-231.	1.2	47
348	Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. <i>Leukemia</i> , 2010, 24, 1343-1349.	3.3	48
349	Quantitation of whole blood Epstein-Barr virus DNA is useful for assessing treatment response in patients with non-Hodgkin's lymphoma. <i>International Journal of Laboratory Hematology</i> , 2010, 32, e106-13.	0.7	9
350	Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin's lymphoma. <i>Pediatric Transplantation</i> , 2010, 14, 109-114.	0.5	2
355	Tumour response evaluation with fluorodeoxyglucose positron emission tomography: research technique or clinical tool?. <i>Cancer Imaging</i> , 2010, 10, S68-S72.	1.2	9

#	ARTICLE	IF	CITATIONS
356	Whole-body diffusion-weighted imaging in lymphoma. <i>Cancer Imaging</i> , 2010, 10, S172-S178.	1.2	36
357	COMPROMISO MUSCULAR POR LINFOMA NO HODGKIN: CASO CLÍNICO Y REVISIÓN DEL TEMA. <i>Revista Chilena De Radiología</i> , 2010, 16, .	0.2	1
358	T-Cell-Depleted Reduced-Intensity Transplantation Followed by Donor Leukocyte Infusions to Promote Graft-Versus-Lymphoma Activity Results in Excellent Long-Term Survival in Patients With Multiply Relapsed Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3695-3700.	0.8	134
359	Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation. <i>Annals of Oncology</i> , 2010, 21, 1211-1216.	0.6	15
360	Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2010, 16, 1894-1903.	3.2	139
361	¹⁸ F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients. <i>Journal of Nuclear Medicine</i> , 2010, 51, 25-30.	2.8	352
362	Reply to A. Hüttmann et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e490-e491.	0.8	1
363	Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1896-1903.	0.8	293
364	How I treat elderly patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2010, 116, 5103-5110.	0.6	124
365	FDG PET/CT of Extranodal Involvement in Non-Hodgkin Lymphoma and Hodgkin Disease. <i>Radiographics</i> , 2010, 30, 269-291.	1.4	288
366	Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Blood</i> , 2010, 115, 2578-2585.	0.6	687
367	FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. <i>Annals of Oncology</i> , 2010, 21, 1877-1883.	0.6	26
368	Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients. <i>Clinical Cancer Research</i> , 2010, 16, 3998-4004.	3.2	60
369	Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v168-v171.	0.6	40
370	CD4 ⁺ CD25 ⁺ Regulatory T Cell Depletion Improves the Graft-Versus-Tumor Effect of Donor Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Science Translational Medicine</i> , 2010, 2, 41ra52.	5.8	83
371	Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death. <i>Cancer Research</i> , 2010, 70, 9062-9072.	0.4	126
372	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v181-v183.	0.6	28
373	¹⁸ F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1337-1343.	2.8	134

#	ARTICLE	IF	CITATIONS
374	Assessment of Metabolic Response to Radioimmunotherapy with ⁹⁰ Y- ¹²⁵ I-britumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Radiology</i> , 2010, 254, 245-252.	3.6	29
375	Unresolved issues in diffuse large B-cell lymphomas. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 387-402.	1.1	6
376	Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2010, 21, 1078-1082.	0.6	99
377	Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v172-v174.	0.6	61
378	¹³¹ I-Tositumomab Radioimmunotherapy: Initial Tumor Dose-Response Results Using 3-Dimensional Dosimetry Including Radiobiologic Modeling. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1155-1162.	2.8	82
379	Improved prognosis for localized malignant lymphomas of the head and neck. <i>Acta Oto-Laryngologica</i> , 2010, 130, 626-631.	0.3	4
380	Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Response Assessment Before High-Dose Chemotherapy for Lymphoma: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , 2010, 15, 750-759.	1.9	50
381	Exploring the role of FDG-PET in the assessment of bone marrow involvement in lymphoma patients as interpreted by qualitative and semiquantitative disease metabolic activity parameter. <i>Indian Journal of Cancer</i> , 2010, 47, 380.	0.2	5
382	Measurement Accuracy and Reproducibility of Semiautomated Metric and Volumetric Lymph Node Analysis in MDCT. <i>American Journal of Roentgenology</i> , 2010, 195, 979-985.	1.0	27
383	The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 28-33.	0.6	27
384	Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection. <i>Leukemia and Lymphoma</i> , 2010, 51, 2063-2069.	0.6	16
385	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. <i>Haematologica</i> , 2010, 95, 1342-1349.	1.7	128
386	Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. <i>Annals of Oncology</i> , 2010, 21, 1217-1221.	0.6	22
387	¹⁸ F-deoxyglucose PET: useful in the management of patients with stem cell transplantation for lymphoma?. <i>Expert Review of Hematology</i> , 2010, 3, 405-410.	1.0	5
388	Hodgkin Lymphoma in HIV Positive Patients. <i>Current HIV Research</i> , 2010, 8, 141-146.	0.2	16
389	Clinical Utility of PET/CT in Lymphoma. <i>American Journal of Roentgenology</i> , 2010, 194, W91-W103.	1.0	122
391	Rituximab. <i>Drugs</i> , 2010, 70, 1445-1476.	4.9	163
392	Surveillance Computed Tomography Scans for Patients With Lymphoma: Is the Risk Worth the Benefits?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 270-277.	0.2	34

#	ARTICLE	IF	CITATIONS
393	A Decade of Progress in Lymphoma: Advances and Continuing Challenges. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 414-423.	0.2	43
394	15 Mantle cell lymphoma: Current standards and new approaches. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 9-10.	2.2	0
397	Handbook of Evidence-Based Radiation Oncology. , 2010, , .		45
398	The indolent course and high incidence of t(14;18) in primary duodenal follicular lymphoma. <i>Annals of Oncology</i> , 2010, 21, 1500-1505.	0.6	32
399	EARLY [¹⁸ F]FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY-BASED RESPONSE EVALUATION AFTER TREATMENT WITH GEMCITABINE AND VINOURELBINE FOR REFRACTORY HODGKIN DISEASE: A CHILDREN'S ONCOLOGY GROUP REPORT. <i>Pediatric Hematology and Oncology</i> , 2010, 27, 650-657.	0.3	2
400	Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SCN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. <i>Annals of Oncology</i> , 2010, 21, 2246-2254.	0.6	56
401	The Bone Marrow in Normal and Disease States. , 2010, , 99-121.		1
402	Therapy of B-cell Lymphoproliferative Disorders. , 2010, , 323-332.		1
403	Treatment of Hodgkin Lymphoma. , 2010, , 367-389.		2
404	High levels of topoisomerase II β protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment. <i>Leukemia and Lymphoma</i> , 2010, 51, 1260-1268.	0.6	14
406	Intérêt de la TEP au 18F-FDG préthérapeutique pour prédire la réponse à la radio-immunothérapie dans les lymphomes non hodgkiniens. <i>Medecine Nucleaire</i> , 2010, 34, 647-654.	0.2	0
407	Apport de la TEP/TDM au 18FDG dans la stadification initiale et l'évaluation précoce de la réponse thérapeutique des rhabdomyosarcomes pédiatriques. <i>Medecine Nucleaire</i> , 2010, 34, 655-663.	0.2	2
408	Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOX) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma. <i>Biomedicine and Pharmacotherapy</i> , 2010, 64, 83-87.	2.5	7
409	Follicular non-Hodgkin's lymphoma. <i>Clinical Radiology</i> , 2010, 65, 408-420.	0.5	17
410	Two decades at the cross-roads of biology, physics and epidemiology: Lessons learned in [18F]-FDG positron emission tomography in oncology. <i>European Journal of Cancer</i> , 2010, 46, 2150-2158.	1.3	1
411	PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. <i>European Journal of Radiology</i> , 2010, 73, 470-480.	1.2	61
412	New-Onset Lymphopenia Assessed during Routine Follow-up Is a Risk Factor for Relapse Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 376-383.	2.0	25
413	Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1145-1154.	2.0	19

#	ARTICLE	IF	CITATIONS
414	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1187-1211.	2.0	76
416	Lymphoma – Emerging realities in sub-Saharan Africa. <i>Transfusion and Apheresis Science</i> , 2010, 42, 141-150.	0.5	14
419	Developments in the management of Hodgkin's lymphoma. <i>Lancet, The</i> , 2010, 375, 786-788.	6.3	9
420	Therapy Response Evaluation with Positron Emission Tomography-Computed Tomography. <i>Seminars in Ultrasound, CT and MRI</i> , 2010, 31, 490-495.	0.7	4
421	Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4485-4491.	0.8	604
422	Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. <i>New England Journal of Medicine</i> , 2010, 363, 1812-1821.	13.9	1,266
423	Imaging of Lymphoma of the Musculoskeletal System. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2010, 18, 75-93.	0.6	7
424	Measuring the –Unmeasurable–. <i>Academic Radiology</i> , 2010, 17, 1175-1185.	1.3	5
425	Clinicopathologic features and treatment options of ocular adnexal lymphoma. <i>Expert Review of Ophthalmology</i> , 2010, 5, 241-258.	0.3	0
426	Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: A report of two cases. <i>Acta OncolÁgica</i> , 2010, 49, 526-528.	0.8	0
427	Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2010, 51, 1225-1232.	0.6	36
428	Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience. <i>Leukemia and Lymphoma</i> , 2010, 51, 2208-2214.	0.6	15
429	Unresolved issues in the comparison of therapies and determination of responses in WaldenstrÅm macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 1767-1770.	0.6	1
430	FDG PET/CT versus CT, MR Imaging, and 67Ga Scintigraphy in the Posttherapy Evaluation of Malignant Lymphoma. <i>Radiographics</i> , 2010, 30, 939-957.	1.4	45
431	Patterns of survival of follicular lymphomas at a single institution through three decades. <i>Leukemia and Lymphoma</i> , 2010, 51, 1028-1034.	0.6	33
432	Hepatic toxicity and prognosis in hepatitis C virus–infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. <i>Blood</i> , 2010, 116, 5119-5125.	0.6	123
433	Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. <i>Annals of Oncology</i> , 2010, 21, 1222-1227.	0.6	40
434	A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. <i>Acta OncolÁgica</i> , 2010, 49, 3-12.	0.8	30

#	ARTICLE	IF	CITATIONS
435	SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 279-283.	0.6	58
436	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. <i>Leukemia and Lymphoma</i> , 2011, 52, 823-832.	0.6	23
437	Economic impact of disease progression in follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 2117-2123.	0.6	16
438	Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. <i>Leukemia and Lymphoma</i> , 2011, 52, 1585-1588.	0.6	48
440	An XRCC1 polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2011, 52, 1249-1254.	0.6	6
441	Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy. <i>Leukemia and Lymphoma</i> , 2011, 52, 1689-1696.	0.6	4
442	Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type. <i>Leukemia and Lymphoma</i> , 2011, 52, 1255-1261.	0.6	44
443	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2766-2772.	0.8	190
444	Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1488-1494.	0.6	39
445	BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. <i>Blood</i> , 2011, 118, 3419-3425.	0.6	123
446	Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group. <i>Leukemia and Lymphoma</i> , 2011, 52, 786-795.	0.6	3
447	Treatment of Mucosa-associated Lymphoid Tissue Lymphoma in Sjögren's Syndrome: A Retrospective Clinical Study. <i>Journal of Rheumatology</i> , 2011, 38, 2198-2208.	1.0	78
448	Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3389-3395.	0.8	104
449	Role of Functional Imaging in the Management of Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1844-1854.	0.8	251
450	<i>Leukemia and Lymphoma</i> . <i>Radiologic Clinics of North America</i> , 2011, 49, 767-797.	0.9	40
451	A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment. <i>PET Clinics</i> , 2011, 6, 299-311.	1.5	4
452	Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 462-466.	0.2	106
453	Treatment of Indolent Lymphoma in Germany - Results of a Representative Population-Based Survey. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 204-211.	0.2	9

#	ARTICLE	IF	CITATIONS
454	FDG-PET/CT in Lymphoma. <i>Methods in Molecular Biology</i> , 2011, 727, 1-19.	0.4	36
455	Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. , 2011, , CD007110.		43
456	Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. , 2011, , CD007941.		39
457	Opportunities and pitfalls of cancer imaging in clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 517-527.	12.5	31
459	Romidepsin. <i>Drugs</i> , 2011, 71, 1469-1480.	4.9	24
460	Prognostic Relevance of Immunohistochemical Subclassification of Diffuse Large B-Cell Lymphoma in Two Prospective Phase III Clinical Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 23-32.	0.2	11
461	Target Definitions for Hodgkin Lymphoma: The Involved Node Radiation Field Concept. , 2011, , 91-122.		0
462	The Role of Imaging in Radiotherapy for Hodgkin Lymphoma. , 2011, , 81-89.		1
463	Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 4053-4061.	0.6	136
464	Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. <i>Leukemia and Lymphoma</i> , 2011, 52, 387-393.	0.6	35
466	Radiotherapy for Hodgkin Lymphoma. , 2011, , .		3
468	Imaging in follicular NHL. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 165-177.	0.7	15
469	Perspective of clinical research in follicular NHL: Interaction between science and industry. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 313-321.	0.7	1
470	Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2011, 47, 1312-1318.	1.3	82
471	No correlation between glucose metabolism and apparent diffusion coefficient in diffuse large B-cell lymphoma: A PET/CT and DW-MRI study. <i>European Journal of Radiology</i> , 2011, 79, e117-e121.	1.2	35
472	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350) Tj ETQq1 1 0.784314 rgBJ /Overlo	2.0	32
473	Relapse of Lymphoma after Allogeneic Hematopoietic Cell Transplantation: Management Strategies and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1497-1504.	2.0	41
474	Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1646-1652.	2.0	92

#	ARTICLE	IF	CITATIONS
475	Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1-14.	0.6	16
476	Anaplastic lymphoma kinase expression in a recurrent primary cutaneous anaplastic large cell lymphoma with eventual systemic involvement. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 671-673.	0.6	7
479	TEP/TDM au FDG et bilan initial des lymphomes: du diagnostic au pronostic. <i>Medecine Nucleaire</i> , 2011, 35, 8-20.	0.2	2
480	Évaluation de la réponse thérapeutique par tomographie par émission de positons (TEP) au 18fluoro-désoxyglucose (FDG) en oncologie-hématologie. <i>Medecine Nucleaire</i> , 2011, 35, 600-607.	0.2	5
481	PET/CT scanning with a high HIV/AIDS prevalence. <i>Transfusion and Apheresis Science</i> , 2011, 44, 167-172.	0.5	19
482	Optimising the lymphoma response criteria in the era of targeted therapy. <i>Lancet Oncology</i> , The, 2011, 12, 616-617.	5.1	10
483	Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2011, 12, 1222-1228.	5.1	168
484	Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cell-Depleted Allogeneic Transplantation for Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 971-978.	0.8	117
485	Minimal Residual Disease Detection in Mantle Cell Lymphoma: Technical Aspects and Clinical Relevance. <i>Seminars in Hematology</i> , 2011, 48, 172-184.	1.8	45
486	Volume and attenuation computed tomography measurements for interim evaluation of Hodgkin and follicular lymphoma as an additional surrogate parameter for more confident response monitoring: a pilot study. <i>Cancer Imaging</i> , 2011, 11, 155-162.	1.2	2
487	Radiation Therapy for Hodgkin Lymphoma and Other Hematopoietic Disorders. <i>Medical Radiology</i> , 2011, , 1099-1140.	0.0	1
488	Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin's lymphoma using 18F-FDG-PET/CT. <i>Neoplasma</i> , 2011, 58, 291-297.	0.7	3
489	Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma. <i>The Korean Journal of Hematology</i> , 2011, 46, 180.	0.7	3
490	Primary gastrointestinal lymphoma. <i>World Journal of Gastroenterology</i> , 2011, 17, 697.	1.4	333
491	Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma. <i>The Korean Journal of Hematology</i> , 2011, 46, 103.	0.7	12
492	Neck Lymphoma. <i>Medical Radiology</i> , 2011, , 341-361.	0.0	0
493	Clinical Trial Risk in Non-Hodgkin's Lymphoma: Endpoint and Target Selection. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2011, 14, 227.	0.9	18
495	Retrospective web-based multicenter evaluation of 18F-FDG-PET and CT derived predictive factors. <i>Nuklearmedizin - NuclearMedicine</i> , 2011, 50, 39-47.	0.3	7

#	ARTICLE	IF	CITATIONS
497	Current and Future Trends in Imaging Informatics for Oncology. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 203-210.	1.0	15
498	Is There a Role for Bortezomib Combinations in the Management of Patients With Follicular Lymphoma?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3349-3350.	0.8	6
502	Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. <i>Blood</i> , 2011, 117, 1817-1821.	0.6	37
503	Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. <i>Blood</i> , 2011, 117, 1834-1839.	0.6	346
504	How I treat: diagnosing and managing diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 117, 3954-3960.	0.6	61
505	Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. <i>Blood</i> , 2011, 117, 5314-5320.	0.6	56
506	High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. <i>Blood</i> , 2011, 117, 6977-6986.	0.6	149
507	miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. <i>Blood</i> , 2011, 118, 1034-1040.	0.6	90
508	PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. <i>Blood</i> , 2011, 118, 5517-5527.	0.6	83
509	Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. <i>Blood</i> , 2011, 118, 5989-5995.	0.6	445
510	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. <i>Blood</i> , 2011, 118, 4421-4430.	0.6	30
511	PET-CT in MM: a new definition of CR. <i>Blood</i> , 2011, 118, 5984-5985.	0.6	13
512	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. <i>Haematologica</i> , 2011, 96, 1136-1143.	1.7	84
513	Clinical Impact of Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma. <i>PLoS ONE</i> , 2011, 6, e16408.	1.1	86
514	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. <i>Haematologica</i> , 2011, 96, 996-1001.	1.7	100
515	Primary Gastric Diffuse Large B-cell Lymphoma with Orbital Involvement: Diagnostic Usefulness of 18F-fluorodeoxyglucose Positron Emission Tomography. <i>Internal Medicine</i> , 2011, 50, 1953-1956.	0.3	4
517	Non-Hodgkin's Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 484-560.	2.3	161
518	Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1020-1058.	2.3	40

#	ARTICLE	IF	CITATIONS
519	Whole-Body Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Treatment Response Assessment in Patients With Diffuse Large B-Cell Lymphoma. <i>Investigative Radiology</i> , 2011, 46, 341-349.	3.5	73
520	Malignant Lymphoma of the Lacrimal Gland. <i>JAMA Ophthalmology</i> , 2011, 129, 1275.	2.6	49
521	Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study. <i>Cancer Science</i> , 2011, 102, 414-418.	1.7	9
522	Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. <i>Cancer Science</i> , 2011, 102, 1687-1692.	1.7	25
523	Rituximab in combination with CODOX/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. <i>British Journal of Haematology</i> , 2011, 152, 175-181.	1.2	29
524	Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim PET positive after two ABVD courses. <i>British Journal of Haematology</i> , 2011, 152, 551-560.	1.2	127
525	Combined ifosfamide, etoposide and oxaliplatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. <i>British Journal of Haematology</i> , 2011, 153, 191-198.	1.2	21
526	Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma. <i>British Journal of Haematology</i> , 2011, 153, 334-340.	1.2	18
527	Multicentre phase II study of the CycLOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers. <i>British Journal of Haematology</i> , 2011, 153, 582-588.	1.2	10
528	Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (COMP14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high life threat impact cardiopathy. <i>British Journal of Haematology</i> , 2011, 154, 579-589.	1.2	55
529	Chemotherapy only for localized Hodgkin lymphoma. <i>Journal of Internal Medicine</i> , 2011, 270, 197-205.	2.7	9
530	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. <i>British Journal of Cancer</i> , 2011, 104, 719-725.	2.9	48
531	The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. <i>Leukemia</i> , 2011, 25, 1502-1509.	3.3	165
532	Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas. <i>European Journal of Haematology</i> , 2011, 87, 547-553.	1.1	2
533	Risk, Predictors, and Clinical Characteristics of Lymphoma Development in Primary Sjögren's Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 415-423.	1.6	139
534	Personalized Treatment of Lymphoma: Promise and Reality. <i>Seminars in Oncology</i> , 2011, 38, 225-235.	0.8	10
535	Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia. <i>Current Medical Research and Opinion</i> , 2011, 27, 1987-1993.	0.9	9
536	Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial. <i>Investigational New Drugs</i> , 2011, 29, 154-160.	1.2	11

#	ARTICLE	IF	CITATIONS
537	Early Treatment Response Evaluation in Patients with Diffuse Large B-Cell Lymphoma—A Pilot Study Comparing Volumetric MRI and PET/CT. <i>Molecular Imaging and Biology</i> , 2011, 13, 785-792.	1.3	18
538	Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: A survey from Tyrolean hospitals. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 269-275.	1.0	0
539	Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast. <i>Archives of Gynecology and Obstetrics</i> , 2011, 284, 405-409.	0.8	10
541	Traitement de maintenance des lymphomes malins non hodgkiniens. <i>Oncologie</i> , 2011, 13, 543-547.	0.2	0
542	Place de la tomographie par Émission de positons au F18-fluorodÉoxyglucose couplÉe au scanner (TEP/TDM) dans le bilan initial des lymphomes de lÉadulte. <i>Oncologie</i> , 2011, 13, 571-575.	0.2	0
543	ADC measurements in the evaluation of lymph nodes in patients with non-Hodgkin lymphoma: feasibility study. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2011, 24, 1-8.	1.1	31
544	Molecular imaging in cancer treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 358-377.	3.3	77
545	Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 832-842.	3.3	63
546	Prognostic value of interim FDG PET/CT in HodgkinÉs lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1064-1071.	3.3	87
547	Manifestation of lymphoma expansion following lymphatic drainage on 18F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2100-2101.	3.3	1
548	Postchemotherapy PET evaluation correlates with patient outcome in paediatric HodgkinÉs disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1620-1627.	3.3	15
549	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). <i>Annals of Hematology</i> , 2011, 90, 401-408.	0.8	28
550	Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience. <i>Annals of Hematology</i> , 2011, 90, 557-568.	0.8	32
551	Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma. <i>Annals of Hematology</i> , 2011, 90, 693-699.	0.8	8
552	Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Annals of Hematology</i> , 2011, 90, 797-802.	0.8	71
553	Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results. <i>Annals of Hematology</i> , 2011, 90, 1399-1407.	0.8	14
554	Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. <i>Annals of Hematology</i> , 2011, 90, 1409-1418.	0.8	7
555	Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 165-175.	1.1	7

#	ARTICLE	IF	CITATIONS
556	t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1387-1395.	1.1	14
557	Clinical characterization and prognostic factors of primary lymphoma of bone in case of Chinese patients. <i>Medical Oncology</i> , 2011, 28, 476-482.	1.2	6
558	Pediatric Hodgkin Lymphoma: CT Features at Presentation, on Treatment and its Prognostic Significance. <i>Indian Journal of Pediatrics</i> , 2011, 78, 549-554.	0.3	2
559	Is contrast material needed after treatment of malignant lymphoma in positron emission tomography/computed tomography?. <i>Annals of Nuclear Medicine</i> , 2011, 25, 93-99.	1.2	9
560	Impact of FDG-PET/CT in the management of lymphoma. <i>Annals of Nuclear Medicine</i> , 2011, 25, 701-716.	1.2	39
561	High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. <i>International Journal of Hematology</i> , 2011, 93, 502-508.	0.7	76
562	The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2011, 27, 136-145.	0.3	1
563	Value of FDG-PET/CT using unfractionated heparin for managing primary cardiac lymphoma and several key findings. <i>Journal of Nuclear Cardiology</i> , 2011, 18, 516-520.	1.4	24
564	Advances in Primary CNS Lymphoma: Randomized Clinical Trials of Chemotherapy and Whole-Brain Radiotherapy. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 243-245.	2.0	2
565	MRI for staging lymphoma: Whole-body or less?. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 33, 1144-1150.	1.9	6
566	Feasibility of the TNM-based staging system of ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). <i>American Journal of Hematology</i> , 2011, 86, 262-266.	2.0	42
567	New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia. <i>American Journal of Hematology</i> , 2011, 86, 619-621.	2.0	4
568	The impact of osteoporosis (as measured by lumbar spine quantitative computed tomography) on disease activity and survival in myeloma patients: A 13-year prospective study. <i>American Journal of Hematology</i> , 2011, 86, 617-619.	2.0	7
569	Fetal hemoglobin in sickle cell anemia: Saudi patients from the Southwestern province have similar <i>HBB</i> haplotypes but higher HbF levels than African Americans. <i>American Journal of Hematology</i> , 2011, 86, 612-614.	2.0	30
570	Hematological characteristics and effective screening for compound heterozygosity for Hb constant spring and deletional β^+ -thalassemia. <i>American Journal of Hematology</i> , 2011, 86, 615-617.	2.0	9
571	Proportions of bone marrow lymphocyte subsets at diagnosis may predict survival in patients with newly diagnosed diffuse large B-cell lymphoma independently of the international prognostic index. <i>American Journal of Hematology</i> , 2011, 86, 622-624.	2.0	0
572	Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 627-630.	2.0	10
573	Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. <i>American Journal of Hematology</i> , 2011, 86, 625-627.	2.0	7

#	ARTICLE	IF	CITATIONS
574	Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. American Journal of Hematology, 2011, 86, 610-611.	2.0	80
575	Utility of positron emission tomography scans in mantle cell lymphoma. American Journal of Hematology, 2011, 86, 841-845.	2.0	55
576	Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL Bâ€ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large Bâ€cell lymphoma. American Journal of Hematology, 2011, 86, E61-4.	2.0	22
577	Diffusionâ€weighted MRI in early chemotherapy response evaluation of patients with diffuse large Bâ€cell lymphoma â€ a pilot study: comparison with 2â€deoxyâ€2â€fluoroâ€D</sup>â€glucoseâ€positron emission tomography/computed tomography. NMR in Biomedicine, 2011, 24, 1181-1190.	1.6	71
578	Midtreatment ¹⁸ Fâ€fluorodeoxyglucose positronâ€emission tomography in aggressive nonâ€Hodgkin lymphoma. Cancer, 2011, 117, 1010-1018.	2.0	60
579	Higher response to lenalidomide in relapsed/refractory diffuse large Bâ€cell lymphoma in nongermlinal center Bâ€cellâ€like than in germinal center Bâ€cellâ€like phenotype. Cancer, 2011, 117, 5058-5066.	2.0	277
580	Diffuse large Bâ€cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. Hematological Oncology, 2011, 29, 38-41.	0.8	29
581	A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma. Hematological Oncology, 2011, 29, 151-153.	0.8	0
582	Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after ⁹⁰ Yâ€Ibritumomabâ€tiuxetan. Hematological Oncology, 2011, 29, 131-138.	0.8	9
583	Impact of 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography on Treatment Strategy and Radiotherapy Planning for Stage Iâ€II Hodgkin Disease: A Prospective Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2011, 79, 823-828.	0.4	29
584	External Beam Radiotherapy Followed by 90Y Ibritumomab Tiuxetan in Relapsed or Refractory Bulky Follicular Lymphoma. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1124-1130.	0.4	20
585	Limited Chemotherapy and Shrinking Field Radiotherapy for Osteolymphoma (Primary Bone Lymphoma): Results From the Trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 Prospective Trial. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1164-1170.	0.4	33
586	Peripheral T-cell lymphoma â€ Not otherwise specified. Critical Reviews in Oncology/Hematology, 2011, 79, 321-329.	2.0	95
587	Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma. Leukemia Research, 2011, 35, 358-362.	0.4	19
588	Predictive Value of Initial ¹⁸ F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment. Journal of Nuclear Medicine, 2011, 52, 690-696.	2.8	65
589	<i>Response to Treatment Series:</i> Part 2, Tumor Response Assessmentâ€Using New and Conventional Criteria. American Journal of Roentgenology, 2011, 197, 18-27.	1.0	66
590	Newly Diagnosed Lymphoma: Initial Results With Whole-Body T1-Weighted, STIR, and Diffusion-Weighted MRI Compared With 18F-FDG PET/CT. American Journal of Roentgenology, 2011, 196, 662-669.	1.0	103
591	End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkinâ€TMs lymphoma. Annals of Oncology, 2011, 22, 910-915.	0.6	90

#	ARTICLE	IF	CITATIONS
592	Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. <i>Leukemia and Lymphoma</i> , 2011, 52, 317-320.	0.6	3
593	T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. <i>Leukemia and Lymphoma</i> , 2011, 52, 214-222.	0.6	16
594	Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network. <i>Leukemia and Lymphoma</i> , 2011, 52, 1920-1928.	0.6	26
595	Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. <i>Bone Marrow Transplantation</i> , 2011, 46, 393-399.	1.3	24
597	A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. <i>Blood</i> , 2011, 118, 5119-5125.	0.6	181
598	Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. <i>Leukemia and Lymphoma</i> , 2011, 52, 597-603.	0.6	45
599	Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1668-1674.	0.6	59
600	Pretreatment Serum Level of 15-kDa Granulysin Might Have a Prognostic Value in Patients with Diffuse Large B Cell Lymphoma. <i>Acta Haematologica</i> , 2011, 126, 79-86.	0.7	5
601	The Role of PET and PET/CT in Managing the Care of Lymphoma Patients. <i>Journal of Nuclear Medicine Technology</i> , 2011, 39, 190-194.	0.4	6
602	Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). <i>Annals of Oncology</i> , 2011, 22, 689-695.	0.6	64
603	Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011, 22, vi55-vi58.	0.6	86
604	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011, 22, vi59-vi63.	0.6	66
605	SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 37-43.	0.6	280
606	Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin's Lymphoma Patients Treated with Rituximab-Containing Regimens. <i>Journal of Immunology</i> , 2011, 186, 6044-6055.	0.4	93
607	A Pilot Study to Evaluate ^{18}F -Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1898-1902.	2.8	29
608	^{18}F -FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation. <i>Journal of Nuclear Medicine</i> , 2011, 52, 386-392.	2.8	151
609	CD23 Expression in Follicular Lymphoma. <i>American Journal of Clinical Pathology</i> , 2011, 135, 46-53.	0.4	34
610	Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography. <i>Advances in Hematology</i> , 2011, 2011, 1-12.	0.6	12

#	ARTICLE	IF	CITATIONS
611	Revisiting the Marrow Metabolic Changes after Chemotherapy in Lymphoma: A Step towards Personalized Care. <i>International Journal of Molecular Imaging</i> , 2011, 2011, 1-6.	1.3	3
612	Meta-Analyses of Early-Stage Hodgkin Lymphoma. <i>Acta Haematologica</i> , 2011, 125, 32-38.	0.7	7
613	High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab. <i>Acta Haematologica</i> , 2011, 126, 44-51.	0.7	48
614	Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma. <i>Hematology Reports</i> , 2011, 3, e26.	0.3	13
615	Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2011, 29, 3023-3029.	0.8	66
616	Positron Emission Tomographyâ€“Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. <i>Journal of Clinical Oncology</i> , 2011, 29, 3194-3200.	0.8	176
617	Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies. <i>Clinical Cancer Research</i> , 2011, 17, 19-30.	3.2	86
618	Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1620-1626.	0.8	70
619	Comparison of four prognostic scores in peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2011, 22, 397-404.	0.6	84
620	Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 498-505.	0.9	372
621	Targeted â€“ Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?. <i>Reviews on Recent Clinical Trials</i> , 2011, 6, 259-265.	0.4	18
622	Optimal Therapy of Advanced Hodgkin Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 310-316.	0.9	21
623	Positron Emission Tomography in the Management of Hodgkin Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 317-322.	0.9	22
624	Clinical End Points and Response Criteria in Mycosis Fungoides and SÃ©zary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2598-2607.	0.8	550
625	Beyond chemotherapy: new agents for targeted treatment of lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 85-96.	12.5	73
626	Brentuximab vedotin for the treatment of CD30 ⁺ lymphomas. <i>Immunotherapy</i> , 2011, 3, 475-485.	1.0	37
627	Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. <i>Leukemia</i> , 2011, 25, 1877-1881.	3.3	96
628	Objective assessment of tumour response to therapy based on tumour growth kinetics. <i>British Journal of Cancer</i> , 2011, 105, 682-686.	2.9	24

#	ARTICLE	IF	CITATIONS
629	Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 31-40.	1.4	4
630	Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. <i>Future Oncology</i> , 2011, 7, 9-14.	1.1	4
631	The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. <i>Blood</i> , 2011, 117, 2807-2812.	0.6	186
632	Magnetic resonance imaging of malignant lymphoma. <i>Expert Review of Hematology</i> , 2011, 4, 161-171.	1.0	16
633	Computational approaches to assist in the evaluation of cancer treatment response. <i>Imaging in Medicine</i> , 2011, 3, 233-246.	0.0	3
635	Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1799-1806.	3.0	131
636	Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. <i>Annals of Oncology</i> , 2011, 22, 1392-1403.	0.6	38
637	Hodgkin's Disease in Patients with HIV Infection. <i>Advances in Hematology</i> , 2011, 2011, 1-7.	0.6	41
638	Therapy of newly diagnosed follicular lymphoma. <i>Frontiers in Oncology</i> , 2012, 2, 188.	1.3	0
639	Usefulness of Flow Cytometric Immunophenotyping for Bone Marrow Staging in Patients With Mantle Cell Lymphoma After Therapy. <i>American Journal of Clinical Pathology</i> , 2012, 137, 634-640.	0.4	6
640	Prognosis and Outcome of Non-Hodgkin Lymphoma in Primary Sjögren Syndrome. <i>Medicine (United States)</i> , 2012, 91, 174-179.	0.4	174
641	Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. <i>Annals of Oncology</i> , 2012, 23, 2695-2703.	0.6	62
642	The diagnostic value of FDG-PET cannot be judged by iliac bone marrow biopsy. <i>British Journal of Radiology</i> , 2012, 85, 1204-1205.	1.0	3
643	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. <i>Oncologist</i> , 2012, 17, 239-249.	1.9	105
644	Use of interim [¹⁸ F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 263-269.	0.6	25
645	Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. <i>Oncologist</i> , 2012, 17, 1073-1080.	1.9	42
646	Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2012, 23, 1280-1286.	0.6	36
647	Advances in the Treatment of Relapsed or Refractory Hodgkin's Lymphoma. <i>Oncologist</i> , 2012, 17, 367-376.	1.9	16

#	ARTICLE	IF	CITATIONS
648	Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 227-235.	1.1	14
649	U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 5845-5849.	3.2	193
650	Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. <i>Journal of Clinical Oncology</i> , 2012, 30, 3848-3853.	0.8	107
651	Chemotherapy Alone for Localized Diffuse Large B-Cell Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 421-426.	1.0	21
652	Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies. <i>Journal of Nuclear Medicine</i> , 2012, 53, 922-927.	2.8	65
653	Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes. <i>Journal of Clinical Oncology</i> , 2012, 30, 4161-4167.	0.8	137
654	Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3460-3467.	0.8	590
655	A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. <i>Annals of Oncology</i> , 2012, 23, 415-420.	0.6	27
656	Perfusion and Flow Extraction Product as Potential Discriminators in Untreated Follicular and Diffuse Large B Cell Lymphomas Using Volume Perfusion CT With Attempt at Histopathologic Explanation. <i>American Journal of Roentgenology</i> , 2012, 198, 1239-1246.	1.0	10
658	MSCT Follow-Up in Malignant Lymphoma: Comparison of Manual Linear Measurements with Semi-Automated Lymph Node Analysis for Therapy Response Classification. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2012, 184, 795-804.	0.7	10
659	The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies. <i>Leukemia and Lymphoma</i> , 2012, 53, 2166-2174.	0.6	13
660	Interim response assessment for Hodgkin lymphoma: size matters. <i>Leukemia and Lymphoma</i> , 2012, 53, 2095-2096.	0.6	0
661	Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. <i>Haematologica</i> , 2012, 97, 410-415.	1.7	56
662	Interim [¹⁸ F]fluorodeoxyglucose positron emission tomography imaging in stage II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. <i>Leukemia and Lymphoma</i> , 2012, 53, 2143-2150.	0.6	54
664	Pediatric Nonlymphoblastic Non-Hodgkin Lymphoma: Baseline, Interim, and Posttreatment PET/CT versus Contrast-enhanced CT for Evaluation—A Prospective Study. <i>Radiology</i> , 2012, 262, 956-968.	3.6	51
665	EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-κB activation. <i>Modern Pathology</i> , 2012, 25, 968-982.	2.9	172
666	Clinical utility of ¹⁸ F FDG-PET/CT in the detection of bone marrow disease in Hodgkin's lymphoma. <i>British Journal of Radiology</i> , 2012, 85, e490-e496.	1.0	38
667	Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. <i>Blood</i> , 2012, 120, 560-568.	0.6	157

#	ARTICLE	IF	CITATIONS
668	Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2197-2203.	0.8	251
669	Clinical Presentation, Treatment, and Outcomes Among 65 Patients with HIV-Associated Lymphoma Treated at the University of North Carolina, 2000-2010. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 798-805.	0.5	18
670	Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 34-42.	0.6	40
671	How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models?. <i>Blood Cancer Journal</i> , 2012, 2, e93-e93.	2.8	14
672	Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1244-1252.	2.8	150
673	Lymphoma Study Group of JCOG. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 85-95.	0.6	25
674	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. <i>Annals of Oncology</i> , 2012, 23, 729-735.	0.6	19
675	Diagnosis and treatment of diffuse large B-cell lymphoma. <i>Swiss Medical Weekly</i> , 2012, 142, w13511.	0.8	27
676	Assessment of Response to Therapy. <i>Medical Radiology</i> , 2012, , 279-322.	0.0	2
677	Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. <i>Bone Marrow Transplantation</i> , 2012, 47, 1082-1086.	1.3	15
678	Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. <i>Haematologica</i> , 2012, 97, 262-269.	1.7	175
679	18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma. <i>ISRN Hematology</i> , 2012, 2012, 1-9.	1.6	3
680	Positron emission tomography in lymphoma: Fine tuning of international harmonization project. <i>Archive of Oncology</i> , 2012, 20, 17-23.	0.2	0
681	Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 807-811.	0.6	11
682	Clinical Trials and Treatment of ATL. <i>Leukemia Research and Treatment</i> , 2012, 2012, 1-12.	2.0	29
683	Lenalidomide in Diffuse Large B-Cell Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-8.	0.6	18
684	Sjögren's Syndrome. , 2012, , .		9
685	Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma. <i>Cancer Imaging</i> , 2012, 12, 403-408.	1.2	35

#	ARTICLE	IF	CITATIONS
686	Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 1461-1468.	0.6	8
687	Value of 18F FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience. <i>Hematology</i> , 2012, 17, 76-84.	0.7	25
688	Therapeutic Monitoring of Gastroenteropancreatic Neuroendocrine Tumors: The Challenges Ahead. <i>Neuroendocrinology</i> , 2012, 96, 261-271.	1.2	51
689	Brown Fat at PET/CT: Correlation with Patient Characteristics. <i>Radiology</i> , 2012, 263, 836-842.	3.6	59
690	Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3368-3375.	0.8	154
691	Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST. <i>American Journal of Roentgenology</i> , 2012, 198, 737-745.	1.0	169
692	Positron emission tomography oncology research in the UK. <i>Nuclear Medicine Communications</i> , 2012, 33, 341-348.	0.5	4
693	Interim fluoro-2-deoxy-D-glucose PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection. <i>Aids</i> , 2012, 26, 861-865.	1.0	18
694	Roles and Limitations of FDG PET in Pediatric Non-Hodgkin Lymphoma. <i>Clinical Nuclear Medicine</i> , 2012, 37, 656-662.	0.7	18
695	Non-Hodgkin's Lymphoma Involving the Ileocecal Region. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 509-514.	1.1	17
696	Comparison Between Endoscopic Macroscopic Classification and F-18 FDG PET Findings in Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Patients. <i>Clinical Nuclear Medicine</i> , 2012, 37, 152-157.	0.7	17
697	Histiocyte-rich Xanthomatous Pseudotumor Mimicking Relapse on Positron Emission Tomography Imaging in an Adolescent With Primary Mediastinal Diffuse Large B-cell Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 232-235.	0.3	11
698	Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: A single center experience. <i>Oncology Reports</i> , 2012, 28, 835-840.	1.2	16
699	Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. <i>Haematologica</i> , 2012, 97, 1523-1531.	1.7	116
700	Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. <i>Haematologica</i> , 2012, 97, 416-422.	1.7	61
701	Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. <i>Blood</i> , 2012, 120, 1581-1588.	0.6	256
702	Nonmyeloablative allogeneic transplantation with or without 90Yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. <i>Blood</i> , 2012, 119, 6373-6378.	0.6	97
703	Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 2644-2656.	0.6	389

#	ARTICLE	IF	CITATIONS
704	CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. <i>Blood</i> , 2012, 119, 3940-3950.	0.6	466
705	Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. <i>Blood</i> , 2012, 119, 4115-4122.	0.6	122
706	Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 4129-4132.	0.6	67
707	Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 6379-6381.	0.6	123
708	Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?. <i>Blood</i> , 2012, 120, 4256-4262.	0.6	128
709	Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. <i>Lancet</i> , The, 2012, 379, 1791-1799.	6.3	564
710	Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2012, 47, 1397-1402.	1.3	20
711	Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1469-1473.	0.6	21
712	HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era. <i>Journal of Clinical Oncology</i> , 2012, 30, 4111-4116.	0.8	145
713	Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2190-2196.	0.8	890
714	A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1299-1305.	0.6	12
715	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2183-2189.	0.8	1,332
716	Guidelines for the investigation and management of mantle cell lymphoma. <i>British Journal of Haematology</i> , 2012, 159, 405-426.	1.2	72
717	Impact of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High-Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. <i>Journal of Clinical Oncology</i> , 2012, 30, 4317-4322.	0.8	168
718	Imaging Follicular Lymphoma Using Positron Emission Tomography With [¹⁸ F]Fluorodeoxyglucose: To What Purpose?. <i>Journal of Clinical Oncology</i> , 2012, 30, 4285-4287.	0.8	10
719	Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography- Staged Treatment-Naive Patients With Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 4508-4514.	0.8	252
720	Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 643-659.	0.8	129
721	Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 2820-2822.	0.8	182

#	ARTICLE	IF	CITATIONS
722	Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. <i>Leukemia and Lymphoma</i> , 2012, 53, 2378-2382.	0.6	58
723	Hodgkin's lymphoma in adults. <i>Lancet, The</i> , 2012, 380, 836-847.	6.3	123
724	Non-Hodgkin lymphoma. <i>Lancet, The</i> , 2012, 380, 848-857.	6.3	522
725	Linfomas no Hodgkin: diagnóstico y tratamiento. <i>EMC - Tratado De Medicina</i> , 2012, 16, 1-6.	0.0	0
727	Radiation exposure and mortality risk from CT and PET imaging of patients with malignant lymphoma. <i>European Radiology</i> , 2012, 22, 1946-1954.	2.3	72
728	Combined Modality Treatment for PET-Positive Non-Hodgkin Lymphoma: Favorable Outcomes of Combined Modality Treatment for Patients With Non-Hodgkin Lymphoma and Positive Interim or Postchemotherapy FDG-PET. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e647-e654.	0.4	17
729	Utilidad de la PET-TC en la valoración de la respuesta precoz al tratamiento en el linfoma B difuso de celula grande. Resultados preliminares. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2012, 31, 135-141.	0.0	6
730	Unusual presentation of sarcoid-like reaction on bone marrow level associated with mediastinal lymphadenopathy on 18F-FDG-PET/CT resembling an early recurrence of Hodgkin's Lymphoma. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2012, 31, 207-209.	0.0	7
731	18F-FDG-PET/TC en linfoma: dos décadas de experiencia. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2012, 31, 340-349.	0.0	5
732	Usefulness of 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin's Lymphoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2012, 46, 269-277.	0.6	14
733	A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2012, 18, 248-255.	3.2	204
734	Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. <i>Blood</i> , 2012, 120, 1470-1472.	0.6	81
735	Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience. <i>Leukemia and Lymphoma</i> , 2012, 53, 862-867.	0.6	52
736	Review of Clinical Applications of Fluorodeoxyglucose-PET/Computed Tomography in Pediatric Patients with Lymphoma. <i>PET Clinics</i> , 2012, 7, 47-56.	1.5	5
738	Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2012, 31, 135-141.	0.1	4
739	The Evolving Role of Medical Imaging in Lymphoma Management: The Clinician's Perspective. <i>PET Clinics</i> , 2012, 7, 35-46.	1.5	1
740	Role of Positron Emission Tomography with Fludeoxyglucose F 18 in Personalization of Therapy in Patients with Lymphoma. <i>PET Clinics</i> , 2012, 7, 57-65.	1.5	2
741	Role of Structural Imaging in Lymphoma. <i>PET Clinics</i> , 2012, 7, 1-19.	1.5	4

#	ARTICLE	IF	CITATIONS
742	My Treatment Approach to Patients With Diffuse Large B-Cell Lymphoma. Mayo Clinic Proceedings, 2012, 87, 161-171.	1.4	58
743	Absolute lymphocyte count at day +21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone. Leukemia and Lymphoma, 2012, 53, 1757-1763.	0.6	10
744	Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. Leukemia and Lymphoma, 2012, 53, 801-806.	0.6	10
745	Role of [18F]-fluoro-2-deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leukemia and Lymphoma, 2012, 53, 64-70.	0.6	56
746	Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the ¹⁸ F-fluoro-2-deoxyglucose positron emission tomography era. Leukemia and Lymphoma, 2012, 53, 381-385.	0.6	41
747	Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leukemia and Lymphoma, 2012, 53, 43-49.	0.6	36
748	Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group. Leukemia and Lymphoma, 2012, 53, 1920-1928.	0.6	16
749	Double-hit Lymphomas Constitute a Highly Aggressive Subgroup in Diffuse Large B-cell Lymphomas in the Era of Rituximab. Japanese Journal of Clinical Oncology, 2012, 42, 1035-1042.	0.6	18
750	Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood, 2012, 119, 2066-2073.	0.6	217
751	Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy. Leukemia and Lymphoma, 2012, 53, 1945-1948.	0.6	12
752	The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leukemia and Lymphoma, 2012, 53, 575-580.	0.6	79
753	Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. Journal of Clinical Oncology, 2012, 30, 2776-2782.	0.8	162
754	Head and Neck Cancer Imaging. Medical Radiology, 2012, , .	0.0	17
755	Spleen in haematological malignancies: spectrum of imaging findings. British Journal of Radiology, 2012, 85, 81-92.	1.0	104
756	Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica, 2012, 97, 1073-1079.	1.7	108
757	Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2012, 23, vii78-vii82.	0.6	119
758	Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood, 2012, 119, 6145-6154.	0.6	107
759	SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood, 2012, 120, 2973-2980.	0.6	361

#	ARTICLE	IF	CITATIONS
760	Intérêt de la TEP dans le bilan d'extension et d'évaluation de la maladie résiduelle des lymphomes testiculaires: Étude rétrospective. <i>Medecine Nucleaire</i> , 2012, 36, 268-277.	0.2	0
761	High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 788-793.	2.0	102
762	Therapeutic strategies in elderly and very elderly patients. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 91-100.	0.7	6
763	Size and attenuation CT (SACT) of residual masses in patients with follicular Non-Hodgkin Lymphoma: More than a status quo?. <i>European Journal of Radiology</i> , 2012, 81, 1657-1661.	1.2	2
764	A comparative study: Diffusion weighted whole body imaging with background body signal suppression and hybrid Positron Emission Computed Tomography on detecting lesions in oncologic clinics. <i>European Journal of Radiology</i> , 2012, 81, 1662-1666.	1.2	12
765	Mucosa-associated lymphoid tissue lymphoma of the salivary glands: MR imaging findings including diffusion-weighted imaging. <i>European Journal of Radiology</i> , 2012, 81, e612-e617.	1.2	30
766	Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 205-216.	1.9	64
767	Novel therapeutic agents for cutaneous T-Cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2012, 5, 24.	6.9	47
768	Homozygous <i>FCGR3A</i> 158V alleles predispose to late onset neutropenia after <i>CHOP</i> for diffuse large <i>B</i> cell lymphoma. <i>Internal Medicine Journal</i> , 2012, 42, 1113-1119.	0.5	23
769	Residual Disease Assessment and Its Role in Monitoring Lymphoid and Plasma Cell Neoplasms. , 2012, , 83-95.		0
770	The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. <i>Bone Marrow Transplantation</i> , 2012, 47, 957-966.	1.3	68
771	PET for Measuring Therapy Response After Radionuclide Therapy. <i>Medical Radiology</i> , 2012, , 917-929.	0.0	0
772	Advances in oncologic imaging. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 364-393.	157.7	53
773	The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2012, 91, 1731-1739.	0.8	31
774	A Phase I Study of the Metal Ionophore Clioquinol in Patients With Advanced Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 330-336.	0.2	31
775	Considerations in the initial management of follicular lymphoma. <i>Community Oncology</i> , 2012, 9, S53-S60.	0.2	6
776	Integration of cell biology, pharmacological modeling and statistical analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 153-169.	2.0	1
777	Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. <i>European Journal of Cancer</i> , 2012, 48, 3319-3327.	1.3	115

#	ARTICLE	IF	CITATIONS
778	Copper levels in patients with hematological malignancies. <i>European Journal of Internal Medicine</i> , 2012, 23, 738-741.	1.0	47
779	PET-MRI in oncology. <i>Medecine Nucleaire</i> , 2012, 36, 459-461.	0.2	0
780	Comparaison de l'IRM de diffusion et de la TEP/TDM au FDG dans le bilan des lymphomes. <i>Medecine Nucleaire</i> , 2012, 36, 504-512.	0.2	0
781	Promise and pitfalls of quantitative imaging in oncology clinical trials. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1301-1312.	1.0	83
782	Early Interim PET Scans in Diffuse Large B-Cell Lymphoma: Can There Be Consensus About Standardized Reporting, and Can PET Scans Guide Therapy Choices?. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 193-199.	1.2	25
783	Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma. <i>Medical Oncology</i> , 2012, 29, 3535-3539.	1.2	7
784	Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma. <i>Annals of Nuclear Medicine</i> , 2012, 26, 616-621.	1.2	30
785	Unusual presentation of sarcoid-like reaction on bone marrow level associated with mediastinal lymphadenopathy on 18F-FDG-PET/CT resembling an early recurrence of Hodgkin's Lymphoma. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2012, 31, 207-209.	0.1	0
786	Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy. <i>Mayo Clinic Proceedings</i> , 2012, 87, 571-580.	1.4	56
787	18F-FDG-PET/CT in lymphoma: Two decades of experience. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2012, 31, 340-349.	0.1	6
788	CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy. <i>Annals of Hematology</i> , 2012, 91, 1897-1906.	0.8	18
789	Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation. <i>Annals of Hematology</i> , 2012, 91, 1907-1915.	0.8	6
790	A unique pattern of extranodal involvement in Korean adults with sporadic Burkitt lymphoma: a single center experience. <i>Annals of Hematology</i> , 2012, 91, 1917-1922.	0.8	21
791	Assessing Response to Therapy. , 2012, , 25-33.		0
792	Hematologic Malignancy. , 2012, , 531-553.		1
793	Role of [18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma. <i>Radiologia Medica</i> , 2012, 117, 1250-1263.	4.7	7
794	Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma. <i>Japanese Journal of Radiology</i> , 2012, 30, 642-647.	1.0	4
795	High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1677-1686.	2.0	43

#	ARTICLE	IF	CITATIONS
796	Bone Marrow Lymphoid Infiltrates. , 2012, , .		1
797	Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. The Cochrane Library, 2012, , CD009045.	1.5	5
798	Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma. Annals of Hematology, 2012, 91, 1393-1401.	0.8	31
800	Malignancy of unknown origin. , 0, , 445-465.		0
801	Methodological aspects of therapeutic response evaluation with FDG-PET. , 0, , 487-500.		0
802	FDG-PET in Follicular Lymphoma Management. Journal of Oncology, 2012, 2012, 1-8.	0.6	13
803	Yttrium-90 Labelled Anti-CD20 Radioimmunotherapy with Stem Cells Support. Medical Radiology, 2012, , 543-550.	0.0	0
804	Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation. The Korean Journal of Hematology, 2012, 47, 8.	0.7	8
805	Aggressive chemotherapy in frail patients with diffuse large B-cell lymphoma: The role of pegylated liposomal doxorubicin. Journal of Hematological Malignancies, 2012, 2, .	0.0	0
807	Treatment of Early Stage Hodgkin Lymphoma. , 2012, , .		0
808	Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. Experimental and Therapeutic Medicine, 2012, 3, 304-308.	0.8	5
809	Clinical significance of standardized uptake value and maximum tumor diameter in patients with primary extranodal diffuse large B cell lymphoma. The Korean Journal of Hematology, 2012, 47, 207.	0.7	11
810	Clinical characteristics and outcomes of primary bone lymphoma in Korea. The Korean Journal of Hematology, 2012, 47, 213.	0.7	12
811	Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer. Cancer Imaging, 2012, 12, 212-224.	1.2	9
812	Prognostic Assessment in Patients with Indolent B-Cell Lymphomas. Scientific World Journal, The, 2012, 2012, 1-5.	0.8	9
813	Guidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy. BMC Research Notes, 2012, 5, 10.	0.6	1
814	Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. Annals of Hematology, 2012, 91, 715-721.	0.8	20
815	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood, 2012, 119, 2709-2720.	0.6	1,296

#	ARTICLE	IF	CITATIONS
816	Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. <i>Annals of Hematology</i> , 2012, 91, 1579-1586.	0.8	27
817	Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. <i>Hematological Oncology</i> , 2012, 30, 194-199.	0.8	16
818	Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non-Hodgkin lymphoma. <i>Hematological Oncology</i> , 2012, 30, 214-215.	0.8	3
819	Cellular (FLICE) like inhibitory protein (cFLIP) expression in diffuse large B-cell lymphoma identifies a poor prognostic subset, but fails to predict the molecular subtype. <i>Hematological Oncology</i> , 2012, 30, 8-12.	0.8	5
820	Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma. <i>Tumor Biology</i> , 2012, 33, 1733-1738.	0.8	7
821	Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group. <i>American Journal of Hematology</i> , 2012, 87, 663-668.	2.0	134
822	Dexrazoxane does not affect treatment outcome in non-Hodgkin's lymphoma patients. <i>American Journal of Hematology</i> , 2012, 87, 830-832.	2.0	4
823	The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 937-940.	2.0	40
824	A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. <i>Cancer</i> , 2012, 118, 3128-3134.	2.0	95
825	A phase I dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. <i>Cancer</i> , 2012, 118, 3538-3548.	2.0	19
826	Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-CHyperCVAD. <i>Cancer</i> , 2012, 118, 3565-3570.	2.0	42
827	A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. <i>Cancer</i> , 2012, 118, 4706-4714.	2.0	98
828	Human immunodeficiency virus-associated plasmablastic lymphoma. <i>Cancer</i> , 2012, 118, 5270-5277.	2.0	147
829	The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Nature Biotechnology</i> , 2012, 30, 631-637.	9.4	637
831	FDG PET/CT predictive role in follicular lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 864-871.	3.3	32
832	Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2012, 91, 687-695.	0.8	85
833	Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. <i>Annals of Hematology</i> , 2012, 91, 697-703.	0.8	130
834	Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1165-1172.	1.1	17

#	ARTICLE	IF	CITATIONS
835	Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy. <i>British Journal of Haematology</i> , 2012, 156, 142-143.	1.2	9
836	Burkitt lymphoma: staging and response evaluation. <i>British Journal of Haematology</i> , 2012, 156, 761-765.	1.2	30
837	Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. <i>Experimental Hematology</i> , 2012, 40, 359-366.	0.2	8
838	A real-time (PCR) for a real life? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice. <i>Experimental Hematology</i> , 2012, 40, 528-539.e4.	0.2	3
839	Mantle cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 78-101.	2.0	75
841	Clinical features and prognostic model for extranasal NK/T-cell lymphoma. <i>European Journal of Haematology</i> , 2012, 89, 103-110.	1.1	53
842	Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. <i>Leukemia Research</i> , 2012, 36, 709-714.	0.4	9
843	Prognostic value of metabolic tumor volume on PET-CT in primary gastrointestinal diffuse large B cell lymphoma. <i>Cancer Science</i> , 2012, 103, 477-482.	1.7	55
844	The use of tumour volumetrics to assess response to therapy in anticancer clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 846-854.	1.1	37
845	Management of children with high-risk Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2012, 157, 3-13.	1.2	26
846	Incidence, risk factors and outcome of histological transformation in follicular lymphoma. <i>British Journal of Haematology</i> , 2012, 157, 188-196.	1.2	89
847	Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2012, 157, 321-330.	1.2	60
848	Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL. <i>British Journal of Haematology</i> , 2012, 157, 543-552.	1.2	12
849	Phase II study of sorafenib in patients with relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2012, 158, 108-119.	1.2	36
850	Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem cell support: still very long survival but late relapses do occur. <i>British Journal of Haematology</i> , 2012, 158, 355-362.	1.2	241
851	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. <i>Journal of Translational Medicine</i> , 2012, 10, 18.	1.8	21
852	A 10-year experience with treatment of high and standard risk Hodgkin disease: Six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved. <i>American Journal of Hematology</i> , 2012, 87, 32-36.	2.0	31
853	The potential role of pre-transplant HBcIgG seropositivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: A study from the Rome Transplant Network. <i>American Journal of Hematology</i> , 2012, 87, 213-217.	2.0	14

#	ARTICLE	IF	CITATIONS
854	Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 258-265.	2.0	30
855	Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 479-483.	2.0	16
856	Clinical Study of Autologous Cytokine-Induced Killer Cells for the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Cell Biochemistry and Biophysics</i> , 2012, 62, 257-265.	0.9	32
857	Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 4-12.	3.3	119
858	Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2012, 91, 375-382.	0.8	23
859	High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. <i>Hematological Oncology</i> , 2013, 31, 34-40.	0.8	20
860	Diffuse large B-cell lymphoma of the ocular adnexal region: A nation-based study. <i>Acta Ophthalmologica</i> , 2013, 91, 163-169.	0.6	29
861	Cellular immunotherapy for refractory hematological malignancies. <i>Journal of Translational Medicine</i> , 2013, 11, 150.	1.8	28
862	Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results. <i>Radiation Oncology</i> , 2013, 8, 152.	1.2	27
863	Assessing the Effectiveness of a Grand Rounds CME Activity for Health-Care Professionals. <i>Journal of Cancer Education</i> , 2013, 28, 591-596.	0.6	1
864	Potential Clinical Applications of PET/Magnetic Resonance Imaging. <i>PET Clinics</i> , 2013, 8, 367-384.	1.5	3
865	Available evidence and outcome of off-label use of rituximab in clinical practice. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1689-1699.	0.8	16
866	PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. <i>Pediatric Radiology</i> , 2013, 43, 860-875.	1.1	136
867	PET/Computed Tomography and Lymphoma. <i>Radiologic Clinics of North America</i> , 2013, 51, 833-844.	0.9	8
868	A Radiologist's Guide to Treatment Response Criteria in Oncologic Imaging: Functional, Molecular, and Disease-Specific Imaging Biomarkers. <i>American Journal of Roentgenology</i> , 2013, 201, 246-256.	1.0	17
869	Bendamustine salvage therapy for T cell neoplasms. <i>Annals of Hematology</i> , 2013, 92, 1249-1254.	0.8	30
870	Adults with Palpable Neck Mass: Evidence-Based Neuroimaging. , 2013, , 641-677.		2
871	Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma. <i>BMC Cancer</i> , 2013, 13, 222.	1.1	40

#	ARTICLE	IF	CITATIONS
872	A Multicenter, Open-Label, Noncomparative Screening Study of Enzastaurin in Adult Patients With Non-Hodgkin Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 398-403.	0.2	2
873	Non-Hodgkin Lymphoma. , 2013, , .		1
874	T-Cell Lymphomas. , 2013, , .		1
875	Burkittâ€™s Lymphoma. , 2013, , .		2
876	Increased Expression of the Spindle Checkpoint Protein BubR1 is Associated with High Cell Proliferation in Primary Gastrointestinal Diffuse Large B Cell Lymphoma. <i>Cell Biochemistry and Biophysics</i> , 2013, 66, 747-752.	0.9	5
877	Prognostic value of Waldeyerâ€™s ring involvement of diffuse large B-cell lymphoma treated with R-CHOP. <i>International Journal of Hematology</i> , 2013, 97, 397-402.	0.7	10
878	The role of maintenance strategies in lymphoma and CLL. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 102-108.	0.3	0
879	A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type. <i>Journal of Hematology and Oncology</i> , 2013, 6, 44.	6.9	65
880	Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1321-1329.	3.3	68
881	Imaging characteristics of cardiac dominant diffuse large B-cell lymphoma demonstrated with MDCT and PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1337-1344.	3.3	40
882	An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ¹⁸ F-SUVmax. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1312-1320.	3.3	235
883	The impact of coaxial core biopsy guided by FDG PET/CT in oncological patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 98-103.	3.3	59
884	Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era. <i>Annals of Hematology</i> , 2013, 92, 1513-1520.	0.8	16
885	Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. <i>Annals of Hematology</i> , 2013, 92, 1503-1511.	0.8	19
886	Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era. <i>Annals of Hematology</i> , 2013, 92, 1495-1501.	0.8	5
887	Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. <i>Annals of Hematology</i> , 2013, 92, 1529-1536.	0.8	68
888	The role of 18F-fluorodeoxyglucose positron emission tomography at response assessment after autologous stem cell transplantation in T-cell non-Hodgkinâ€™s lymphoma patients. <i>Annals of Hematology</i> , 2013, 92, 1369-1377.	0.8	9
889	DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. <i>Annals of Hematology</i> , 2013, 92, 1041-1048.	0.8	15

#	ARTICLE	IF	CITATIONS
890	Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2013, 92, 239-244.	0.8	30
891	Using a cut-off SUV level to define bone marrow lesions on FDG PET is not appropriate. <i>Annals of Hematology</i> , 2013, 92, 283-284.	0.8	6
892	Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 241-249.	1.1	13
893	PET/CT in Oncology: Current Status and Perspectives. <i>Current Radiology Reports</i> , 2013, 1, 177-190.	0.4	77
895	Whole-body PET/MRI in oncology: current status and clinical applications. <i>Clinical and Translational Imaging</i> , 2013, 1, 31-44.	1.1	41
896	A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1921-1927.	0.6	2
897	A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas. <i>Investigational New Drugs</i> , 2013, 31, 1514-1521.	1.2	9
898	Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. <i>Cancer</i> , 2013, 119, 1195-1202.	2.0	136
899	Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. <i>Leukemia</i> , 2013, 27, 1902-1909.	3.3	197
900	Long term results of a phase 2 study of vincristine sulfate liposome injection (^Marqibo[®]) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2013, 162, 631-638.	1.2	30
902	Bilan d'extension et suivi dans le traitement des lymphomes. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 150-163.	0.0	0
903	Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 746-753.	2.0	83
904	Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria. <i>Radiographics</i> , 2013, 33, 1323-1341.	1.4	251
905	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 507-516.	13.9	1,449
906	Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 611-620.	1.2	23
907	Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 311-316.	0.4	35
908	Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: An investigation of clinical and histopathological features. <i>Acta Ophthalmologica</i> , 2013, 91, 1-27.	0.6	37
909	An Update on Criteria for Assessing Tumor Response to Treatment. <i>Current Problems in Diagnostic Radiology</i> , 2013, 42, 209-219.	0.6	1

#	ARTICLE	IF	CITATIONS
910	Application of PET and PET-CT in Peritoneal Imaging. , 2013, , 1541-1562.		2
911	Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4199-4206.	0.8	433
912	Open questions in the management of mantle cell lymphoma. <i>Cancer Treatment Reviews</i> , 2013, 39, 602-609.	3.4	9
913	Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. <i>Lancet Oncology</i> , The, 2013, 14, 1348-1356.	5.1	251
914	Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. <i>Lancet Oncology</i> , The, 2013, 14, e548-e561.	5.1	21
915	Vinorelbine, Paclitaxel, Etoposide, Cisplatin, and Cytarabine (VTEPA) Is an Effective Second Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 657-663.	0.2	12
916	Update on Pediatric Leukemia and Lymphoma Imaging. <i>Seminars in Ultrasound, CT and MRI</i> , 2013, 34, 578-599.	0.7	21
917	PET/CT in malignant lymphoma: basic information, clinical application, and proposal. <i>International Journal of Hematology</i> , 2013, 98, 398-405.	0.7	11
918	Evaluation of imaging findings differentiating extranodal non-Hodgkin's lymphoma from squamous cell carcinoma in naso- and oropharynx. <i>Clinical Imaging</i> , 2013, 37, 657-663.	0.8	27
919	Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 471-478.	0.4	18
920	Anthracycline-containing regimens for treatment of follicular lymphoma in adults. <i>The Cochrane Library</i> , 2013, , CD008909.	1.5	4
921	Comparison of Outcomes after Two Standards-of-Care Reduced-Intensity Conditioning Regimens and Two Different Graft Sources for Allogeneic Stem Cell Transplantation in Adults with Hematologic Diseases: A Single-Center Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 934-939.	2.0	22
922	Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 410-417.	2.0	61
923	Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group. <i>International Journal of Hematology</i> , 2013, 98, 463-471.	0.7	4
924	Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement. <i>Journal of Hematology and Oncology</i> , 2013, 6, 76.	6.9	18
925	Development of IgG4-related disease 10 years after chemotherapy for diffuse large B cell lymphoma and longstanding bronchial asthma. <i>International Journal of Hematology</i> , 2013, 98, 122-128.	0.7	15
926	Lymphomes non hodgkiniens primitifs du cavum : À propos de 32 cas pris en charge À l'Institut national d'oncologie (Rabat, Maroc) entre 1997 et 2009. <i>Journal Africain Du Cancer</i> , 2013, 5, 51-56.	0.1	0
927	18F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 249-256.	0.6	10

#	ARTICLE	IF	CITATIONS
928	Diagnosing celiac disease in patients with a history of lymphoma: factors that matter. <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 696-703.	1.0	0
929	Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 714-719.	0.6	16
930	Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 1183-1187.	0.6	41
931	Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 62-68.	0.6	14
932	Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2627-2630.	0.6	5
933	High dose cytarabine with rituximab is an effective first-line therapy for mantle cell lymphoma and produces ample stem cell harvest yields after multiple chemotherapy cycles. <i>Leukemia and Lymphoma</i> , 2013, 54, 2303-2305.	0.6	3
934	Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2013, 91, 122-128.	1.1	28
935	A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. <i>Cancer</i> , 2013, 119, 1683-1689.	2.0	8
936	Phase I Study of a Modified Regimen of 90Yttrium- ⁹⁰ Yttrium-ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 370-379.	0.7	2
937	The risk of CNS involvement in aggressive lymphomas in the rituximab era. <i>Expert Review of Hematology</i> , 2013, 6, 643-652.	1.0	1
938	International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers. <i>Journal of Nuclear Medicine</i> , 2013, 54, 683-690.	2.8	267
939	Response assessment in lymphoma: time to lower the bar?. <i>Leukemia and Lymphoma</i> , 2013, 54, 673-674.	0.6	1
940	Combination of albumin-bound paclitaxel and pegylated liposomal doxorubicin is effective in treatment of heavily treated relapsed/refractory diffuse large B-cell lymphoma: a case report. <i>Leukemia and Lymphoma</i> , 2013, 54, 2553-2555.	0.6	3
941	Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202). <i>Journal of Clinical Oncology</i> , 2013, 31, 3061-3068.	0.8	408
942	Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2013, 121, 840-848.	0.6	28
943	Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus ¹³¹ Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016. <i>Journal of Clinical Oncology</i> , 2013, 31, 314-320.	0.8	152
944	Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 565-572.	0.8	198
945	Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2645-2653.	0.6	12

#	ARTICLE	IF	CITATIONS
946	Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. <i>Leukemia and Lymphoma</i> , 2013, 54, 1915-1920.	0.6	12
947	Are We Ready for Positron Emission Tomography/Computed Tomography-based Target Volume Definition in Lymphoma Radiation Therapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 14-20.	0.4	14
948	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	0.6	193
949	Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 456-460.	0.8	175
950	<scp>SIE</scp>, <scp>SIES</scp>, <scp>GITMO</scp> revised guidelines for the management of follicular lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 185-192.	2.0	32
951	Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 277-283.	0.6	43
952	Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. <i>Cell</i> , 2013, 152, 714-726.	13.5	1,202
953	Hodgkin lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 216-237.	2.0	93
954	Brentuximab Vedotin: A <scp>CD</scp>30â€Directed Antibodyâ€Cytotoxic Drug Conjugate. <i>Pharmacotherapy</i> , 2013, 33, 93-104.	1.2	51
955	Diffuse large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 146-171.	2.0	323
956	Staging and monitoring in the treatment of lymphomas. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 145-157.	1.8	10
957	Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkinâ€™s lymphoma. <i>Radiotherapy and Oncology</i> , 2013, 109, 133-139.	0.3	22
958	Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1368-1373.	2.0	29
959	Stage IE/IIIE extranodal NK/T-cell lymphoma arising in the nasal cavity: Analysis of CT findings and their prognostic value. <i>Clinical Radiology</i> , 2013, 68, e384-e390.	0.5	12
960	Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 82-86.	2.0	6
962	Quantitative and qualitative evaluation of the interim PET/CT in lymphoma treatment in the prediction of complete metabolic response. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2013, 32, 70-76.	0.1	1
963	FDG-PET in the evaluation of myeloma in 2012. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 184-189.	1.8	7
964	Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2606-2612.	0.6	14

#	ARTICLE	IF	CITATIONS
965	Patterns of Failure in Advanced Stage Diffuse Large B-Cell Lymphoma Patients After Complete Response to R-CHOP Immunochemotherapy and the Emerging Role of Consolidative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 569-577.	0.4	76
966	Non-Hodgkin Lymphomas Presenting as Soft Tissue Masses: A Single Center Experience and Meta-Analysis of the Published Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 258-265.	0.2	21
967	Specific Features Identify Patients with Relapsed or Refractory Mantle Cell Lymphoma Benefitting from Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1403-1406.	2.0	25
968	A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: Clinical significance of treatment intensity and comprehensive geriatric assessment. <i>Journal of Geriatric Oncology</i> , 2013, 4, 242-248.	0.5	32
969	Phase I Trial of the HSP90 Inhibitor PF-04929113 (SNX5422) in Adult Patients With Recurrent, Refractory Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 385-391.	0.2	35
970	Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1087-1093.	2.0	12
971	Clinical Significance of Serum-Soluble Interleukin-2 Receptor in Patients With Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 410-416.	0.2	22
973	La TEP au FDG dans l'évaluation du myélome en 2012. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 190-195.	0.0	0
974	Treatment for patients with indolent and mantle cell lymphoma. <i>Lancet, The</i> , 2013, 382, 1093-1094.	6.3	0
976	Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma. <i>Medical Oncology</i> , 2013, 30, 339.	1.2	18
977	Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma. <i>Medical Oncology</i> , 2013, 30, 350.	1.2	10
978	Brentuximab Vedotin. <i>Clinical Cancer Research</i> , 2013, 19, 22-27.	3.2	134
979	Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. <i>British Journal of Haematology</i> , 2013, 160, 47-52.	1.2	79
980	Two-weekly dose-adjusted (DA) EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EPOCH14R) in poor-prognostic untreated diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 160, 510-514.	1.2	12
981	Brentuximab Vedotin Combined With Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma After Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission. <i>Journal of Clinical Oncology</i> , 2013, 31, e59-e63.	0.8	62
982	Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2144-2148.	0.6	31
983	Diagnosis and Treatment of Non-Hodgkin's Lymphoma of Adults. , 2013, , 1027-1047.		0
984	Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 368, 1408-1416.	13.9	485

#	ARTICLE	IF	CITATIONS
985	Therapeutic Approaches to Burkitt's Lymphoma. , 2013, , 251-268.		1
986	R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma. British Journal of Haematology, 2013, 161, 383-388.	1.2	23
987	FDG PET and PET/CT. Recent Results in Cancer Research, 2013, 187, 351-369.	1.8	52
988	The Role of Imaging in Nuclear Medicine: The Medical Perspective. , 2013, , 7-18.		0
989	Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leukemia and Lymphoma, 2013, 54, 2399-2404.	0.6	25
990	Ocular Adnexal Lymphoma Staging and Treatment: American Joint Committee on Cancer versus Ann Arbor. European Journal of Ophthalmology, 2013, 23, 344-355.	0.7	68
991	The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leukemia and Lymphoma, 2013, 54, 1405-1410.	0.6	27
992	Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials. European Journal of Cancer, 2013, 49, 769-781.	1.3	49
993	The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free Survival. Clinical Cancer Research, 2013, 19, 2621-2628.	3.2	20
994	Pharmacogenetic analysis in the treatment of Hodgkin lymphoma. Leukemia and Lymphoma, 2013, 54, 1706-1712.	0.6	5
995	High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma, 2013, 54, 2620-2626.	0.6	5
996	Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease' added value of low-dose CT. Pediatric Radiology, 2013, 43, 86-92.	1.1	19
997	Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2013, 54, 2122-2130.	0.6	16
998	Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2013, 369, 32-42.	13.9	2,019
999	The role of hematopoietic SCT in adult Burkitt lymphoma. Bone Marrow Transplantation, 2013, 48, 617-629.	1.3	5
1000	End-Therapy Positron Emission Tomography for Treatment Response Assessment in Follicular Lymphoma: A Systematic Review and Meta-analysis. Clinical Cancer Research, 2013, 19, 6566-6577.	3.2	21
1001	R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLLO5 Trial Conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology, 2013, 31, 1506-1513.	0.8	223
1002	A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies. Investigational New Drugs, 2013, 31, 355-362.	1.2	26

#	ARTICLE	IF	CITATIONS
1003	Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1026-1031.	2.8	75
1004	Upfront Autologous Stem Cell Transplantation for Untreated High-Risk Diffuse Large B-Cell Lymphoma in Patients Up to 60 Years of Age. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 404-409.	0.2	7
1005	Rituximab Maintenance Therapy Until Progression After Rituximab and Chemotherapy Induction in Patients With Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 253-257.	0.2	8
1006	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , 2013, 98, 255-263.	1.7	142
1007	Quantification of Dose Nonuniformities by Voxel-Based Dosimetry in Patients Receiving 90Y-Ibritumomab-Tiuxetan. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 98-107.	0.7	7
1008	MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Haematologica</i> , 2013, 98, 1554-1562.	1.7	196
1009	Mantle Cell Lymphoma. , 2013, , 157-175.		0
1010	Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2013, 31, 88-94.	0.8	991
1011	MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. <i>Modern Pathology</i> , 2013, 26, 171-181.	2.9	19
1012	Rituximab in the treatment of diffuse large B-cell lymphoma primary of the lung. <i>Hematology</i> , 2013, 18, 81-84.	0.7	8
1013	Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab: a single-center experience. <i>Hematology</i> , 2013, 18, 74-80.	0.7	4
1015	The incidence of secondary central nervous system involvement in patients with non-Hodgkin's lymphoma as detected by 18F-FDG PET/CT. <i>Nuclear Medicine Communications</i> , 2013, 34, 50-56.	0.5	13
1016	Long-term outcome of primary endocrine non-Hodgkin lymphomas: does the site make the difference?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 623-630.	0.2	5
1017	Correlation Between Standardized Uptake Value and Apparent Diffusion Coefficient of Neoplastic Lesions Evaluated With Whole-Body Simultaneous Hybrid PET/MRI. <i>American Journal of Roentgenology</i> , 2013, 201, 1115-1119.	1.0	65
1018	The use of interim 18F-fluorodeoxyglucose PET to guide therapy in lymphoma. <i>Future Oncology</i> , 2013, 9, 807-815.	1.1	3
1019	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013, 98, 1232-1236.	1.7	65
1020	CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. <i>Haematologica</i> , 2013, 98, 1250-1258.	1.7	56
1021	Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. <i>Annals of Oncology</i> , 2013, 24, 1385-1392.	0.6	99

#	ARTICLE	IF	CITATIONS
1024	Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 483-490.	0.6	13
1025	Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. <i>Leukemia and Lymphoma</i> , 2013, 54, 497-502.	0.6	16
1026	¹⁸ F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2163-2167.	0.6	60
1027	Evaluating the place of 18-fluoro-2-deoxy-d-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2093-2095.	0.6	3
1028	Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2013, 48, 1212-1217.	1.3	28
1029	Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response. <i>Bone Marrow Transplantation</i> , 2013, 48, 1484-1485.	1.3	9
1030	Para-Aortic Lymphoma Simulating Mycotic Abdominal Aortic Aneurysm. <i>Circulation</i> , 2013, 128, 674-675.	1.6	10
1031	FDG-PET/CT in lymphoma. <i>Indian Journal of Radiology and Imaging</i> , 2013, 23, 354.	0.3	36
1032	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2013, 24, 2108-2112.	0.6	124
1033	First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 5494-5504.	3.2	43
1034	Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose ⁹⁰ Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. <i>Journal of Clinical Oncology</i> , 2013, 31, 2974-2976.	0.8	14
1035	Interim 18F-FDG PET in Hodgkin Lymphoma: Would PET-Adapted Clinical Trials Lead to a Paradigm Shift?. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1082-1093.	2.8	45
1036	Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogeneously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment. <i>Nuclear Medicine Communications</i> , 2013, 34, 946-952.	0.5	27
1037	Bendamustine as Monotherapy and in Combination Regimens for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma: A Retrospective Analysis. <i>Chemotherapy</i> , 2013, 59, 280-289.	0.8	4
1038	The metabolism of lymphomas. <i>Current Opinion in Hematology</i> , 2013, 20, 345-354.	1.2	19
1039	An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. <i>Annals of Oncology</i> , 2013, 24, 3065-3069.	0.6	43
1040	Reporting Guidance for Oncologic ¹⁸ F-FDG PET/CT Imaging. <i>Journal of Nuclear Medicine</i> , 2013, 54, 756-761.	2.8	32
1041	Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 5.	0.8	64

#	ARTICLE	IF	CITATIONS
1042	Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus-Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Clinical Infectious Diseases</i> , 2013, 57, 794-802.	2.9	196
1043	Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. <i>Journal of Clinical Pathology</i> , 2013, 66, 956-961.	1.0	24
1044	Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 2607-2612.	3.2	63
1045	Comparison of the efficacy and safety of Rituximab (Mabthera,®) and its biosimilar (Reditux,®) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2013, 34, 292.	0.1	41
1046	Prognostic Significance of Pretreatment 18F-FDG PET/CT in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Treated by Radioimmunotherapy Using 131I-Rituximab. <i>Acta Haematologica</i> , 2013, 130, 74-82.	0.7	13
1047	Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1442-1449.	0.8	167
1048	Successive B-Cell Lymphomas Mostly Reflect Recurrences Rather Than Unrelated Primary Lymphomas. <i>American Journal of Clinical Pathology</i> , 2013, 140, 114-126.	0.4	14
1049	Prognostic Value of Interim and Posttherapy ¹⁸ F-FDG PET/CT in Patients with Mature T-Cell and Natural Killer Cell Lymphomas. <i>Journal of Nuclear Medicine</i> , 2013, 54, 507-515.	2.8	35
1050	In Newly Diagnosed Diffuse Large B-Cell Lymphoma, Determination of Bone Marrow Involvement with ¹⁸ F-FDG PET/CT Provides Better Diagnostic Performance and Prognostic Stratification Than Does Biopsy. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1244-1250.	2.8	156
1051	Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse. <i>Haematologica</i> , 2013, 98, 620-625.	1.7	12
1052	Prognostic Role of Serum Lactate Dehydrogenase Beyond Initial Diagnosis: A Retrospective Analysis of Patients with Diffuse Large B Cell Lymphoma. <i>Acta Haematologica</i> , 2013, 130, 305-311.	0.7	22
1053	Peripheral T-cell lymphoma in HIV-infected patients: a study of 17 cases in the combination antiretroviral therapy era. <i>British Journal of Haematology</i> , 2013, 161, 843-851.	1.2	9
1054	Prognostic impact of monocyte count at presentation in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2013, 162, 465-473.	1.2	46
1055	Fluoro-deoxy-glucose positron emission tomography/computed tomography in lymphoma: A pictorial essay. <i>Indian Journal of Nuclear Medicine</i> , 2013, 28, 85.	0.1	1
1056	State-of-the-Art Research on Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response. <i>Frontiers in Oncology</i> , 2013, 3, 212.	1.3	31
1057	Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 162, 138-141.	1.2	37
1058	Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation. <i>Bone Marrow Research</i> , 2013, 2013, 1-8.	1.7	18
1059	Brentuximab vedotin: An anti-CD30 antibody-drug conjugate. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 589-597.	0.5	33

#	ARTICLE	IF	CITATIONS
1060	Fludarabineâ€mitoxantroneâ€rituximab regimen in untreated intermediate/highâ€risk follicular nonâ€Hodgkin's lymphoma: Experience on 142 patients. American Journal of Hematology, 2013, 88, E273-6.	2.0	9
1061	Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica, 2013, 98, 615-619.	1.7	58
1062	A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. British Journal of Haematology, 2013, 163, 334-342.	1.2	40
1063	Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. American Journal of Hematology, 2013, 88, 890-894.	2.0	108
1064	Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy. Hematological Oncology, 2013, 31, 151-155.	0.8	10
1065	A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer, 2013, 119, 3797-3804.	2.0	47
1066	Absolute monocyte count at diagnosis and survival in mantle cell lymphoma. British Journal of Haematology, 2013, 163, 545-547.	1.2	14
1067	Advanced MR techniques in multicenter clinical trials. Journal of Magnetic Resonance Imaging, 2013, 37, 761-769.	1.9	12
1068	Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2013, 31, 2103-2109.	0.8	149
1069	Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving Râ€CHOP. Cancer Science, 2013, 104, 1245-1251.	1.7	12
1070	Strikingly high false positivity of surveillance FDGâ€PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. American Journal of Hematology, 2013, 88, 400-405.	2.0	78
1071	Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantroneâ€containing regimens. Hematological Oncology, 2013, 31, 183-188.	0.8	27
1072	Comparison of different MRI sequences in lesion detection and early response evaluation of diffuse large B-cell lymphoma â€ a wholeâ€body MRI and diffusionâ€weighted imaging study. NMR in Biomedicine, 2013, 26, 1186-1194.	1.6	24
1073	Cytarabine, Kiâ€67, and SOX11 in patients with mantle cell lymphoma receiving rituximabâ€containing autologous stem cell transplantation during first remission. Cancer, 2013, 119, 3318-3325.	2.0	5
1074	Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood, 2013, 122, 2104-2113.	0.6	52
1075	A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOPâ€Rituximab versus CHOP + 131Iodineâ€Tositumomab. Clinical Cancer Research, 2013, 19, 6624-6632.	3.2	32
1076	Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies. Leukemia, 2013, 27, 1920-1923.	3.3	18
1077	Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma. Blood Cancer Journal, 2013, 3, e110-e110.	2.8	23

#	ARTICLE	IF	CITATIONS
1078	A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. <i>British Journal of Cancer</i> , 2013, 109, 2560-2565.	2.9	8
1079	Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2631-2638.	0.6	38
1080	Pralatrexate: evaluation of clinical efficacy and toxicity in T-cell lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 515-523.	0.9	10
1081	Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6882-6890.	3.2	103
1082	Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 592-598.	0.8	94
1083	Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1662-1668.	0.8	161
1084	Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 731-742.	3.2	91
1085	Low-Intensity Therapy in Adults with Burkitt's Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 1915-1925.	13.9	307
1086	Measuring tumour response: RECIST 1.1 and beyond. <i>Imaging</i> , 2013, 22, 20110083.	0.0	1
1087	Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. <i>Blood</i> , 2013, 122, 499-506.	0.6	60
1088	CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. <i>Blood</i> , 2013, 121, 4740-4748.	0.6	175
1089	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). <i>Blood</i> , 2013, 122, 1137-1143.	0.6	120
1090	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013, 122, 1448-1454.	0.6	23
1091	Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2013, 122, 4129-4139.	0.6	537
1092	Abnormal F-18 Fluorodeoxyglucose Uptake of the Lung in Immunocompromised Lymphoma Patients in Complete Remission: Report of Two Cases and Revision of Literature. <i>European Journal of Inflammation</i> , 2013, 11, 893-899.	0.2	2
1093	Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. <i>Haematologica</i> , 2013, 98, 611-614.	1.7	88
1094	PET scan integration in lymphoma management. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 121-135.	0.7	0
1095	MR perfusion imaging in oncology: applications outside the brain. , 0, , 238-254.		0

#	ARTICLE	IF	CITATIONS
1096	Potential of compressed sensing in quantitative MR imaging of cancer. <i>Cancer Imaging</i> , 2013, 13, 633-644.	1.2	16
1097	Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. <i>OncoTargets and Therapy</i> , 2013, 7, 45.	1.0	15
1098	The Metabolic Signature of Tumors as an Imaging Biomarker in Staging, Restaging and Therapy Response on FDG PET. <i>OMICS Journal of Radiology</i> , 2013, 02, .	0.0	0
1099	Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study. <i>Cancer Imaging</i> , 2013, 13, 53-62.	1.2	36
1100	Management of mantle cell lymphoma in the elderly patient. <i>Clinical Interventions in Aging</i> , 2013, 8, 1229.	1.3	11
1101	Analysis of Immunoglobulin and T Cell Receptor Gene Rearrangement in the Bone Marrow of Lymphoid Neoplasia Using BIOMED-2 Multiplex Polymerase Chain Reaction. <i>International Journal of Medical Sciences</i> , 2013, 10, 1510-1517.	1.1	12
1102	CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma. <i>Blood Research</i> , 2013, 48, 121.	0.5	8
1103	Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type. <i>Blood Research</i> , 2013, 48, 274.	0.5	26
1104	Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis. <i>Current Biomarker Findings</i> , 0, , 17.	0.4	1
1105	Predicting tumour response. <i>Cancer Imaging</i> , 2013, 13, 381-390.	1.2	7
1106	Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy. <i>Plasmatology</i> , 2013, 6, CMBD.S12713.	4.0	0
1107	Case presentation: Nodular sclerosis classical Hodgkin lymphoma bearing Epstein-Barr virus that developed in an older man. <i>Tenri Medical Bulletin</i> , 2013, 16, 119-125.	0.1	0
1108	Positron emission tomography/CT in the management of lymphoma. <i>Imaging</i> , 2013, 22, 20110086.	0.0	2
1109	Matrix Metalloproteinase-9 Expression by Hodgkin-Reed-Sternberg Cells Is Associated with Reduced Overall Survival in Young Adult Patients with Classical Hodgkin Lymphoma. <i>PLoS ONE</i> , 2013, 8, e74793.	1.1	6
1110	Acute Kidney Injury in Patients with Newly Diagnosed High-Grade Hematological Malignancies: Impact on Remission and Survival. <i>PLoS ONE</i> , 2013, 8, e55870.	1.1	108
1111	Imaging of musculoskeletal lymphoma. <i>Cancer Imaging</i> , 2013, 13, 448-457.	1.2	71
1112	NÃ©oplasies lymphoÃ©des etÃ©myÃ©loÃ©des. , 2013, , 649-683.		1
1113	Prognostic factors for lymphomas. , 0, , 11-31.		0

#	ARTICLE	IF	CITATIONS
1114	Clinical trials in lymphoma. , 0, , 45-60.		0
1115	PET â€“ Assessment of Oncologic Treatment Response. , 0, , .		0
1116	The Effect of Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) Chemotherapy in Patients with Ocular Adnexal Extranodal Marginal Zone B Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Journal of Korean Ophthalmological Society, 2013, 54, 1157.	0.0	2
1117	Clinicopathologic Characterization of Diffuse-Large-B-Cell Lymphoma with an Associated Serum Monoclonal IgM Component. PLoS ONE, 2014, 9, e93903.	1.1	37
1119	Dynamic Metabolic Changes during the First 3 Months after⁹⁰Y-Ibritumomab Tiuxetan Radioimmunotherapy. Scientific World Journal, The, 2014, 2014, 1-6.	0.8	2
1120	Profile of pacritinib and its potential in the treatment of hematologic disorders. Journal of Blood Medicine, 2014, 5, 143.	0.7	21
1121	Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia. OncoTargets and Therapy, 2014, 7, 1717.	1.0	12
1122	Efficacy of â€“pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma. Neoplasma, 2014, 61, 225-232.	0.7	21
1123	R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma. Blood Research, 2014, 49, 107.	0.5	10
1124	Unilateral lower extremity swelling as a rare presentation of non-Hodgkin's lymphoma. BMJ Case Reports, 2014, 2014, bcr2013202424-bcr2013202424.	0.2	6
1125	Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience. Blood Research, 2014, 49, 170.	0.5	14
1126	Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. Blood Research, 2014, 49, 15.	0.5	16
1127	Primary mediastinal large B-cell lymphoma: a single-center experience in Korea. Blood Research, 2014, 49, 36.	0.5	3
1128	Large B cells lymphoma. Hematologie, 2014, 20, 183-188.	0.0	0
1129	Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection. Blood Research, 2014, 49, 115.	0.5	3
1130	Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget, 2014, 5, 7368-7380.	0.8	7
1131	High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. Leukemia and Lymphoma, 2014, 55, 2319-2327.	0.6	9
1132	Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma. Acta OncolÃ³gica, 2014, 53, 1093-1099.	0.8	10

#	ARTICLE	IF	CITATIONS
1133	Lymphoma: Management Using PET/CT. , 2014, , 257-260.		0
1134	Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1563-1569.	0.6	7
1135	Hematologic findings predictive of bone marrow disease in dogs with multicentric large B-cell lymphoma. <i>Veterinary Clinical Pathology</i> , 2014, 43, 505-512.	0.3	11
1136	Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. <i>Leukemia and Lymphoma</i> , 2014, 55, 802-810.	0.6	28
1137	The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy. <i>Cancer Imaging</i> , 2014, 14, 34.	1.2	19
1138	Evaluation of regional cerebral glucose metabolism in patients with malignant lymphoma of the body using statistical image analysis. <i>Annals of Nuclear Medicine</i> , 2014, 28, 950-960.	1.2	10
1139	Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2014, 32, 1246-1257.	1.2	95
1140	Clinical impact of contrast-enhanced computed tomography combined with low-dose ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography on routine lymphoma patient management. <i>Leukemia and Lymphoma</i> , 2014, 55, 2887-2892.	0.6	29
1141	Characterization of Tissue Findings in Bone Marrow Biopsy Specimens With Small Monoclonal B-Cell Populations. <i>American Journal of Clinical Pathology</i> , 2014, 141, 687-696.	0.4	12
1142	Validity of reduced radiation dose for localized diffuse large B-cell lymphoma showing a good response to chemotherapy. <i>Journal of Radiation Research</i> , 2014, 55, 359-363.	0.8	1
1143	Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. <i>Blood Cancer Journal</i> , 2014, 4, e236-e236.	2.8	54
1144	Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. <i>Blood Cancer Journal</i> , 2014, 4, e251-e251.	2.8	43
1145	In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. <i>Modern Pathology</i> , 2014, 27, 1599-1611.	2.9	22
1147	Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2514-2519.	0.6	10
1148	Predictive value of [¹⁸ F]fluoro-2-deoxy-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2014, 55, 276-282.	0.6	19
1149	Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. <i>Leukemia and Lymphoma</i> , 2014, 55, 1854-1860.	0.6	83
1150	Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2064-2070.	0.6	22
1151	Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2312-2318.	0.6	19

#	ARTICLE	IF	CITATIONS
1152	Relationship between 2-deoxy-2-[18F]-fluoro-d-glucose uptake and clinicopathological factors in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 520-525.	0.6	14
1153	Positron Emission Tomography (PET) in Oncology. <i>Cancers</i> , 2014, 6, 1821-1889.	1.7	231
1154	Functional Imaging in Lymphoma. , 2014, , 1311-1334.		0
1155	Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-9.	1.4	83
1156	Prognostic Value of Interim Positron Emission Tomography in Patients With Peripheral T-Cell Lymphoma. <i>Oncologist</i> , 2014, 19, 746-750.	1.9	25
1157	Biomarker Validation: Common Data Analysis Concerns. <i>Oncologist</i> , 2014, 19, 886-891.	1.9	24
1158	Asparagine synthetase expression and its potential prognostic value in patients with NK/T cell lymphoma. <i>Oncology Reports</i> , 2014, 32, 853-859.	1.2	15
1159	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 135-143.	0.9	10
1160	Optimal disease surveillance strategies in non-Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 481-487.	0.9	12
1161	Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 773-780.	0.6	69
1162	Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2384-2386.	0.6	2
1163	R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. <i>Haematologica</i> , 2014, 99, 1343-1349.	1.7	79
1165	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. <i>Haematologica</i> , 2014, 99, 505-510.	1.7	34
1166	Radiological Monitoring of the Treatment of Solid Tumors in Practice. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2014, 186, 466-473.	0.7	10
1167	Radiological Evaluation of the Therapeutic Response of Malignant Diseases: Status Quo, Innovative Developments and Requirements for Radiology. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2014, 186, 927-936.	0.7	5
1168	Therapy Response Evaluation of Malignant Lymphoma in a Multicenter Study: Comparison of Manual and Semiautomatic Measurements in CT. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2014, 186, 768-779.	0.7	1
1169	Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2728-2738.	0.6	44
1170	Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. <i>American Journal of Hematology</i> , 2014, 89, 363-368.	2.0	79

#	ARTICLE	IF	CITATIONS
1171	Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. <i>British Journal of Haematology</i> , 2014, 165, 489-496.	1.2	65
1172	Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2014, 89, 1011-1013.	2.0	6
1173	Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3736-3743.	0.8	283
1174	Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. <i>Leukemia and Lymphoma</i> , 2014, 55, 526-532.	0.6	42
1175	Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. <i>Cancer Science</i> , 2014, 105, 840-846.	1.7	48
1176	Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 583-587.	0.6	21
1177	Prospective International Cohort Study Demonstrates Inability of Interim PET to Predict Treatment Failure in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1936-1944.	2.8	63
1178	Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. <i>Clinical Cancer Research</i> , 2014, 20, 5641-5651.	3.2	31
1179	Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. <i>British Journal of Haematology</i> , 2014, 166, 140-142.	1.2	31
1180	The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia. <i>Human Pathology</i> , 2014, 45, 2471-2479.	1.1	24
1181	Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. <i>British Journal of Haematology</i> , 2014, 167, 327-336.	1.2	42
1182	Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. <i>Cancer</i> , 2014, 120, 2122-2129.	2.0	29
1183	Synchronous diffuse large B-cell lymphoma and squamous cell lung carcinoma. <i>Respirology Case Reports</i> , 2014, 2, 33-35.	0.3	9
1184	Efficacy of ⁹⁰ Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma. <i>Hematological Oncology</i> , 2014, 32, 10-15.	0.8	24
1185	Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease. <i>Leukemia and Lymphoma</i> , 2014, 55, 1281-1287.	0.6	9
1186	Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma. <i>British Journal of Haematology</i> , 2014, 167, 141-144.	1.2	9
1187	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. <i>Blood</i> , 2014, 123, 2944-2952.	0.6	505
1188	A phase I/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. <i>Cancer</i> , 2014, 120, 1194-1202.	2.0	26

#	ARTICLE	IF	CITATIONS
1189	Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone. <i>Hematological Oncology</i> , 2014, 32, 139-144.	0.8	11
1190	Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2014, 55, 1053-1060.	0.6	12
1191	R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2014, 93, 70-76.	1.1	12
1192	A study of gemcitabine, asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type. <i>Leukemia and Lymphoma</i> , 2014, 55, 2955-2957.	0.6	17
1193	Peripheral blood CD4/CD19 cell ratio is an independent prognostic factor in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1596-1601.	0.6	5
1194	Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. <i>European Journal of Haematology</i> , 2014, 93, 129-136.	1.1	25
1195	The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLLO5 trial of the Fondazione Italiana Linfomi (FIL). <i>Annals of Oncology</i> , 2014, 25, 442-447.	0.6	67
1196	Prognostic significance of soft tissue extension, international prognostic index, and multifocality in primary bone lymphoma: a single institutional experience. <i>British Journal of Haematology</i> , 2014, 166, 60-68.	1.2	32
1197	Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study. <i>NMR in Biomedicine</i> , 2014, 27, 681-691.	1.6	26
1198	Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era. <i>Cancer Science</i> , 2014, 105, 1170-1175.	1.7	58
1199	Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome. <i>Leukemia and Lymphoma</i> , 2014, 55, 2048-2055.	0.6	30
1200	Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer. <i>EJNMMI Research</i> , 2014, 4, 12.	1.1	19
1201	Imaging Biomarkers and Surrogate Endpoints in Oncology Clinical Trials. , 2014, , 29-42.		1
1203	Does tumoral ¹¹¹ In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing ⁹⁰ Y-ibritumomab radioimmunotherapy?. <i>European Radiology</i> , 2014, 24, 3191-3198.	2.3	4
1204	Whole-body DWI in patients with lymphoma: imaging findings, pitfalls, and limitations. <i>Cancer Imaging</i> , 2014, 14, .	1.2	0
1205	A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival. <i>BMC Medical Genetics</i> , 2014, 15, 113.	2.1	17
1206	Insight on automated lesion delineation methods for PET data. <i>EJNMMI Research</i> , 2014, 4, 69.	1.1	17
1207	Treatment outcome in T-cell lymphoblastic lymphoma in adults – a population-based study from the Swedish Lymphoma Registry. <i>Acta Oncologica</i> , 2014, 53, 927-934.	0.8	28

#	ARTICLE	IF	CITATIONS
1208	Sarcoidosis Occurring After Lymphoma. <i>Medicine (United States)</i> , 2014, 93, e121.	0.4	60
1209	Use of 18F-FDG PET/CT Imaging for Evaluation of Patients With Primary Splenic Lymphoma. <i>Clinical Nuclear Medicine</i> , 2014, 39, 772-776.	0.7	16
1210	Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy. <i>Nuclear Medicine Communications</i> , 2014, 35, 908-915.	0.5	14
1211	Clinical Significance of MYC Expression and/or "High-grade" Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, 494-501.	2.1	43
1212	High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma. <i>Histopathology</i> , 2014, 65, 490-500.	1.6	42
1213	Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. <i>Clinical Cancer Research</i> , 2014, 20, 6398-6405.	3.2	94
1214	Rare Lymphomas. , 2014, , .		0
1215	Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. <i>Haematologica</i> , 2014, 99, 1738-1745.	1.7	25
1216	Musculoskeletal Applications of PET/MR. <i>Seminars in Musculoskeletal Radiology</i> , 2014, 18, 203-216.	0.4	18
1217	Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival. <i>International Journal of Hematology</i> , 2014, 100, 370-378.	0.7	7
1218	Ocular adnexal lymphoma: validation of American Joint Committee on Cancer seventh edition staging guidelines. <i>British Journal of Ophthalmology</i> , 2014, 98, 1255-1260.	2.1	39
1219	Ocular Adnexal Follicular Lymphoma. <i>JAMA Ophthalmology</i> , 2014, 132, 851.	1.4	68
1220	Clinical Features and Treatment Outcomes of Intravascular Large B-Cell Lymphoma: A Single-Center Experience in Korea. <i>Acta Haematologica</i> , 2014, 131, 18-27.	0.7	17
1221	Clinical Features of Testicular Lymphoma. <i>Acta Haematologica</i> , 2014, 131, 187-192.	0.7	3
1222	Matched-Pair Analysis Comparing the Outcomes of T Cell/Histiocyte-Rich Large B Cell Lymphoma and Diffuse Large B Cell Lymphoma in Patients Treated with Rituximab-CHOP. <i>Acta Haematologica</i> , 2014, 131, 156-161.	0.7	11
1223	A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. <i>Journal of Hematology and Oncology</i> , 2014, 7, 44.	6.9	76
1224	Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 ⁺ Peripheral T-Cell Lymphomas: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3137-3143.	0.8	153
1225	Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients. <i>Acta Haematologica</i> , 2014, 131, 193-199.	0.7	23

#	ARTICLE	IF	CITATIONS
1226	Limited Positron Emission Tomography-Computed Tomography for Restaging of Lymphoma: A Strategy for Reducing Radiation Exposure among Patients with Early-Stage Curable Lymphoma. <i>Acta Haematologica</i> , 2014, 131, 239-244.	0.7	4
1227	Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2508-2513.	0.6	24
1228	Comparison of the International Harmonization Project, London and Gallamini criteria in the interpretation of 18F-FDG PET/CT examinations after first-line treatment in Hodgkin's lymphoma. <i>Nuclear Medicine Communications</i> , 2014, 35, 169-175.	0.5	7
1229	Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. <i>Annals of Oncology</i> , 2014, 25, 447-454.	0.6	38
1230	The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2014, 38, 323-328.	0.4	18
1231	The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community. <i>European Journal of Cancer</i> , 2014, 50, 260-266.	1.3	34
1232	Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 69-77.	5.1	518
1233	Hematopoietic Cell Transplantation for Mantle Cell Lymphoma: Predictive Value of Pretransplant Positron Emission Tomography/Computed Tomography and Bone Marrow Evaluations for Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 114-121.	0.2	20
1234	Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study. <i>Leukemia and Lymphoma</i> , 2014, 55, 533-537.	0.6	16
1236	Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma. <i>Annals of Hematology</i> , 2014, 93, 995-1000.	0.8	24
1237	Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 867-877.	3.3	40
1238	Phase I study of MLN8237, an investigational Aurora A kinase inhibitor, in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Investigational New Drugs</i> , 2014, 32, 489-499.	1.2	67
1239	Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: Comparison with CT in a prospective multicenter study. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 26-36.	1.9	52
1241	Evaluation of Significance of Lymphocyte Subpopulations and Non-specific Serologic Markers in B-cell Non-Hodgkin's Lymphoma Patients. <i>Pathology and Oncology Research</i> , 2014, 20, 649-654.	0.9	2
1242	HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China. <i>Medical Oncology</i> , 2014, 31, 845.	1.2	16
1243	The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients. <i>Medical Oncology</i> , 2014, 31, 880.	1.2	3
1244	Assessment of the nature of residual masses at end of treatment in lymphoma patients using volume perfusion computed tomography. <i>European Radiology</i> , 2014, 24, 770-779.	2.3	7
1245	Current role of FDG PET/CT in lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1004-1027.	3.3	63

#	ARTICLE	IF	CITATIONS
1246	Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2014, 93, 403-409.	0.8	90
1247	PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 408-415.	3.3	39
1248	Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass. <i>British Journal of Haematology</i> , 2014, 164, 694-700.	1.2	34
1249	Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the international extranodal lymphoma study group. <i>British Journal of Haematology</i> , 2014, 166, 69-76.	1.2	39
1250	Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins. <i>Journal of Clinical Oncology</i> , 2014, 32, 798-808.	0.8	433
1251	Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10A002. <i>British Journal of Haematology</i> , 2014, 165, 102-111.	1.2	78
1252	PI3K Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. <i>New England Journal of Medicine</i> , 2014, 370, 1008-1018.	13.9	956
1253	Hematopoietic tumors of the female genital system: imaging features with pathologic correlation. <i>Abdominal Imaging</i> , 2014, 39, 922-934.	2.0	8
1254	Medical Imaging in Clinical Trials. , 2014, , .		19
1255	Role of PET in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2014, 15, 248-261.	1.3	37
1256	How we manage follicular lymphoma. <i>Leukemia</i> , 2014, 28, 1388-1395.	3.3	83
1257	Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma. <i>European Journal of Haematology</i> , 2014, 93, 469-475.	1.1	6
1258	Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 253-264.	3.2	117
1259	Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas. <i>Journal of Clinical Oncology</i> , 2014, 32, 44-50.	0.8	185
1260	PI3-Kinase Inhibitors in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 33-43.	1.2	21
1261	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 48-58.	5.1	438
1262	Balancing Risks and Benefits of Therapy for Patients with Favorable-Risk Limited-Stage Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 49-63.	0.9	19
1263	FDG-PET Response-adapted Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 87-103.	0.9	9

#	ARTICLE	IF	CITATIONS
1264	Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy- ¹⁸ F-glucoseâ€“positron emission tomography/computed tomography in mantle cell lymphoma?. <i>Leukemia and Lymphoma</i> , 2014, 55, 2484-2489.	0.6	23
1265	Dexamethasone, methotrexate, ifosfamide, l-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2196-2198.	0.6	3
1266	Combined PET and Biopsy Evidence of Marrow Involvement Improves Prognostic Prediction in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1591-1597.	2.8	62
1267	The utility of restaging bone marrow biopsy in PETâ€“negative patients with diffuse large Bâ€“cell lymphoma and baseline bone marrow involvement. <i>American Journal of Hematology</i> , 2014, 89, 865-867.	2.0	9
1268	â€“Doubleâ€“Hitâ€“™ cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. <i>British Journal of Haematology</i> , 2014, 166, 369-374.	1.2	45
1269	Phase I/II, multicentre, openâ€“label study of the CD40 antagonistic monoclonal antibody lincociclimab in adult patients with advanced nonâ€“Hodgkin or Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 164, 258-265.	1.2	65
1270	Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. <i>British Journal of Haematology</i> , 2014, 164, 659-667.	1.2	31
1271	Bone marrow ¹⁸ Fâ€“fluoroâ€“2â€“deoxyâ€“ ¹⁸ F-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large Bâ€“cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 726-731.	2.0	70
1272	Radiation Therapy Is an Effective Modality in the Treatment of Mantle Cell Lymphoma, Even in Heavily Pretreated Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 474-479.	0.2	20
1273	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. <i>Leukemia Research</i> , 2014, 38, 1446-1450.	0.4	13
1274	Advanced-stage Hodgkin Lymphoma: US/Chest Radiography for Detection of Relapse in Patients in First Complete Remissionâ€“A Randomized Trial of Routine Surveillance Imaging Procedures. <i>Radiology</i> , 2014, 272, 262-274.	3.6	37
1275	Rituximab, alkylating agents or combination therapy for gastric mucosaâ€“associated lymphoid tissue lymphoma: a monocentric nonâ€“randomised observational study. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 619-628.	1.9	19
1276	Brentuximab vedotin in heavily treated Hodgkin and anaplastic largeâ€“cell lymphoma, a single centre study on 45 patients. <i>British Journal of Haematology</i> , 2014, 166, 306-308.	1.2	12
1277	Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 637-646.	1.1	25
1278	Interim and end-treatment positron emission tomography scan in aggressive B-cell lymphoma: we still lack an interpretation key. <i>Leukemia and Lymphoma</i> , 2014, 55, 1447-1448.	0.6	1
1279	Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large Bâ€“cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2014, 92, 204-210.	1.1	55
1280	Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2023-2030.	3.3	10
1281	Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7. <i>Leukemia Research</i> , 2014, 38, 1320-1326.	0.4	3

#	ARTICLE	IF	CITATIONS
1282	The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2014, 38, 1291-1298.	0.4	13
1283	PET-CT restaging: a surrogate for follicular lymphoma?. <i>Lancet Haematology</i> , 2014, 1, e2-e3.	2.2	2
1284	Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. <i>Lancet Haematology</i> , 2014, 1, e17-e27.	2.2	138
1285	Tumor-Absorbed Dose Predicts Progression-Free Survival Following ¹³¹ I-Tositumomab Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1047-1053.	2.8	51
1286	Rituximab-Including Combined Modality Treatment for Primary Thyroid Lymphoma: An Effective Regimen for Elderly Patients. <i>Thyroid</i> , 2014, 24, 994-999.	2.4	18
1287	Early Determination of Prognosis by Interim ¹⁸ F-Fluorodeoxythymidine PET in Patients with Non-Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 216-222.	2.8	27
1288	Influence of <i>ex vivo</i> purging with ³⁴ CliniMACS CD ³⁴ selection on outcome after autologous stem cell transplantation in non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 164, 555-564.	1.2	8
1289	British HIV Association guidelines for HIV-associated malignancies 2014. <i>HIV Medicine</i> , 2014, 15, 1-92.	1.0	67
1290	False-Positive [¹⁸ F]Fluorodeoxyglucose-Avid Lymph Nodes on Positron Emission Tomography-Computed Tomography After Allogeneic but Not Autologous Stem-Cell Transplantation in Patients With Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 51-56.	0.8	22
1291	Interim ¹⁸ F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 569-573.	2.8	76
1292	Evolving Treatment Paradigms for Primary Mediastinal Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1751-1753.	0.8	7
1293	Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. <i>Journal of Clinical Oncology</i> , 2014, 32, 3059-3067.	0.8	3,729
1294	[¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1769-1775.	0.8	149
1295	Double hit lymphoma: the MD Anderson Cancer Center clinical experience. <i>British Journal of Haematology</i> , 2014, 166, 891-901.	1.2	310
1296	Guidelines for the first line management of classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 166, 34-49.	1.2	70
1297	Role of FDG-PET in the Implementation of Involved-Node Radiation Therapy for Hodgkin Lymphoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 1047-1052.	0.4	41
1298	A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics. <i>Clinical Immunology</i> , 2014, 154, 37-46.	1.4	25
1299	How to manage mantle cell lymphoma. <i>Leukemia</i> , 2014, 28, 2117-2130.	3.3	44

#	ARTICLE	IF	CITATIONS
1300	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naïve patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. <i>Lancet Oncology, The</i> , 2014, 15, 1019-1026.	5.1	246
1301	In Vivo Treatment Sensitivity Testing With Positron Emission Tomography/Computed Tomography After One Cycle of Chemotherapy for Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2705-2711.	0.8	83
1303	Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology, The</i> , 2014, 15, 966-974.	5.1	345
1304	Precision therapy for lymphoma—current state and future directions. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 585-596.	12.5	69
1305	Primary Mediastinal Large B-cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 273-283.	1.2	31
1306	Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy. <i>Medical Oncology</i> , 2014, 31, 185.	1.2	12
1307	Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning. <i>Journal of Clinical Oncology</i> , 2014, 32, 3497-3505.	0.8	234
1308	Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma. <i>PET Clinics</i> , 2014, 9, 443-455.	1.5	6
1309	A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2014, 25, 2398-2404.	0.6	14
1310	Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 1394-1400.	1.9	15
1311	Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era. <i>International Journal of Hematology</i> , 2014, 100, 386-392.	0.7	13
1312	The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab. <i>Annals of Hematology</i> , 2014, 93, 1755-1764.	0.8	30
1313	CD19 as a molecular target in CNS autoimmunity. <i>Acta Neuropathologica</i> , 2014, 128, 177-190.	3.9	22
1314	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3048-3058.	0.8	1,269
1315	Infused Autograft Lymphocyte to Monocyte Ratio and Survival in Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1804-1812.	2.0	22
1316	Utility of quantitative FDG-PET/CT for the detection of bone marrow involvement in follicular lymphoma: a histopathological correlation study. <i>Skeletal Radiology</i> , 2014, 43, 1231-1236.	1.2	15
1317	Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1735-1743.	3.3	152
1318	Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens. <i>Annals of Hematology</i> , 2014, 93, 617-626.	0.8	46

#	ARTICLE	IF	CITATIONS
1319	Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. <i>Annals of Hematology</i> , 2014, 93, 1305-1312.	0.8	60
1320	Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis. <i>Annals of Hematology</i> , 2014, 93, 1287-1295.	0.8	37
1321	The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1297-1304.	0.8	53
1322	Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study. <i>Annals of Hematology</i> , 2014, 93, 1345-1351.	0.8	11
1323	A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1637-1644.	0.8	12
1324	ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1745-1753.	0.8	33
1325	Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. <i>Annals of Hematology</i> , 2014, 93, 1853-1857.	0.8	14
1326	Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification. <i>Annals of Hematology</i> , 2014, 93, 1867-1877.	0.8	16
1327	Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. <i>Annals of Hematology</i> , 2014, 93, 1879-1887.	0.8	59
1328	Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. <i>Annals of Hematology</i> , 2014, 93, 1889-1894.	0.8	52
1329	Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR [®] , _ç therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. <i>Investigational New Drugs</i> , 2014, 32, 1213-1225.	1.2	21
1330	Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2014, 7, 24.	6.9	144
1331	A phase 1 study of the PI3K ^γ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). <i>Blood</i> , 2014, 123, 3398-3405.	0.6	245
1332	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2014, 27, 958-971.	2.9	112
1333	Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1864-1868.	2.0	56
1334	Which Hodgkin's Patients in the Unites States Should Be Treated with BEACOPP?. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 222-226.	1.2	2
1335	Managing HIV and Hodgkin Lymphoma in the Twenty-first century. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 227-232.	1.2	5
1336	Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Medical Oncology</i> , 2014, 31, 56.	1.2	12

#	ARTICLE	IF	CITATIONS
1337	Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. <i>Medical Oncology</i> , 2014, 31, 902.	1.2	36
1338	Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. <i>International Journal of Hematology</i> , 2014, 99, 737-742.	0.7	31
1339	Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy. <i>International Journal of Hematology</i> , 2014, 100, 88-95.	0.7	19
1340	Prognostic Value of Metabolic Tumor Volume Estimated by ^{18}F -FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 187-195.	0.6	41
1341	CD30 as a Therapeutic Target for Lymphoma. <i>BioDrugs</i> , 2014, 28, 181-209.	2.2	32
1342	R-CHOP versus R-COMP: Are They Really Equally Effective?. <i>Clinical Oncology</i> , 2014, 26, 648-652.	0.6	12
1343	Limited-Stage Hodgkin Lymphoma: Managing Uncertainty. <i>Journal of Clinical Oncology</i> , 2014, 32, 1180-1182.	0.8	9
1344	A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2014, 20, 5255-5264.	3.2	82
1345	Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (<sc>RICER</sc>) in firstâ€relapse/primary refractory diffuse large Bâ€cell lymphoma. <i>British Journal of Haematology</i> , 2014, 166, 77-83.	1.2	49
1346	Response evaluation and monitoring of multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 33-42.	1.0	8
1347	When should <sc>FDG</sc>â€<sc>PET</sc> be used in the modern management of lymphoma?. <i>British Journal of Haematology</i> , 2014, 164, 315-328.	1.2	52
1348	Refinement of the Definition of Permissible HLA-DPB1 Mismatches with Predicted Indirectly ReCognizable HLA-DPB1 Epitopes. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1705-1710.	2.0	31
1349	Phase <sc>II</sc> study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. <i>British Journal of Haematology</i> , 2014, 166, 920-928.	1.2	12
1350	Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 37-42.	0.2	31
1351	Standardized uptake value for ^{18}F -fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with Diffuse Large B-Cell Lymphoma. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2014, 33, 148-152.	0.0	5
1352	Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: A multicenter phase 2 study. <i>Leukemia Research</i> , 2014, 38, 34-41.	0.4	24
1353	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014, 25, 1404-1410.	0.6	133
1354	Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. <i>Hematological Oncology</i> , 2014, 32, 187-191.	0.8	42

#	ARTICLE	IF	CITATIONS
1355	Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 50-55.	0.2	28
1356	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 730-737.	5.1	164
1357	Prognostic evaluation of PET/CT in residual post-chemotherapy masses in patients with diffuse large B-cell lymphoma and its impact on survival. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2014, 45, 921-928.	0.3	2
1358	Antifungal Agents for Secondary Prophylaxis Based on Response to Initial Antifungal Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Prior Pulmonary Aspergillosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1198-1203.	2.0	21
1359	Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 277-283.	0.2	21
1360	Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma. <i>Experimental Hematology</i> , 2014, 42, 39-45.	0.2	12
1361	High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 73-79.	2.0	17
1362	Standardized uptake value for 18F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with Diffuse Large B-Cell Lymphoma. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2014, 33, 148-152.	0.1	0
1363	Towards integrating positron emission tomography for work-up of patients with Sjögren's syndrome and associated lymphomas. <i>Autoimmunity Reviews</i> , 2014, 13, 327-329.	2.5	12
1364	PET/CT in initial staging and therapy response assessment of early mediastinal lymphoma. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2014, 45, 61-67.	0.3	3
1365	Impact of Cytomegalovirus Replication and Cytomegalovirus Serostatus on the Outcome of Patients with B Cell Lymphoma after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 885-890.	2.0	42
1366	Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. <i>European Journal of Internal Medicine</i> , 2014, 25, 296-302.	1.0	31
1367	Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. <i>Leukemia and Lymphoma</i> , 2014, 55, 2328-2334.	0.6	48
1368	18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 811-816.	0.6	18
1369	Should the cutoff values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients?. <i>European Journal of Haematology</i> , 2014, 93, 340-348.	1.1	27
1370	Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1776-1781.	0.8	63
1371	Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity: A preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging. <i>European Journal of Radiology</i> , 2014, 83, 1655-1664.	1.2	32
1372	Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 384-391.	0.4	8

#	ARTICLE	IF	CITATIONS
1373	Primary Non-Hodgkin Lymphoma of the Ovary. <i>Seminars in Oncology</i> , 2014, 41, e19-e30.	0.8	9
1374	A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 213-220.	3.2	105
1375	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , 2014, 123, 1214-1217.	0.6	518
1376	Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 689-703.	1.8	52
1377	Bendamustine Combined with Donor Lymphocytes Infusion in Hodgkin's Lymphoma Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1444-1447.	2.0	21
1378	Diffuse large B-cell lymphoma in elderly patients: A retrospective analysis. <i>European Journal of Internal Medicine</i> , 2014, 25, 577-582.	1.0	7
1380	Prognostic Factors and Treatment Efficacy in Patients with Primary Diffuse Large B-cell Lymphoma of the Bone: Single Institute Experience Over 11 Years. <i>Internal Medicine</i> , 2014, 53, 95-101.	0.3	15
1381	¹⁸ F-FDG PET/CT imaging for a gastrointestinal mantle cell lymphoma with multiple lymphomatous polyposis. <i>World Journal of Gastroenterology</i> , 2014, 20, 5141.	1.4	7
1382	Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 346-352.	1.7	153
1383	Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. <i>Haematologica</i> , 2014, 99, e138-e141.	1.7	2
1384	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. <i>Haematologica</i> , 2014, 99, e126-e126.	1.7	8
1385	Midtreatment Evaluation of Lymphoma Response to Chemotherapy by Volume Perfusion Computed Tomography. <i>Journal of Computer Assisted Tomography</i> , 2014, 38, 123-130.	0.5	6
1386	Neurolymphomatosis in a Patient with Extranodal NK/T-cell Lymphoma, Nasal-type: A Case Report and Literature Review. <i>Internal Medicine</i> , 2014, 53, 471-475.	0.3	10
1387	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. <i>Blood</i> , 2014, 124, 3553-3560.	0.6	56
1388	Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. <i>Blood</i> , 2014, 124, 3029-3031.	0.6	40
1389	Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). <i>Blood</i> , 2014, 123, 1665-1673.	0.6	61
1390	Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- β , as therapy for previously treated indolent non-Hodgkin lymphoma. <i>Blood</i> , 2014, 123, 3406-3413.	0.6	203
1391	Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. <i>Blood</i> , 2014, 123, 3567-3573.	0.6	76

#	ARTICLE	IF	CITATIONS
1392	Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. <i>Blood</i> , 2014, 123, 2953-2959.	0.6	90
1393	Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. <i>Blood</i> , 2014, 123, 3095-3100.	0.6	280
1394	The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. <i>Blood</i> , 2014, 124, 2190-2195.	0.6	108
1395	A prospective study of mediastinal gray-zone lymphoma. <i>Blood</i> , 2014, 124, 1563-1569.	0.6	100
1396	Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2014, 124, 1259-1265.	0.6	34
1397	Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. <i>Blood</i> , 2014, 124, 1570-1577.	0.6	309
1398	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. <i>Blood</i> , 2014, 124, 3356-3364.	0.6	36
1399	BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. <i>Blood</i> , 2014, 124, 2306-2312.	0.6	35
1401	Ibritumomab tiuxetan plus BEAM in refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2014, 99, e108-e108.	1.7	0
1402	Post-thrombotic syndrome is an independent determinant of health-related quality of life following both first proximal and distal deep vein thrombosis. <i>Haematologica</i> , 2014, 99, e41-e43.	1.7	33
1403	Segmental ⁶⁸ Ge-Mesentery on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, 84-86.	0.7	4
1404	Role of radiotherapy in the treatment of primary mediastinal large B-cell lymphoma. <i>Oncology Letters</i> , 2015, 10, 2925-2930.	0.8	6
1405	HIV-infection impact on clinical biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. <i>Aids</i> , 2015, 29, 811-818.	1.0	37
1406	Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma. <i>Journal of Chemotherapy</i> , 2015, 27, 99-105.	0.7	9
1407	Autologous stem cell transplantation with <i>in vivo</i> purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 230-234.	2.0	9
1408	Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review. <i>Cancer Medicine</i> , 2015, 4, 1817-1827.	1.3	2
1409	A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 170, 886-890.	1.2	27
1410	Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 662-665.	1.2	2

#	ARTICLE	IF	CITATIONS
1411	BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. <i>Blood</i> , 2015, 125, 658-667.	0.6	108
1412	Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. <i>Blood</i> , 2015, 125, 82-89.	0.6	45
1413	How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. <i>Blood</i> , 2015, 125, 1226-1235.	0.6	41
1414	Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 1236-1243.	0.6	199
1415	A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 242-248.	0.6	124
1416	Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. <i>Blood</i> , 2015, 125, 1394-1402.	0.6	242
1417	FDG PET-CT in follicular lymphoma: a case-based evidence review. <i>Blood</i> , 2015, 125, 1078-1082.	0.6	19
1418	The efficacy of ibrutinib in the treatment of Richter syndrome. <i>Blood</i> , 2015, 125, 1676-1678.	0.6	83
1419	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015, 126, 950-956.	0.6	138
1420	Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. <i>Blood</i> , 2015, 126, 36-41.	0.6	44
1421	Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. <i>Blood</i> , 2015, 126, 842-850.	0.6	125
1422	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. <i>Blood</i> , 2015, 125, 3024-3031.	0.6	259
1423	Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. <i>Blood</i> , 2015, 126, 1893-1901.	0.6	117
1424	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , 2015, 126, 739-745.	0.6	349
1425	Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. <i>Blood</i> , 2015, 126, 2798-2804.	0.6	118
1426	Radiotherapy for advanced-stage aggressive non-Hodgkin lymphoma. <i>The Cochrane Library</i> , 2015, , .	1.5	0
1427	Hodgkin Lymphoma, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 554-586.	2.3	37
1428	Bone marrow uptake of indolent non-Hodgkin lymphoma on PET/CT with histopathological correlation. <i>Nuclear Medicine Communications</i> , 2015, 36, 1035-1041.	0.5	6

#	ARTICLE	IF	CITATIONS
1429	Correspondence. Indian Pediatrics, 2015, 52, 439-444.	0.2	1
1430	FDG-PET scan in lymphoma: silver anniversary. Clinical and Translational Imaging, 2015, 3, 251-252.	1.1	1
1431	Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy. Journal of Geriatric Oncology, 2015, 6, 470-478.	0.5	27
1432	Chłoniak rozlany z duÅylych limfocytÅw B â€œ czy R-CHOP-21 jest leczeniem optymalnym?. Acta Haematologica Polonica, 2015, 46, 100-106.	0.1	0
1433	Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study. Journal of Hematology and Oncology, 2015, 8, 70.	6.9	28
1434	Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. Journal of Hematology and Oncology, 2015, 8, 80.	6.9	7
1435	Qualitative visual trichotomous assessment improves the value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in predicting the prognosis of diffuse large B-cell lymphoma. Chinese Journal of Cancer, 2015, 34, 264-71.	4.9	4
1436	Gray zone lymphoma with features intermediate between classical <sc>H</sc>odgkin lymphoma and diffuse large <sc>B</sc>â€cell lymphoma: <sc>C</sc>haracteristics, outcomes, and prognostication among a large multicenter cohort. American Journal of Hematology, 2015, 90, 778-783.	2.0	71
1437	The combination of milatuzumab, a humanized antiâ€CD74 antibody, and veltuzumab, a humanized antiâ€CD20 antibody, demonstrates activity in patients with relapsed and refractory Bâ€cell nonâ€Hodgkin lymphoma. British Journal of Haematology, 2015, 169, 701-710.	1.2	31
1438	A phase <sc>II</sc> trial of <sc>RCHOP</sc> followed by radioimmunotherapy for early stage (stages I<sc>I</sc>) diffuse large Bâ€cell nonâ€Hodgkin lymphoma: <sc>ECOG</sc> 3402. British Journal of Haematology, 2015, 170, 679-686.	1.2	19
1439	Ambulatory Medical Assistance - After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy. BMC Cancer, 2015, 15, 781.	1.1	23
1440	Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkittâ€™s lymphoma. Chinese Journal of Cancer, 2015, 34, 608-13.	4.9	11
1441	Platinum and highâ€dose cytarabineâ€based regimens are efficient in ultra high/highâ€risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study. European Journal of Haematology, 2015, 95, 160-167.	1.1	28
1442	Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy. Aids, 2015, 29, 903-910.	1.0	29
1443	Follicular Lymphoma in a Patient with Previously Treated Early Breast Cancer; the Role of PET Imaging and Repeat Tissue Diagnosis. Breast Journal, 2015, 21, 691-692.	0.4	1
1444	Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology, 2015, 171, 463-470.	1.2	81
1445	High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. British Journal of Haematology, 2015, 171, 788-797.	1.2	11
1446	The clinical impact of staging bone marrow examination on treatment decisions and prognostic assessment of lymphoma patients. British Journal of Haematology, 2015, 170, 175-178.	1.2	5

#	ARTICLE	IF	CITATIONS
1447	Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 509-516.	1.2	15
1448	Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression. <i>International Journal of Experimental Pathology</i> , 2015, 96, 232-239.	0.6	4
1449	ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 610-620.	0.6	9
1450	The Deauville 5-Point Scale Improves the Prognostic Value of Interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma. <i>Clinical Nuclear Medicine</i> , 2015, 40, 767-773.	0.7	25
1451	Autologous Transplant in Lymphoma: Experience in a Limited Resource Mexican Reference Center. <i>Journal of Blood Disorders & Transfusion</i> , 2015, 06, .	0.1	0
1452	Red blood cell distribution width as a simple negative prognostic factor in patients with diffuse large B-cell lymphoma: a retrospective study. <i>Croatian Medical Journal</i> , 2015, 56, 334-343.	0.2	51
1453	Maximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Blood Research</i> , 2015, 50, 97.	0.5	4
1454	The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy. <i>Journal of Blood Medicine</i> , 2015, 6, 87.	0.7	2
1455	Enhanced International Prognostic Index (NCCN-IPI), Charlson Comorbidity Index and absolute lymphocyte count as predictors for survival of elderly patients with diffuse large B-cell lymphoma treated by immunochemotherapy. <i>Neoplasma</i> , 2015, 62, 988-995.	0.7	13
1456	Monitoring Reader Metrics in Blinded Independent Central Review of Oncology Studies. <i>Journal of Clinical Trials</i> , 2015, 05, .	0.1	0
1457	Real Benefit of Anthracycline-Based Chemotherapy in Elderly and Impaired Patients: a Retrospective Analysis. <i>Journal of Integrative Oncology</i> , 2015, 04, .	0.3	0
1458	Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma. <i>Journal of Blood Medicine</i> , 2015, 6, 45.	0.7	8
1459	The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma. <i>PLoS ONE</i> , 2015, 10, e0126615.	1.1	22
1460	Skeletal Muscle Radio-Density Is an Independent Predictor of Response and Outcomes in Follicular Lymphoma Treated with Chemoimmunotherapy. <i>PLoS ONE</i> , 2015, 10, e0127589.	1.1	41
1461	Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy. <i>PLoS ONE</i> , 2015, 10, e0129064.	1.1	14
1462	The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0138341.	1.1	16
1463	Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma. <i>PLoS ONE</i> , 2015, 10, e0140830.	1.1	90
1464	Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	3

#	ARTICLE	IF	CITATIONS
1465	Post-Transplant Lymphoproliferative Disorder in Liver Transplant Recipients: Characteristics, Management and Outcome from a Single-Centre Experience with >1000 Liver Transplantations. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 417-422.	0.8	23
1466	Imaging the posterior mediastinum: a multimodality approach. <i>Diagnostic and Interventional Radiology</i> , 2015, 21, 293-306.	0.7	26
1467	Staging of Primary Abdominal Lymphomas: Comparison of Whole-Body MRI with Diffusion-Weighted Imaging and ¹⁸ F-FDG-PET/CT. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-8.	0.7	11
1468	Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	26
1469	Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma. <i>Molecular Medicine</i> , 2015, 21, 824-832.	1.9	3
1470	Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation. <i>Blood Research</i> , 2015, 50, 160.	0.5	3
1471	Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). <i>Annals of Oncology</i> , 2015, 26, 873-879.	0.6	151
1472	The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study. <i>Leukemia and Lymphoma</i> , 2015, 56, 2585-2591.	0.6	13
1473	Rethinking Clinical Response and Outcome Assessment in a Biologic Age. <i>Current Oncology Reports</i> , 2015, 17, 27.	1.8	3
1474	Ocular Adnexal Diffuse Large B-cell Lymphoma. <i>JAMA Ophthalmology</i> , 2015, 133, 165.	1.4	60
1475	Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. <i>Oncolmmunology</i> , 2015, 4, e990773.	2.1	27
1476	Myeloablative Intravenous Pharmacokinetically Targeted Busulfan Plus Fludarabine As Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 335-340.	0.2	8
1477	Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant hodgkin lymphoma: Long-term outcomes from a 30-year experience. <i>American Journal of Hematology</i> , 2015, 90, E103-10.	2.0	31
1478	A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 4024-4031.	0.6	265
1479	High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study. <i>International Journal of Hematology</i> , 2015, 102, 181-187.	0.7	34
1480	Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies. <i>Sao Paulo Medical Journal</i> , 2015, 133, 141-150.	0.4	19
1481	Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Leukemia and Lymphoma</i> , 2015, 56, 2569-2578.	0.6	36
1482	Impact of Pretransplantation ¹⁸ F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39

#	ARTICLE	IF	CITATIONS
1483	Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Journal of Clinical Pathology</i> , 2015, 68, 733-738.	1.0	14
1484	Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 927-935.	0.6	28
1485	Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry. <i>Hematological Oncology</i> , 2015, 33, 120-128.	0.8	15
1486	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2492-2499.	0.8	394
1487	Outcomes of Treatment in Slovene Follicular Lymphoma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 586-591.	0.2	1
1488	Utility of F-18 FDG PET/CT on the evaluation of primary bone lymphoma. <i>European Journal of Radiology</i> , 2015, 84, 2275-2279.	1.2	19
1489	Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 914-920.	0.6	0
1490	Incidentally Discovered Diffuse Large B-Cell Lymphoma Limited to the Endocervical Mucosa in a Young Female Patient. <i>Gynecologic and Obstetric Investigation</i> , 2015, 80, 134-138.	0.7	2
1491	The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 676-681.	0.6	5
1492	Outcomes and endpoints in cancer trials: bridging the divide. <i>Lancet Oncology</i> , The, 2015, 16, e43-e52.	5.1	72
1493	A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 811-819.	1.2	172
1494	Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients. <i>Leukemia and Lymphoma</i> , 2015, 56, 293-300.	0.6	7
1495	CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment. <i>Leukemia and Lymphoma</i> , 2015, 56, 332-341.	0.6	32
1496	Phase II study of ⁹⁰ Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1750-1755.	0.6	26
1497	¹⁸ F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. <i>Leukemia and Lymphoma</i> , 2015, 56, 2005-2012.	0.6	28
1498	Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas. <i>Medical Oncology</i> , 2015, 32, 353.	1.2	5
1499	Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. <i>Leukemia and Lymphoma</i> , 2015, 56, 2032-2038.	0.6	43
1500	Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era. <i>Leukemia Research</i> , 2015, 39, 211-215.	0.4	8

#	ARTICLE	IF	CITATIONS
1501	Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy. <i>Leukemia Research</i> , 2015, 39, 198-203.	0.4	9
1502	Manifestaciones otorrinolaringológicas de las hemopatías del adulto. <i>EMC - Otorrinolaringología</i> , 2015, 44, 1-15.	0.0	0
1503	Prognostic significance of the number and type of extra nodal localizations of DLBCL in the rituximab era. <i>Acta Haematologica Polonica</i> , 2015, 46, 49-55.	0.1	0
1504	Management of Diffuse Large B-Cell Lymphoma (DLBCL). <i>Cancer Treatment and Research</i> , 2015, 165, 271-288.	0.2	53
1505	FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 1525-1529.	3.2	126
1506	Prognostic value of tumor necrosis at CT in diffuse large B-cell lymphoma. <i>European Journal of Radiology</i> , 2015, 84, 372-377.	1.2	29
1507	The absolute lymphocyte to monocyte ratio is associated with poor prognosis in classical Hodgkin lymphoma patients younger than 60 years of age. <i>Hematological Oncology</i> , 2015, 33, 133-140.	0.8	16
1508	Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. <i>Cancer</i> , 2015, 121, 423-431.	2.0	34
1509	Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. <i>Hematological Oncology</i> , 2015, 33, 151-158.	0.8	38
1510	Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. <i>Lancet Haematology</i> , 2015, 2, e66-e74.	2.2	85
1511	FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease. <i>Clinical Cancer Research</i> , 2015, 21, 950-954.	3.2	89
1512	High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. <i>Bone Marrow Transplantation</i> , 2015, 50, 499-504.	1.3	9
1513	Phase II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2015, 168, 663-670.	1.2	31
1514	Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma. <i>PET Clinics</i> , 2015, 10, 207-225.	1.5	11
1515	General features and epidemiology of lymphoma in Colombia. A multicentric study. <i>Annals of Hematology</i> , 2015, 94, 975-980.	0.8	4
1516	Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. <i>Bone Marrow Transplantation</i> , 2015, 50, 579-584.	1.3	49
1517	Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1763-1770.	0.6	28
1518	Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. <i>Blood</i> , 2015, 125, 22-32.	0.6	445

#	ARTICLE	IF	CITATIONS
1519	Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study. <i>Hematological Oncology</i> , 2015, 33, 42-47.	0.8	8
1521	Primary mediastinal lymphoma: diagnosis and treatment options. <i>Expert Review of Hematology</i> , 2015, 8, 173-186.	1.0	28
1522	Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma. <i>Annals of Hematology</i> , 2015, 94, 431-436.	0.8	23
1523	Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. <i>Bone Marrow Transplantation</i> , 2015, 50, 679-684.	1.3	21
1524	Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 341-348.	0.2	39
1525	Does the presence of tumor-induced cortical bone destruction at CT have any prognostic value in newly diagnosed diffuse large B-cell lymphoma?. <i>Skeletal Radiology</i> , 2015, 44, 687-694.	1.2	1
1526	Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 851-859.	1.1	53
1527	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC13 lympho study. <i>American Journal of Hematology</i> , 2015, 90, 197-203.	2.0	84
1528	Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2015, 31, 346-351.	0.3	6
1529	Diffuse thyroid 18F-FDG uptake after R-CHOP therapy predicts favorable outcome in patients with DLBCL. <i>Annals of Hematology</i> , 2015, 94, 995-1001.	0.8	2
1530	Sarcoidosis and lymphoma: a comparative study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2015, 108, 871-878.	0.2	25
1531	Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). <i>Annals of Hematology</i> , 2015, 94, 437-444.	0.8	32
1532	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. <i>Investigational New Drugs</i> , 2015, 33, 423-431.	1.2	33
1533	Single arm NCR1 phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome. <i>BMC Cancer</i> , 2015, 15, 52.	1.1	9
1534	Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: A nationwide population-based study. <i>International Journal of Cancer</i> , 2015, 137, 658-665.	2.3	36
1535	Prognostic impact of 125 I-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 688-693.	0.6	19
1536	Imaging of Non-Hodgkin Lymphomas: Diagnosis and Response-Adapted Strategies. <i>Cancer Treatment and Research</i> , 2015, 165, 125-146.	0.2	12
1537	Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1077-1083.	0.4	28

#	ARTICLE	IF	CITATIONS
1538	Lack of durable disease control with chemotherapy for mycosis fungoides and S�azary syndrome: a comparative study of systemic therapy. <i>Blood</i> , 2015, 125, 71-81.	0.6	181
1539	Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2136-2140.	2.0	131
1540	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2115-2122.	2.0	26
1541	Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2015, 2, e326-e333.	2.2	50
1542	Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. <i>Mayo Clinic Proceedings</i> , 2015, 90, 756-764.	1.4	39
1543	Safety and efficacy of Temozolomide in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. <i>Leukemia</i> , 2015, 29, 1695-1701.	3.3	39
1544	Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies. <i>Bone Marrow Transplantation</i> , 2015, 50, 1526-1535.	1.3	23
1545	CD20-positive primary gastric T-cell lymphoma poorly responding to initial treatment with rituximab plus CHOP, and a literature review. <i>International Journal of Hematology</i> , 2015, 102, 702-708.	0.7	17
1546	Immune independent crosstalk between lymphoma and myeloid suppressor CD14 ⁺ HLA-DR ^{low/neg} monocytes mediates chemotherapy resistance. <i>Oncotarget</i> , 2015, 4, e996470.	2.1	10
1547	Evaluation of Clinical and Biological Prognostic Factors in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients After Previous Treatment With Rituximab and Chemotherapy: Results of the PRO-R-IPi Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 398-403.	0.2	6
1548	Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). <i>Journal of Clinical Oncology</i> , 2015, 33, 2523-2529.	0.8	157
1549	Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2015, 26, 774-779.	0.6	17
1550	Lymphopenia predicts preclinical relapse in the routine follow-up of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1261-1265.	0.6	4
1551	Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. <i>Bone Marrow Transplantation</i> , 2015, 50, 1286-1292.	1.3	9
1552	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1914-1920.	2.0	46
1553	Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy?. <i>Acta Oncologica</i> , 2015, 54, 953-955.	0.8	3
1554	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.	0.8	97
1555	The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. <i>Leukemia Research</i> , 2015, 39, 853-858.	0.4	15

#	ARTICLE	IF	CITATIONS
1556	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. <i>Nature Medicine</i> , 2015, 21, 922-926.	15.2	927
1557	Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experience. <i>Leukemia and Lymphoma</i> , 2015, 56, 267-269.	0.6	35
1558	Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab. <i>Leukemia and Lymphoma</i> , 2015, 56, 342-346.	0.6	10
1559	Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2015, 56, 3065-3070.	0.6	20
1560	Additional Survival Benefit of Involved-Lesion Radiation Therapy After R-CHOP Chemotherapy in Limited Stage Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 91-98.	0.4	22
1561	Predictors of Local Recurrence After Rituximab-Based Chemotherapy Alone in Stage III and IV Diffuse Large B-Cell Lymphoma: Guiding Decisions for Consolidative Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 107-112.	0.4	24
1562	Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2015, 56, 3071-3081.	0.6	16
1563	Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma. <i>Blood Reviews</i> , 2015, 29, 417-425.	2.8	54
1564	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , 2015, 100, 517-524.	1.7	6
1566	Primary Bone Lymphoma: A Clinical Analysis of 17 Patients in a Single Institution. <i>Acta Haematologica</i> , 2015, 134, 80-85.	0.7	19
1567	PET/CT, MR, and PET/MR in Lymphoma and Melanoma. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 322-331.	2.5	32
1568	Alternative intensive induction chemotherapeutic regimens in MYC-expressing diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 797-800.	0.6	3
1569	Brentuximab Vedotin in Patients With Hodgkin Lymphoma and a Failed Allogeneic Stem Cell Transplantation: Results From a Named Patient Program at Four Italian Centers. <i>Oncologist</i> , 2015, 20, 323-328.	1.9	29
1570	Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. <i>Annals of Oncology</i> , 2015, 26, 1058-1068.	0.6	67
1571	Radioimmunotherapy (90Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab. <i>American Journal of Transplantation</i> , 2015, 15, 1976-1981.	2.6	16
1572	Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event) Tj ETQq1 1 0.784314.6BT /Overlock 10	1.7	22
1573	FDG-PET Response Prediction in Pediatric Hodgkin's Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value. <i>Cancers</i> , 2015, 7, 287-304.	1.7	22
1574	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2015, 33, 710-719.	1.2	24

#	ARTICLE	IF	CITATIONS
1575	Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CTâ€”Controlled Prospective Study in 64 Patients. <i>Clinical Cancer Research</i> , 2015, 21, 2506-2513.	3.2	78
1576	Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 404-408.	0.2	18
1577	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. <i>Current Medical Research and Opinion</i> , 2015, 31, 993-1001.	0.9	17
1578	Prognostic value of interim FDGâ€”PET in Hodgkin lymphoma: systematic review and metaâ€”analysis. <i>British Journal of Haematology</i> , 2015, 170, 356-366.	1.2	50
1579	Outcome of patients older than 60Â”years with classical Hodgkin lymphoma treated with front line <scp>ABVD</scp> chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. <i>British Journal of Haematology</i> , 2015, 170, 179-184.	1.2	69
1580	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. <i>Blood</i> , 2015, 125, 3679-3687.	0.6	270
1581	Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 278-285.e1.	0.2	19
1582	Safety and activity of the anti-CD79B antibodyâ€”drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 704-715.	5.1	272
1583	A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas. <i>British Journal of Haematology</i> , 2015, 169, 528-533.	1.2	12
1584	Beta-2 microglobulin predicts the outcome after autologous stem cell transplantation in non-Hodgkin lymphoma. <i>Transfusion and Apheresis Science</i> , 2015, 52, 65-71.	0.5	2
1586	Peripheral Blood Lymphocyte/Monocyte Ratio Predicts Outcome in Follicular Lymphoma and in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 208-213.	0.2	35
1587	Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. <i>Journal of Clinical Oncology</i> , 2015, 33, 1482-1490.	0.8	60
1588	UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan. <i>Annals of Hematology</i> , 2015, 94, 65-69.	0.8	7
1589	Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. <i>Annals of Hematology</i> , 2015, 94, 803-812.	0.8	74
1590	Suggestion of response evaluation criteria in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML). <i>Annals of Hematology</i> , 2015, 94, 1185-1193.	0.8	4
1591	Trends in quality of non-Hodgkinâ€™s lymphoma care: is it getting better?. <i>Annals of Hematology</i> , 2015, 94, 1195-1203.	0.8	3
1592	Salvage therapy with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin for relapsed or refractory pediatric Hodgkin lymphoma. Results of a retrospective series of four children. <i>Annals of Hematology</i> , 2015, 94, 1401-1406.	0.8	5
1593	Use of Model-Based Iterative Reconstruction (MBIR) in reduced-dose CT for routine follow-up of patients with malignant lymphoma: dose savings, image quality and phantom study. <i>European Radiology</i> , 2015, 25, 2362-2370.	2.3	37

#	ARTICLE	IF	CITATIONS
1594	A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma. <i>Medical Oncology</i> , 2015, 32, 79.	1.2	3
1595	PET in lymphoma: who, when, how often, pitfalls?. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 43-47.	0.3	1
1596	Biosimilar monoclonal antibodies in lymphoma: a critical appraisal. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 569-578.	1.1	12
1597	Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. <i>Leukemia</i> , 2015, 29, 1524-1529.	3.3	95
1598	Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. <i>BMC Cancer</i> , 2015, 15, 198.	1.1	28
1599	Heterogeneity of intratumoral ¹¹¹ In-ibrutinomab tiuxetan and ¹⁸ F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma. <i>EJNMMI Research</i> , 2015, 5, 10.	1.1	31
1600	Clinical Features and Outcome of Primary Pancreatic Lymphoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1176-1184.	0.7	36
1601	A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2863-2869.	0.6	33
1602	Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 359-369.	2.0	30
1603	Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. <i>Annals of Hematology</i> , 2015, 94, 1525-1533.	0.8	39
1604	Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With Prognosis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1379-1388.	0.8	94
1605	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2015, 385, 1853-1862.	6.3	633
1606	Treatment Approach to Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Seminars in Hematology</i> , 2015, 52, 107-118.	1.8	16
1607	Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 3216-3218.	0.6	32
1609	CD34+ selected versus unselected autologous stem cell transplantation in patients with advanced-stage mantle cell and diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2015, 39, 561-567.	0.4	9
1610	Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1597-1604.	2.0	76
1611	Lymphoma in older patients: clinical and therapeutic characteristics. <i>Reviews in Clinical Gerontology</i> , 2015, 25, 1-11.	0.5	0
1612	International Pediatric Non-Hodgkin Lymphoma Response Criteria. <i>Journal of Clinical Oncology</i> , 2015, 33, 2106-2111.	0.8	64

#	ARTICLE	IF	CITATIONS
1613	Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma. <i>Journal of the Chinese Medical Association</i> , 2015, 78, 400-407.	0.6	2
1614	An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 1843-1850.	3.2	90
1615	Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. <i>Leukemia and Lymphoma</i> , 2015, 56, 2630-2636.	0.6	11
1616	Response criteria for malignant lymphoma. <i>Nuclear Medicine Communications</i> , 2015, 36, 398-405.	0.5	1
1617	Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 944-953.	13.9	343
1618	Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. <i>Blood</i> , 2015, 125, 2497-2506.	0.6	618
1619	Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. <i>British Journal of Haematology</i> , 2015, 170, 185-191.	1.2	57
1620	Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort. <i>American Journal of Hematology</i> , 2015, 90, 493-498.	2.0	47
1621	Whole-Body Diffusion-weighted Imaging in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. <i>Radiographics</i> , 2015, 35, 747-764.	1.4	50
1622	Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 122-129.	0.4	37
1623	Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. <i>Lancet Haematology</i> , 2015, 2, e160-e165.	2.2	95
1624	Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma. <i>International Journal of Hematology</i> , 2015, 101, 536-542.	0.7	16
1625	Efficacy and Tolerability of Anthracycline-Based Therapy in Elderly Patients With Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 270-277.	0.2	10
1626	Phase I Trial of the Pan-PI3K Inhibitor Pivalarisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 3160-3169.	3.2	51
1627	Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2015, 102, 101-110.	0.7	8
1628	Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease. <i>BioDrugs</i> , 2015, 29, 399-406.	2.2	3
1629	Histologic transformation in marginal zone lymphomas. <i>Annals of Oncology</i> , 2015, 26, 2329-2335.	0.6	104
1630	Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1406-1414.	0.3	55

#	ARTICLE	IF	CITATIONS
1631	PET-directed therapy in Hodgkin lymphoma: Ready for prime time?. Expert Review of Anticancer Therapy, 2015, 15, 1431-1441.	1.1	1
1632	Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients. Oncologist, 2015, 20, 1413-1416.	1.9	22
1633	Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. New England Journal of Medicine, 2015, 373, 1835-1844.	13.9	201
1634	PET-CT in the sub-arctic region of Norway 2010-2013. At the edge of what is possible?. BMC Medical Imaging, 2015, 15, 36.	1.4	6
1635	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). Oncologist, 2015, 20, 1149-1153.	1.9	52
1636	Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy. Leukemia and Lymphoma, 2015, 56, 3096-3102.	0.6	8
1637	Decisional Early Interim 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography after Two Cycles of Chemotherapy in de novo Hodgkin Lymphoma. Acta Haematologica, 2015, 133, 172-178.	0.7	4
1638	Programmed haploidentical hematopoietic stem cell infusion combined with systemic chemotherapy improves the outcomes of patients with refractory or relapsed lymphoma. Leukemia and Lymphoma, 2015, 56, 270-273.	0.6	6
1639	Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. Leukemia and Lymphoma, 2015, 56, 1151-1153.	0.6	11
1640	Imaging for Staging and Response Assessment in Lymphoma. Radiology, 2015, 276, 323-338.	3.6	139
1641	Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer. Current Medical Research and Opinion, 2015, 31, 547-556.	0.9	10
1642	High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. Clinical Infectious Diseases, 2015, 61, 1469-1475.	2.9	47
1643	Otlertuzumab (TRU -016), an anti-CD 37 monospecific ADAPTIR , therapeutic protein, for relapsed or refractory NHL patients. British Journal of Haematology, 2015, 168, 38-45.	1.2	33
1644	A phase 1 dose-escalation study of XmAb [®] 2513 in patients with relapsed or refractory Hodgkin lymphoma. British Journal of Haematology, 2015, 168, 902-904.	1.2	11
1645	Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). European Journal of Haematology, 2015, 94, 504-510.	1.1	16
1646	Diagnostic imaging in paraneoplastic autoimmune multiorgan syndrome: retrospective single site study and literature review of 225 patients. International Journal of Dermatology, 2015, 54, 424-437.	0.5	18
1647	The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review. Cancer and Metastasis Reviews, 2015, 34, 511-525.	2.7	1
1648	FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2015, 21, 3586-3590.	3.2	113

#	ARTICLE	IF	CITATIONS
1649	Yttrium-90 Ibritumomab Tiuxetan Followed by Rituximab Maintenance as Treatment for Patients with Diffuse Large B-Cell Lymphoma Are Not Candidates for Autologous Stem Cell Transplant. <i>Acta Haematologica</i> , 2015, 133, 347-353.	0.7	7
1650	A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 392-397.	0.2	52
1651	Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. <i>Annals of Oncology</i> , 2015, 26, 2323-2328.	0.6	30
1652	Outcome prediction by extranodal involvement, IPI, Râ€¦IPI, and NCCNâ€¦IPI in the PET/CT and rituximab era: A <scp>D</scp>anishâ€¦ <scp>C</scp>anadian study of 443 patients with diffuseâ€¦large <scp>B</scp>â€¦cell lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 1041-1046.	2.0	71
1653	Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. <i>Annals of Hematology</i> , 2015, 94, 2025-2032.	0.8	26
1654	A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2569-2575.	1.9	98
1655	Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. <i>Annals of Hematology</i> , 2015, 94, 1845-1851.	0.8	41
1656	Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. <i>Bone Marrow Transplantation</i> , 2015, 50, 1293-1298.	1.3	15
1657	Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies. <i>Journal of Controlled Release</i> , 2015, 219, 295-312.	4.8	11
1658	Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danishâ€¦Swedish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3993-3998.	0.8	74
1659	Next-generation prognostic assessment for diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2015, 11, 2443-2457.	1.1	8
1660	Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 105-114.	0.3	6
1661	Current status of FDG-PET/CT in staging of adult lymphoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 253-269.	1.1	4
1662	FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 271-281.	1.1	2
1663	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. <i>Journal of Clinical Oncology</i> , 2015, 33, 3152-3161.	0.8	215
1664	Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. <i>Radiology</i> , 2015, 277, 518-526.	3.6	23
1665	Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. <i>Bone Marrow Transplantation</i> , 2015, 50, 1299-1305.	1.3	7
1666	High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3903-3910.	0.8	99

#	ARTICLE	IF	CITATIONS
1667	Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Annals of Hematology</i> , 2015, 94, 1865-1873.	0.8	14
1668	Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 664-670.e2.	0.2	4
1669	A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 655-663.	0.2	4
1670	Life expectancy of young adults with follicular lymphoma. <i>Annals of Oncology</i> , 2015, 26, 2317-2322.	0.6	31
1671	Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement. <i>International Journal of Hematology</i> , 2015, 102, 678-688.	0.7	6
1672	Comparative effectiveness analysis of different salvage therapy intensities used for diffuse large B-cell lymphoma in Northern or Southern Alberta: an instrumental variable analysis. <i>Leukemia and Lymphoma</i> , 2015, 56, 1756-1762.	0.6	1
1673	Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015, 37, 184-189.	0.7	5
1674	Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1529-1531.	2.0	4
1675	Evaluation correlates C-reactive protein with advanced stage Hodgkin's lymphoma and response to treatment in a tertiary university hospital in Brazil. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015, 37, 242-246.	0.7	6
1676	Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. <i>Leukemia and Lymphoma</i> , 2015, 56, 3045-3051.	0.6	77
1677	Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. <i>Investigational New Drugs</i> , 2015, 33, 942-953.	1.2	27
1678	Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1839-1845.	0.6	23
1679	Rates and Durability of Response to Salvage Radiation Therapy Among Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 223-231.	0.4	40
1680	T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. <i>Lancet, The</i> , 2015, 385, 517-528.	6.3	2,476
1681	PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 215-221.	3.3	24
1682	Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 152-158.	0.2	34
1683	Fludarabine+“Mitoxantrone+“Rituximab regimen in untreated indolent non+“follicular non+“Hodgkin's lymphoma: experience on 143 patients. <i>Hematological Oncology</i> , 2015, 33, 141-146.	0.8	13
1684	Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 137-145.	0.6	7

#	ARTICLE	IF	CITATIONS
1685	CD68 staining correlates with the size of residual mass but not with survival in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1315-1319.	0.6	17
1686	The role of ^{FDG}â€^{PET}/^{CT} in the evaluation of residual disease in paediatric nonâ€Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 845-853.	1.2	37
1687	Ten yearsâ€™ experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study. <i>Leukemia and Lymphoma</i> , 2015, 56, 2013-2018.	0.6	4
1688	Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. <i>Medical Oncology</i> , 2015, 32, 446.	1.2	57
1690	Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1020-1026.	0.6	30
1691	PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 311-319.	13.9	3,099
1692	The role of rituximab and positron emission tomography in the treatment of primary mediastinal large Bâ€cell lymphoma: experience on 74 patients. <i>Hematological Oncology</i> , 2015, 33, 145-150.	0.8	30
1693	Riskâ€tailored ^{CNS} prophylaxis in a monoâ€institutional series of 200 patients with diffuse large Bâ€cell lymphoma treated in the rituximab era. <i>British Journal of Haematology</i> , 2015, 168, 654-662.	1.2	90
1694	Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 703-710.	0.6	29
1695	High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2015, 33, 110-112.	0.8	82
1696	A â€PETâ€topic in primary mediastinal large B-cell lymphoma: positive or negative, and how to handle it in the end. <i>Leukemia and Lymphoma</i> , 2015, 56, 3-5.	0.6	11
1697	Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. <i>Annals of Hematology</i> , 2015, 94, 415-420.	0.8	27
1698	Circulating myeloidâ€derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated upâ€front with a riskâ€adapted strategy. <i>British Journal of Haematology</i> , 2015, 168, 689-700.	1.2	76
1699	Long-Term Outcomes of Patients with Persistent Indolent Bâ€Cell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 281-287.	2.0	19
1701	Tumors of Lymphoid and Hematopoietic Tissues. , 2015, , 103-149.		0
1702	Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. <i>Annals of Hematology</i> , 2015, 94, 593-601.	0.8	6
1703	Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2015, 56, 2025-2031.	0.6	6
1704	Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (Râ€GEMâ€P) is an effective regimen in relapsed diffuse large Bâ€cell lymphoma. <i>European Journal of Haematology</i> , 2015, 94, 219-226.	1.1	11

#	ARTICLE	IF	CITATIONS
1705	Clinical Efficacy and Safety in Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 1-12.e7.	0.2	13
1707	Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor. <i>Journal of Clinical Oncology</i> , 2015, 33, 540-549.	0.8	1,397
1708	Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. <i>Annals of Hematology</i> , 2015, 94, 71-78.	0.8	58
1709	Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009. <i>Leukemia and Lymphoma</i> , 2015, 56, 694-702.	0.6	6
1710	Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 915-920.	0.6	29
1711	Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 993-998.	0.6	3
1712	Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. <i>Hematological Oncology</i> , 2015, 33, 136-144.	0.8	2
1713	The role of ¹⁸F-FDG PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. <i>Cancer Medicine</i> , 2015, 4, 7-15.	1.3	18
1714	Phase II study of first-line ¹³¹I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic ¹⁸F-fluorodeoxyglucose positron emission tomography. <i>Leukemia and Lymphoma</i> , 2015, 56, 1271-1277.	0.6	22
1715	Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. <i>Hematological Oncology</i> , 2015, 33, 187-191.	0.8	10
1716	Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 55-62.	1.2	44
1717	Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). <i>Leukemia and Lymphoma</i> , 2015, 56, 958-964.	0.6	36
1718	Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 251-257.	0.8	319
1719	R-CHOP or R-HyperCVAD With or Without Autologous Stem Cell Transplantation for Older Patients With Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 92-97.	0.2	9
1720	Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2016, 1, 122-131.	2.5	15
1721	Primary mediastinal B-cell lymphoma - metabolic and anatomical features in 18FDG-PET/CT and response to therapy. <i>Wspolczesna Onkologia</i> , 2016, 4, 297-301.	0.7	2
1722	Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Blood Research</i> , 2016, 51, 113.	0.5	12
1723	Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. <i>OncoTargets and Therapy</i> , 2016, 9, 2027.	1.0	3

#	ARTICLE	IF	CITATIONS
1724	THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, e2016045.	0.5	4
1725	Diffuse Infiltrative Splenic Lymphoma: Diagnostic Efficacy of Arterial-Phase CT. Korean Journal of Radiology, 2016, 17, 734.	1.5	4
1726	FDG-PET SCAN: A NEW PARADIGM FOR FOLLICULAR LYMPHOMA MANAGEMENT.. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017029.	0.5	17
1727	Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2016, 56, 28-33.	0.3	5
1728	Comorbidity as an independent prognostic factor in elderly patients with peripheral T-cell lymphoma. OncoTargets and Therapy, 2016, 9, 1795.	1.0	4
1729	Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). OncoTargets and Therapy, 2016, 9, 3799.	1.0	5
1730	IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017010.	0.5	9
1731	Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma. Oncotarget, 2016, 7, 29092-29101.	0.8	51
1732	Functional Imaging Using 18-Fluorodeoxyglucose PET in the Management of Primary Mediastinal Large B-Cell Lymphoma: The Contributions of the International Extranodal Lymphoma Study Group. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e368-e375.	1.8	5
1733	Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma. Oncotarget, 2016, 7, 35412-35422.	0.8	37
1734	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Oncotarget, 2016, 7, 76934-76943.	0.8	33
1735	Emerging treatments in Castleman disease – a critical appraisal of siltuximab. Biologics: Targets and Therapy, 2016, 10, 9.	3.0	4
1736	Clinical Prognostic Models in Diffuse Large B Cell Lymphoma Patients are Still Essential in the Rituximab Era. Journal of Hematology & Thromboembolic Diseases, 2016, 4, .	0.1	0
1737	Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico. BioMed Research International, 2016, 2016, 1-10.	0.9	9
1738	Burkitt lymphoma in adolescents and young adults: management challenges. Adolescent Health, Medicine and Therapeutics, 2017, Volume 8, 11-29.	0.7	54
1740	GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. Medicine (United States), 2016, 95, e2787.	0.4	32
1741	Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma. Nuclear Medicine Communications, 2016, 37, 689-698.	0.5	15
1742	FDG PET/CT Findings in Primary Diffuse Large B-cell Lymphoma, Leg Type. Clinical Nuclear Medicine, 2016, 41, 65-68.	0.7	5

#	ARTICLE	IF	CITATIONS
1743	Phase Ib trial of the <scp>PI</scp>3K/<scp>mTOR</scp> inhibitor voxtalisib (<scp>SAR</scp>245409) in combination with chemoimmunotherapy in patients with relapsed or refractory Bâ€cell malignancies. British Journal of Haematology, 2016, 175, 55-65.	1.2	12
1744	Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naïve rituximab follicular lymphoma patients: a single institution experience. Annals of Hematology, 2016, 95, 1287-1293.	0.8	10
1745	Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 281-288.	1.1	51
1746	Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. Journal of Clinical Oncology, 2016, 34, 3293-3299.	0.8	90
1747	Clinical approach to diffuse large B cell lymphoma. Blood Reviews, 2016, 30, 477-491.	2.8	26
1748	A phase <scp>II</scp> study of cyclophosphamide, etoposide, vincristine and prednisone (<scp>CEOP</scp>) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral Tâ€cell lymphoma (<scp>PTCL</scp>): final results from the Tâ€cell consortium trial. British Journal of Haematology, 2016, 172, 535-544.	1.2	71
1749	A phase 2 study of inotuzumab ozogamicin in patients with indolent Bâ€cell nonâ€Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. British Journal of Haematology, 2016, 174, 571-581.	1.2	43
1750	Clinical characteristics of primary gastric lymphoma detected during screening for gastric cancer in Korea. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1572-1583.	1.4	8
1751	Computed Tomography Observer Agreement in Staging Malignant Lymphoma. Journal of Computer Assisted Tomography, 2016, 40, 261-265.	0.5	1
1752	Vincristine Sulfate Liposomes Injection (VSLI, Marqiboâ€): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias. Pediatric Blood and Cancer, 2016, 63, 997-1005.	0.8	64
1754	A phase <scp>II</scp>, singleâ€arm, multicentre study of coltuximab ravtansine (<scp>SAR</scp>3419) and rituximab in patients with relapsed or refractory diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2016, 173, 722-730.	1.2	49
1755	Results of a multicentre <scp>UK</scp>-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma. British Journal of Haematology, 2016, 173, 896-904.	1.2	19
1756	Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer networkâ€international prognostic index and positron emission tomographyâ€defined remission status; a populationâ€based analysis. British Journal of Haematology, 2016, 172, 246-254.	1.2	28
1757	No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danishâ€Swedish populationâ€based observational study. British Journal of Haematology, 2016, 173, 236-244.	1.2	28
1758	Lenalidomide in combination with Râ€<scp>ESHAP</scp> in patients with relapsed or refractory diffuse large Bâ€cell lymphoma: a phase 1b study from <scp>GELTAMO</scp> group. British Journal of Haematology, 2016, 173, 245-252.	1.2	24
1759	Bendamustine+â€Rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: Aâ€Wisconsin Oncology Network Study. British Journal of Haematology, 2016, 173, 283-291.	1.2	13
1760	A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for nonâ€Hodgkin lymphoma. British Journal of Haematology, 2016, 173, 432-443.	1.2	23
1761	The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. British Journal of Haematology, 2016, 175, 102-114.	1.2	56

#	ARTICLE	IF	CITATIONS
1762	Inter- and intra-rater reliability of calliper-based lymph node measurement in dogs with peripheral nodal lymphomas. <i>Veterinary and Comparative Oncology</i> , 2016, 14, 74-81.	0.8	7
1763	Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution. <i>American Journal of Hematology</i> , 2016, 91, 233-237.	2.0	89
1764	The role of fluorine-18 fluorodeoxyglucose PET in prognosis evaluation for stem cell transplantation of lymphoma. <i>Nuclear Medicine Communications</i> , 2016, 37, 338-347.	0.5	5
1765	Low absolute CD4+ T cell counts in peripheral blood are associated with inferior survival in follicular lymphoma. <i>Tumor Biology</i> , 2016, 37, 12589-12595.	0.8	7
1766	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. <i>Cancer</i> , 2016, 122, 2680-2688.	2.0	48
1767	TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, 400-405.	2.0	89
1768	S-tatin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study. <i>American Journal of Hematology</i> , 2016, 91, 410-415.	2.0	5
1769	Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating IDARAM chemotherapy. <i>British Journal of Haematology</i> , 2016, 172, 545-553.	1.2	25
1770	The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≥ 12 months. <i>British Journal of Haematology</i> , 2016, 173, 260-264.	1.2	12
1771	Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib. <i>European Journal of Haematology</i> , 2016, 96, 650-654.	1.1	13
1772	Long-term outcomes of high dose treatment and autologous stem cell transplantation in follicular and mantle cell lymphomas – a single centre experience. <i>Radiology and Oncology</i> , 2016, 51, 81-87.	0.6	1
1773	Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. <i>Blood</i> , 2016, 128, 1814-1820.	0.6	75
1774	Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. <i>Cancer Science</i> , 2016, 107, 1785-1790.	1.7	19
1775	Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30 ⁺ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. <i>Haematologica</i> , 2016, 101, 466-473.	1.7	35
1777	Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. <i>Blood</i> , 2016, 128, 2510-2516.	0.6	56
1778	Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era. <i>Nuclear Medicine Communications</i> , 2016, 37, 1095-1101.	0.5	15
1779	Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2016, 101, e27-e29.	1.7	24
1780	Kikuchi's Disease Masquerading As Refractory Lymphoma. <i>Journal of Oncology Practice</i> , 2016, 12, 94-96.	2.5	1

#	ARTICLE	IF	CITATIONS
1781	Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. <i>Lancet Oncology</i> , The, 2016, 17, 622-631.	5.1	149
1783	A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2016, 9, 38.	6.9	34
1784	Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)/T cell lymphoma. <i>Leukemia Research</i> , 2016, 47, 26-31.	0.4	22
1785	Mad2 overexpression is associated with high cell proliferation and reduced disease-free survival in primary gastrointestinal diffuse large B-cell lymphoma. <i>Hematology</i> , 2016, 21, 399-403.	0.7	9
1786	Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. <i>Leukemia and Lymphoma</i> , 2016, 57, 2575-2583.	0.6	39
1787	Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy. <i>Annals of Hematology</i> , 2016, 95, 1259-1269.	0.8	11
1788	Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors. <i>Journal of Immunotherapy</i> , 2016, 39, 140-148.	1.2	16
1789	A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. <i>European Journal of Cancer</i> , 2016, 56, 1-9.	1.3	76
1790	Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 99-105.	0.7	1
1791	Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. <i>AAPS Journal</i> , 2016, 18, 1101-1116.	2.2	52
1792	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1440-1448.	2.0	44
1793	Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2016, 51, 928-932.	1.3	9
1794	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1197-1205.	2.0	17
1795	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , the, 2016, 3, e217-e227.	2.2	442
1796	Plasma Epstein Barr viral load in adult-onset Hodgkin lymphoma in South India. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 8-13.	0.6	4
1797	DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China. <i>Clinical Cancer Research</i> , 2016, 22, 5223-5228.	3.2	112
1798	Safety and efficacy of radioimmunotherapy (RIT) in treatment of non-Hodgkin's lymphoma in the community setting. <i>Nuclear Medicine and Biology</i> , 2016, 43, 227-231.	0.3	6
1799	FDG-PET imaging in hematological malignancies. <i>Blood Reviews</i> , 2016, 30, 317-331.	2.8	43

#	ARTICLE	IF	CITATIONS
1800	Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma. <i>Pediatric Radiology</i> , 2016, 46, 1258-1268.	1.1	54
1801	Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 2784-2790.	0.6	15
1802	<i>Real Life</i> experience in a <i>difficult to treat</i> patient population of non-Hodgkin lymphomas using the R-COMP regimen. <i>Leukemia and Lymphoma</i> , 2016, 57, 2919-2922.	0.6	1
1803	PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 185-195.	1.2	22
1804	Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients. <i>Abdominal Radiology</i> , 2016, 41, 1338-1348.	1.0	54
1805	Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan. <i>International Journal of Hematology</i> , 2016, 104, 256-265.	0.7	11
1806	Response Assessment Criteria and Their Applications in Lymphoma: Part 1. <i>Journal of Nuclear Medicine</i> , 2016, 57, 928-935.	2.8	21
1807	Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. <i>Annals of Hematology</i> , 2016, 95, 1107-1114.	0.8	25
1808	PET/CT in Hodgkin Lymphoma. , 2016, , 51-107.		0
1809	Aggressive B-Cell Lymphomas. , 2016, , 111-171.		0
1810	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. <i>Leukemia</i> , 2016, 30, 2011-2018.	3.3	41
1811	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.	0.8	239
1812	PET/CT in Lymphomas. , 2016, , .		4
1813	Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 127, 1410-1416.	0.6	295
1814	TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. <i>Blood</i> , 2016, 128, 72-81.	0.6	29
1815	Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. <i>Blood</i> , 2016, 127, 2411-2415.	0.6	131
1816	Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 185-194.	0.6	122
1817	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. <i>Blood</i> , 2016, 128, 1112-1120.	0.6	177

#	ARTICLE	IF	CITATIONS
1818	Minimising the impact of errors in the interpretation of CT images for surveillance and evaluation of therapy in cancer. <i>Clinical Radiology</i> , 2016, 71, 1083-1094.	0.5	9
1819	End-of-treatment FDG-PET lacks usefulness in Hodgkin lymphoma. <i>Annals of Hematology</i> , 2016, 95, 2083-2084.	0.8	0
1820	Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma. <i>Leukemia Research</i> , 2016, 49, 80-87.	0.4	9
1821	Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of α -1, α -CD163 and α -CD30 with TARC. <i>British Journal of Haematology</i> , 2016, 175, 868-875.	1.2	44
1822	Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. <i>Blood</i> , 2016, 128, 1050-1058.	0.6	74
1823	PET/CT in initial staging and therapy response assessment of lymphoma. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2016, 47, 1639-1647.	0.3	5
1824	Basal 18F-FDG PET/CT in follicular lymphoma: A comparison of metabolic and clinical variables in the prognostic assessment. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 298-305.	0.0	0
1825	Mantle cell lymphoma, response to treatment and prognosis in 45 patients. <i>Medicina Clínica (English)</i> Tj ETQq1 1 0,784314 ggBT /Over	0.1	0
1826	Basal 18 F-FDG PET/CT in follicular lymphoma: A comparison of metabolic and clinical variables in the prognostic assessment. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 298-305.	0.1	0
1827	Pediatric Hodgkin's Lymphoma. , 2016, , 1464-1485.e5.		0
1828	Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them. <i>Expert Review of Hematology</i> , 2016, 9, 1007-1009.	1.0	10
1829	First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2016, 27, 1928-1940.	0.6	185
1830	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1582-1587.	2.0	20
1831	Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis. <i>European Journal of Radiology</i> , 2016, 85, 1963-1970.	1.2	70
1832	Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2016, 128, 1562-1566.	0.6	324
1833	ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. <i>Haematologica</i> , 2016, 101, 968-975.	1.7	52
1834	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 4015-4022.	0.8	66
1835	Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?. <i>Oncologist</i> , 2016, 21, 1107-1112.	1.9	33

#	ARTICLE	IF	CITATIONS
1836	R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2016, 95, 1705-1714.	0.8	30
1837	15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (<sc>MCL</sc>2): prolonged remissions without survival plateau. <i>British Journal of Haematology</i> , 2016, 175, 410-418.	1.2	170
1838	Quality of life amongst lymphoma survivors in a developing country. <i>Supportive Care in Cancer</i> , 2016, 24, 5015-5023.	1.0	9
1839	Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. <i>Oncologist</i> , 2016, 21, 1436-1441.	1.9	15
1840	Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma. <i>International Journal of Hematology</i> , 2016, 104, 591-595.	0.7	14
1841	Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, 1032-1035.	2.0	53
1842	90-year tritium-rituximab consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7.5 years. <i>Cancer Medicine</i> , 2016, 5, 1093-1097.	1.3	16
1843	The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1288-1295.	1.0	34
1844	Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 567-576.	2.9	83
1845	Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. <i>British Journal of Haematology</i> , 2016, 174, 692-699.	1.2	26
1846	Sole rearrangement but not amplification of <i><sc>MYC</sc></i> is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. <i>British Journal of Haematology</i> , 2016, 175, 631-640.	1.2	55
1847	CT perfusion in evaluation of post therapy cervical lymphoma. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2016, 47, 1673-1679.	0.3	0
1848	Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. <i>Journal of Clinical Oncology</i> , 2016, 34, 3618-3626.	0.8	231
1849	A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. <i>Clinical Cancer Research</i> , 2016, 22, 5696-5705.	3.2	245
1850	Clinical value of imaging for lymph nodes evaluation with particular emphasis on ultrasonography. <i>Zeitschrift Fur Gastroenterologie</i> , 2016, 54, 774-790.	0.2	15
1851	Hodgkin lymphoma: a negative interim PET cannot circumvent the need for end-of-treatment PET evaluation. <i>British Journal of Haematology</i> , 2016, 175, 652-660.	1.2	23
1852	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. <i>Blood</i> , 2016, 128, 2489-2496.	0.6	370
1853	Role of Positron Emission Tomography in Diffuse Large B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1215-1228.	0.9	2

#	ARTICLE	IF	CITATIONS
1854	Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma. <i>Scientific Reports</i> , 2016, 6, 23996.	1.6	7
1855	Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab. <i>Haematologica</i> , 2016, 101, e385-e386.	1.7	20
1856	Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e66-e68.	1.7	36
1857	Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. <i>Haematologica</i> , 2016, 101, 1094-1101.	1.7	97
1858	Low dose palliative radiotherapy for refractory aggressive lymphoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 2016, 21, 495-499.	0.3	11
1859	<sc>NCRI</sc> phase <sc>II</sc> study of <sc>CHOP</sc> in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. <i>British Journal of Haematology</i> , 2016, 175, 43-54.	1.2	53
1860	<sc>SPIB</sc> is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the <sc>PI</sc>3K<sc>AKT</sc> pathway. <i>Cancer Science</i> , 2016, 107, 1270-1280.	1.7	22
1861	PET-CT: reliable cornerstone for Hodgkin lymphoma treatment?. <i>Blood</i> , 2016, 127, 1521-1522.	0.6	3
1862	Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome. <i>Annals of Hematology</i> , 2016, 95, 2023-2031.	0.8	33
1863	A convenient prognostic score consisting of the Glasgow prognostic score and serum lactate dehydrogenase predicts clinical outcome in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2460-2463.	0.6	4
1864	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 1283-1294.	5.1	818
1865	Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model. <i>Annals of Hematology</i> , 2016, 95, 1661-1669.	0.8	23
1866	Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. <i>British Journal of Haematology</i> , 2016, 174, 923-931.	1.2	64
1867	A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1848-1855.	0.6	33
1868	A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 281-289.	1.2	50
1869	Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum Î²2-microglobulin level in patients with diffuse large B-cell lymphoma: a new prognostic model. <i>British Journal of Haematology</i> , 2016, 175, 290-299.	1.2	31
1870	Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. <i>Oncology Letters</i> , 2016, 11, 423-432.	0.8	57
1871	European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. <i>Haematologica</i> , 2016, 101, e407-e410.	1.7	38

#	ARTICLE	IF	CITATIONS
1872	Mature B cell neoplasms: retrospective analysis of 93 cases diagnosed between 2011 and 2014 in a University Hospital in southern Brazil. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 121-127.	0.7	1
1873	Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor. <i>Lung Cancer</i> , 2016, 100, 24-29.	0.9	5
1874	Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography. <i>European Journal of Radiology</i> , 2016, 85, 2195-2199.	1.2	11
1875	FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?. <i>Haematologica</i> , 2016, 101, 1279-1283.	1.7	14
1876	Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis. <i>Clinica Chimica Acta</i> , 2016, 463, 47-52.	0.5	7
1877	Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 182-189.	2.0	6
1878	Review of siltuximab in the treatment of multicentric Castleman's disease. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 360-366.	1.1	38
1879	Evaluation of a method for calculating carboplatin dosage in DeVICAR therapy (combination therapy) Tj ETQq1 1 0.784314 rgBT /Dv therapy in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 305-312.	1.1	1
1880	Is the lymphoma better? Not easy to determine. <i>Blood</i> , 2016, 128, 2481-2482.	0.6	1
1881	2 Gy vs 4 Gy for palliative treatment of mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2219-2224.	1.1	4
1882	NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease. <i>American Journal of Surgical Pathology</i> , 2016, 40, 192-201.	2.1	40
1883	Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial. <i>BMC Cancer</i> , 2016, 16, 932.	1.1	33
1884	FDG PET/CT response in diffuse large B-cell lymphoma. <i>Medicine (United States)</i> , 2016, 95, e4983.	0.4	18
1885	Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). <i>Haematologica</i> , 2016, 101, 346-355.	1.7	44
1888	Flow Cytometric Evaluation of Double/Triple Hit Lymphoma. <i>Oncology Research</i> , 2016, 23, 137-146.	0.6	17
1889	Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 159-166.	0.7	1
1890	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2698-2704.	0.8	868
1891	Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 865-873.	1.1	10

#	ARTICLE	IF	CITATIONS
1892	Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2016, 104, 236-244.	0.7	17
1893	Short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results. <i>Blood Cancer Journal</i> , 2016, 6, e425-e425.	2.8	13
1894	Pixantrone+rituximab versus gemcitabine+rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. <i>Future Oncology</i> , 2016, 12, 1759-1768.	1.1	16
1895	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i> , The, 2016, 388, 565-575.	6.3	328
1896	Rituximab plus reduced-dose cyclophosphamide, doxorubicin, vincristine and prednisone (RD R-CHOP) chemotherapy is feasible for very elderly patients (≥80 years) with B-cell lymphoma: analysis of treatment outcome. <i>Journal of Chemotherapy</i> , 2016, 28, 487-493.	0.7	3
1897	Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Future Oncology</i> , 2016, 12, 2077-2094.	1.1	9
1898	The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. <i>Annals of Hematology</i> , 2016, 95, 1491-1501.	0.8	9
1899	Molecular targeted therapy in gynaecologic malignancies: primer for radiologists. <i>British Journal of Radiology</i> , 2016, 89, 20160086.	1.0	2
1900	Peripheral T-Cell Lymphomas. , 2016, , 197-216.		0
1901	Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1081-1093.	5.1	297
1902	Flow-cytometry-based evaluation of peripheral blood lymphocytes in prognostication of newly diagnosed DLBCL patients. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 59, 92-96.	0.6	8
1903	Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085) Tj ETQq1 1 0.784314 rgBT / Oncology, 2016, 17, e309-e316.	2.2	50
1904	RECIST 1.1 + Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , 2016, 62, 138-145.	1.3	211
1905	Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting. <i>Clinical Trials</i> , 2016, 13, 545-554.	0.7	2
1906	Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. <i>Oncolmmunology</i> , 2016, 5, e1150399.	2.1	94
1907	Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 4807-4816.	3.2	32
1908	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. <i>Journal of Clinical Oncology</i> , 2016, 34, 3733-3739.	0.8	586
1909	De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. <i>American Journal of Hematology</i> , 2016, 91, 395-399.	2.0	39

#	ARTICLE	IF	CITATIONS
1910	Reduced intensity ^{VEPEMB} regimen compared with standard ^{ABVD} in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (^{FIL}). British Journal of Haematology, 2016, 172, 879-888.	1.2	29
1911	¹⁸F-â€‹FDG PET/â€‹CT and trephine biopsy assessment of bone marrow involvement in lymphoma. British Journal of Haematology, 2016, 174, 410-416.	1.2	30
1912	Phase ^{II} trial of ofatumumab plus ^{ESHAP} (Oâ€‹ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. British Journal of Haematology, 2016, 174, 859-867.	1.2	12
1913	Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP. British Journal of Haematology, 2016, 174, 876-886.	1.2	7
1914	Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era. Cancer Research and Treatment, 2016, 48, 304-311.	1.3	9
1915	Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK). Annals of Hematology, 2016, 95, 619-624.	0.8	4
1916	Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. Cancer Immunology Research, 2016, 4, 215-224.	1.6	128
1917	Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Annals of Hematology, 2016, 95, 11-18.	0.8	33
1918	Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. International Journal of Hematology, 2016, 103, 86-94.	0.7	28
1919	Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. Journal of Clinical Oncology, 2016, 34, 1112-1121.	0.8	513
1920	Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma. Hematology, 2016, 21, 99-105.	0.7	37
1921	Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 76-81.	0.2	8
1922	Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 117-121.	0.2	9
1923	Combined prognostic value of absolute lymphocyte/monocyte ratio in peripheral blood and interim PET/CT results in Hodgkin lymphoma. International Journal of Hematology, 2016, 103, 63-69.	0.7	8
1924	Reduced-dose ICE chemotherapyâ€‹rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 1633-1639.	0.6	12
1925	Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research, 2016, 22, 34-43.	3.2	159
1926	Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. Immunotherapy, 2016, 8, 17-26.	1.0	19
1927	Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet, The, 2016, 387, 770-778.	6.3	389

#	ARTICLE	IF	CITATIONS
1928	Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2016, 58, 112-121.	1.3	64
1929	Ibrutinib for treatment of chronic lymphocytic leukemia. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 367-375.	0.5	12
1930	Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment. <i>Leukemia and Lymphoma</i> , 2016, 57, 2425-2428.	0.6	0
1931	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. <i>Lancet Haematology</i> , 2016, 3, e196-e204.	2.2	344
1932	Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. <i>Oncolmmunology</i> , 2016, 5, e1139274.	2.1	24
1933	¹⁸ F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 855-860.	2.8	40
1934	Recommendations to stage and assess the response to therapy of lymphomas with [18F]FDG-PET-CT. <i>Medecine Nucleaire</i> , 2016, 40, 55-64.	0.2	2
1935	High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma. <i>Experimental Hematology</i> , 2016, 44, 238-246.e2.	0.2	46
1936	Interim Positron Emission Tomography Response – Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1376-1385.	0.8	128
1937	Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. <i>Radiology</i> , 2016, 280, 220-229.	3.6	39
1938	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. <i>Leukemia and Lymphoma</i> , 2016, 57, 2370-2374.	0.6	5
1939	Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma. <i>Annals of Hematology</i> , 2016, 95, 801-808.	0.8	18
1940	Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. <i>Annals of Hematology</i> , 2016, 95, 809-816.	0.8	16
1941	Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1355-1362.	0.6	36
1942	B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2016, 57, 2375-2381.	0.6	7
1943	Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China. <i>Oncology Research and Treatment</i> , 2016, 39, 45-52.	0.8	8
1944	High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan. <i>Acta Haematologica</i> , 2016, 135, 156-161.	0.7	9
1945	Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. <i>Bone Marrow Transplantation</i> , 2016, 51, 654-662.	1.3	9

#	ARTICLE	IF	CITATIONS
1946	High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma. <i>Annals of Hematology</i> , 2016, 95, 49-54.	0.8	7
1947	<i><i>MYD88</i> L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. <i>Clinical Cancer Research</i>, 2016, 22, 2755-2764.</i>	3.2	55
1948	High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era. <i>Leukemia Research</i> , 2016, 42, 1-6.	0.4	49
1949	Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 673-679.	1.3	6
1950	LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy. <i>International Journal of Hematology</i> , 2016, 103, 292-298.	0.7	12
1951	Prognostic value of baseline total metabolic tumor volume (TMTVO) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). <i>Annals of Oncology</i> , 2016, 27, 719-724.	0.6	90
1952	The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2016, 57, 1876-1882.	0.6	11
1953	A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. <i>Annals of Oncology</i> , 2016, 27, 712-718.	0.6	41
1954	Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1017-1023.	2.0	20
1955	Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings. <i>Medicine (United States)</i> , 2016, 95, e2808.	0.4	16
1956	Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens. <i>Oncologist</i> , 2016, 21, 343-353.	1.9	24
1957	Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castlemans disease. <i>Current Medical Research and Opinion</i> , 2016, 32, 1193-1200.	0.9	5
1958	Assessment of Sequential PET/MRI in Comparison With PET/CT of Pediatric Lymphoma: A Prospective Study. <i>American Journal of Roentgenology</i> , 2016, 206, 623-631.	1.0	67
1959	Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection. <i>Annals of Hematology</i> , 2016, 95, 593-601.	0.8	45
1960	Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. <i>Annals of Hematology</i> , 2016, 95, 603-611.	0.8	7
1961	Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 3801-3809.	3.2	151
1962	The evolving role of response-adapted PET imaging in Hodgkin lymphoma. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 108-125.	1.1	14
1963	Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology. <i>Radiographics</i> , 2016, 36, 481-496.	1.4	80

#	ARTICLE	IF	CITATIONS
1964	Epsteinâ€Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. <i>Annals of Oncology</i> , 2016, 27, 508-513.	0.6	51
1965	The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. <i>Oncologist</i> , 2016, 21, 102-109.	1.9	34
1966	Prognostic value of negative interim 2-[18F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma. <i>Clinical Radiology</i> , 2016, 71, 280-286.	0.5	12
1967	A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). <i>European Journal of Cancer</i> , 2016, 54, 11-17.	1.3	63
1968	Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy. <i>Annals of Hematology</i> , 2016, 95, 1-9.	0.8	37
1969	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2016, 57, 1823-1830.	0.6	30
1970	Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 347-364.	1.4	4
1971	Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 48-56.	5.1	189
1972	Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2016, 57, 635-643.	0.6	21
1973	A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 880-887.	0.6	9
1974	Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 842-851.	0.6	7
1975	FDG PET/CT Response Assessment Criteria for Patients with Hodgkinâ€™s and Non-Hodgkinâ€™s Lymphoma at End of Therapy: A Multiparametric Approach. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 46-53.	0.6	13
1976	Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 380-385.	2.0	37
1977	Clinical Nuclear Medicine in Pediatrics. , 2016, , .		0
1978	Role of WB-MR/DWIBS compared to 18F-FDG PET/CT in the therapy response assessment of lymphoma. <i>Radiologia Medica</i> , 2016, 121, 132-143.	4.7	28
1979	Exploring the role of bone marrow increased FDG uptake on PET/CT in patients with lymphoma-associated hemophagocytic lymphohistiocytosis: a reflection of bone marrow involvement or cytokine storm?. <i>Leukemia and Lymphoma</i> , 2016, 57, 291-298.	0.6	13
1980	Ionizing radiation exposure as a result of diagnostic imaging in patients with lymphoma. <i>Clinical and Translational Oncology</i> , 2016, 18, 533-536.	1.2	6
1981	Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 493-498.	2.0	38

#	ARTICLE	IF	CITATIONS
1982	Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients. <i>Experimental Hematology</i> , 2016, 44, 3-13.	0.2	7
1983	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. <i>Leukemia and Lymphoma</i> , 2016, 57, 717-720.	0.6	13
1984	CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases. <i>Tumor Biology</i> , 2016, 37, 3619-3637.	0.8	20
1985	Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. <i>Leukemia</i> , 2016, 30, 361-372.	3.3	55
1986	Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL. <i>Irish Journal of Medical Science</i> , 2016, 185, 773-777.	0.8	3
1987	Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2016, 57, 28-33.	0.6	14
1988	Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas. <i>Hematological Oncology</i> , 2017, 35, 17-24.	0.8	9
1989	Stem cell transplantation outcomes in lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 366-371.	0.6	11
1990	Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 316-323.	0.6	10
1991	FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. <i>Leukemia and Lymphoma</i> , 2017, 58, 372-381.	0.6	13
1992	Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis. <i>Leukemia and Lymphoma</i> , 2017, 58, 457-460.	0.6	3
1993	Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers. <i>Cancer Letters</i> , 2017, 387, 25-31.	3.2	24
1994	Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series. <i>Hematological Oncology</i> , 2017, 35, 510-519.	0.8	46
1995	Beta α 2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 440-446.	0.8	27
1996	Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment. <i>Hematological Oncology</i> , 2017, 35, 69-78.	0.8	25
1997	A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemother. <i>Hematological Oncology</i> , 2017, 35, 288-295.	0.8	8
1998	International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. <i>Blood</i> , 2017, 129, 1646-1657.	0.6	381
1999	Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2017, 102, e203-e206.	1.7	21

#	ARTICLE	IF	CITATIONS
2000	Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL): Methodology statement. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26421.	0.8	35
2001	Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2051-2056.	0.6	7
2002	Prognóstico similar de los linfomas transformados y los linfomas difusos de células B grandes de novo en pacientes tratados con inmunoterapia. <i>Medicina Clínica</i> , 2017, 148, 243-249.	0.3	1
2003	Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. <i>Blood</i> , 2017, 129, 1469-1479.	0.6	276
2004	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. <i>Molecular Therapy</i> , 2017, 25, 285-295.	3.7	498
2005	Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. <i>Bone Marrow Transplantation</i> , 2017, 52, 697-703.	1.3	9
2006	Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 367-373.	1.9	6
2007	Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 778-784.	0.8	72
2008	Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma: a real world study. <i>Hematological Oncology</i> , 2017, 35, 528-535.	0.8	56
2009	Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2017, 52, 689-696.	1.3	31
2010	HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. <i>Modern Pathology</i> , 2017, 30, 745-760.	2.9	60
2011	Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients. <i>Medical Oncology</i> , 2017, 34, 29.	1.2	9
2012	Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva. <i>Radiotherapy and Oncology</i> , 2017, 122, 445-451.	0.3	12
2013	A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1349-1357.	0.6	20
2014	Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2074-2079.	0.6	18
2015	A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. <i>British Journal of Haematology</i> , 2017, 177, 243-253.	1.2	61
2016	Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies. <i>AAPS Journal</i> , 2017, 19, 669-681.	2.2	8
2017	Results from the Belgian mantle cell lymphoma registry. <i>Acta Clinica Belgica</i> , 2017, 72, 172-178.	0.5	3

#	ARTICLE	IF	CITATIONS
2018	A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LRâ€CD) for untreated lowâ€grade nonâ€Hodgkin lymphoma requiring therapy. <i>American Journal of Hematology</i> , 2017, 92, 467-472.	2.0	15
2019	Clinical Features and Prognosis Analysis of Hodgkin Lymphoma: A Multicenter Retrospective Study Over a Decade of Patients in China. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 274-282.	0.2	4
2020	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e137-e146.	2.2	28
2021	Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma. <i>International Journal of Clinical Oncology</i> , 2017, 22, 585-592.	1.0	5
2022	Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 544-551.	0.8	172
2023	Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 922-929.	2.0	9
2024	Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin. <i>Oncologist</i> , 2017, 22, 422-431.	1.9	25
2025	A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2017, 58, 2310-2318.	0.6	43
2026	B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study. <i>EBioMedicine</i> , 2017, 16, 106-114.	2.7	15
2027	Clinical and pathological characteristics of HIV- and HHV-8â€negative Castleman disease. <i>Blood</i> , 2017, 129, 1658-1668.	0.6	127
2028	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. <i>Blood</i> , 2017, 129, 2224-2232.	0.6	243
2029	Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. <i>Haematologica</i> , 2017, 102, 150-159.	1.7	61
2030	Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. <i>Haematologica</i> , 2017, 102, 903-909.	1.7	64
2031	Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 886-898.	1.0	16
2032	Utility of baseline, interim and end-of-treatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase. <i>Scientific Reports</i> , 2017, 7, 41057.	1.6	23
2033	Population pharmacokinetics of rituximab in patients with diffuse large Bâ€cell lymphoma and association with clinical outcome. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1782-1790.	1.1	38
2034	Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. <i>Blood</i> , 2017, 129, 2328-2330.	0.6	72
2035	Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. <i>Haematologica</i> , 2017, 102, 765-772.	1.7	21

#	ARTICLE	IF	CITATIONS
2036	Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP <i>versus</i> R-CHOP in the phase 3 LYM-3002 study. <i>Haematologica</i> , 2017, 102, 895-902.	1.7	6
2037	The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy. <i>Molecular Imaging and Biology</i> , 2017, 19, 787-794.	1.3	13
2038	Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma. <i>Drugs</i> , 2017, 77, 435-445.	4.9	90
2039	Allogeneic hematopoietic stem cell transplantation for non-Hodgkinâ€™s lymphomas: a retrospective analysis of 77 cases. <i>Annals of Hematology</i> , 2017, 96, 787-796.	0.8	3
2040	Neither Posttreatment PET/CT Nor Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 684-685.	2.8	4
2041	High-Dose Methotrexate and Cytarabine-Based Multi-Agent Chemotherapy (Modified Bonn Protocol) for Systemic Lymphoma with CNS Involvement. <i>Acta Haematologica</i> , 2017, 137, 93-99.	0.7	4
2042	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. <i>Blood</i> , 2017, 129, 3419-3427.	0.6	335
2043	Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP. <i>Hematology</i> , 2017, 22, 521-526.	0.7	10
2044	Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2017, 7, e558-e558.	2.8	16
2045	Unmet needs in the first-line treatment of follicular lymphoma. <i>Annals of Oncology</i> , 2017, 28, 2094-2106.	0.6	31
2046	Transformed follicular lymphoma (tFL): consolidation therapy may improve survival. <i>Irish Journal of Medical Science</i> , 2017, 186, 589-595.	0.8	1
2047	Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy. <i>Acta Haematologica</i> , 2017, 137, 76-85.	0.7	38
2048	FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 97-110.	3.3	208
2049	A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2017, 22, 554-560.	1.9	35
2050	Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?. <i>Blood</i> , 2017, 129, 3059-3070.	0.6	30
2051	Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. <i>Oncologist</i> , 2017, 22, 549-553.	1.9	4
2052	Advanced Hodgkinâ€™s lymphoma: End-of-treatment FDG-PET should be maintained. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1254-1257.	3.3	7
2053	Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2017, 130, 267-270.	0.6	255

#	ARTICLE	IF	CITATIONS
2054	Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography. <i>Annals of Hematology</i> , 2017, 96, 1147-1153.	0.8	15
2055	Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e272-e282.	2.2	91
2056	Toward common response evaluation criteria for solid tumors and lymphomas: RECIL and RECIST?. <i>Annals of Oncology</i> , 2017, 28, 1409-1411.	0.6	6
2057	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. <i>Blood</i> , 2017, 129, 3175-3183.	0.6	126
2058	Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 243-249.	0.1	0
2059	Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with Refractory or Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1276-1281.	2.0	5
2060	FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma. <i>Oncologist</i> , 2017, 22, 585-591.	1.9	124
2061	Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. <i>The Cochrane Library</i> , 2017, 4, CD007110.	1.5	8
2062	Time to publish: challenging the performance of cooperative group lymphoma trials. <i>Lancet Haematology</i> , 2017, 4, e8-e10.	2.2	2
2063	A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. <i>Cancer</i> , 2017, 123, 1174-1183.	2.0	51
2064	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology</i> , 2017, 4, e15-e23.	2.2	106
2065	Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients. <i>European Journal of Haematology</i> , 2017, 98, 355-362.	1.1	2
2066	ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma. <i>Annals of Oncology</i> , 2017, 28, 849-854.	0.6	24
2067	Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. <i>Rheumatology</i> , 2017, 56, 940-946.	0.9	44
2068	<sc>L</sc>-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 759-768.	1.1	29
2069	Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. <i>Annals of Oncology</i> , 2017, 28, 2191-2198.	0.6	11
2070	No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status. <i>Cancer Epidemiology</i> , 2017, 48, 110-116.	0.8	8
2071	Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. <i>American Journal of Hematology</i> , 2017, 92, 879-884.	2.0	28

#	ARTICLE	IF	CITATIONS
2072	Comparison of clinicopathologic characteristics of gastric follicular lymphomas and duodenal follicular lymphomas. <i>Human Pathology</i> , 2017, 65, 201-208.	1.1	9
2073	BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. <i>Statistics in Medicine</i> , 2017, 36, 3302-3314.	0.8	62
2074	Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim ^{PET}/^{CT} is beneficial: a prospective multicentre trial of 355 patients. <i>British Journal of Haematology</i> , 2017, 178, 709-718.	1.2	31
2075	The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus ^{CHOP} in patients with newly diagnosed peripheral Tâ€cell lymphoma with analysis of biomarkers. <i>British Journal of Haematology</i> , 2017, 178, 772-780.	1.2	25
2076	Multicenter phase ^{II} study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. <i>Cancer Science</i> , 2017, 108, 1007-1012.	1.7	55
2077	Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 94-102.	0.4	31
2078	Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. <i>The Cochrane Library</i> , 2017, 5, CD007941.	1.5	47
2079	Evolution of lymphoma staging and response evaluation: current limitations and future directions. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 631-645.	12.5	26
2080	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 117.	6.9	20
2081	Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 608-638.	2.3	81
2082	Impact of comorbidities on outcomes of elderly patients with diffuse large Bâ€cell lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 989-996.	2.0	33
2083	Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. <i>Annals of Oncology</i> , 2017, 28, 1064-1069.	0.6	65
2084	Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+â€R) is an effective treatment with low toxicity in Hodgkinâ€™s and non-Hodgkinâ€™s lymphomas. <i>Annals of Hematology</i> , 2017, 96, 943-950.	0.8	13
2085	Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. <i>Blood</i> , 2017, 129, 3037-3039.	0.6	68
2086	The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma. <i>American Journal of the Medical Sciences</i> , 2017, 353, 459-465.	0.4	13
2087	Phase II study of idelalisib, a selective inhibitor of PI3KÎ, for relapsed/refractory classical Hodgkin lymphoma. <i>Annals of Oncology</i> , 2017, 28, 1057-1063.	0.6	43
2088	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017, 28, 1436-1447.	0.6	249
2089	Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. <i>British Journal of Haematology</i> , 2017, 178, 403-412.	1.2	57

#	ARTICLE	IF	CITATIONS
2090	Hodgkin Lymphoma Outcome: A Retrospective Study from 3 Tertiary Centers in Saudi Arabia. <i>Oncology Research and Treatment</i> , 2017, 40, 288-292.	0.8	11
2091	Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 2745-2747.	0.6	3
2092	Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 305-311.e2.	0.2	6
2093	Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 1066-1076.	0.4	19
2094	Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14756.	5.8	70
2095	Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort. <i>Journal of Hematology and Oncology</i> , 2017, 10, 70.	6.9	66
2096	Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. <i>Lancet Haematology</i> , 2017, 4, e176-e182.	2.2	77
2097	A phase 2 trial of alisertib in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2268-2269.	0.6	4
2098	Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2815-2823.	0.6	19
2099	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4119-4126.	3.2	17
2100	Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma. <i>Advances in Radiation Oncology</i> , 2017, 2, 197-203.	0.6	11
2101	Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment. <i>Annals of Hematology</i> , 2017, 96, 411-420.	0.8	19
2102	The emerging role of immune checkpoint inhibition in malignant lymphoma. <i>Haematologica</i> , 2017, 102, 30-42.	1.7	101
2103	Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. <i>Hematological Oncology</i> , 2017, 35, 679-684.	0.8	32
2104	Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e35-e45.	2.2	33
2105	Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. <i>Annals of Oncology</i> , 2017, 28, 843-848.	0.6	83
2106	Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan. <i>Journal of Clinical Oncology</i> , 2017, 35, 32-39.	0.8	122
2107	Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013. <i>Leukemia and Lymphoma</i> , 2017, 58, 1805-1813.	0.6	13

#	ARTICLE	IF	CITATIONS
2108	Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. <i>Haematologica</i> , 2017, 102, e156-e159.	1.7	68
2109	Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan. <i>International Journal of Hematology</i> , 2017, 105, 470-477.	0.7	12
2110	<sc>RB</sc> but not Râ€œ<sc>HCVAD</sc> is a feasible induction regimen prior to autoâ€œ<sc>HCT</sc> in frontline <sc>MCL</sc>: results of <sc>SWOG</sc> Study S1106. <i>British Journal of Haematology</i> , 2017, 176, 759-769.	1.2	40
2111	Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization. <i>Haematologica</i> , 2017, 102, 52-59.	1.7	26
2112	Serum level of <sc>CXCL10</sc> is associated with inflammatory prognostic biomarkers in patients with diffuse large <sc>B</sc>-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 480-486.	0.8	23
2113	Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. <i>British Journal of Haematology</i> , 2017, 176, 591-599.	1.2	46
2114	The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma. <i>British Journal of Haematology</i> , 2017, 176, 750-758.	1.2	78
2115	A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. <i>Cancer</i> , 2017, 123, 1363-1371.	2.0	18
2116	A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type. <i>EBioMedicine</i> , 2017, 25, 41-49.	2.7	45
2117	Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1331-1344.	13.9	575
2118	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e510-e523.	2.2	258
2119	Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. <i>Blood</i> , 2017, 130, 2709-2717.	0.6	176
2120	Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. <i>Leukemia Research</i> , 2017, 62, 12-16.	0.4	32
2121	Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged â‰¥60 years with HL. <i>Blood</i> , 2017, 130, 2829-2837.	0.6	69
2122	A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkinâ€™s lymphoma (NHL): CALGB 50803 (Alliance). <i>Annals of Oncology</i> , 2017, 28, 2806-2812.	0.6	72
2123	Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores. <i>Annals of Hematology</i> , 2017, 96, 1873-1881.	0.8	3
2124	Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 70-77.	0.7	5
2125	Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. <i>Cancer</i> , 2017, 123, 4851-4859.	2.0	45

#	ARTICLE	IF	CITATIONS
2126	A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral Tâ€cell lymphomas. American Journal of Hematology, 2017, 92, 1287-1294.	2.0	21
2127	Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma. Drugs, 2017, 77, 1645-1655.	4.9	5
2128	18 F-FDG PET/CT in the clinical management of patients with lymphoma. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2017, 36, 312-321.	0.1	3
2129	Optimization of metabolic criteria in the prognostic assessment of patients with lymphoma. A multicenter study. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2017, 36, 304-311.	0.1	1
2130	Phase II<sc> study of pralatrexate in Japanese patients with relapsed or refractory peripheral Tâ€cell lymphoma. Cancer Science, 2017, 108, 2061-2068.	1.7	29
2131	CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. Haematologica, 2017, 102, 1923-1930.	1.7	98
2132	Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. Aids, 2017, 31, 2493-2501.	1.0	51
2134	A MALT lymphoma prognostic index. Blood, 2017, 130, 1409-1417.	0.6	149
2135	Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematology, the, 2017, 4, e350-e361.	2.2	69
2136	Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials. British Journal of Haematology, 2017, 179, 242-245.	1.2	12
2137	Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents. Clinical Cancer Research, 2017, 23, 7158-7164.	3.2	11
2138	FDG-PETâ€driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood, 2017, 130, 1315-1326.	0.6	87
2139	Debate on the value of end-of-treatment FDG-PET response evaluation in follicular lymphoma. Acta OncolÃ³gica, 2017, 56, 1789-1791.	0.8	4
2140	Linfomas con reordenamiento de MYC distintos del linfoma de Burkitt: comparaciÃ³n entre R-CHOP y la inmunoterapia tipo Burkitt. Medicina ClÃnica, 2017, 149, 339-342.	0.3	2
2141	OptimizaciÃ³n de los criterios metabÃ³licos en la valoraciÃ³n pronÃ³stica de los pacientes con linfoma. Estudio multicÃ©ntrico. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2017, 36, 304-311.	0.0	2
2142	Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplantation, 2017, 52, 1342-1344.	1.3	12
2143	Longâ€term analysis of phase II studies of singleâ€agent lenalidomide in relapsed/refractory mantle cell lymphoma. American Journal of Hematology, 2017, 92, E575-E583.	2.0	17
2144	Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor Tâ€Cell Therapy. Molecular Therapy, 2017, 25, 2245-2253.	3.7	227

#	ARTICLE	IF	CITATIONS
2145	18 F-FDG PET/TC en el manejo cl�nico de los linfomas. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2017, 36, 312-321.	0.0	3
2146	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica, 2017, 102, 1796-1805.	1.7	200
2148	Precision Medicine and PET�Computed Tomography in Pediatric Malignancies. PET Clinics, 2017, 12, 423-435.	1.5	1
2149	Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma. Annals of Oncology, 2017, 28, 2799-2805.	0.6	22
2150	Patterns of failure of diffuse large B�cell lymphoma patients after involved-site radiotherapy. Strahlentherapie Und Onkologie, 2017, 193, 1014-1023.	1.0	3
2151	Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of 18FDG-PET/CT according to �SUVmax, Deauville 5-point scale and IHP criteria. Annals of Nuclear Medicine, 2017, 31, 660-668.	1.2	21
2152	Clinical characteristics and prognosis of primary Waldenstrom's ring and lymph node diffuse large B-cell lymphoma in the rituximab era. Leukemia Research, 2017, 60, 89-93.	0.4	4
2153	Response to the letter by Adams and Kwee, entitled: �Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma�. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1937-1939.	3.3	0
2154	Interim FDG-PET in lymphoma, a questionable practice in hematology. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2014-2017.	3.3	2
2155	Pediatric Hodgkin Lymphoma. Medicine (United States), 2017, 96, e5973.	0.4	21
2156	Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. British Journal of Haematology, 2017, 178, 699-708.	1.2	61
2157	The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. Blood, 2017, 130, 1491-1498.	0.6	29
2158	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica, 2017, 102, 1931-1935.	1.7	11
2159	Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. American Journal of Surgical Pathology, 2017, 41, 1309-1321.	2.1	32
2160	Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case. Clinical Case Reports (discontinued), 2017, 5, 1385-1388.	0.2	5
2161	Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. Journal of Drug Assessment, 2017, 6, 10-17.	1.1	20
2162	Transformed Waldenstr�m macroglobulinaemia: clinical presentation and outcome. A multi�institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (<scp>FILO</scp>). British Journal of Haematology, 2017, 179, 439-448.	1.2	39
2163	Axicabtagene CiloleuceL CART T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine, 2017, 377, 2531-2544.	13.9	3,865

#	ARTICLE	IF	CITATIONS
2164	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. <i>New England Journal of Medicine</i> , 2017, 377, 2545-2554.	13.9	1,390
2165	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. <i>Lancet Haematology</i> , 2017, 4, e595-e606.	2.2	130
2166	Tumor and bone marrow uptakes on [18F]fluorodeoxyglucose positron emission tomography/computed tomography predict prognosis in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. <i>Medicine (United States)</i> , 2017, 96, e8655.	0.4	5
2167	Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study. <i>BMJ Open</i> , 2017, 7, e017904.	0.8	23
2168	Progression-free survival at 2 years post autologous transplant: a surrogate end point for overall survival in follicular lymphoma. <i>Cancer Medicine</i> , 2017, 6, 2766-2774.	1.3	11
2169	MYC-rearranged lymphomas other than Burkitt: Comparison between R-CHOP and Burkitt-type immunochemotherapy. <i>Medicina Clínica (English Edition)</i> , 2017, 149, 339-342.	0.1	0
2170	Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2017, 102, 2104-2112.	1.7	41
2171	Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1168-1176.	1.0	21
2172	Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation. <i>British Journal of Haematology</i> , 2017, 178, 927-935.	1.2	8
2173	Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type. <i>Annals of Hematology</i> , 2017, 96, 1477-1483.	0.8	20
2174	Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. <i>International Journal of Hematology</i> , 2017, 106, 655-665.	0.7	33
2175	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , 2017, 18, 1076-1088.	5.1	100
2176	How to Approach a Patient With Limited Stage Hodgkin Lymphoma Who Remains PET Positive at the End of Chemotherapy: Radiation Therapy?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 710-715.	0.2	2
2177	Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 637-644.	0.2	14
2178	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	1.2	49
2179	Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2017, 179, 75-82.	1.2	15
2180	The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients. <i>BMC Cancer</i> , 2017, 17, 276.	1.1	10
2181	Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 216-222.	0.7	8

#	ARTICLE	IF	CITATIONS
2182	Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. <i>Annals of Oncology</i> , 2017, 28, 2496-2502.	0.6	60
2183	Systematic Review on the Additional Value of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging Follicular Lymphoma. <i>Journal of Computer Assisted Tomography</i> , 2017, 41, 98-103.	0.5	16
2184	Efficacy of prophylactic irradiation to the contralateral testis for patients with advanced-stage primary testicular lymphoma: an analysis of outcomes at a single institution. <i>International Journal of Hematology</i> , 2017, 106, 533-540.	0.7	4
2185	Imaging for Oncologic Response Assessment in Lymphoma. <i>American Journal of Roentgenology</i> , 2017, 208, 18-31.	1.0	22
2186	Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 60-66.	2.0	17
2187	The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. <i>Leukemia and Lymphoma</i> , 2017, 58, 1358-1365.	0.6	35
2188	Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 1570-1580.	0.6	8
2189	Peripheral blood lymphocyte/monocyte ratio following completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2017, 96, 237-243.	0.8	3
2190	Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose. <i>Leukemia and Lymphoma</i> , 2017, 58, 1589-1597.	0.6	2
2191	The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 1144-1152.	0.6	28
2192	A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. <i>Modern Rheumatology</i> , 2017, 27, 849-854.	0.9	62
2193	The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 45-52.	0.6	2
2194	Pretreatment 14C3 epsilon level is predictive for advanced extranodal NK/T cell lymphoma therapeutic response to asparaginase-based chemotherapy. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1600111.	0.8	10
2195	Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with) Tj ETQq1 1 0.784314 rgBT /Overl... Aggressive B Cell Lymphoma: A GELTAMO Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 53-59.	2.0	12
2196	Investigator and independent review committee exploratory assessment and verification of tumor response in a non-Hodgkin lymphoma study. <i>Leukemia and Lymphoma</i> , 2017, 58, 1332-1340.	0.6	3
2197	Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. <i>Molecular Imaging and Biology</i> , 2017, 19, 429-436.	1.3	12
2198	Targeting histone deacetylases in T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1306-1319.	0.6	84
2199	Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 465-471.	0.8	5

#	ARTICLE	IF	CITATIONS
2200	T-cell subsets in lymph nodes identify a subgroup of follicular lymphoma patients with favorable outcome. <i>Leukemia and Lymphoma</i> , 2017, 58, 842-850.	0.6	6
2201	Dose-Adjusted EPOCH and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. <i>British Journal of Haematology</i> , 2017, 179, 851-854.	1.2	15
2202	Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score?. <i>British Journal of Haematology</i> , 2017, 177, 319-320.	1.2	4
2203	The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 536-541.	0.8	13
2204	Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 623-632.	0.6	5
2205	Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma. <i>Journal of Radiation Research</i> , 2017, 58, 114-122.	0.8	12
2206	Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study. <i>Hematological Oncology</i> , 2017, 35, 548-553.	0.8	22
2207	Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. <i>Clinical Cancer Research</i> , 2017, 23, 1156-1166.	3.2	275
2208	Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 1167-1176.	3.2	77
2209	¹⁸ F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab. <i>Journal of Nuclear Medicine</i> , 2017, 58, 62-68.	2.8	15
2210	Prognostic nutritional index as a predictor of prognosis in patients with diffuse large B-cell lymphoma. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 411-419.	1.0	21
2211	Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 577-583.	2.8	28
2212	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 42-49.	0.4	31
2213	Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study. <i>Leukemia and Lymphoma</i> , 2017, 58, 1130-1134.	0.6	11
2214	Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 822-833.	0.6	22
2215	Molecular Imaging and Precision Medicine. <i>PET Clinics</i> , 2017, 12, 105-118.	1.5	16
2216	The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions. <i>Leukemia and Lymphoma</i> , 2017, 58, 1178-1183.	0.6	1
2217	Rebound Thymic Hyperplasia after Chemotherapy in Children with Lymphoma. <i>Pediatrics and Neonatology</i> , 2017, 58, 151-157.	0.3	20

#	ARTICLE	IF	CITATIONS
2218	Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 752-753.	0.6	5
2219	Response Assessment Criteria and Their Applications in Lymphoma: Part 2. <i>Journal of Nuclear Medicine</i> , 2017, 58, 13-22.	2.8	33
2220	Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma. <i>JAMA Oncology</i> , 2017, 3, 83.	3.4	64
2221	Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. <i>Leukemia and Lymphoma</i> , 2017, 58, 1607-1616.	0.6	46
2222	Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Clinical Pharmacokinetics</i> , 2017, 56, 515-523.	1.6	42
2223	High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy. <i>Blood Cancer Journal</i> , 2017, 7, e614-e614.	2.8	11
2224	Whole-body magnetic resonance imaging and FDG-PET/CT for lymphoma staging: Assessment of patient experience. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2017, 48, 1043-1047.	0.3	7
2225	The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients—the Polish Lymphoma Research Group (PLRG) Observational Study. <i>Annals of Oncology</i> , 2017, 28, 3051-3057.	0.6	16
2226	Clinical manifestations and epigenetic mechanisms of gastric mucosa associated lymphoid tissue lymphoma and long-term follow-up following <i>Helicobacter</i> eradication. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 553-561.	0.8	11
2227	An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma. <i>Seminars in Oncology</i> , 2017, 44, 404-419.	0.8	14
2228	Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1295-1306.	2.0	11
2229	Estimation of joint angle based on surface electromyogram signals recorded at different load levels. , 2017, 2017, 2538-2541.		2
2230	HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. <i>Blood Advances</i> , 2017, 1, 1347-1357.	2.5	8
2231	Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. <i>Blood Advances</i> , 2017, 1, 2600-2609.	2.5	62
2232	Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes. <i>Journal of Clinical Investigation</i> , 2017, 127, 3462-3471.	3.9	301
2233	MYC Gene Rearrangements Are Closely Associated with Poor Survival of Diffuse Large B Cell Lymphoma with Hepatitis B Virus Infection. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	10
2234	Hodgkin Lymphoma and Castleman Disease: When One Blood Disease Can Hide Another. <i>Case Reports in Hematology</i> , 2017, 2017, 1-3.	0.3	10
2235	Assessment of chemotherapy response in non-Hodgkin lymphoma involving the neck utilizing diffusion kurtosis imaging: a preliminary study. <i>Diagnostic and Interventional Radiology</i> , 2017, 23, 245-249.	0.7	8

#	ARTICLE	IF	CITATIONS
2236	Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma. <i>Blood Research</i> , 2017, 52, 270.	0.5	6
2237	Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1719-1728.	2.0	69
2238	Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>PLoS ONE</i> , 2017, 12, e0169828.	1.1	50
2239	PD1 is highly expressed in diffuse large B-cell lymphoma with hepatitis B virus infection. <i>PLoS ONE</i> , 2017, 12, e0180390.	1.1	7
2240	3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis. <i>Internal Medicine</i> , 2017, 56, 2407-2413.	0.3	3
2241	TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP. <i>BMC Cancer</i> , 2017, 17, 743.	1.1	9
2242	Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). <i>Journal of Hematology and Oncology</i> , 2017, 10, 171.	6.9	41
2243	Significance of stromal-1 and stromal-2 signatures and biologic prognostic model in diffuse large B-cell lymphoma. <i>Cancer Biology and Medicine</i> , 2017, 14, 151.	1.4	16
2244	La bendamustine en association avec la gemcitabine et la vinorelbine: traitement d'induction avant une autogreffe de cellules souches dans le lymphome de Hodgkin en rechute ou réfractaire?. <i>Hematologie</i> , 2017, 23, 15-16.	0.0	0
2245	Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin's lymphoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5727-5738.	1.0	7
2246	Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2125-2132.	0.8	830
2247	Parameters for Contrast-Enhanced Ultrasound (CEUS) of Enlarged Superficial Lymph Nodes for the Evaluation of Therapeutic Response in Lymphoma: A Preliminary Study. <i>Medical Science Monitor</i> , 2017, 23, 5430-5438.	0.5	17
2248	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 2260-2267.	0.8	132
2249	Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3458-3464.	0.8	45
2250	Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. <i>Journal of Clinical Oncology</i> , 2017, 35, 1803-1813.	0.8	460
2251	Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3898-3905.	0.8	320
2252	Reply to H.J.A. Adams et al and E. Laffon et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 920-923.	0.8	3
2253	Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3529-3537.	0.8	333

#	ARTICLE	IF	CITATIONS
2254	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 826-833.	0.8	596
2255	Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3538-3546.	0.8	151
2256	Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3215-3221.	0.8	315
2257	Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy. <i>Oncotarget</i> , 2017, 8, 11480-11488.	0.8	13
2258	A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma. <i>Journal of Thoracic Disease</i> , 2017, 9, 1081-1092.	0.6	11
2259	Safety, tolerability, and preliminary activity of IMG529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. <i>Investigational New Drugs</i> , 2018, 36, 869-876.	1.2	33
2260	Umbralisib, a novel PI3K and casein kinase-1 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. <i>Lancet Oncology</i> , 2018, 19, 486-496.	5.1	178
2261	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. <i>Blood</i> , 2018, 131, 2515-2527.	0.6	307
2262	Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2018, 103, e215-e218.	1.7	131
2263	Response rates and recurrence patterns after low-dose radiotherapy with 4 Gy in patients with low-grade lymphomas. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 454-461.	1.0	22
2264	The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2018, 67, 82-85.	0.4	9
2265	Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. <i>Blood</i> , 2018, 131, 2120-2124.	0.6	56
2267	25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?. <i>Supportive Care in Cancer</i> , 2018, 26, 2825-2832.	1.0	9
2268	Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2018, 24, 2304-2311.	3.2	11
2269	Prognostic significance of retention index of bone marrow on dual-phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma. <i>Medicine (United States)</i> , 2018, 97, e9513.	0.4	7
2270	Feasibility of state of the art PET/CT systems performance harmonisation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1344-1361.	3.3	100
2271	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1602-1609.	2.0	15
2272	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). <i>Oncologist</i> , 2018, 23, 1033-1038.	1.9	3

#	ARTICLE	IF	CITATIONS
2273	Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience. <i>Annals of Hematology</i> , 2018, 97, 1619-1626.	0.8	4
2275	Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1705-1709.	3.3	4
2276	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. <i>Lancet Haematology</i> , 2018, 5, e190-e200.	2.2	50
2277	Extralymphatic Disease Is an Independent Prognostic Factor in Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e261-e266.	0.2	6
2278	The use of Deauville criteria in follow-up assessment of response to therapy in extra-nodal Non-Hodgkin's lymphoma. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2018, 49, 209-215.	0.3	3
2280	Voxtalib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e170-e180.	2.2	44
2281	Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2018, 101, 28-37.	1.1	8
2282	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. <i>Annals of Hematology</i> , 2018, 97, 1437-1443.	0.8	16
2283	Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1173-1183.	1.2	4
2284	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. <i>Lancet Oncology</i> , 2018, 19, 649-659.	5.1	450
2285	Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. <i>Clinical Cancer Research</i> , 2018, 24, 3273-3281.	3.2	20
2286	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	2.0	61
2287	Final results of a phase 1b study of the safety and efficacy of the PI3KÎ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. <i>Blood Cancer Journal</i> , 2018, 8, 16.	2.8	19
2288	Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 297-299.	0.2	1
2289	R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	2.2	20
2290	Safety and Preliminary Efficacy of Vorinostat WithÂR-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 180-190.e2.	0.2	11
2291	Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. <i>European Journal of Cancer</i> , 2018, 91, 136-144.	1.3	32
2292	Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2018, 29, 1266-1272.	0.6	106

#	ARTICLE	IF	CITATIONS
2293	The clinical manifestation, survival outcome and predictive prognostic factors of 137 patients with primary gastrointestinal lymphoma (PGIL). <i>Medicine (United States)</i> , 2018, 97, e9583.	0.4	12
2294	Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. <i>Haematologica</i> , 2018, 103, 857-864.	1.7	27
2295	BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 1051-1054.	1.3	4
2296	Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. <i>Blood</i> , 2018, 131, 1910-1919.	0.6	339
2297	Intra- and inter-observer agreement in the visual interpretation of interim 18F-FDG PET/CT in malignant lymphoma: influence of clinical information. <i>Acta Radiologica</i> , 2018, 59, 1218-1224.	0.5	3
2298	Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study. <i>Leukemia and Lymphoma</i> , 2018, 59, 896-903.	0.6	15
2299	Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution. <i>Acta Haematologica</i> , 2018, 139, 52-57.	0.7	0
2300	Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1187-1195.	2.0	38
2301	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. <i>Blood</i> , 2018, 131, 1456-1463.	0.6	130
2302	Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 983-988.	2.0	5
2303	Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 680-688.	3.3	72
2304	A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. <i>Haematologica</i> , 2018, 103, 840-848.	1.7	45
2305	PET/MRI in Lymphoma. , 2018, , 373-400.		1
2306	Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 2096-2104.	0.6	0
2307	Non-cancer drug consumption during the early trajectory of lymphoma survivorship. <i>Therapie</i> , 2018, 73, 307-317.	0.6	1
2308	Prognostic impact of activation-induced cytidine deaminase expression for patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2085-2095.	0.6	9
2309	Consolidation Radiation Therapy for Patients With Advanced Hodgkin Lymphoma in Complete Metabolic Response According to PET-CT or Gallium Imaging. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 145-151.	0.2	4
2310	The Deauville criteria cannot differentiate between responding and non-responding non-Hodgkin lymphoma patients. <i>Annals of Hematology</i> , 2018, 97, 719-720.	0.8	2

#	ARTICLE	IF	CITATIONS
2311	Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. <i>Clinical Cancer Research</i> , 2018, 24, 1011-1018.	3.2	31
2312	Activity of the PI3K- γ , δ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. <i>Blood</i> , 2018, 131, 888-898.	0.6	224
2313	A phase I/II trial of vorinostat (SAHA) in combination with rituximab+CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. <i>American Journal of Hematology</i> , 2018, 93, 486-493.	2.0	38
2314	Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 257-266.	5.1	89
2315	Validation and Refinement of the Age, Comorbidities, and Albumin Index in Elderly Patients with Diffuse Large B-Cell Lymphoma: An Effective Tool for Comprehensive Geriatric Assessment. <i>Oncologist</i> , 2018, 23, 722-729.	1.9	19
2316	A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2128-2134.	0.6	5
2317	Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2018, 53, 400-409.	1.3	34
2318	HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e143-e146.	0.2	15
2319	Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. <i>Oncologist</i> , 2018, 23, 454-460.	1.9	22
2320	Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. <i>Annals of Oncology</i> , 2018, 29, 707-714.	0.6	46
2321	HCV load as a possible prognostic factor in patients with HCV-related DLBCL. <i>Annals of Hematology</i> , 2018, 97, 351-354.	0.8	1
2322	Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol. <i>BMC Cancer</i> , 2018, 18, 122.	1.1	9
2323	The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders. <i>Annals of Hematology</i> , 2018, 97, 1611-1618.	0.8	12
2324	E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study. <i>Cancer Science</i> , 2018, 109, 794-802.	1.7	27
2325	Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2018, 132, 179-186.	0.6	63
2326	Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2856-2859.	0.6	25
2327	Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes. <i>Hematological Oncology</i> , 2018, 36, 533-542.	0.8	5
2328	Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2018, 132, 40-48.	0.6	199

#	ARTICLE	IF	CITATIONS
2329	Phase 1 study of the PI3KÎ inhibitor INCB040093 + JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. <i>Blood</i> , 2018, 132, 293-306.	0.6	45
2330	Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1672-1679.	3.3	24
2331	Resistance to Ibritumomab in Lymphoma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , .	0.1	0
2332	A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1982-1989.	0.3	27
2333	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. <i>Haematologica</i> , 2018, 103, 1191-1197.	1.7	90
2334	Endovascular Treatment of Symptomatic Thoracic Aneurysm Due to Periaortic Lymphoma. <i>Vascular and Endovascular Surgery</i> , 2018, 52, 367-370.	0.3	5
2335	Retrospective Analysis of a New Prognostic Score for Diffuse Large B-Cell Lymphoma Based on Interim Positron Emission Tomography-Computed Tomography. <i>Acta Haematologica</i> , 2018, 139, 148-157.	0.7	3
2336	Late duodenal metastasis from renal cell carcinoma with newly developed malignant lymphoma: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 8, 549-552.	0.4	2
2337	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	2.3	476
2338	Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. <i>Investigational New Drugs</i> , 2018, 36, 877-885.	1.2	5
2339	University of Chicago phase II consortium trial of selumetinib (<scp>MEK</scp>i) demonstrates low tolerability and efficacy in relapsed DLBCL. <i>British Journal of Haematology</i> , 2018, 181, 264-267.	1.2	4
2340	Complete metabolic response (CMR) in positron emission tomography-computed tomography (PET-CT) scans may have prognostic significance in patients with marginal zone lymphomas (MZL). <i>Hematological Oncology</i> , 2018, 36, 56-61.	0.8	6
2341	Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with <scp>PD</scp>1 inhibition. <i>British Journal of Haematology</i> , 2018, 181, 837-840.	1.2	24
2342	Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study. <i>Hematological Oncology</i> , 2018, 36, 159-165.	0.8	10
2343	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. <i>Hematological Oncology</i> , 2018, 36, 174-181.	0.8	15
2344	Combination of rituximab and nonpegylated liposomal doxorubicin (<scp>R-IPLD</scp>) as front-line therapy for aggressive non-Hodgkin lymphoma (<scp>NHL</scp>) in patients 80 years of age or older: a single-center retrospective study. <i>Hematological Oncology</i> , 2018, 36, 44-48.	0.8	13
2345	Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores. <i>Leukemia and Lymphoma</i> , 2018, 59, 340-347.	0.6	22
2346	Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry. <i>Leukemia and Lymphoma</i> , 2018, 59, 85-96.	0.6	5

#	ARTICLE	IF	CITATIONS
2347	¹⁸ F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor. <i>Journal of Nuclear Medicine</i> , 2018, 59, 15-24.	2.8	102
2348	Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. <i>Investigational New Drugs</i> , 2018, 36, 62-74.	1.2	3
2349	Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 93-97.	0.8	22
2350	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. <i>Leukemia</i> , 2018, 32, 353-363.	3.3	36
2351	Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 715-718.	1.2	4
2352	Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials. <i>Hematological Oncology</i> , 2018, 36, 37-43.	0.8	16
2353	Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 343-352.	2.0	61
2354	Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients. <i>International Journal of Cancer</i> , 2018, 142, 940-948.	2.3	13
2355	Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 282-287.	2.0	8
2356	Alternating R-CHOP and R-ctarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 110-115.	0.8	18
2357	Relapse in stage I(E) diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 416-421.	0.8	9
2358	Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e35-e39.	0.2	18
2359	Polymorphic lymphoproliferative disorders in patients with rheumatoid arthritis are associated with a better clinical outcome. <i>Modern Rheumatology</i> , 2018, 28, 621-625.	0.9	8
2360	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. <i>Blood</i> , 2018, 131, 182-190.	0.6	130
2361	Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma. <i>Clinical Nuclear Medicine</i> , 2018, 43, 1-8.	0.7	20
2362	PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 28-36.	2.5	22
2363	Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 91-93.	1.3	6
2364	Positron Emission Tomography-Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 64-70.	2.0	19

#	ARTICLE	IF	CITATIONS
2365	PET/CT in Lymphoma: Current Overview and Future Directions. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 76-81.	2.5	57
2366	Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 58-64.	0.2	10
2367	A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 13-25.e6.	0.2	14
2368	Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 146-154.	1.3	9
2369	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 78-85.	2.0	9
2370	Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 294-300.	2.0	21
2371	Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 29-33.	1.3	14
2372	Phase I dose escalation study of the anti-CD2 monoclonal antibody, sipilizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2018, 59, 1466-1469.	0.6	10
2373	Mathematical modeling of efficacy and safety for anticancer drugs clinical development. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 5-21.	2.5	7
2374	Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type: a retrospective controlled study in a single center. <i>International Journal of Hematology</i> , 2018, 107, 98-104.	0.7	16
2375	Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). <i>Hematological Oncology</i> , 2018, 36, 62-67.	0.8	12
2376	Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients. <i>Journal of Nuclear Medicine</i> , 2018, 59, 589-595.	2.8	48
2377	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.	13.9	564
2378	Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2018, 391, 659-667.	6.3	324
2379	Acalabrutinib in mantle cell lymphoma. <i>Lancet, The</i> , 2018, 391, 633-634.	6.3	7
2380	Efficacy and tolerance of GEMOXD/GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study. <i>European Journal of Haematology</i> , 2018, 100, 247-256.	1.1	22
2381	Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance. <i>Annals of Hematology</i> , 2018, 97, 289-297.	0.8	3
2382	Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 1861-1870.	0.6	12

#	ARTICLE	IF	CITATIONS
2383	Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 365-373.	1.2	10
2384	PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 37-49.	2.5	28
2385	Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. <i>Annals of Hematology</i> , 2018, 97, 255-266.	0.8	30
2386	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 486-493.	2.0	3
2387	Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 1785-1794.	3.2	42
2388	DA-EPOCH-R in Aggressive CD 20 Positive B Cell Lymphomas: Real-World Experience. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 454-459.	0.3	5
2389	R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience. <i>Annals of Hematology</i> , 2018, 97, 277-287.	0.8	11
2390	Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. <i>Leukemia and Lymphoma</i> , 2018, 59, 1586-1595.	0.6	10
2391	A retrospective analysis of post-transplant lymphoproliferative disorder following liver transplantation. <i>European Journal of Haematology</i> , 2018, 100, 98-103.	1.1	6
2392	The case for lymphoma-specific survival. <i>Expert Review of Hematology</i> , 2018, 11, 263-264.	1.0	0
2393	The Role of Radiotherapy in Early-stage Primary Diffuse Large B-Cell Lymphoma of the Waldeyer Ring. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 802-806.	0.6	3
2394	A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 114-121.	1.0	5
2395	Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin,) Tj ETQq0 0 0 rgBT /Overlock 10 863-870.	0.6	22
2396	Can the SUV _{max-liver} -based interpretation improve prognostic accuracy of interim and posttreatment ¹⁸ F-FDG PET/CT in patients with diffuse large B-cell lymphoma?. <i>Leukemia and Lymphoma</i> , 2018, 59, 660-669.	0.6	21
2397	Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 871-879.	0.6	20
2398	A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D ₂); Tj ETQq1 1 0.784314 rgBT /Overlock 110	0.8	110
2399	Reply to H.J.A. Adams et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 3274-3275.	0.8	0
2400	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1428-1439.	0.8	551

#	ARTICLE	IF	CITATIONS
2401	Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. <i>Journal of Clinical Oncology</i> , 2018, 36, 2395-2404.	0.8	165
2402	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 942-950.	0.8	273
2403	Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2259-2266.	0.8	107
2404	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2405-2412.	0.8	81
2405	A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. <i>Blood Advances</i> , 2018, 2, 762-768.	2.5	19
2406	<i>Advances in Oncology Imaging</i> , 2018, , .		0
2407	Outcome of adult T-lymphoblastic lymphoma depends on ALL-type chemotherapy, prognostic factors, and performance of allogeneic hematopoietic stem cell transplantation. <i>Medicine (United States)</i> , 2018, 97, e11374.	0.4	13
2408	The Clinical Utility of Circulating Epstein-Barr Virus DNA Concentrations in NK/T-Cell Lymphoma: A Meta-Analysis. <i>Disease Markers</i> , 2018, 2018, 1-8.	0.6	7
2409	Predictors of Poor Response to Salvage Chemotherapy in Relapsed/ Refractory Pediatric Hodgkin Lymphoma- A Retrospective Analysis from Tertiary Cancer Centre in India. <i>Annals of the National Academy of Medical Sciences (India)</i> , 2018, 54, 160-170.	0.2	0
2410	Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia. <i>Acta Clinica Croatica</i> , 2018, 57, 542-553.	0.1	10
2411	Hepatic Lymphoma: A Perplexing CT Diagnosis made Easy by 18F-FDG PET CT Imaging. <i>Journal of Nuclear Medicine & Radiation Therapy</i> , 2018, 09, .	0.2	0
2412	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. <i>British Journal of Haematology</i> , 2018, 183, 755-765.	1.2	41
2413	Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study. <i>Cancer Management and Research</i> , 2018, Volume 10, 5061-5069.	0.9	9
2414	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. <i>Lancet Haematology</i> , 2018, 5, e543-e553.	2.2	53
2415	Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. <i>British Journal of Haematology</i> , 2019, 184, 797-807.	1.2	13
2416	Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and Tj ETQq1 1 0.784314 rgBT /Overlo prospective, multicentre, single-arm phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e609-e617.	2.2	152
2417	<i>Imaging Criteria for Tumor Treatment Response Evaluation</i> , 2018, , 11-23.		0
2418	The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. <i>Blood</i> , 2018, 132, 2446-2455.	0.6	261

#	ARTICLE	IF	CITATIONS
2419	The Role of 18FDG-PET/CT in Malignant Lymphomas: Clinical Implications. , 2018, , 619-647.		0
2420	Improvements in Imaging of Hodgkin Lymphoma. Cancer Journal (Sudbury, Mass), 2018, 24, 215-222.	1.0	5
2421	Malignant Lymphomas Introduction. , 2018, , 605-608.		0
2422	Lymphomas: The Role of CT and MRI in Staging and Restaging. , 2018, , 609-618.		0
2423	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1530-1542.	5.1	91
2424	PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity. BMC Cancer, 2018, 18, 910.	1.1	9
2425	European research trends in nuclear medicine. Annals of Nuclear Medicine, 2018, 32, 579-582.	1.2	10
2426	Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood, 2018, 132, 2305-2309.	0.6	124
2427	High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial. Journal of Adolescent and Young Adult Oncology, 2018, 7, 546-552.	0.7	21
2428	Bone Involvement in Hodgkin's Lymphoma: Clinical Features and Outcome. Acta Haematologica, 2018, 140, 178-182.	0.7	21
2429	Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy. Leukemia Research, 2018, 74, 80-85.	0.4	2
2430	Evaluation of diffuse large B-cell lymphoma patients with 64-slice multidetector computed tomography versus 18FDG positron emission tomography/computed tomography in initial staging and restaging after treatment. Medicina Clínica (English Edition), 2018, 151, 255-264.	0.1	3
2431	Positron emission tomography/computed tomography in the diagnosis, staging, and prognostic evaluation of natural killer/T-cell lymphoma. Journal of International Medical Research, 2018, 46, 4920-4929.	0.4	6
2432	In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Molecular Therapy, 2018, 26, 2727-2737.	3.7	180
2433	Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematology, the, 2018, 5, e450-e461.	2.2	79
2434	Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. Blood Research, 2018, 53, 223.	0.5	0
2435	Comparison of Selection and Long-term Clinical Outcomes Between Chemotherapy and Radiotherapy as Primary Therapeutic Modality for Ocular Adnexal MALT Lymphoma. EClinicalMedicine, 2018, 4-5, 32-42.	3.2	11
2436	Low-dose trofosamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience. BMC Cancer, 2018, 18, 1000.	1.1	10

#	ARTICLE	IF	CITATIONS
2437	Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center. <i>Acta Haematologica</i> , 2018, 140, 194-202.	0.7	4
2438	Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. <i>Blood</i> , 2018, 132, 2016-2025.	0.6	93
2439	Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. <i>British Journal of Haematology</i> , 2018, 183, 601-607.	1.2	7
2440	Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 805-819.	3.3	38
2441	Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy. <i>Clinical and Translational Imaging</i> , 2018, 6, 417-427.	1.1	8
2442	A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified. <i>Leukemia Research</i> , 2018, 73, 5-11.	0.4	7
2443	Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2018, Volume 8, 13-20.	1.2	4
2444	Comparison of Native <i>Escherichia coli</i> L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Cancer Research and Treatment</i> , 2018, 50, 670-680.	1.3	9
2445	Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas. <i>International Journal of Medical Sciences</i> , 2018, 15, 867-874.	1.1	14
2446	Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. <i>British Journal of Haematology</i> , 2018, 183, 400-410.	1.2	18
2447	Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. <i>Blood Advances</i> , 2018, 2, 607-620.	2.5	75
2448	Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma. <i>Blood Advances</i> , 2018, 2, 871-876.	2.5	18
2449	Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma. <i>Blood Advances</i> , 2018, 2, 807-816.	2.5	107
2450	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	2.5	27
2451	Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID). <i>Blood Advances</i> , 2018, 2, 1386-1392.	2.5	22
2452	Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified. <i>Blood Advances</i> , 2018, 2, 2533-2542.	2.5	8
2453	Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. <i>Blood Advances</i> , 2018, 2, 3618-3626.	2.5	9
2454	How I manage patients with relapsed/refractory diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 633-643.	1.2	127

#	ARTICLE	IF	CITATIONS
2455	Guideline for the management of mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 46-62.	1.2	38
2456	Evaluaci3n de la estadificaci3n inicial y la respuesta final al tratamiento de los pacientes con linfoma difuso de c3lula grande B con la tomograf3a computarizada de 64 detectores frente a la 18FDC tomograf3a por emisi3n de positrones/tomograf3a computarizada. <i>Medicina Cl3nica</i> , 2018, 151, 255-264.	0.3	2
2457	A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1814-1822.	2.0	18
2458	A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2018, 59, 2888-2895.	0.6	31
2459	Treatment of localized3stage follicular lymphoma. <i>European Journal of Haematology</i> , 2018, 101, 245-256.	1.1	6
2460	An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 508-518.e14.	0.2	11
2461	Feasibility and Efficacy of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for HIV-Associated Lymphoma: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 548-551.	0.2	2
2462	Prognostic Significance of Blood Transfusion in Elderly Patients with Primary Diffuse Large B-Cell Lymphoma. <i>BioMed Research International</i> , 2018, 2018, 1-6.	0.9	5
2463	Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study. <i>Hematological Oncology</i> , 2018, 36, 633-637.	0.8	14
2464	Dual-energy CT-based iodine quantification to differentiate abdominal malignant lymphoma from lymph node metastasis. <i>European Journal of Radiology</i> , 2018, 105, 255-260.	1.2	21
2465	Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. <i>Annals of Oncology</i> , 2018, 29, 1932-1938.	0.6	63
2466	Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2287-2293.	1.0	27
2467	Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 679-686.	0.2	3
2468	Selective contrast-enhanced computed tomography is appropriate in diffuse large B-cell lymphoma therapy response assessment. <i>European Journal of Haematology</i> , 2018, 101, 613-619.	1.1	2
2469	Lymphoma associated hemophagocytic syndrome: A single-center retrospective study. <i>Oncology Letters</i> , 2018, 16, 1275-1284.	0.8	28
2470	Diagnosis and Treatment of Non-Hodgkin's Lymphoma of Adults. , 2018, , 951-973.		0
2471	R3high3CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. <i>Cancer Science</i> , 2018, 109, 2830-2840.	1.7	14
2472	The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms. <i>Annals of Hematology</i> , 2018, 97, 2363-2372.	0.8	13

#	ARTICLE	IF	CITATIONS
2473	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. <i>Blood</i> , 2018, 132, 1486-1494.	0.6	25
2474	Optimizing initial therapy in DLBCL. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 199-208.	0.7	15
2475	The <scp>MCL</scp>35 gene expression proliferation assay predicts high-risk <scp>MCL</scp> patients in a Norwegian cohort of younger patients given intensive first line therapy. <i>British Journal of Haematology</i> , 2018, 183, 225-234.	1.2	24
2476	Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2471-2478.	2.0	24
2477	Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2018, 108, 510-515.	0.7	9
2478	CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. <i>Blood</i> , 2018, 132, 1013-1021.	0.6	90
2479	Duvelisib, an oral dual PI3K α/β inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. <i>American Journal of Hematology</i> , 2018, 93, 1311-1317.	2.0	32
2480	Prognostic impact of pretreatment albumin to globulin ratio in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia Research</i> , 2018, 71, 100-105.	0.4	13
2481	Clinical Manifestations, Staging, and Treatment of Follicular Lymphoma. , 2018, , 1288-1297.e3.		0
2482	Radiological Evaluation of Response and Resistance of Ibritumomab. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 67-77.	0.1	0
2483	Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment. <i>Frontiers in Immunology</i> , 2018, 9, 621.	2.2	21
2484	Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. <i>Haematologica</i> , 2018, 103, e590-e593.	1.7	16
2485	Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma. <i>Journal of Translational Medicine</i> , 2018, 16, 162.	1.8	17
2486	The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. <i>Cancers</i> , 2018, 10, 204.	1.7	37
2487	Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 285-292.	0.7	6
2488	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2018, 11, 87.	6.9	12
2489	Metabolic tumor volume changes assessed by interval 18fluorodeoxyglucose positron emission tomography-computed tomography for the prediction of complete response and survival in patients with diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2018, 16, 1411-1418.	0.8	9
2490	Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients. <i>Oncology Letters</i> , 2018, 16, 1602-1614.	0.8	22

#	ARTICLE	IF	CITATIONS
2491	Positron Emission Tomographyâ€“Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2024-2034.	0.8	176
2492	Role of FDG PET-CT in the treatment management of Hodgkin lymphoma. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2018, 22, 393-400.	0.6	7
2493	Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial. <i>International Journal of Hematology</i> , 2018, 108, 499-509.	0.7	9
2494	Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada. <i>American Journal of Clinical Pathology</i> , 2018, 150, 393-405.	0.4	6
2495	Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD. <i>European Journal of Radiology</i> , 2018, 103, 90-98.	1.2	25
2496	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the <i>Fondazione Italiana Linfomi</i>. <i>Haematologica</i> , 2018, 103, 1345-1350.	1.7	45
2497	Excellent realâ€“world outcomes of adults with Burkitt lymphoma treated with ^MIVAC plus or minus rituximab. <i>British Journal of Haematology</i> , 2018, 181, 782-790.	1.2	15
2498	Interobserver Agreement of Interim and End-of-Treatment ¹⁸F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1831-1836.	2.8	23
2499	Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 447-451.	0.2	3
2500	A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. <i>Haematologica</i> , 2018, 103, 1351-1358.	1.7	49
2501	A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma. <i>Tumori</i> , 2018, 104, 292-299.	0.6	14
2502	Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e261-e269.	2.2	37
2503	Bendamustine and rituximab in elderly patients with lowâ€“tumour burden follicular lymphoma. Results of the ^{LYSA} phase ^{II BRIEF} study. <i>British Journal of Haematology</i> , 2018, 183, 76-86.	1.2	14
2504	Subcutaneous panniculitis-like T-cell lymphoma: Clinical features, therapeutic approach, and outcome in a case series of 16 patients. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 892-898.	0.6	55
2505	First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. <i>Oncotarget</i> , 2018, 9, 13023-13035.	0.8	70
2506	<i>In Situ</i> Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. <i>Cancer Discovery</i> , 2018, 8, 1258-1269.	7.7	136
2507	Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program. <i>Hematological Oncology</i> , 2018, 36, 689-692.	0.8	5
2508	Populationâ€“based outcome analysis of diffuse large Bâ€“cell lymphoma in people living with HIV infection and competent individuals. <i>Hematological Oncology</i> , 2018, 36, 757-764.	0.8	4

#	ARTICLE	IF	CITATIONS
2509	Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2018, 24, 6150-6159.	3.2	27
2510	An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e327-e331.	0.2	26
2511	The Berlin-Frankfurt-Amsterdam protocol for the upfront treatment of aggressive lymphomas: The Bologna experience. <i>American Journal of Hematology</i> , 2018, 93, E209.	2.0	1
2512	R-CHOP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial. <i>Hematological Oncology</i> , 2018, 36, 638-644.	0.8	23
2513	A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 569-575.e1.	0.2	30
2514	Extranodal <sc>NK</sc>/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases. <i>European Journal of Haematology</i> , 2018, 101, 379-388.	1.1	26
2515	Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2133-2138.	2.0	24
2516	Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. <i>Leukemia and Lymphoma</i> , 2019, 60, 309-316.	0.6	8
2517	Diagnosis of diffuse spleen involvement in haematological malignancies using a spleen-to-liver attenuation ratio on contrast-enhanced CT images. <i>European Radiology</i> , 2019, 29, 450-457.	2.3	4
2518	Interobserver Variation in Response Evaluation Criteria in Solid Tumors 1.1. <i>Academic Radiology</i> , 2019, 26, 489-501.	1.3	9
2519	High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study. <i>Bone Marrow Transplantation</i> , 2019, 54, 465-468.	1.3	13
2520	Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma. <i>Hematology</i> , 2019, 24, 52-59.	0.7	7
2521	Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment. <i>Haematologica</i> , 2019, 104, e21-e24.	1.7	20
2522	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. <i>Investigational New Drugs</i> , 2019, 37, 297-306.	1.2	51
2523	Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma. <i>Annals of Hematology</i> , 2019, 98, 131-142.	0.8	24
2524	Extranodal lymphomas in the public health system in Chile: A analysis of 1251 patients from the National Adult Cancer Program. <i>Hematological Oncology</i> , 2019, 37, 47-53.	0.8	3
2525	Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. <i>Blood</i> , 2019, 134, 1144-1153.	0.6	255
2526	Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome. <i>British Journal of Haematology</i> , 2019, 187, 478-487.	1.2	9

#	ARTICLE	IF	CITATIONS
2527	Primary Mediastinal Large B-Cell Lymphoma: A Review for Radiologists. American Journal of Roentgenology, 2019, 213, W194-W210.	1.0	9
2528	Incidence of solid cancer in patients with follicular lymphoma. Acta Oncologica, 2019, 58, 1564-1569.	0.8	5
2529	Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood, 2019, 134, 1024-1036.	0.6	100
2530	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood, 2019, 134, 1238-1246.	0.6	86
2531	Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma. Cancer Medicine, 2019, 8, 5012-5022.	1.3	24
2532	Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital. Leukemia and Lymphoma, 2019, 60, 3442-3448.	0.6	9
2533	Rituximab-PECC induction followed by ⁹⁰ Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study. British Journal of Haematology, 2019, 187, 347-355.	1.2	8
2534	Chronic hepatitis B virus infection is associated with a poorer prognosis in diffuse large B-cell lymphoma: a meta-analysis and systemic review. Journal of Cancer, 2019, 10, 3450-3458.	1.2	19
2535	End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma. PET Clinics, 2019, 14, 307-315.	1.5	8
2536	Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study. Annals of Hematology, 2019, 98, 2131-2138.	0.8	3
2537	Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematology, 2019, 6, e429-e437.	2.2	64
2538	Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial. Biology of Blood and Marrow Transplantation, 2019, 25, 2160-2166.	2.0	27
2539	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). Leukemia and Lymphoma, 2019, 60, 2890-2898.	0.6	8
2541	A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and ¹⁸ F-SUV _{max} . Cancer Medicine, 2019, 8, 5137-5147.	1.3	18
2542	Relationship between semiquantitative ¹⁸ F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma. Scientific Reports, 2019, 9, 11073.	1.6	4
2543	Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. Cancers, 2019, 11, 1071.	1.7	32
2544	Pediatric Molecular Imaging. Pediatric Oncology, 2019, , 347-367.	0.5	0
2545	Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma. JNCI Cancer Spectrum, 2019, 3, pkz030.	1.4	0

#	ARTICLE	IF	CITATIONS
2546	Reducing Hospitalizations: Institution of Outpatient Infusional EPOCH-Based Chemotherapy at a Safety Net Hospital. <i>Journal of Oncology Practice</i> , 2019, 15, e644-e651.	2.5	11
2547	The neutrophil/lymphocyte ratio ≥ 3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network "Rete Ematologica del Lazio per i Linfomi" (RELLI). <i>Leukemia and Lymphoma</i> , 2019, 60, 3386-3394.	0.6	11
2548	Rituximab biosimilar RTX83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. <i>Leukemia and Lymphoma</i> , 2019, 60, 3375-3385.	0.6	22
2549	Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2019, 94, 1325-1334.	2.0	34
2550	Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. <i>Pediatric Radiology</i> , 2019, 49, 1545-1564.	1.1	71
2551	<p></p>Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8277-8284.	0.9	0
2552	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3291-3299.	0.8	195
2553	Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. <i>Clinical Therapeutics</i> , 2019, 41, 2357-2379.e1.	1.1	10
2554	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. <i>BMC Cancer</i> , 2019, 19, 1080.	1.1	17
2555	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7331-7339.	3.2	110
2556	ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 1420-1428.	0.6	20
2557	Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. <i>Cancer Communications</i> , 2019, 39, 1-10.	3.7	12
2558	<p></p>Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2019, Volume 9, 33-43.	1.2	6
2559	Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 767.	1.3	98
2560	Revised staging system for malignant lymphoma based on the Lugano classification. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 895-900.	0.6	12
2561	Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. <i>Blood</i> , 2019, 134, 1395-1405.	0.6	100
2562	Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma. <i>Turkish Journal of Medical Sciences</i> , 2019, 49, 985-992.	0.4	5
2563	Treatment Outcome in Patients with Primary or Secondary Transformed Indolent B-Cell Lymphomas. <i>Oncology Research and Treatment</i> , 2019, 42, 580-588.	0.8	4

#	ARTICLE	IF	CITATIONS
2564	Clinical characteristics and prognostic factors in Chinese patients with classical Hodgkin lymphoma involving extranodal sites: a retrospective single-center study. <i>Hematology</i> , 2019, 24, 661-668.	0.7	1
2565	Are Biosimilars the Future of Oncology and Haematology?. <i>Drugs</i> , 2019, 79, 1609-1624.	4.9	10
2566	Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience. <i>Hematology</i> , 2019, 24, 623-630.	0.7	3
2567	Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6932-6938.	3.2	15
2568	Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 1811-1820.	0.6	75
2569	Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma. <i>Annals of Nuclear Medicine</i> , 2019, 33, 881-890.	1.2	5
2570	Primary Lymphoma of the Skull Base in the Chinese: Clinical, Radiological, Pathological, and Therapeutic Experience in a Series of 8 Patients. <i>World Neurosurgery</i> , 2019, 123, e171-e179.	0.7	3
2571	The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. <i>Cancer</i> , 2019, 125, 1507-1517.	2.0	106
2572	Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. <i>Lancet Haematology</i> , 2019, 6, e100-e109.	2.2	65
2573	The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1958-1964.	0.6	4
2574	Phase 1 study of lenalidomide plus dose-adjusted EPOCH in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. <i>Cancer</i> , 2019, 125, 1830-1836.	2.0	16
2575	High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2019, 98, 823-831.	0.8	2
2576	Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). <i>Annals of Oncology</i> , 2019, 30, 612-620.	0.6	88
2577	Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas. <i>Blood Cancer Journal</i> , 2019, 9, 52.	2.8	11
2578	Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab chemotherapy combinations. <i>British Journal of Haematology</i> , 2019, 187, 73-81.	1.2	19
2579	Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study. <i>American Journal of Hematology</i> , 2019, 94, 992-1001.	2.0	14
2580	The role of PET/CT in the modern treatment of Hodgkin lymphoma. <i>Cancer Treatment Reviews</i> , 2019, 77, 44-56.	3.4	51
2581	Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status. <i>Leukemia and Lymphoma</i> , 2019, 60, 3266-3271.	0.6	4

#	ARTICLE	IF	CITATIONS
2582	Predictive value of soluble interleukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy. <i>Annals of Hematology</i> , 2019, 98, 2121-2129.	0.8	3
2583	FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?. <i>European Journal of Haematology</i> , 2019, 103, 145-151.	1.1	8
2584	Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFN γ -Dendritic Cells and Rituximab: a Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5231-5241.	3.2	34
2585	Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). <i>Cancer</i> , 2019, 125, 3378-3389.	2.0	10
2586	Proportion of false-positive follow-up FDG-PET scans in lymphoma: Systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 73-81.	2.0	9
2587	Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial. <i>Lancet Haematology</i> , 2019, 6, e328-e337.	2.2	31
2588	A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial). <i>Leukemia and Lymphoma</i> , 2019, 60, 3251-3257.	0.6	4
2589	Phase 1/2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 845-854.	1.2	18
2590	Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. <i>British Journal of Haematology</i> , 2019, 187, 39-48.	1.2	44
2591	Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study. <i>International Journal of Hematology</i> , 2019, 110, 77-85.	0.7	6
2592	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58
2593	Diabetes mellitus predicts inferior survival in diffuse large B-cell lymphoma: a propensity score-matched analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 2849-2870.	0.9	11
2594	Response Assessment in Pediatric Non-Hodgkin Lymphoma. , 2019, , 113-118.		0
2595	JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma overview. <i>International Journal of Hematology</i> , 2019, 110, 3-10.	0.7	3
2596	Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1292-1300.	1.0	28
2597	Imaging response evaluation after novel neoadjuvant treatments of pancreatic cancer. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2019, 51, 146-152.	0.3	7
2598	Clinicopathological characteristics of diffuse large B-cell lymphoma involving small and large intestines: an analysis of 126 patients. <i>International Journal of Hematology</i> , 2019, 110, 340-346.	0.7	11
2599	PET beyond Deauville in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1851-1852.	0.6	0

#	ARTICLE	IF	CITATIONS
2600	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1997-2007.	0.8	170
2601	First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. <i>Annals of Hematology</i> , 2019, 98, 1961-1972.	0.8	23
2602	Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. <i>Blood</i> , 2019, 134, 353-362.	0.6	45
2603	One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 467-476.	1.8	6
2604	Interim PET-CTâ€“guided therapy in elderly patients with Hodgkin lymphomaâ€“a retrospective national multi-center study. <i>Annals of Hematology</i> , 2019, 98, 1665-1674.	0.8	6
2605	Clinical characteristics, treatment patterns and outcomes of patients older than 80Âyears diagnosed with DLBCL in China over a 10-year period. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 127-137.	1.1	3
2606	Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4634-4643.	3.2	49
2607	Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1bâ€“2 study. <i>Lancet Oncology</i> , The, 2019, 20, 998-1010.	5.1	101
2609	Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogeneic stem cell transplantation. <i>European Journal of Cancer</i> , 2019, 115, 47-56.	1.3	33
2610	The prognostic impact of hypermethylation for a panel of tumor suppressor genes and cell of origin subtype on diffuse large B-cell lymphoma. <i>Molecular Biology Reports</i> , 2019, 46, 4063-4076.	1.0	7
2611	Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphomaâ€“an analysis of 386 Portuguese patients. <i>Annals of Hematology</i> , 2019, 98, 1937-1946.	0.8	4
2612	Autograft immune content and survival in non-Hodgkinâ€™s lymphoma: A post hoc analysis. <i>Leukemia Research</i> , 2019, 81, 1-9.	0.4	12
2613	Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2576-2579.	0.6	0
2614	Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIIE extranodal natural killer/Tâ€“cell lymphoma, nasal type. <i>Cancer Medicine</i> , 2019, 8, 3349-3358.	1.3	8
2615	The imaging of local glucose levels in tumor periphery via peroxoxalate chemiluminescent nanoparticleâ€“glucose oxidaseâ€“doped alginate hydrogel. <i>Analytical Methods</i> , 2019, 11, 2763-2768.	1.3	16
2616	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-III trial. <i>Haematologica</i> , 2019, 104, 2241-2248.	1.7	13
2617	Relative dose intensity of Râ€“CHOP therapy and patient outcomes in advanced follicular lymphoma. <i>Hematological Oncology</i> , 2019, 37, 303-307.	0.8	1
2618	Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 345-355.e7.	0.2	4

#	ARTICLE	IF	CITATIONS
2619	Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. <i>Leukemia and Lymphoma</i> , 2019, 60, 2802-2805.	0.6	10
2620	The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma. <i>Investigational New Drugs</i> , 2019, 37, 548-558.	1.2	10
2621	Single agents vs combination chemotherapy in relapsed and refractory peripheral Tâ€cell lymphoma: Results from the comprehensive oncology measures for peripheral Tâ€cell lymphoma treatment (COMPLETE) registry. <i>American Journal of Hematology</i> , 2019, 94, 641-649.	2.0	25
2622	Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders. <i>Kidney International</i> , 2019, 96, 94-103.	2.6	16
2623	<p>Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1363-1372.	0.9	8
2624	Allogeneic Transplantation after Myeloablative Rituximab/BEAM Â± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1347-1354.	2.0	4
2625	L-Type Cav 1.2 Calcium Channel-Î±-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 4168-4178.	3.2	18
2626	Prognostic value of some inflammatory markers in patients with lymphoma. <i>Bioscience Reports</i> , 2019, 39, .	1.1	10
2628	A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma. <i>International Journal of Hematology</i> , 2019, 109, 657-664.	0.7	25
2630	PET â€adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH â€05 trial. <i>British Journal of Haematology</i> , 2019, 185, 865-873.	1.2	11
2631	Frequency, characteristics, and outcome of PTLD after alloâ€SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH). <i>European Journal of Haematology</i> , 2019, 102, 465-471.	1.1	18
2632	Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkinâ€™s lymphoma patients. <i>Annals of Hematology</i> , 2019, 98, 1449-1455.	0.8	8
2633	Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with firstâ€line immunochemotherapy. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1495-1506.	1.1	7
2634	DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 912-922.	0.8	201
2635	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1188-1199.	0.8	277
2636	Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1926-1933.	0.6	3
2637	Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 356-364.e3.	0.2	88
2638	Clinical features and outcomes of pulmonary lymphoma: A single center experience of 180 cases. <i>Lung Cancer</i> , 2019, 132, 39-44.	0.9	16

#	ARTICLE	IF	CITATIONS
2639	Consolidation with ^{90}Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up. <i>Leukemia and Lymphoma</i> , 2019, 60, 2689-2696.	0.6	6
2640	Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 677-687.	1.0	13
2641	Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis. <i>BMC Cancer</i> , 2019, 19, 338.	1.1	21
2642	Reply to H.J.A. Adams et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 526-527.	0.8	0
2643	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). <i>Lancet Haematology</i> , 2019, 6, e254-e265.	2.2	184
2644	Renal Dysfunction in Patients With Direct Infiltration by B-Cell Lymphoma. <i>Kidney International Reports</i> , 2019, 4, 688-697.	0.4	14
2645	Prognostic value of metabolic tumour volume on baseline ^{18}F -FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1417-1427.	3.3	49
2646	Mucosa-associated lymphoid tissue lymphoma with $t(11;18)(q21;q21)$ translocation: long-term follow-up results. <i>Annals of Hematology</i> , 2019, 98, 1675-1687.	0.8	12
2647	Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2516-2523.	0.6	13
2648	Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 45-53.	1.2	25
2649	Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma. <i>Leukemia</i> , 2019, 33, 2454-2465.	3.3	38
2650	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019, 134, 22-29.	0.6	129
2651	Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 481-489.	0.8	265
2652	Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 96-101.	0.4	11
2653	Further Examining the TROG 99.03 Trial in Early-Stage Follicular Lymphoma: Cure Rate and the Role of Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2019, 37, 256-257.	0.8	2
2654	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1285-1295.	0.8	388
2655	Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on ^{18}F -FDG PET/CT in newly diagnosed patients with diffuse large B-cell lymphoma. <i>Cancer Medicine</i> , 2019, 8, 953-962.	1.3	10
2656	Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 303-318.	2.1	34

#	ARTICLE	IF	CITATIONS
2657	Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. <i>British Journal of Haematology</i> , 2019, 185, 480-491.	1.2	26
2658	Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2019, 185, 713-717.	1.2	21
2659	Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP. <i>Cancer Medicine</i> , 2019, 8, 982-989.	1.3	15
2660	Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). <i>British Journal of Haematology</i> , 2019, 185, 53-64.	1.2	9
2661	Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. <i>Hematological Oncology</i> , 2019, 37, 160-167.	0.8	15
2662	FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma. <i>Hematological Oncology</i> , 2019, 37, 168-175.	0.8	25
2663	Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 468-479.	1.2	17
2664	Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma. <i>Frontiers of Medicine</i> , 2019, 13, 94-103.	1.5	2
2665	The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients. <i>Cancer Medicine</i> , 2019, 8, 1103-1109.	1.3	15
2666	Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth. <i>European Journal of Cancer</i> , 2019, 109, 196-203.	1.3	9
2667	ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma. <i>Cancer Cell International</i> , 2019, 19, 32.	1.8	21
2668	Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1334-1344.	3.3	14
2669	The comparison of clinical and imaging characteristics between AIDS-related diffuse large B-cell lymphoma and Burkitt's lymphoma. <i>Radiology of Infectious Diseases</i> , 2019, 6, 100-107.	2.4	0
2670	Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. <i>Blood Advances</i> , 2019, 3, 132-135.	2.5	15
2671	Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019, 24, 1246-1252.	1.9	10
2672	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019, 3, 360-369.	2.5	92
2673	MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 1185-1196.	2.5	19
2674	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 3132-3135.	2.5	18

#	ARTICLE	IF	CITATIONS
2675	Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 2035-2039.	2.5	12
2676	Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2019, 59, 179-186.	0.3	1
2677	Radiotherapy after immunochemotherapy improves outcomes in patients with primary mediastinal large B-cell lymphoma. <i>Precision Radiation Oncology</i> , 2019, 3, 145-148.	0.4	3
2678	Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia. <i>Journal of Cancer</i> , 2019, 10, 5041-5048.	1.2	9
2679	Clinical features and treatment outcomes of Hodgkin lymphoma: A retrospective review in a Malaysian tertiary hospital. <i>Blood Research</i> , 2019, 54, 210-217.	0.5	6
2680	Evolving Role of PET-Based Novel Quantitative Techniques in the Management of Hematological Malignancies. <i>PET Clinics</i> , 2019, 14, 331-340.	1.5	11
2681	Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. <i>The Cochrane Library</i> , 2019, , .	1.5	2
2682	Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-15.	1.0	7
2683	Multi-b value diffusion-weighted magnetic resonance imaging and intravoxel incoherent motion modeling. <i>Medicine (United States)</i> , 2019, 98, e14459.	0.4	4
2684	Beneficial effect of consolidative radiotherapy for patients with lymphoma and skeletal involvement. <i>Medicine (United States)</i> , 2019, 98, e16688.	0.4	3
2685	Coexistence of colon adenocarcinoma, diffuse large B-cell lymphoma, and myelodysplastic syndrome. <i>Medicine (United States)</i> , 2019, 98, e16742.	0.4	4
2686	18F-FDG PET/CT for Prognostic Stratification of Patients With Extranodal Natural Killer/T-Cell Lymphoma. <i>Clinical Nuclear Medicine</i> , 2019, 44, 201-208.	0.7	12
2687	Rituximab-Mediated Complement-Dependent Cytotoxicity Enhanced by Gemcitabine in Older Patients with Previously Rituximab-Treated Diffuse Large B-Cell Lymphoma: Study Protocol. <i>Kurume Medical Journal</i> , 2019, 66, 37-42.	0.0	1
2688	Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2019, 59, 145-155.	0.3	17
2689	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2019, 394, 2271-2281.	6.3	155
2690	Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. <i>Blood Cancer Journal</i> , 2019, 9, 97.	2.8	11
2691	The Value of Prognostic Nutritional Index in Follicular Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 202-207.	0.6	13
2692	Tumor Identification of Less Aggressive or Indolent Lymphoma With Whole-Body 11C-Acetate PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, 276-281.	0.7	7

#	ARTICLE	IF	CITATIONS
2693	Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 862-869.	0.6	6
2694	Prognostic Value of Pretreatment Radiomic Features of 18F-FDG PET in Patients With Hodgkin Lymphoma. <i>Clinical Nuclear Medicine</i> , 2019, 44, e559-e565.	0.7	41
2695	False-Positive Positron Emission Tomography After Combined-Modality Induction Therapy in a Patient With Newly Diagnosed Early-Stage Bulky Classic Hodgkin Lymphoma. <i>Journal of Oncology Practice</i> , 2019, 15, 499-501.	2.5	1
2696	First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. <i>Blood Cancer Journal</i> , 2019, 9, 100.	2.8	33
2697	Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. <i>Scientific Reports</i> , 2019, 9, 20302.	1.6	12
2698	Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Blood Research</i> , 2019, 54, 244-252.	0.5	4
2699	Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	31
2700	Predictors of response to anti-IL-6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. <i>British Journal of Haematology</i> , 2019, 184, 232-241.	1.2	36
2701	The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2019, 37, 27-34.	0.8	10
2702	FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 97-106.	3.3	9
2703	An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 215-222.	1.2	35
2704	A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 90-98.	3.2	73
2705	Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study. <i>Leukemia and Lymphoma</i> , 2019, 60, 675-684.	0.6	17
2706	Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin. <i>Hematological Oncology</i> , 2019, 37, 35-38.	0.8	6
2707	Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia and Lymphoma</i> , 2019, 60, 734-741.	0.6	9
2708	Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. <i>Haematologica</i> , 2019, 104, 1202-1208.	1.7	64
2709	Hematopoietic stem cell transplantation for subcutaneous panniculitis-like T-cell lymphoma: single center experience in an Asian population. <i>International Journal of Hematology</i> , 2019, 109, 187-196.	0.7	11
2710	Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas. <i>Bone Marrow Transplantation</i> , 2019, 54, 1237-1244.	1.3	5

#	ARTICLE	IF	CITATIONS
2711	Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 999-1005.	1.2	29
2712	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1128-1135.	2.0	38
2713	Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 149-156.	0.2	2
2714	Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHS) phase III trial. <i>British Journal of Haematology</i> , 2019, 185, 42-52.	1.2	15
2715	A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks. <i>British Journal of Haematology</i> , 2019, 186, 159-162.	1.2	3
2716	Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 906-911.	2.0	6
2717	Treatment effect quantification for time-to-event endpoints—Estimands, analysis strategies, and beyond. <i>Pharmaceutical Statistics</i> , 2019, 18, 145-165.	0.7	38
2718	Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 250-257.	0.2	17
2719	Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2019, 98, 401-411.	0.8	41
2720	Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. <i>Haematologica</i> , 2019, 104, e211-e214.	1.7	122
2721	Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma. <i>International Journal of Hematology</i> , 2019, 109, 175-186.	0.7	14
2722	Efficacy of the GMALL-BALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin lymphomas with or without CNS involvement. <i>European Journal of Haematology</i> , 2019, 102, 241-250.	1.1	7
2723	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 1718-1726.	3.2	26
2724	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 6.	6.9	29
2725	Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease. <i>Leukemia Research</i> , 2019, 79, 75-80.	0.4	8
2726	Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) trial. <i>Annals of Hematology</i> , 2019, 98, 897-907.	0.8	24
2727	Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e12-e19.	2.2	176
2728	Acalabrutinib for adults with mantle cell lymphoma. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 179-187.	1.3	9

#	ARTICLE	IF	CITATIONS
2729	PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 202-215.	5.1	145
2730	Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma. <i>Acta Haematologica</i> , 2019, 141, 84-90.	0.7	10
2731	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. <i>Cancer</i> , 2019, 125, 90-98.	2.0	15
2732	A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study. <i>Leukemia and Lymphoma</i> , 2019, 60, 912-919.	0.6	18
2733	Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma: a United States payer perspective. <i>Journal of Medical Economics</i> , 2019, 22, 16-25.	1.0	3
2734	Validation of the Marginal Zone Lymphoma International Prognostic Index. <i>Annals of Hematology</i> , 2019, 98, 457-464.	0.8	11
2735	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1087-1091.	0.6	6
2736	Bexarotene in Patients With Peripheral T-cell Lymphomas: Results of a Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 109-115.	0.2	3
2737	Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1204-1213.	0.6	4
2738	A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. <i>Cancer</i> , 2019, 125, 99-108.	2.0	17
2739	DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 117-127.	1.2	17
2740	Phase I study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 744-752.	1.2	21
2741	Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed/refractory peripheral T cell lymphomas. <i>Annals of Hematology</i> , 2019, 98, 1237-1247.	0.8	8
2742	Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. <i>British Journal of Haematology</i> , 2019, 184, 753-759.	1.2	49
2743	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. <i>Lancet Haematology</i> , the, 2019, 6, e48-e57.	2.2	195
2744	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 31-42.	5.1	1,467
2745	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 229-240.	6.3	517
2746	Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 35-40.	0.2	10

#	ARTICLE	IF	CITATIONS
2747	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019, 60, 940-946.	0.6	3
2748	Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. <i>Leukemia and Lymphoma</i> , 2019, 60, 894-903.	0.6	18
2749	A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 460-462.	1.2	10
2750	Clinical characteristics and treatment outcomes of natural killer/T-cell lymphoma involving the ocular adnexa. <i>British Journal of Ophthalmology</i> , 2019, 103, 269-273.	2.1	10
2751	Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. <i>Leukemia and Lymphoma</i> , 2019, 60, 172-179.	0.6	11
2752	Combined use of DDGP and IMRT has a good effect on extranodal natural killer/T-cell lymphoma, nasal type. <i>Hematological Oncology</i> , 2020, 38, 103-105.	0.8	3
2753	Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial. <i>Haematologica</i> , 2020, 105, e29-e32.	1.7	15
2754	¹⁸ F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome. <i>Journal of Nuclear Medicine</i> , 2020, 61, 40-45.	2.8	109
2755	CBeV (cyclophosphamide, bendamustine and etoposide) pre-autotransplant conditioning in persons with lymphoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 265-267.	1.3	1
2756	Computed tomography patterns of pulmonary and pleural involvement in lymphoma. <i>Medical Journal Armed Forces India</i> , 2020, 76, 77-83.	0.3	1
2757	<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , 2020, 105, 1604-1612.	1.7	96
2758	<i>De novo</i> CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. <i>Leukemia and Lymphoma</i> , 2020, 61, 328-336.	0.6	7
2759	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. <i>Leukemia and Lymphoma</i> , 2020, 61, 318-327.	0.6	9
2760	The prognostic value of PET/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: a multi-institutional study of KROG 17-02. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 125-131.	1.7	9
2761	Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2020, 61, 309-317.	0.6	22
2762	No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. <i>British Journal of Haematology</i> , 2020, 188, 685-691.	1.2	16
2763	Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. <i>Practical Radiation Oncology</i> , 2020, 10, 44-52.	1.1	10
2765	Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment. <i>Bone Marrow Transplantation</i> , 2020, 55, 117-125.	1.3	12

#	ARTICLE	IF	CITATIONS
2766	Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy. <i>British Journal of Haematology</i> , 2020, 188, 249-258.	1.2	16
2767	Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. <i>Journal of Geriatric Oncology</i> , 2020, 11, 37-40.	0.5	14
2768	Non-indolent mantle cell lymphoma at a single public hospital in Brazil: real world first-line treatment cohort study data. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 93-97.	0.1	1
2769	Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1184-1187.	1.3	32
2770	Proposed rituximab biosimilar BCDâ€œ20 versus reference rituximab for treatment of patients with indolent nonâ€œHodgkin lymphomas: An international multicenter randomized trial. <i>Hematological Oncology</i> , 2020, 38, 67-73.	0.8	9
2771	PET/Computed Tomography in Treatment Response Assessment in Cancer. <i>PET Clinics</i> , 2020, 15, 101-123.	1.5	8
2772	DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. <i>Haematologica</i> , 2020, 105, 2308-2315.	1.7	21
2773	Disease characteristics of diffuse large Bâ€œcell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience. <i>Hematological Oncology</i> , 2020, 38, 38-50.	0.8	1
2774	Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 796-803.	1.3	9
2775	Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 633-640.	1.3	5
2777	Treatment of classical Hodgkin lymphoma in young adults aged 18â€œ30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012). <i>British Journal of Haematology</i> , 2020, 189, 128-132.	1.2	2
2778	Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2020, 188, 540-549.	1.2	16
2779	Outcomes in patients with aggressive Bâ€œcell nonâ€œHodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303.	2.0	18
2780	Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma â€œ a LWPâ€œEBMT study. <i>British Journal of Haematology</i> , 2020, 188, 745-756.	1.2	20
2781	Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1063-1074.	0.6	6
2783	A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkinâ€œs lymphoma. <i>Annals of Hematology</i> , 2020, 99, 255-264.	0.8	3
2784	Non-Hodgkin Lymphomas. , 2020, , 1926-1947.e5.		0
2785	Pembrolizumab monotherapy in patients with primary refractory classical Hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 950-954.	0.6	13

#	ARTICLE	IF	CITATIONS
2786	Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models. <i>Clinical Cancer Research</i> , 2020, 26, 1787-1795.	3.2	51
2787	Bone marrow infiltration by flow cytometry at diffuse large B-cell lymphoma NOS diagnosis implies worse prognosis without considering bone marrow histology. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 525-528.	0.7	9
2788	Prognostic Nomogram for Overall Survival in Early Stage Extranodal Natural Killer/T Cell Lymphoma Treated With High-Dose Radiotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 289-295.	0.2	4
2789	Diffusion-weighted MRI for initial staging in Hodgkin's lymphoma: comparison with FDG PET. <i>European Journal of Radiology</i> , 2020, 123, 108775.	1.2	3
2790	Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for RHOA G17V mutated subtype. <i>Leukemia and Lymphoma</i> , 2020, 61, 1108-1118.	0.6	6
2791	Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. <i>American Journal of Hematology</i> , 2020, 95, 362-371.	2.0	102
2792	Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 354-361.	2.0	19
2793	A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL). <i>BioDrugs</i> , 2020, 34, 171-181.	2.2	29
2794	Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas. <i>PET Clinics</i> , 2020, 15, 23-34.	1.5	11
2795	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients. <i>Cancer Medicine</i> , 2020, 9, 194-203.	1.3	13
2796	Surveillance Imaging after Autologous Hematopoietic Cell Transplantation Predicts Survival in Patients with Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 272-277.	2.0	2
2797	Intratumor Heterogeneity Assessed by 18F-FDG PET/CT Predicts Treatment Response and Survival Outcomes in Patients with Hodgkin Lymphoma. <i>Academic Radiology</i> , 2020, 27, e183-e192.	1.3	34
2798	Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP. <i>British Journal of Haematology</i> , 2020, 188, 860-871.	1.2	5
2799	First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. <i>British Journal of Haematology</i> , 2020, 188, 898-906.	1.2	16
2800	Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2020, 104, 400-408.	1.1	3
2801	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 121-133.	5.1	204
2802	Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. <i>Haematologica</i> , 2020, 105, 2298-2307.	1.7	34
2803	Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). <i>Leukemia</i> , 2020, 34, 1458-1461.	3.3	15

#	ARTICLE	IF	CITATIONS
2804	Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. <i>Journal of Infection</i> , 2020, 80, 219-224.	1.7	8
2805	Production of CAR-T Cells for Clinical Applications. , 2020, , 51-62.		0
2806	The Utility of PET/CT in Guiding Radiotherapy Reduction for Children With Hodgkin Lymphoma Treated With ABVD. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e87-e93.	0.3	4
2807	Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. <i>Cancer</i> , 2020, 126, 1235-1242.	2.0	8
2808	High intratumoural galectin-1 expression predicts adverse outcome in ALK ⁺ ALCL and CD30 ⁺ PTCL ^{NOS} . <i>Hematological Oncology</i> , 2020, 38, 59-66.	0.8	6
2809	Study of L-Asparaginase, Vincristine, and Dexamethasone Combined With Intensity-modulated Radiation Therapy in Early-Stage Nasal NK/T-Cell Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 257-262.	0.6	9
2810	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
2811	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. <i>Annals of Hematology</i> , 2020, 99, 105-112.	0.8	6
2812	A First-in-human Study of Tenzalisib (RP6530), a Dual PI3K γ/δ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 78-86.	0.2	19
2813	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1b/2 study. <i>Lancet Oncology</i> , The, 2020, 21, 134-144.	5.1	103
2814	Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden. <i>Journal of Immunotherapy</i> , 2020, 43, 32-37.	1.2	56
2815	Prognostic value of baseline 18 F-FDG PET/CT metabolic parameters in paediatric lymphoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 87-95.	0.9	7
2816	Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). <i>British Journal of Haematology</i> , 2020, 188, 240-248.	1.2	17
2817	Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2020, 111, 409-416.	0.7	6
2818	Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072094734.	1.1	2
2819	Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3805-3815.	0.8	129
2820	Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multicentre propensity score-matched study. <i>British Journal of Haematology</i> , 2020, 191, 806-815.	1.2	7
2821	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 5579-5587.	3.2	16

#	ARTICLE	IF	CITATIONS
2822	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4898-4911.	2.5	238
2823	Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. <i>Blood Advances</i> , 2020, 4, 4802-4811.	2.5	33
2824	A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma. <i>Advances in Therapy</i> , 2020, 37, 4877-4893.	1.3	8
2825	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1433-1442.	5.1	306
2826	Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with 18F-FDG PET/CT, in patients with diffuse large cell B-cell lymphoma. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2020, 39, 340-346.	0.1	3
2827	Positron Emission Tomographyâ€Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	0.8	75
2828	Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center. <i>Annals of Palliative Medicine</i> , 2020, 9, 1442-1452.	0.5	4
2829	A novel semiâ€mechanistic tumor growth fraction model for translation of preclinical efficacy of antiâ€glypican 3 antibody drug conjugate to human. <i>Biopharmaceutics and Drug Disposition</i> , 2020, 41, 319-333.	1.1	2
2830	EvaluaciÃ³n del valor pronÃ³stico de los diferentes mÃ©todos de cÃ¡lculo del volumen metabÃ³lico tumoral con 18F-FDG PET/TC, en pacientes con linfoma B difuso de cÃ©lulas grandes. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2020, 39, 340-346.	0.0	0
2831	Alectinib for relapsed or refractory anaplastic lymphoma kinaseâ€positive anaplastic large cell lymphoma: An openâ€label phase II trial. <i>Cancer Science</i> , 2020, 111, 4540-4547.	1.7	50
2832	Sintilimab: A Promising Anti-Tumor PD-1 Antibody. <i>Frontiers in Oncology</i> , 2020, 10, 594558.	1.3	76
2833	Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 594692.	1.3	8
2834	Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma. <i>Diagnostics</i> , 2020, 10, 1002.	1.3	2
2835	First Line Systemic Treatment for MALT Lymphomaâ€Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna. <i>Cancers</i> , 2020, 12, 3533.	1.7	4
2836	<p>Salvage Therapy for Hodgkinâ€™s Lymphoma: A Review of Current Regimens and Outcomes</p>. <i>Journal of Blood Medicine</i> , 2020, Volume 11, 389-403.	0.7	6
2837	Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CT. <i>European Journal of Radiology</i> , 2020, 133, 109301.	1.2	9
2838	Direct comparison of diagnostic accuracies of F-18 FDG PET and MRI for detection of bone marrow involvement in lymphoma patients; A meta-analysis. <i>Leukemia Research</i> , 2020, 99, 106475.	0.4	1
2839	Event-free survival at 24Âmonths is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2020, 99, 2847-2857.	0.8	3

#	ARTICLE	IF	CITATIONS
2840	Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma—Romanian Experience. <i>Journal of Clinical Medicine</i> , 2020, 9, 2417.	1.0	12
2841	Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2667-2672.	1.7	92
2842	Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2346-2358.	2.0	4
2843	Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. <i>Leukemia and Lymphoma</i> , 2020, 61, 3014-3017.	0.6	2
2844	MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era. <i>Leukemia Research</i> , 2020, 97, 106426.	0.4	4
2845	Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study. <i>Scientific Reports</i> , 2020, 10, 13359.	1.6	4
2846	First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. <i>Cancers</i> , 2020, 12, 2192.	1.7	16
2847	Hodgkin Lymphoma in Adolescent and Young Adults: Real-World Data from a Single Tertiary Cancer Center in India. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, 10, 581-587.	0.7	2
2848	A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2223-2228.	2.0	3
2849	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. <i>Lancet Haematology</i> , 2020, 7, e649-e659.	2.2	24
2850	Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1811-1818.	2.0	4
2851	Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	26
2852	Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3378-3386.	0.6	2
2853	Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 4091-4101.	2.5	33
2854	Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum. <i>Blood Advances</i> , 2020, 4, 1013-1019.	2.5	11
2855	Effectiveness of chemotherapy after anti-CD19 blockade failure for relapsed and refractory Hodgkin lymphoma. <i>Cancer Medicine</i> , 2020, 9, 7830-7836.	1.3	17
2856	Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single-center retrospective study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 17, 289-299.	0.7	4
2857	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 2931-2938.	0.6	13

#	ARTICLE	IF	CITATIONS
2858	Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3905-3913.	0.8	36
2859	Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial. <i>Hematological Oncology</i> , 2020, 38, 715-725.	0.8	14
2860	R-CHOP14 versus R-CHOP14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study. <i>Cancer Science</i> , 2020, 111, 3770-3779.	1.7	3
2861	Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience. <i>Hematological Oncology</i> , 2020, 38, 737-741.	0.8	7
2862	Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1265-1273.	0.6	14
2863	A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in INHL relapsed after rituximab-containing therapy. <i>Blood Advances</i> , 2020, 4, 3886-3893.	2.5	26
2864	Diffuse Large B-Cell Lymphoma. , 0, , .		0
2865	Identifying high-risk patients with natural killer/T-cell lymphoma undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2020, 61, 3404-3411.	0.6	2
2866	Phase II/III Study of Tenalisib (RP6530), a Dual PI3K γ/β Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. <i>Cancers</i> , 2020, 12, 2293.	1.7	44
2867	Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies. <i>Scientific Reports</i> , 2020, 10, 21418.	1.6	6
2869	Phase II study of dose-adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B-cell lymphoma patients. <i>EJHaem</i> , 2020, 1, 507-516.	0.4	1
2870	Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients. <i>Annals of Hematology</i> , 2021, 100, 2261-2268.	0.8	4
2871	Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. <i>Modern Rheumatology</i> , 2022, 32, 41-49.	0.9	7
2872	Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. <i>Blood Advances</i> , 2020, 4, 5773-5784.	2.5	67
2874	An increase in <i>MYC</i> copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens. <i>Haematologica</i> , 2020, 105, 1369-1378.	1.7	19
2875	Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 2170-2179.	1.3	8
2876	ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study. <i>American Journal of Hematology</i> , 2020, 95, 1030-1037.	2.0	6
2877	Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. <i>Annals of Hematology</i> , 2020, 99, 1595-1604.	0.8	22

#	ARTICLE	IF	CITATIONS
2878	Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study. <i>Annals of Hematology</i> , 2020, 99, 2801-2809.	0.8	4
2879	Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS. <i>Haematologica</i> , 2020, 105, e512.	1.7	3
2880	Tumor Segmentation and Feature Extraction from Whole-Body FDG-PET/CT Using Cascaded 2D and 3D Convolutional Neural Networks. <i>Journal of Digital Imaging</i> , 2020, 33, 888-894.	1.6	51
2881	Neck Lymphoma. <i>Medical Radiology</i> , 2020, , 441-465.	0.0	0
2882	Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 705-714.	1.0	8
2883	Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2020, 99, 2149-2157.	0.8	4
2884	Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. <i>Blood Advances</i> , 2020, 4, 2064-2072.	2.5	6
2885	A Comparison of the BEAM and MITO/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicity. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 652-660.	0.2	7
2886	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020, 135, 2182-2191.	0.6	62
2887	Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy. <i>Annals of Hematology</i> , 2020, 99, 2141-2148.	0.8	9
2888	Molecular profiling of Chinese <sc>Râ€CHOP</sc> treated <sc>DLBCL</sc> patients: Identifying a highâ€risk subgroup. <i>International Journal of Cancer</i> , 2020, 147, 2611-2620.	2.3	12
2889	Development of a core outcome set for myelodysplastic syndromes â€ a Delphi study from the EUMDS Registry Group. <i>British Journal of Haematology</i> , 2020, 191, 405-417.	1.2	10
2890	Prognostic impact of Bâ€vitamins involved in oneâ€carbon metabolism in patients with diffuse large Bâ€cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 456-466.	0.8	4
2891	Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation. <i>Investigational New Drugs</i> , 2020, 38, 1796-1806.	1.2	1
2892	Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2519-2529.	0.8	93
2893	Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). <i>Blood</i> , 2020, 136, 1284-1297.	0.6	39
2894	BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult Tâ€cell lymphoblastic lymphoma. <i>Cancer Communications</i> , 2020, 40, 245-259.	3.7	14
2895	Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1736-1743.	1.0	16

#	ARTICLE	IF	CITATIONS
2896	Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma. <i>Nuclear Medicine Communications</i> , 2020, 41, 540-549.	0.5	4
2897	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. <i>Clinical Cancer Research</i> , 2020, 26, 4468-4477.	3.2	16
2898	Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. <i>Blood</i> , 2020, 135, 996-1007.	0.6	49
2899	Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 744-748.	0.2	8
2900	The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL). <i>Annals of Hematology</i> , 2020, 99, 1583-1594.	0.8	0
2901	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020, 6, 1011.	3.4	39
2902	Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 978-988.	5.1	320
2903	Type II enteropathy-associated T cell lymphoma in the duodenum. <i>Medicine (United States)</i> , 2020, 99, e20050.	0.4	7
2904	Pembrolizumab in relapsed or refractory Richter syndrome. <i>British Journal of Haematology</i> , 2020, 190, e117-e120.	1.2	29
2905	Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. <i>Annals of Hematology</i> , 2020, 99, 2565-2576.	0.8	19
2906	A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. <i>Journal of Hematology and Oncology</i> , 2020, 13, 71.	6.9	82
2907	ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 2548-2555.	2.5	19
2908	Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study. <i>International Journal of Hematology</i> , 2020, 112, 369-376.	0.7	1
2909	KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. <i>Blood Advances</i> , 2020, 4, 2617-2622.	2.5	38
2910	It's About Quality, Not Quantity: Qualitative FDG PET/CT Criteria for Therapy Response Assessment in Clinical Practice. <i>American Journal of Roentgenology</i> , 2020, 215, 313-324.	1.0	4
2911	The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. <i>British Journal of Haematology</i> , 2020, 189, 650-660.	1.2	21
2912	Prognostic Values of Baseline ¹⁸ F-FDG PET/CT in Patients with Peripheral T-Cell Lymphoma. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	11
2913	MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index. <i>BMC Cancer</i> , 2020, 20, 237.	1.1	9

#	ARTICLE	IF	CITATIONS
2914	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. <i>Clinical Cancer Research</i> , 2020, 26, 2096-2103.	3.2	31
2915	Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy. <i>Journal of Dermatology</i> , 2020, 47, 636-640.	0.6	9
2916	KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2020, 382, 1331-1342.	13.9	1,067
2917	Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma. <i>Future Oncology</i> , 2020, 16, 817-825.	1.1	1
2919	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 593-602.	5.1	55
2920	Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072090291.	1.1	21
2921	Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression. <i>British Journal of Haematology</i> , 2020, 189, 1064-1073.	1.2	6
2922	Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients. <i>Hematological Oncology</i> , 2020, 38, 487-492.	0.8	11
2923	Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience. <i>Internal Medicine Journal</i> , 2021, 51, 1825-1834.	0.5	0
2924	Radiation Therapy for Advanced-Stage Hodgkin Lymphoma. <i>Advances in Radiation Oncology</i> , 2020, 5, 809-816.	0.6	4
2925	Mantle cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103038.	2.0	21
2926	Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma. <i>Annals of Hematology</i> , 2020, 99, 1823-1831.	0.8	14
2927	Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome. <i>Radiotherapy and Oncology</i> , 2020, 150, 236-244.	0.3	5
2928	Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma. <i>In Vivo</i> , 2020, 34, 2127-2134.	0.6	3
2929	Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma. <i>International Journal of Hematology</i> , 2020, 112, 504-509.	0.7	5
2930	Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk. <i>Frontiers in Oncology</i> , 2020, 10, 989.	1.3	15
2931	Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. <i>British Journal of Haematology</i> , 2020, 189, 244-256.	1.2	21
2932	The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt. <i>Diagnostic Pathology</i> , 2020, 15, 10.	0.9	8

#	ARTICLE	IF	CITATIONS
2933	Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP – the PLRG report. <i>Scientific Reports</i> , 2020, 10, 3517.	1.6	12
2934	The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1857-1863.	0.5	3
2935	Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. <i>Lancet Haematology</i> , 2020, 7, e284-e294.	2.2	78
2936	Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1534-1542.	2.0	18
2937	Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 653-664.	1.4	39
2938	A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study. <i>Leukemia</i> , 2020, 34, 2392-2404.	3.3	13
2939	Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma – type post-transplant lymphoproliferative disorder. <i>British Journal of Haematology</i> , 2020, 189, 97-105.	1.2	12
2940	Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 275-284.	2.0	6
2941	Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 510-520.	2.0	56
2942	Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study. <i>International Journal of Hematology</i> , 2020, 111, 567-573.	0.7	0
2943	Survival of Patients With Second Primary Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 316-323.e2.	0.2	3
2944	Significance of bulky mass and residual tumor – Treated with or without consolidative radiotherapy – To the risk of relapse in DLBCL patients. <i>Cancer Medicine</i> , 2020, 9, 1966-1977.	1.3	17
2945	Outcome of elderly patients with classical Hodgkin's lymphoma. <i>Leukemia Research</i> , 2020, 90, 106311.	0.4	8
2946	Objective quantification of BCL2 protein by multiplex immunofluorescence in routine biopsy samples of diffuse large B-cell lymphoma demonstrates associations with survival and <i>BCL2</i> gene alterations. <i>Leukemia and Lymphoma</i> , 2020, 61, 1334-1344.	0.6	1
2947	PET positivity – the agony of choice: response assessment and interpretation of increased FDG uptake of residual mediastinal tissue after frontline therapy in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 251-254.	0.6	2
2948	Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. <i>Hematological Oncology</i> , 2020, 38, 137-145.	0.8	3
2949	Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr Virus positive diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2020, 189, 257-268.	1.2	21
2950	Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. <i>Nature Medicine</i> , 2020, 26, 270-280.	15.2	182

#	ARTICLE	IF	CITATIONS
2951	Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma. <i>Annals of Hematology</i> , 2020, 99, 819-828.	0.8	2
2952	Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B-cell lymphoma. <i>Cancer Medicine</i> , 2020, 9, 2330-2342.	1.3	13
2953	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, 573-582.	1.2	19
2954	Lymphocyte-monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low-grade B-cell lymphoma. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 431-438.	0.7	7
2955	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. <i>Clinical Cancer Research</i> , 2020, 26, 2524-2534.	3.2	40
2956	Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation. <i>Hematological Oncology</i> , 2020, 38, 257-265.	0.8	7
2957	Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Oncologist</i> , 2020, 25, 793-802.	1.9	13
2958	A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 453-458.	0.2	2
2959	Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1810-1822.	0.6	6
2960	Impact of relative dose intensity of standard regimens on survival in elderly patients aged 80 years and older with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, e415-e418.	1.7	14
2961	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 3546-3556.	3.2	13
2962	SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. <i>Blood Advances</i> , 2020, 4, 1082-1092.	2.5	47
2963	High total metabolic tumor volume at baseline predicts survival independent of response to therapy. <i>Blood</i> , 2020, 135, 1396-1405.	0.6	119
2964	Criteria-Based Imaging and Response Evaluation of Lymphoma 20 Years After Cheson: What is New?. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 657-668.	0.7	5
2965	Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. <i>Blood Advances</i> , 2020, 4, 1589-1593.	2.5	16
2967	Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma. <i>International Journal of Hematology</i> , 2020, 112, 74-83.	0.7	6
2968	Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 563-571.	0.2	10
2969	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020, 135, 735-742.	0.6	86

#	ARTICLE	IF	CITATIONS
2970	Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma. <i>Cancer Research</i> , 2020, 80, 1875-1884.	0.4	36
2971	Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. <i>Clinical Cancer Research</i> , 2020, 26, 3918-3927.	3.2	123
2972	A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 3760-3770.	3.2	11
2973	On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 468-478.	1.9	29
2974	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. <i>Blood</i> , 2020, 135, 274-286.	0.6	81
2975	Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 136-140.	2.5	27
2976	Assessment of viral RNA in idiopathic pulmonary fibrosis using RNA-seq. <i>BMC Pulmonary Medicine</i> , 2020, 20, 81.	0.8	12
2977	<p>High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1903-1912.	0.9	19
2978	The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent. <i>Journal of Clinical Medicine</i> , 2020, 9, 1005.	1.0	3
2979	Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors. <i>Haematologica</i> , 2021, 106, 593-596.	1.7	1
2980	Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2021, 192, 1011-1014.	1.2	2
2981	Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. <i>Haematologica</i> , 2021, 106, 1705-1713.	1.7	34
2982	A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. <i>Leukemia</i> , 2021, 35, 777-786.	3.3	78
2983	Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. <i>Blood</i> , 2021, 137, 2161-2170.	0.6	88
2984	Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 347-356.	1.3	9
2985	Primary Bone Lymphoma: A 13 Year Retrospective Institutional Analysis in the Chemo-Immunotherapy Era. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 240-248.	0.3	4
2986	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386.	0.6	59
2987	Chemotherapy with a Pegylated Liposomal Doxorubicin-Containing Regimen in Newly Diagnosed Hodgkin Lymphoma Patients. <i>Cardiovascular Toxicology</i> , 2021, 21, 12-16.	1.1	5

#	ARTICLE	IF	CITATIONS
2988	Consolidation with ⁹⁰ Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma. <i>Hematological Oncology</i> , 2021, 39, 51-59.	0.8	1
2989	Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 55.e1-55.e7.	0.6	7
2990	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 57.e1-57.e8.	0.6	7
2991	CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 473-484.	3.2	68
2992	Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study. <i>International Journal of Cancer</i> , 2021, 148, 1470-1477.	2.3	10
2993	Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 70-77.	0.6	6
2994	Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/ MYC rearrangement in Japan. <i>Hematological Oncology</i> , 2021, 39, 66-74.	0.8	2
2995	Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. <i>Blood</i> , 2021, 137, 1318-1326.	0.6	85
2996	Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 238-245.	0.2	7
2997	Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 58-66.	0.6	21
2998	A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the CARMEN-phase II trial. <i>British Journal of Haematology</i> , 2021, 192, 119-128.	1.2	7
2999	Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 655-663.	1.3	7
3000	DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients. <i>Clinical and Translational Science</i> , 2021, 14, 405-411.	1.5	8
3001	Advanced Imaging in Musculoskeletal Oncology: Moving Away From RECIST and Embracing Advanced Bone and Soft Tissue Tumor Imaging (ABASTI) - Part I - Tumor Response Criteria and Established Functional Imaging Techniques. <i>Seminars in Ultrasound, CT and MRI</i> , 2021, 42, 201-214.	0.7	4
3002	Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry. <i>Blood Reviews</i> , 2021, 47, 100778.	2.8	8
3003	Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan. <i>Leukemia and Lymphoma</i> , 2021, 62, 819-827.	0.6	3
3004	The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. <i>European Journal of Haematology</i> , 2021, 106, 428-432.	1.1	1
3005	Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1205-1208.	1.3	13

#	ARTICLE	IF	CITATIONS
3006	Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies. <i>Cancer Science</i> , 2021, 112, 331-338.	1.7	8
3008	FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of ¹⁷⁷ Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1902-1914.	3.3	6
3009	Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e373-e380.	0.2	6
3010	Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma. <i>British Journal of Haematology</i> , 2021, 193, 299-306.	1.2	5
3011	R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience. <i>Annals of Hematology</i> , 2021, 100, 1517-1524.	0.8	5
3012	Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas. <i>Annals of Hematology</i> , 2021, 100, 189-196.	0.8	2
3013	Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 590-597.	0.6	2
3014	Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1098-1106.	0.6	15
3015	Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study. <i>Modern Rheumatology</i> , 2022, 32, 50-58.	0.9	4
3016	Comparison of the International Workshop Criteria and the Response Evaluation Criteria in Solid Tumors for indolent B-cell lymphoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 429-437.	1.0	1
3017	Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?. <i>Blood</i> , 2021, 137, 1416-1423.	0.6	49
3018	Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. <i>International Journal of Hematology</i> , 2021, 113, 370-380.	0.7	8
3019	Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma. <i>Cancer</i> , 2021, 127, 372-380.	2.0	25
3020	A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 60-65.	0.8	2
3021	Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 218-227.	0.6	12
3022	Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 641-647.	2.8	4
3023	A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 104-111.	0.6	9
3024	Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. <i>Blood</i> , 2021, 137, 637-645.	0.6	69

#	ARTICLE	IF	CITATIONS
3025	Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , 2021, 137, 929-938.	0.6	57
3026	PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 239-242.	0.6	0
3027	Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 869-874.	2.0	6
3028	A comparison of R-EPOCH and R-CHOP as a first-line regimen in <i>de novo</i> DLBCL patients with high Ki-67 expression in a single institution. <i>Oncotarget</i> , 0, 7, 41242-41250.	0.8	11
3029	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Post-Radiotherapy Setting. , 2021, , 59-81.		0
3030	ASPM Predicts Poor Clinical Outcome and Promotes Tumorigenesis for Diffuse Large B-cell Lymphoma. <i>Current Cancer Drug Targets</i> , 2021, 21, 80-89.	0.8	7
3031	CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 10.	7.1	93
3032	A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Oncology Letters</i> , 2021, 21, 218.	0.8	2
3033	A brief rituximab, bendamustine, mitoxantrone (R ² BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021, 193, 280-289.	1.2	4
3034	Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab. <i>Leukemia and Lymphoma</i> , 2021, 62, 1353-1360.	0.6	1
3035	Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China. <i>Cancer Communications</i> , 2021, 41, 229-239.	3.7	15
3036	Trends in Phase II Trials for Cancer Therapies. <i>Cancers</i> , 2021, 13, 178.	1.7	4
3037	The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series. <i>British Journal of Haematology</i> , 2021, 192, e84-e87.	1.2	8
3038	Isolated Splenic tuberculosis masquerading as disease progression of hodgkin's lymphoma on interim ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography scan. <i>Indian Journal of Nuclear Medicine</i> , 2021, 36, 100.	0.1	0
3039	Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation. <i>Oncology Research and Treatment</i> , 2021, 44, 375-381.	0.8	5
3040	Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study. <i>International Journal of Hematology</i> , 2021, 113, 404-412.	0.7	6
3041	Bone Marrow Involvement by Aggressive B Cell Lymphoma Undetected by Aspirate Immunophenotyping. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 14-17.	0.4	1
3042	Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 539-548.	2.5	38

#	ARTICLE	IF	CITATIONS
3043	Immunohistochemical subtyping of diffuse large B-cell lymphoma into germinal center B-cell and activated B-cell subtype, along with correlation of the subtypes with extranodal involvement, serum lactate dehydrogenase, and positron emission tomography scan-based response assessment to chemotherapy. <i>Journal of Cancer Research and Therapeutics</i> , 2021, .	0.3	3
3044	PET/CT: Normal Variants, Artefacts and Pitfalls in Non-Hodgkin Lymphoma. , 2021, , 71-83.		0
3045	Râ€œCOMP versus Râ€œCHOP as firstâ€œline therapy for diffuse large Bâ€œcell lymphoma in patients â%¥60Âyears: Results of a randomized phase 2 study from the Spanish GELTAMO group. <i>Cancer Medicine</i> , 2021, 10, 1314-1326.	1.3	13
3046	Transformation of A Marginal Lymphoma in Hepatitis C Virus-Infected Patient After Clearance of HCV Viral Load. , 2021, 06, .		0
3047	Identification of an Optimal Population for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Mature T and NK Cell Neoplasms. <i>In Vivo</i> , 2021, 35, 2379-2390.	0.6	0
3048	Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma. <i>Journal of Cancer</i> , 2021, 12, 163-169.	1.2	3
3049	The role of tazemetostat in relapsed/refractory follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110158.	1.1	11
3050	Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. <i>Blood Cancer Journal</i> , 2021, 11, 9.	2.8	32
3051	The role of PET in first-line treatment of Hodgkin lymphoma. <i>Lancet Haematology,the</i> , 2021, 8, e67-e79.	2.2	23
3052	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology,the</i> , 2021, 8, e34-e44.	2.2	29
3053	Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas. <i>Cell Transplantation</i> , 2021, 30, 096368972199961.	1.2	1
3054	Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response. <i>Oncolmmunology</i> , 2021, 10, 1936392.	2.1	14
3055	MATRixâ€œRICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. <i>Lancet Haematology,the</i> , 2021, 8, e110-e121.	2.2	54
3056	Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 467-475.	0.8	13
3057	A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Investigational New Drugs</i> , 2021, 39, 1028-1035.	1.2	4
3058	A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. <i>Blood Advances</i> , 2021, 5, 984-993.	2.5	9
3059	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	1.7	21
3060	Influence of Severe Gastrointestinal Complications in Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 1041-1052.	0.9	5

#	ARTICLE	IF	CITATIONS
3061	Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1629-1638.	0.6	1
3062	Quantitative FDG PET Assessment for Oncology Therapy. <i>Cancers</i> , 2021, 13, 869.	1.7	20
3063	Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2021, 10, 15.	2.0	29
3064	First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma. <i>Oncologist</i> , 2021, 26, 184-e366.	1.9	32
3065	Response criteria for intraocular retinoblastoma: RBâ€¦RECIST. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28964.	0.8	6
3066	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. <i>Annals of Hematology</i> , 2021, 100, 2279-2292.	0.8	10
3067	The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 1541-1549.	0.9	6
3069	Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma. <i>Annals of Hematology</i> , 2021, 100, 1231-1239.	0.8	3
3070	Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. <i>Blood Advances</i> , 2021, 5, 823-828.	2.5	19
3071	A novel scoring system for TIGIT expression in classic Hodgkin lymphoma. <i>Scientific Reports</i> , 2021, 11, 7059.	1.6	10
3072	Realâ€¦life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive Bâ€¦cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 336-348.	0.8	25
3073	Central Nervous System Involvement in Epsteinâ€¦Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 261.e1-261.e7.	0.6	4
3074	Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of ¹⁸ F-FDGâ€¦Avid Lymphomas: A Prospective Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1372-1379.	2.8	4
3075	Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatments. <i>Anti-Cancer Drugs</i> , 2021, 32, 323-329.	0.7	1
3076	Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkinâ€¦s lymphoma. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S245-S252.	0.7	0
3077	Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1919-1928.	1.3	13
3078	Conditional survival and hazards of death for peripheral T-cell lymphomas. <i>Aging</i> , 2021, 13, 10225-10239.	1.4	6
3079	Clinical Impact of Extranodal Metabolic Tumor Volume in 240 Diffuse Large B cell Lymphoma Patients with Extranodal Involvement. <i>Annals of Hematology</i> , 2021, 100, 1221-1229.	0.8	1

#	ARTICLE	IF	CITATIONS
3080	Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. <i>Leukemia and Lymphoma</i> , 2021, 62, 2161-2168.	0.6	17
3081	Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. <i>Blood</i> , 2021, 138, 213-220.	0.6	53
3082	Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT. <i>Annals of Oncology</i> , 2021, 32, 404-411.	0.6	77
3083	Efficacy of Palliative Radiation Therapy (RT) for Chemotherapy Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Population-Based Retrospective Review. <i>Practical Radiation Oncology</i> , 2021, 11, e203-e209.	1.1	6
3084	End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. <i>Blood Advances</i> , 2021, 5, 1283-1290.	2.5	21
3085	The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 424-432.	0.7	5
3086	R-CHOP compared to R-CHOP+X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2021, 60, 744-749.	0.8	8
3087	Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors. <i>Clinical Epigenetics</i> , 2021, 13, 62.	1.8	42
3088	Safety of switching between rituximab biosimilars in onco-hematology. <i>Scientific Reports</i> , 2021, 11, 5956.	1.6	8
3089	Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: A retrospective, multicenter, case-control study. <i>Modern Rheumatology</i> , 2022, 32, 24-31.	0.9	13
3090	Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population. <i>Leukemia and Lymphoma</i> , 2021, 62, 1869-1876.	0.6	1
3091	Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. <i>Cancer Science</i> , 2021, 112, 1943-1954.	1.7	11
3092	Interim and end-of-treatment PET/CT suffers from high false-positive rates in DLBCL: Biopsy is needed prior to treatment decisions. <i>Cancer Medicine</i> , 2021, 10, 3035-3044.	1.3	5
3093	Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 246-256.e2.	0.2	2
3094	Integrative Statistics, Machine Learning and Artificial Intelligence Neural Network Analysis Correlated CSF1R with the Prognosis of Diffuse Large B-Cell Lymphoma. <i>Hemato</i> , 2021, 2, 182-206.	0.2	13
3095	High pretreatment plasma D-dimer levels predict poor survival in patients with diffuse large B-cell lymphoma in the real world. <i>Translational Cancer Research</i> , 2021, 10, 1723-1731.	0.4	3
3096	Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up. <i>Cancers</i> , 2021, 13, 1760.	1.7	7
3097	Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial. <i>International Journal of Hematology</i> , 2021, 114, 205-216.	0.7	3

#	ARTICLE	IF	CITATIONS
3098	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , 2021, 138, 11-22.	0.6	90
3099	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338.	0.8	60
3100	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2021, 22, 512-524.	5.1	144
3101	Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma. <i>Medicine (United States)</i> , 2021, 100, e25194.	0.4	6
3102	Cancer Clinical Trials: What Every Radiologist Wants to Know but Is Afraid to Ask. <i>American Journal of Roentgenology</i> , 2021, 216, 1099-1111.	1.0	3
3103	A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. <i>Haematologica</i> , 2021, 106, 2277-2280.	1.7	9
3104	Novel model predicts prognosis for patients with diffuse large B-cell lymphoma in first relapse after initial R-CHOP therapy: a single-institution study in China. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110029.	0.4	1
3106	High Expression of Caspase-8 Associated with Improved Survival in Diffuse Large B-Cell Lymphoma: Machine Learning and Artificial Neural Networks Analyses. <i>BioMedInformatics</i> , 2021, 1, 18-46.	1.0	14
3107	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	0.8	132
3108	Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	0.6	1
3109	The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy. <i>British Journal of Haematology</i> , 2021, 193, 1060-1075.	1.2	13
3110	Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 3339-3350.	3.2	26
3111	PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4159.	1.8	41
3112	Prognostic Value of 2-Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography/Computed Tomography after Autologous Hematopoietic Stem Cell Transplantation in Lymphoma Using Deauville Scores. <i>Contrast Media and Molecular Imaging</i> , 2021, 2021, 1-8.	0.4	3
3113	Comparison of 18F-labelled fluoro-2-deoxyglucose-PET with conventional computed tomography for staging and response assessment in paediatric and adult patients with nodular lymphocyte-predominant Hodgkin's lymphoma. <i>Nuclear Medicine Communications</i> , 2021, Publish Ahead of Print, 899-906.	0.5	0
3114	18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2883-2893.	3.3	8
3115	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	0.8	37
3116	Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation. <i>Advances in Therapy</i> , 2021, 38, 3489-3505.	1.3	2

#	ARTICLE	IF	CITATIONS
3117	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/SC lymphoma, nasal type: A French study from the Soci�t� Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGMTC). American Journal of Hematology, 2021, 96, 834-845.	2.0	5
3118	Current and future best practice in imaging, staging, and response assessment for Non-Hodgkin's lymphomas: the Specialist Integrated Haematological Malignancy Imaging Reporting (SIHMIR) paradigm shift. Clinical Radiology, 2021, 76, 391.e1-391.e18.	0.5	4
3119	A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan. Scientific Reports, 2021, 11, 10069.	1.6	3
3120	Outcome of Diffuse Large B-Cell Lymphoma with First-line Chemotherapy. Haematology Journal of Bangladesh, 2021, 5, 03-09.	0.1	0
3121	Adding value to tumor staging in head and neck cancer: The role of metabolic parameters as prognostic factors. Head and Neck, 2021, 43, 2477-2487.	0.9	6
3122	A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A+B study). British Journal of Haematology, 2021, 193, 1123-1133.	1.2	7
3123	Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma. Oncogene, 2021, 40, 3989-4003.	2.6	22
3124	Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience. Annals of Hematology, 2021, 100, 1837-1847.	0.8	11
3125	Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous B-cell lymphoma. Cancer Science, 2021, 112, 2426-2435.	1.7	26
3126	Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study. Chinese Medical Journal, 2021, 134, 1299-1309.	0.9	4
3127	Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1. Advances in Therapy, 2021, 38, 3266-3280.	1.3	10
3128	Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome After High-Dose Chemotherapy. Cancers, 2021, 13, 2558.	1.7	2
3129	Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study. British Journal of Haematology, 2021, 193, 906-914.	1.2	12
3130	Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e432-e448.	0.2	11
3131	Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. Cancer Medicine, 2021, 10, 5101-5109.	1.3	4
3132	Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure. Frontiers in Oncology, 2021, 11, 687374.	1.3	9
3133	Impact of High-Dose Methotrexate on the Outcome of Patients with Diffuse Large B-Cell Lymphoma and Skeletal Involvement. Cancers, 2021, 13, 2945.	1.7	0
3134	Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study. Haematologica, 2022, 107, 500-509.	1.7	5

#	ARTICLE	IF	CITATIONS
3135	Imaging Assessment of Tumor Response in the Era of Immunotherapy. <i>Diagnostics</i> , 2021, 11, 1041.	1.3	3
3136	Dismal outcome of relapsed or primary refractory adult Tâ€cell lymphoblastic lymphoma: A retrospective study from China. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	0.7	3
3137	MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy. , 2021, 9, e002029.		4
3138	The Clinical and Biological Effects of PD-1 Expression on Tumor Cells in Diffuse Large B-Cell Lymphoma. <i>Hemato</i> , 2021, 2, 368-381.	0.2	1
3139	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021, 26, 597-609.	1.9	15
3140	Long-term Follow-up of Patients with Relapsed or Refractory Nonâ€Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. <i>Clinical Cancer Research</i> , 2021, 27, 4690-4695.	3.2	38
3141	Brentuximab vedotin consolidation therapy after autologous stemâ€cell transplantation in patients with highâ€risk Hodgkin lymphoma: Multicenter retrospective study. <i>Hematological Oncology</i> , 2021, 39, 498-505.	0.8	12
3142	Is It Time to Call Time on Bone Marrow Biopsy for Staging Ewing Sarcoma (ES)?. <i>Cancers</i> , 2021, 13, 3261.	1.7	6
3143	Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. , 2021, 9, e002240.		4
3144	Older patients (aged â‰¥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. <i>Haematologica</i> , 2022, 107, 1086-1094.	1.7	24
3145	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. <i>Cancer</i> , 2021, 127, 3390-3402.	2.0	6
3146	A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China. <i>Chinese Medical Journal</i> , 2021, 134, 1584-1592.	0.9	1
3147	A mass transfer model for computational prediction of proliferation and therapy outcome of non-Hodgkin lymphoma. <i>International Communications in Heat and Mass Transfer</i> , 2021, 125, 105332.	2.9	3
3148	Efficacy of siltuximab in the treatment of idiopathic multicentric castelman disease, the first Polish, real-world experience with long-term observation. <i>Leukemia and Lymphoma</i> , 2021, 62, 3031-3034.	0.6	4
3149	Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 647733.	2.2	6
3150	A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 823-830.	0.2	2
3151	Phase II study of tazemetostat for relapsed or refractory Bâ€cell nonâ€Hodgkin lymphoma with <i>EZH2</i> mutation in Japan. <i>Cancer Science</i> , 2021, 112, 3627-3635.	1.7	32
3152	Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e946-e959.	0.2	6

#	ARTICLE	IF	CITATIONS
3153	Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1145-1154.	0.4	29
3154	Imaging biomarkers for evaluating tumor response: RECIST and beyond. <i>Biomarker Research</i> , 2021, 9, 52.	2.8	55
3155	Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update. <i>Cancer</i> , 2021, 127, 3727-3741.	2.0	10
3156	Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. <i>Haematologica</i> , 2022, 107, 1608-1618.	1.7	16
3157	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	2.5	24
3158	Clinical impact of comprehensive geriatric assessment in patients aged 80 years and older with diffuse large B-cell lymphoma receiving rituximab-mini-CHOP: a single-institute retrospective study. <i>European Geriatric Medicine</i> , 2022, 13, 195-201.	1.2	5
3159	Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103377.	2.0	10
3160	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 194, 690-700.	1.2	88
3161	Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma. <i>Cancer Research and Treatment</i> , 2021, 53, 837-846.	1.3	9
3162	A picture is worth a thousand words: a history of diagnostic imaging for lymphoma. <i>British Journal of Radiology</i> , 2021, 94, 20210285.	1.0	1
3163	Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1211-1222.	1.2	4
3164	Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center. <i>Pathology and Oncology Research</i> , 2021, 27, 1609867.	0.9	1
3165	Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1178-1178.	0.7	3
3166	Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3320-3332.	0.6	8
3167	A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma. <i>Translational Oncology</i> , 2021, 14, 101085.	1.7	21
3168	CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. <i>Cancer Immunology Research</i> , 2021, 9, 1061-1070.	1.6	37
3169	Correlation between alterations in blood flow of malignant lymphomas after induction chemotherapies and clinical outcomes: a pilot study utilising contrast-enhanced ultrasonography for early interim evaluation of lymphoma treatment. <i>Clinical Radiology</i> , 2021, 76, 550.e9-550.e17.	0.5	1
3170	Independent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development. <i>Contemporary Clinical Trials</i> , 2021, 106, 106434.	0.8	7

#	ARTICLE	IF	CITATIONS
3171	Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2417-2426.	1.7	81
3172	Significance of initial, interim and end-of-therapy 18F-FDG PET/CT for predicting transformation risk in follicular lymphoma. <i>Cancer Cell International</i> , 2021, 21, 394.	1.8	3
3173	The Role of Interim PET/CT on Survival in Diffuse Large B Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e922-e927.	0.2	3
3174	Treatment Regimens for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review. <i>Cancers</i> , 2021, 13, 4268.	1.7	9
3175	Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial. <i>Blood Cancer Journal</i> , 2021, 11, 147.	2.8	10
3176	Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 40-51.	0.8	22
3177	Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 89-97.	0.2	6
3178	Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. <i>Blood Advances</i> , 2021, 5, 3445-3456.	2.5	22
3179	Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma. <i>Expert Review of Hematology</i> , 2021, 14, 867-875.	1.0	11
3180	Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 941-956.	1.1	3
3181	Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy. <i>Leukemia and Lymphoma</i> , 2021, , 1-4.	0.6	1
3182	Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma – first analysis of toxicity and efficacy signals. <i>Leukemia and Lymphoma</i> , 2021, , 1-9.	0.6	1
3183	Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 911.e1-911.e7.	0.6	6
3184	Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 713577.	1.3	27
3185	A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2022, 63, 117-123.	0.6	5
3186	New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT. <i>Cancers</i> , 2021, 13, 3998.	1.7	12
3187	RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6124-6134.	3.2	24
3188	Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. <i>Blood Advances</i> , 2021, 5, 3647-3655.	2.5	4

#	ARTICLE	IF	CITATIONS
3189	Next-Generation Sequencing-Based Monitoring of Circulating Tumor DNA Reveals Clonotypic Heterogeneity in Untreated PTCL. <i>Blood Advances</i> , 2021, 5, 4198-4210.	2.5	8
3190	Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. <i>ESMO Open</i> , 2021, 6, 100172.	2.0	9
3191	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. <i>Lancet Haematology</i> , 2021, 8, e562-e571.	2.2	28
3192	Long-term efficacy and safety of chemotherapy-free first-line iodine-131 rituximab radioimmunotherapy of follicular lymphoma. <i>British Journal of Haematology</i> , 2022, 196, 237-241.	1.2	6
3193	Increased MALAT1 expression predicts poor prognosis in primary gastrointestinal diffuse large B-cell lymphoma. <i>Clinical and Experimental Medicine</i> , 2022, 22, 183-191.	1.9	5
3194	A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV+ lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 3493-3500.	0.6	17
3195	Fimepinostat (CUDC907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. <i>British Journal of Haematology</i> , 2021, 195, 201-209.	1.2	17
3196	Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-9.	1.0	3
3197	Improved Progression-Free Survival for Bulky and Non-Bulky Advanced Stage Diffuse Large B-Cell Lymphoma With Consolidative Radiation Therapy: A Bi-Institutional Analysis. <i>Cureus</i> , 2021, 13, e17107.	0.2	1
3198	Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study. <i>Blood Advances</i> , 2021, 5, 3862-3872.	2.5	19
3199	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. <i>Clinical Cancer Research</i> , 2021, 27, 5847-5856.	3.2	3
3200	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4149-4155.	2.5	42
3201	Experience of Nivolumab Prior to Autologous Stem Cell Transplant for Relapsed Refractory Hodgkin Lymphoma. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 585-590.	0.3	1
3202	Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. <i>Blood Advances</i> , 2021, 5, 3387-3396.	2.5	17
3203	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. <i>Blood Advances</i> , 2021, 5, 3528-3539.	2.5	24
3204	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. <i>Blood</i> , 2022, 139, 1330-1339.	0.6	52
3205	Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience. <i>Cancer Cell International</i> , 2021, 21, 498.	1.8	4
3206	PET Imaging for Hematologic Malignancies. <i>Radiologic Clinics of North America</i> , 2021, 59, 705-723.	0.9	3

#	ARTICLE	IF	CITATIONS
3207	Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2021, , 1.	0.7	1
3208	The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL “ Results From the Phase-II STORM Trial. <i>HemaSphere</i> , 2021, 5, e636.	1.2	7
3209	Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 140.	6.9	24
3210	Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience. <i>Cancers</i> , 2021, 13, 4789.	1.7	18
3211	Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. <i>Blood Advances</i> , 2021, 5, 3354-3361.	2.5	6
3212	Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. <i>British Journal of Haematology</i> , 2022, 196, 146-155.	1.2	17
3213	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. <i>Blood Cancer Journal</i> , 2021, 11, 160.	2.8	3
3214	In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PET. <i>EJNMMI Research</i> , 2021, 11, 97.	1.1	4
3215	Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. <i>The Cochrane Library</i> , 2021, 2021, CD013365.	1.5	18
3216	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. <i>Cancers</i> , 2021, 13, 4503.	1.7	7
3217	Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. <i>Blood Advances</i> , 2021, 5, 4674-4685.	2.5	10
3218	Risk factors for neutropenic fever in non-Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1181-1189.	0.7	1
3219	Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation. <i>Annals of Transplantation</i> , 2021, 26, e933365.	0.5	1
3220	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021, 195, 757-763.	1.2	5
3221	Comparison between RECIST 1.1, Choi and PERCIST 1.0 criteria to evaluate response to SBRT of liver metastasis. <i>AME Medical Journal</i> , 0, 6, 26-26.	0.4	0
3222	Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. <i>Blood</i> , 2022, 139, 1026-1038.	0.6	67
3223	Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110380.	0.5	1
3224	Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study. <i>Chinese Medical Journal</i> , 2022, 135, 433-440.	0.9	2

#	ARTICLE	IF	CITATIONS
3225	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. <i>Blood Advances</i> , 2021, 5, 4504-4514.	2.5	14
3226	Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. <i>International Journal of Clinical Oncology</i> , 2022, 27, 213-223.	1.0	10
3227	Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 863.e1-863.e5.	0.6	4
3228	BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas. <i>Leukemia Research</i> , 2021, 110, 106689.	0.4	2
3229	FDG-PET/CT Variants and Pitfalls in Haematological Malignancies. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 554-571.	2.5	9
3230	Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. <i>European Journal of Cancer</i> , 2021, 157, 132-139.	1.3	4
3231	The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era. <i>Leukemia Research</i> , 2021, 110, 106715.	0.4	6
3232	R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with MYC rearrangement or double expression of MYC and BCL-2. <i>Journal of Cancer</i> , 2021, 12, 2059-2064.	1.2	1
3233	The presence of a bulky mediastinal mass of 7â€‰cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT. <i>Leukemia and Lymphoma</i> , 2021, 62, 1313-1324.	0.6	5
3234	Circulating long non-coding RNAs HOTAIR, Linc-p21, GAS5 and XIST expression profiles in diffuse large B-cell lymphoma: association with R-CHOP responsiveness. <i>Scientific Reports</i> , 2021, 11, 2095.	1.6	13
3235	Relmacabtagene autoleucel (relmaâ€œcel) CD19 CARâ€œT therapy for adults with heavily pretreated relapsed/refractory large Bâ€œcell lymphoma in China. <i>Cancer Medicine</i> , 2021, 10, 999-1011.	1.3	50
3236	Outcomes of rituximabâ€œBEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	2.0	17
3237	Baseline and interim PETâ€œbased outcome prediction in peripheral Tâ€œcell lymphoma: A subgroup analysis of the PETAL trial. <i>Hematological Oncology</i> , 2020, 38, 244-256.	0.8	18
3238	Non-Hodgkinâ€œTMs Lymphoma. , 2010, , 583-592.		2
3239	Orbital and Ocular Adnexal Lymphoma. , 2015, , 145-153.		2
3240	HTLV-1-Associated T-cell Diseases. , 2013, , 113-135.		2
3241	Cancer Imaging in Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 309-324.	0.8	4
3242	Clinical Evaluation. <i>Hematologic Malignancies</i> , 2015, , 95-106.	0.2	1

#	ARTICLE	IF	CITATIONS
3243	Functional Imaging in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2015, , 107-130.	0.2	2
3244	Background and Rationale for Radiotherapy in Early-Stage Hodgkin Lymphoma. , 2011, , 7-20.		1
3245	Prognostic Factors. , 2011, , 97-115.		1
3246	Multi-state Models Used in Oncology Trials. , 2014, , 283-304.		1
3247	Head and Neck Tumors. , 2016, , 441-480.		3
3248	Clinical Implications of the Role of 18FDG-PET/CT in Malignant Lymphomas. , 2014, , 249-265.		1
3249	Non-Hodgkin's Lymphoma. , 2008, , 2371-2404.		3
3250	Malignant Lymphomas and Lymphadenopathies. , 2009, , 417-505.		5
3251	Non-Hodgkin Lymphoma. , 2014, , 2033-2059.e8.		1
3252	Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1099-1105.	2.0	7
3253	A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 347-353.	0.2	23
3255	Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients. <i>Scientific Reports</i> , 2016, 6, 28834.	1.6	17
3256	A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 2136-2144.	0.6	5
3257	Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlo</i>		
3258	Postchemotherapy Histiocyte-rich Pseudotumor Mimicking Residual Lymphoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 160-168.	2.1	5
3259	Clinical features and outcome of lymphoma patients with pre-existing autoimmune diseases. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 93-101.	0.9	5
3260	Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 226-233.	0.7	2
3261	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. <i>British Journal of Haematology</i> , 2020, 189, 661-671.	1.2	12

#	ARTICLE	IF	CITATIONS
3262	Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 189, e86-e90.	1.2	25
3263	Comparison of CART-19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkin's lymphoma. <i>JCI Insight</i> , 2019, 4, .	2.3	14
3264	Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade refractory idiopathic multicentric Castleman disease. <i>Journal of Clinical Investigation</i> , 2019, 129, 4451-4463.	3.9	87
3265	CD28 costimulation improves expansion and persistence of chimeric antigen receptor modified T cells in lymphoma patients. <i>Journal of Clinical Investigation</i> , 2011, 121, 1822-1826.	3.9	876
3266	Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. <i>Journal of Clinical Investigation</i> , 2016, 126, 2588-2596.	3.9	241
3267	Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072090289.	1.1	13
3268	How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 322-7.	0.9	14
3269	How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 322-327.	0.9	19
3270	Interim PET-CT in the management of diffuse large B-cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 397-401.	0.9	26
3271	Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells. <i>Blood</i> , 2020, 135, 2425-2427.	0.6	22
3272	Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes.. <i>Blood</i> , 2010, 116, 2830-2830.	0.6	6
3273	Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 22.	0.9	6
3274	PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. <i>European Radiology Experimental</i> , 2020, 4, 63.	1.7	38
3275	Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience. <i>Annals of Transplantation</i> , 2019, 24, 175-184.	0.5	12
3276	Circulating MicroRNA-21, MicroRNA-23a, and MicroRNA-125b as Biomarkers for Diagnosis and Prognosis of Burkitt Lymphoma in Children. <i>Medical Science Monitor</i> , 2016, 22, 4992-5002.	0.5	8
3277	Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study. <i>Medical Science Monitor</i> , 2016, 22, 4297-4311.	0.5	2
3278	Blood Lymphocyte-to-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated with R-CHOP. <i>PLoS ONE</i> , 2012, 7, e41658.	1.1	129
3279	Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin's Lymphoma: Correlation with Long-Term Survival. <i>PLoS ONE</i> , 2014, 9, e106745.	1.1	18

#	ARTICLE	IF	CITATIONS
3280	Clinicopathological Analysis of Ocular Adnexal Extranodal Marginal Zone B-Cell Lymphoma with IgG4-Positive Cells. PLoS ONE, 2015, 10, e0131458.	1.1	13
3281	Simultaneous [18F]FDG-PET/MRI: Correlation of Apparent Diffusion Coefficient (ADC) and Standardized Uptake Value (SUV) in Primary and Recurrent Cervical Cancer. PLoS ONE, 2015, 10, e0141684.	1.1	41
3282	Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. PLoS ONE, 2016, 11, e0162965.	1.1	27
3283	A purified, fermented, extract of <i>Triticum aestivum</i> has lymphomacidal activity mediated via natural killer cell activation. PLoS ONE, 2018, 13, e0190860.	1.1	9
3284	Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma. Sao Paulo Medical Journal, 2010, 128, 14-17.	0.4	5
3285	The H/R Fcγ3RIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population. Clinics, 2011, 66, 919-922.	0.6	7
3286	Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China. Oncologist, 2020, 25, e1202-e1208.	1.9	15
3287	Comparison of the Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Glasgow Prognostic Score in Diffuse Large B-Cell Lymphoma. Shiraz E Medical Journal, 2016, 17, .	0.1	1
3288	MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma. Oncotarget, 2016, 7, 53808-53819.	0.8	21
3289	Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin's lymphoma. Oncotarget, 2016, 7, 56574-56583.	0.8	7
3290	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531.	0.8	44
3291	Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. Oncotarget, 2016, 7, 72219-72228.	0.8	8
3292	Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Oncotarget, 2016, 7, 83544-83553.	0.8	48
3293	A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy. Oncotarget, 2017, 8, 20362-20370.	0.8	7
3294	Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). Oncotarget, 2017, 8, 13367-13374.	0.8	6
3295	Intensity-modulated radiotherapy has superior outcomes to three-dimensional conformal radiotherapy in patients with stage IE-IIIE extranodal nasal-type natural killer/T-cell lymphoma. Oncotarget, 2017, 8, 60504-60513.	0.8	5
3296	Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of <i>de novo</i> diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas. Oncotarget, 2017, 8, 33487-33500.	0.8	26
3297	A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one. Oncotarget, 2017, 8, 47007-47019.	0.8	26

#	ARTICLE	IF	CITATIONS
3298	Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 47790-47800.	0.8	11
3299	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. <i>Oncotarget</i> , 2017, 8, 91703-91710.	0.8	21
3300	Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas. <i>Oncotarget</i> , 2017, 8, 81329-81342.	0.8	6
3301	Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 76231-76240.	0.8	23
3302	Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT. <i>Oncotarget</i> , 2017, 8, 85110-85119.	0.8	2
3303	Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients. <i>Oncotarget</i> , 2017, 8, 99104-99111.	0.8	5
3304	Clinical and histological features of primary testicular diffuse large B-cell lymphoma: a single center experience in China. <i>Oncotarget</i> , 2017, 8, 112384-112389.	0.8	10
3305	Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study. <i>Oncotarget</i> , 2017, 8, 68583-68590.	0.8	15
3306	Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies. <i>Oncotarget</i> , 2017, 8, 79864-79875.	0.8	15
3307	Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding. <i>Oncotarget</i> , 2017, 8, 72818-72834.	0.8	14
3308	Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. <i>Oncotarget</i> , 2017, 8, 99587-99600.	0.8	41
3309	The prognostic significance of CD11b+CX3CR1+ monocytes in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92289-92299.	0.8	5
3310	Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92312-92323.	0.8	11
3311	Indolent lymphoma with composite histology and simultaneous transformation at initial diagnosis exhibit clinical features similar to de novo diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2018, 9, 19613-19622.	0.8	8
3312	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23443-23450.	0.8	12
3314	Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Oncotarget</i> , 2019, 10, 5403-5411.	0.8	12
3315	A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma. <i>Oncotarget</i> , 2016, 7, 18585-18593.	0.8	6
3316	Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. <i>Oncotarget</i> , 2016, 7, 27676-27688.	0.8	78

#	ARTICLE	IF	CITATIONS
3317	Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial. Nagoya Journal of Medical Science, 2017, 79, 407-413.	0.6	9
3318	Extranodal involvement in young patients with diffuse large B-cell lymphoma: distribution, prognostic value and treatment options. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 57-65.	0.7	9
3319	PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 66-74.	0.7	10
3320	High-dose Chemotherapy with Stem Cell Rescue Provided Durable Remission for Classical Hodgkin Lymphoma-type Post-transplant Lymphoproliferative Disorder after Unrelated Cord Blood Transplantation: A Case Report and Review of the Literature. Internal Medicine, 2017, 56, 1873-1877.	0.3	1
3321	PET Imaging to Monitor Cancer Therapy. Current Pharmaceutical Biotechnology, 2014, 14, 669-682.	0.9	7
3322	Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study. Anticancer Research, 2017, 37, 2655-2662.	0.5	7
3323	Small clonal B-cell population in the bone marrow as a possible tool in the diagnosis of occult primary parotid lymphoma. Colombia Medica, 2016, , 59-62.	0.7	6
3325	Prognostic Value of Baseline Radiomic Features of 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma. Diagnostics, 2021, 11, 36.	1.3	28
3326	Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma. Nuklearmedizin - NuclearMedicine, 2015, 54, 241-246.	0.3	5
3327	<i>Helicobacter pylori</i> infection in gastric mucosa-associated lymphoid tissue lymphoma. World Journal of Gastroenterology, 2014, 20, 2751.	1.4	23
3328	Patterns of care and treatment outcomes for primary thyroid lymphoma: a single institution study. Radiation Oncology Journal, 2013, 31, 177.	0.7	23
3329	Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience. Radiation Oncology Journal, 2017, 35, 317-324.	0.7	2
3330	Association between Lactate Dehydrogenase Levels to the Response of Non-Hodgkin Lymphoma in Elderly Patients Who Treated with First-Line Chemotherapy in Sanglah General Hospital. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 1984-1986.	0.1	5
3331	miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma. Oncology Letters, 2020, 19, 3487-3494.	0.8	5
3332	Clinical significance of nuclear factor κ B and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. Korean Journal of Internal Medicine, 2014, 29, 785.	0.7	17
3333	Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party. Korean Journal of Internal Medicine, 2016, 31, 1030-1041.	0.7	18
3334	Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review. Korean Journal of Internal Medicine, 2015, 30, 684-693.	0.7	7
3335	The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation. Korean Journal of Internal Medicine, 2018, 33, 1169-1181.	0.7	5

#	ARTICLE	IF	CITATIONS
3336	Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system. Korean Journal of Internal Medicine, 2020, 35, 946-956.	0.7	8
3337	Superior Clinical Impact of FDG-PET Compared to MRI for the Follow-up of a Patient with Sacral Lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2009, 49, 109-115.	0.3	5
3338	Single-fraction image-guided extracranial radiosurgery for recurrent and metastatic abdominal and pelvic cancers: short-term local control, metabolic response, and toxicity. Journal of Gastrointestinal Oncology, 2010, 1, 16-23.	0.6	10
3339	Staging and response assessment in lymphomas: the new Lugano classification. Chinese Clinical Oncology, 2015, 4, 5.	0.4	99
3340	PET/CT: appropriate application in lymphoma. Chinese Clinical Oncology, 2015, 4, 4.	0.4	15
3341	Efficacy and safety of biosimilar rituximab (ZytuxTM) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Reports, 2020, 12, 8296.	0.3	2
3342	Treatment results in advanced stage Hodgkin's lymphoma. Journal of Postgraduate Medicine, 2015, 61, 88-91.	0.2	8
3343	Appropriateness criteria of FDG PET/CT in oncology. Indian Journal of Radiology and Imaging, 2015, 25, 88-101.	0.3	35
3344	Indian Council of Medical Research consensus document for the management of non-hodgkin's lymphoma (high grade). Indian Journal of Medical and Paediatric Oncology, 2017, 38, 51.	0.1	4
3345	Lomustine, cytarabine, cyclophosphamide, etoposide " An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors. Journal of Cancer Research and Therapeutics, 2018, 14, 926.	0.3	9
3346	Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era. Journal of Cancer Research and Therapeutics, 2018, 14, S248-S253.	0.3	11
3347	Quantitative assessment of radionuclide uptake and positron emission tomography-computed tomography image contrast. World Journal of Nuclear Medicine, 2016, 15, 167-172.	0.3	2
3348	Efficacy and safety of ibrutinib in indian patients with relapsed or refractory chronic lymphocytic leukemia and mantle cell lymphoma: Cases from a named patient program. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 508.	0.1	7
3349	Peripheral T cell lymphoma: Clinico-pathological characteristics & outcome from a tertiary care centre in south India. Indian Journal of Medical Research, 2018, 147, 464.	0.4	5
3350	Diffuse large B-cell lymphoma: An institutional analysis. South Asian Journal of Cancer, 2018, 07, 200-202.	0.2	16
3351	Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement. Cancer Research and Treatment, 2013, 45, 112-117.	1.3	6
3352	Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. Cancer Research and Treatment, 2015, 47, 173-181.	1.3	10
3353	Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. Cancer Research and Treatment, 2019, 51, 1302-1312.	1.3	6

#	ARTICLE	IF	CITATIONS
3354	Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma. <i>Cancer Research and Treatment</i> , 2019, 51, 1479-1487.	1.3	15
3355	Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labelled Phase II Trial. <i>Cancer Research and Treatment</i> , 2020, 52, 374-387.	1.3	26
3356	Safety and Efficacy of Radioimmunotherapy with ⁹⁰ Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study. <i>Journal of Cancer Science & Therapy</i> , 2012, 04, .	1.7	2
3357	Day 15 Peripheral Blood Lymphocyte/monocyte Ratio Post-autologous Peripheral Hematopoietic Stem Cell Transplantation and Survival in Diffuse Large B-cell Lymphoma. <i>Journal of Stem Cell Research & Therapy</i> , 2011, 01, .	0.3	10
3358	Absolute Lymphocyte/Monocyte Ratio at Diagnosis and Interim Positron-Emission Tomography Predict Survival in Classical Hodgkin Lymphoma. <i>Journal of Cancer Therapy</i> , 2013, 04, 452-459.	0.1	2
3359	Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE. <i>Turkish Journal of Haematology</i> , 2016, 33, 209-215.	0.2	2
3360	Two-stage design for phase II oncology trials with relaxed futility stopping. <i>Statistics and Its Interface</i> , 2016, 9, 93-98.	0.2	3
3361	Evaluation of cancer treatment in the abdomen: Trends and advances. <i>World Journal of Radiology</i> , 2013, 5, 126.	0.5	2
3362	Diagnosis and treatment of follicular lymphoma. <i>Swiss Medical Weekly</i> , 2011, 141, w13247.	0.8	10
3363	Immune checkpoint inhibitors in patients with pretreated Hodgkin's lymphoma: a Korean single-center, retrospective study. <i>Blood Research</i> , 2020, 55, 85-90.	0.5	3
3364	18F-FDG PET/CT for identifying the potential causes and extent of secondary hemophagocytic lymphohistiocytosis. <i>Diagnostic and Interventional Radiology</i> , 2016, 22, 471-475.	0.7	32
3365	LONG-TERM OUTCOME OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA TREATED WITH FIRST-LINE INTENSIVE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION. <i>Biomedical Papers of the Medical Faculty of the University Palacký; Olomouc, Czechoslovakia</i> , 2011, 155, 63-69.	0.2	15
3366	PROGNOSTIC FACTORS IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: HOW TO IDENTIFY A HIGH-RISK PATIENT?. <i>Biomedical Papers of the Medical Faculty of the University Palacký; Olomouc, Czechoslovakia</i> , 2011, 155, 99-108.	0.2	4
3367	The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma. <i>Chinese Journal of Cancer</i> , 2012, 31, 348-353.	4.9	7
3368	NCCN Task Force Report: Positron Emission Tomography (PET)/Computed Tomography (CT) Scanning in Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, S-1-S-22.	2.3	72
3369	Quantitative Imaging Assessment for Clinical Trials in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1505-1511.	2.3	4
3370	Time-to-treatment of diffuse large B-cell lymphoma in São Paulo. <i>Clinics</i> , 2014, 69, 367-371.	0.6	3
3371	High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center. <i>Journal of Cancer</i> , 2020, 11, 57-68.	1.2	8

#	ARTICLE	IF	CITATIONS
3372	Prognostic Sub-Grouping of Diffuse Large B-Cell Lymphomas into Germinal Centre And Post Germinal Centre Groups by Immunohistochemistry after 6 Cycles of Chemotherapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 1341-1347.	0.5	6
3373	Comparison of WHO and RECIST Criteria for Evaluation of Clinical Response to Chemotherapy in Patients with Advanced Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 3213-3218.	0.5	35
3374	Efficacy and Tolerance of Pegaspargase-Based Chemotherapy in Patients with Nasal-Type Extranodal NK/T-Cell Lymphoma: a Pilot Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6275-6281.	0.5	8
3375	Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review. <i>In Vivo</i> , 2021, 35, 3401-3406.	0.6	4
3376	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.	0.6	7
3377	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. <i>Blood Advances</i> , 2022, 6, 486-494.	2.5	25
3378	End of treatment FDG-PET in primary mediastinal B-cell lymphoma treated with R-chemotherapy: Prognostic indicator and implications for consolidation radiotherapy. <i>European Journal of Haematology</i> , 2021, , .	1.1	2
3379	Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era. <i>Cytotherapy</i> , 2022, 24, 49-58.	0.3	5
3380	Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Cancer Investigation</i> , 2021, 39, 871-879.	0.6	6
3381	Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 5300-5311.	2.5	9
3382	A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 49-58.	1.1	2
3383	Analysis of competing risks of causes of death and their variation over different time periods in Hodgkin disease. <i>Journal of Clinical Oncology</i> , 2007, 25, 18528-18528.	0.8	0
3385	The Role of Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma. <i>Cancer Treatment and Research</i> , 2009, 144, 399-414.	0.2	0
3387	Recent advances in the treatment of B-cell lymphoma. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	0
3389	Monoclonal Antibody Therapy for Hematologic Malignancies. , 2010, , 493-536.		0
3390	Non-Hodgkin's Lymphoma: Allogeneic Reduced Intensity Conditioning. , 2010, , 109-125.		0
3392	Lymphoma: Diagnostic and Therapeutic Applications of Radiopharmaceuticals. , 2010, , 199-203.		0
3393	A Case of Nodal Malignant Lymphoma in the Regional Lymph Node at Operation for Esophageal and Laryngeal Cancer. <i>Japanese Journal of Gastroenterological Surgery</i> , 2010, 43, 33-37.	0.0	0

#	ARTICLE	IF	CITATIONS
3395	Non-Hodgkin's Lymphomas. , 2010, , 1371-1379.		0
3396	Localisation gastro-intestinale. , 2010, , 75-79.		0
3399	Hodgkin Lymphoma in Special Populations and Rare Localizations. , 2011, , 167-182.		0
3400	Background and Rationale for Radiotherapy in Advanced-Stage Hodgkin Lymphoma. , 2011, , 21-29.		0
3401	Functional Imaging. , 2011, , 77-95.		0
3402	The Management of HIV-Hodgkin Lymphoma. , 2011, , 249-258.		0
3403	Evaluation of Response After Radiotherapy for Hodgkin Lymphoma. , 2011, , 161-166.		0
3404	Clinical Evaluation. , 2011, , 65-76.		0
3405	Overview of the Lymphoid Neoplasms. , 2012, , 3-39.		0
3406	Economic Impact of Disease Progression In Follicular Non-Hodgkin's Lymphoma.. Blood, 2010, 116, 1522-1522.	0.6	0
3412	Lymphoproliferation and Lymphoma in Sjögren's Syndrome. , 2011, , 345-355.		0
3413	Lymphoma: Differential Diagnosis of Mediastinal Masses and Response. , 2011, , 193-198.		0
3414	Association of CD57+ Natural Killer Cells with Better Overall Survival in DLBCL Patients. Korean Journal of Pathology, 2011, 45, 361.	1.2	1
3416	A Case of an Abdominal Mass: Follicular Lymphoma. , 2011, 15, 61-4.		0
3417	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
3418	Pediatric Hodgkin's Lymphoma. , 2012, , 1489-1503.		0
3419	Non-Hodgkin's Lymphoma. , 2012, , 1545-1572.		0
3420	Diagnostic and Treatment Response Imaging in Lymphomas. , 0, , .		1

#	ARTICLE	IF	CITATIONS
3421	Esplenectomía para patologías hematológicas en la Fundación Santa Fe de Bogotá : caracterización y evaluación de múltiples desenlaces.. Revista Colombiana De Hematología Y Oncología, 2012, 1, 24-35.	0.0	0
3422	Lymphomas. , 2013, , 153-187.		0
3424	Brentuximab Vedotin (SGN-35) for CD30-Positive Malignancies. , 2013, , 161-175.		0
3425	Lymphoma Surveillance Counterpoint: Japan. , 2013, , 467-468.		0
3426	Future Directions in Aggressive Lymphomas. , 2013, , 173-189.		0
3427	A case of primary malignant lymphoma of the lung with pleural dissemination. The Journal of the Japanese Association for Chest Surgery, 2013, 27, 170-174.	0.0	0
3428	Successful Treatment of Elderly Diffuse Large B-Cell Lymphoma with Central Nervous System Recurrence by Rituximab, Ranimusutine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy. Journal of Cancer Therapy, 2013, 04, 448-451.	0.1	0
3429	Interim FDG-PET/CT as a predictor of prognosis for HIV-related malignant lymphoma: Preliminary study. Journal of Solid Tumors, 2013, 3, .	0.1	1
3430	Day 100 Absolute Monocyte/Lymphocyte Prognostic Score and Survival Post Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma. Journal of Cancer Therapy, 2013, 04, 1298-1305.	0.1	0
3431	Diffuse Large B-Cell Lymphoma. , 2013, , 177-202.		0
3432	Lymphoma: streamlining follow ups. Revista Brasileira De Hematologia E Hemoterapia, 2013, 35, 162.	0.7	0
3433	PATHOLOGIE TUMORALE DU PARENCHYME PULMONAIRE. , 2013, , 277-451.		0
3434	Imaging Criteria for Tumor Treatment Response Evaluation. , 2014, , 13-25.		0
3435	Introduction to Lymphomas. , 2014, , 235-238.		1
3436	Lymphomas: The Role of CT and MRI in Staging and Restaging. , 2014, , 239-247.		1
3437	Functional Imaging in Clinical Use for the Assessment of Lymph Nodes in Oncological Patients. , 2014, , 1271-1309.		0
3438	Monitoring Responses to Therapy in Oncology. , 2014, , 155-171.		1
3439	The Effect of Low Dose CT Matrix Size Variation on Qualitative and Semi-Quantitative Analysis of Positron Emission Tomography (PET) Images. The Egyptian Journal Nuclear Medicine, 2013, 8, 63-69.	0.0	0

#	ARTICLE	IF	CITATIONS
3440	Imaging Review Charters and Operational Considerations. , 2014, , 65-82.		1
3441	Clinical Significance of Clonal Rearrangement of the Immunoglobulin Gene in the Bone Marrow of Patients with B-cell Non-Hodgkin Lymphoma. Laboratory Medicine Online, 2014, 4, 125.	0.0	1
3442	Pediatric Molecular Imaging. , 2014, , 571-595.		1
3443	Adult T-Cell Leukemia-Lymphoma. , 2014, , 2076-2092.e4.		0
3445	Clinical features and treatment outcomes of patients with Hodgkin lymphoma: A single-center study of 36 cases. Tenri Medical Bulletin, 2014, 17, 15-24.	0.1	0
3446	Lymphomas and Lymphoproliferative Disorders. , 2014, , 479-496.		0
3447	Lymphomes : principes th�rapeutiques et imagerie post-th�rapeutique. , 2014, , 265-298.		0
3448	Adult Burkitt Lymphoma and Leukemia. , 2014, , 171-194.		0
3449	Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading. BMJ Case Reports, 2014, 2014, bcr2014206034-bcr2014206034.	0.2	5
3450	The Challenge of Treating Elderly Patients with Mantle Cell Lymphoma. , 2015, , 143-168.		0
3451	Treatment of Early Favorable Hodgkin Lymphoma. Hematologic Malignancies, 2015, , 201-220.	0.2	0
3453	Infused Autograft Lymphocyte to Monocyte Ratio and Survival in Classical Hodgkin Lymphoma. Blood, 2014, 124, 1189-1189.	0.6	0
3454	Prognostic Factors. Hematologic Malignancies, 2015, , 131-155.	0.2	1
3455	Role of radiation therapy for Hodgkin's lymphoma. Onkologiya Zhurnal Imeni P A Gertsena, 2015, 4, 17.	0.0	0
3456	Retrospective audit of clinico-pathologic features and treatment outcomes in a cohort of elderly non-Hodgkin's lymphoma patients in a tertiary cancer center. Indian Journal of Cancer, 2015, 52, 541.	0.2	1
3457	Efficacy of pegaspargase in extra nodal natural killer/T-cell lymphoma nasal type: A case report from China. Journal of Cancer Research and Therapeutics, 2015, 11, 665.	0.3	0
3458	Post-therapy Surveillance of Bone Tumors. Pediatric Oncology, 2015, , 211-219.	0.5	0
3459	Evaluation of Response in Malignant Tumors Treated with Targeted Agents. Current Clinical Pathology, 2015, , 43-55.	0.0	0

#	ARTICLE	IF	CITATIONS
3460	Managing advanced stage Hodgkin lymphoma. Journal of Postgraduate Medicine, 2015, 61, 75-76.	0.2	0
3461	FDG PET/CT in the Imaging of Mediastinal Masses. , 2015, , 202-208.		0
3462	Treatment Outcomes of Patients with Primary Mediastinal Diffuse Large B-Cell Lymphoma: A Single-Center Experience. Journal of Hematology & Thromboembolic Diseases, 2015, 03, .	0.1	0
3463	Onkologische Bildgebung zur Beurteilung des Therapieansprechens. , 2015, , 91-100.		0
3464	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
3468	PET Scan Reporting in Clinical Practice. , 2016, , 117-136.		0
3469	Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2016, , 1-42.		0
3471	Hodgkin Lymphoma in Children. , 2016, , 295-304.		0
3472	PET/CT in RT Planning. , 2016, , 99-115.		0
3474	18F-FDG PET/CT Imaging in Detection of Intravascular Large B-Cell Lymphoma. Journal of Cancer Research Updates, 2016, 5, 10-11.	0.3	0
3475	PET Response-Adapted Treatment in Hodgkin Lymphoma. , 2016, , 31-64.		0
3476	PET Scan for HL Restaging. , 2016, , 15-30.		0
3477	FDG PET/CT for Initial Staging of Diffuse Large B-Cell Lymphoma: Is Diffuse Bone Marrow Uptake a Reflection of Disease Involvement?. Journal of Bone Marrow Research, 2016, 04, .	0.2	0
3478	Role of 18F-fl uorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Evaluation and Management of Lymphoma. , 2016, , 14-23.		0
3479	Role of PET/CT in Pediatric Malignancy. , 2017, , 537-575.		0
3480	Role of Positron-Emission Tomography in Prognosis of Outcomes of High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Hodgkinâ€™s Lymphoma. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2016, 9, 406-412.	0.1	0
3481	Primary Orbital Follicular Lymphoma: A Case Report and Review. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, XD01-XD03.	0.8	2
3482	Responses and response evaluation of immune checkpoint inhibitors in lymphoma. Annals of Lymphoma, 0, 1, 1-1.	4.5	0

#	ARTICLE	IF	CITATIONS
3483	Radiological Imaging in Lymphoma. , 2017, , 25-31.		0
3484	Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2017, , 353-393.		0
3485	Soft Tissue Lymphoma. , 2017, , 577-592.		0
3486	Clinical applications of PET/CT and SPECT/CT imaging. Imaging in Medical Diagnosis and Therapy, 2017, , 439-472.	0.0	0
3488	The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials. , 2017, 37, 5727-5736.		13
3489	Blood biomarkers in adults with lymph node enlargement contribute to diagnostic significance of malignancy. Oncotarget, 2017, 8, 98533-98541.	0.8	2
3490	Resistance and Heterogeneity of Intratumoral Antibody Distribution. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 99-104.	0.1	0
3491	Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis. Laboratory Medicine Online, 2018, 8, 41.	0.0	0
3492	Conventional and Conformai Radiotherapy with and without Beam Intensity Modulation in Patients with Stage II Hodgkin's Lymphoma with Supradiaphragmal Lesions. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2018, 11, 70-77.	0.1	0
3493	PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin's Lymphoma. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2018, 11, 213-219.	0.1	3
3494	Adult Burkitt lymphoma: An institutional experience with a uniform chemotherapy protocol. South Asian Journal of Cancer, 2018, 07, 195-199.	0.2	2
3495	Extranodal Localization of Aggressive Lymphoma. Springer Reference Medizin, 2019, , 201-212.	0.0	0
3496	Clinical and Hematological Predictors of Response to First-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2019, 12, 68-72.	0.1	2
3497	Role of Modern Imaging with FDG-PET/CT in Aggressive Lymphoma. Technik Im Fokus, 2019, , 285-295.	0.2	0
3498	Hybrid Imaging and Radionuclide Therapy in Hemato-oncology. , 2019, , 655-705.		0
3499	The Lower Peripheral Blood Lymphocyte to Monocyte Ratio Following Completion of First Line Chemotherapy Is a Risk Factor for Predicting Relapse in Patients with Diffuse Large B-Cell Lymphoma. Journal of Cancer Therapy, 2019, 10, 53-68.	0.1	0
3500	Quintessential role of 18fluorine fluorodeoxyglucose positron emission tomography/computed tomography in differentiation of viable tumor tissue and nondisease desmoplastic residue. Indian Journal of Nuclear Medicine, 2019, 34, 129.	0.1	0
3501	Development of methods to evaluate probability of reviewer's assessment bias in blinded independent central review (BICR) imaging studies. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
3502	Estimation of the most Appropriate Threshold for Lesion Delineation and Volumetric Quantification in 18F-FDG PET. Arab Journal of Nuclear Sciences and Applications, 2019, 52, 169-180.	0.1	1
3503	Agresif B h ¹⁴ Crelil Hodgkin d ¹⁴ ve Hodgkin lenfomada ilk basamak tedavi yan ¹⁴ n FDG-PET/BT ile de ¹⁴ erlendirilmesinde rezid ¹⁴ el SUVmax. Uluda ¹⁴ Aeniversitesi T ¹⁴ p Fak ¹⁴ ltesi Dergisi, 0, .	0.2	0
3504	Primary Bone Lymphomas: Long-Term Results of a Prospective Single-Center Trial. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2019, 12, 247-262.	0.1	2
3505	The Role of Positron Emission Tomography/Computed Tomography (PET/CT) in Assessment of Therapeutic Response in Non-Hodgkin Lymphoma. Medical Journal of the University of Cairo Faculty of Medicine, 2019, 87, 2925-2925.	0.0	0
3506	APPLICATION OF POSITRON EMISSION TOMOGRAPHY / COMPUTER TOMOGRAPHY FOR EVALUATING THE RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA / LYMPHOBLASTIC LYMPHOMA. Gematologiya I Transfuziologiya, 2019, 64, 138-149.	0.1	0
3507	Evolution of Response Criteria in Immunotherapy. , 2020, , 7-11.		0
3508	Clinical Features of Plasmablastic Lymphoma: Case Series From an Asian Tertiary Cancer Center and Literature Review. Journal of Hematology (Brossard, Quebec), 2020, 9, 71-78.	0.4	3
3510	2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 219-225.	0.4	0
3511	Follicular lymphoma. Journal of Modern Oncology, 2020, 22, 34-51.	0.1	4
3512	Hodgkin's lymphoma. Journal of Modern Oncology, 2020, 22, 6-33.	0.1	5
3513	A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?. Journal of Clinical Medicine, 2021, 10, 5114.	1.0	3
3514	Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R ¹⁴ €CHOP14: A SAKK 38/07 trial post ¹⁴ hoc analysis. Hematological Oncology, 2022, 40, 12-22.	0.8	13
3515	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. Journal of Clinical Oncology, 2022, 40, 729-739.	0.8	34
3516	Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study. Leukemia and Lymphoma, 2022, 63, 599-607.	0.6	0
3517	Treatment of Early Favorable Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 219-236.	0.2	0
3518	F-18 FDG PET Tests in Malignant Lymphoma. , 2021, , 135-147.		0
3519	Prognostic Impact of Peripheral Blood T-Cell Subsets at the Time of Diagnosis on Survival in Patients with Diffuse Large B-Cell Lymphoma. Acta Haematologica, 2021, 144, 427-437.	0.7	6
3520	Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma. Oncolmmunology, 2021, 10, 1995166.	2.1	12

#	ARTICLE	IF	CITATIONS
3521	Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis. <i>Cell Transplantation</i> , 2021, 30, 096368972110570.	1.2	4
3522	Evolution of Clinical Trial Imaging and Co-clinical Imaging. <i>Medical Radiology</i> , 2020, , 239-253.	0.0	1
3523	A Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive- and CD30-Positive Lymphomas. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3525	: Differentielle Indikationsstellung für Diagnostik in der Onkologie (Röntgen, CT, MRT, Sonografie). <i>Springer Reference Medizin</i> , 2020, , 1-19.	0.0	0
3526	Response Assessment and Follow-Up by Imaging in Gastrointestinal Tumours. <i>Medical Radiology</i> , 2020, , 475-494.	0.0	0
3527	PET in Lymphoma. , 2020, , 685-729.		0
3528	PRIMARY BONE LYMPHOMAS: 18F-FDG PET AND PET-CT AS METHODS OF DIAGNOSIS AND EFFICACY ESTIMATION OF ANTITUMOR TREATMENT. <i>Klinicheskaya Onkologematologiya/Clinical Oncohematology</i> , 2020, 13, 33-49.	0.1	0
3529	Therapy Response Imaging in Lymphoma and Hematologic Malignancies. <i>Medical Radiology</i> , 2020, , 177-200.	0.0	0
3530	Functional Imaging in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020, , 113-143.	0.2	0
3531	Metrics to Evaluate PET Response to Therapy Based on 3D Analysis. <i>Open Journal of Medical Imaging</i> , 2020, 10, 133-142.	0.1	0
3532	Prognostic Factors. <i>Hematologic Malignancies</i> , 2020, , 145-169.	0.2	0
3534	Interim response in diffuse large B cell lymphoma on CT: what is the optimal size reduction (\hat{I}^{SPD}) for predicting outcome?. <i>European Radiology</i> , 2020, 30, 3094-3100.	2.3	0
3535	Clinical significance of oxidative stress for untreated patients with diffuse large B cell lymphoma. <i>Molecular and Clinical Oncology</i> , 2021, 16, 4.	0.4	1
3536	Rituximab exposure-response in triweekly R-CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes. <i>Clinical and Translational Science</i> , 2022, 15, 680-690.	1.5	3
3537	Synthetic control arms in studies of multiple myeloma and diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2022, 196, 1274-1277.	1.2	9
3538	Current Role of Functional Imaging in the Management of Lymphoma. <i>Current Oncology Reports</i> , 2021, 23, 144.	1.8	11
3539	Hematological Neoplasia. , 2008, , 400-526.		0
3540	A Case of Periaortic Lymphoma Mimicking Complicated Type B Acute Aortic Dissection: A Pitfall in the Endovascular Surgery Era. <i>Annals of Vascular Diseases</i> , 2020, 13, 312-315.	0.2	0

#	ARTICLE	IF	CITATIONS
3541	Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China. Chinese Medical Journal, 2020, 133, 2796-2802.	0.9	4
3543	Imaging techniques for Kaposi's sarcoma. Journal of HIV Therapy, 2008, 13, 65-71.	0.6	14
3544	Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects. Biologics: Targets and Therapy, 2007, 1, 215-27.	3.0	13
3545	Semantic reasoning with image annotations for tumor assessment. AMIA ... Annual Symposium proceedings, 2009, 2009, 359-63.	0.2	7
3546	The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma. European Journal of Clinical & Medical Oncology, 2010, 2, 131-138.	0.0	4
3547	C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma. American Journal of Blood Research, 2011, 1, 204-14.	0.6	1
3548	Prognostic value of interim (18)F-FDG PET/CT in diffuse large B-cell lymphoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 95-101.	0.7	6
3549	The role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphoma. Indian Journal of Nuclear Medicine, 2012, 27, 141-4.	0.1	2
3550	PET imaging of apoptosis in tumor-bearing mice and rabbits after paclitaxel treatment with (18)F(-)labeled recombinant human His10-annexin V. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 27-37.	1.0	14
3551	Prognostic value of interim (18)F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 15340-50.	1.3	5
3553	Small clonal B-cell population in the bone marrow as a possible tool in the diagnosis of occult primary parotid lymphoma. Colombia Medica, 2016, 47, 59-62.	0.7	4
3555	Prognostic Value of FDG-PET, Based on the Revised Response Criteria, in Patients with Malignant Lymphoma: A Comparison with CT/MRI Evaluations, Based on the International Working Group/Cotswolds Meeting Criteria. Asia Oceania Journal of Nuclear Medicine and Biology, 2015, 3, 91-8.	0.1	1
3556	Mantle Cell Lymphoma: A North Indian Tertiary Care Centre Experience. Asian Pacific Journal of Cancer Prevention, 2016, 17, 4583-4586.	0.5	4
3557	Diagnostic and Prognostic Relevance of Bone Marrow Microenvironment Components in Non-Hodgkin's Lymphoma Cases Before and After Therapy. Asian Pacific Journal of Cancer Prevention, 2016, 17, 5273-5280.	0.5	2
3558	Follicular lymphoma: an Institutional Analysis. Asian Pacific Journal of Cancer Prevention, 2017, 18, 681-685.	0.5	5
3559	Consolidation radiotherapy for advanced-stage aggressive B-cell non-Hodgkin lymphoma: A systematic review and meta-analysis. EXCLI Journal, 2017, 16, 1233-1248.	0.5	2
3560	To Determine the Prognostic Significance of 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan-Derived Parameters (Total Lesion Glycolysis and Metabolic Tumor-to-Liver Ratio) in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2020, 35, 100-104.	0.1	0
3590	Prognostic impact of tumor-associated macrophages, lymphocyte-to-monocyte and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma. American Journal of Blood Research, 2020, 10, 97-108.	0.6	3

#	ARTICLE	IF	CITATIONS
3591	Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type. <i>American Journal of Cancer Research</i> , 2020, 10, 4498-4512.	1.4	6
3593	Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma. <i>Blood Advances</i> , 2021, 5, 1412-1424.	2.5	1
3595	Deep learning convolutional neural network (DLCNN): unleashing the potential of F-FDG PET/CT in lymphoma. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 327-331.	1.0	1
3596	Computer-aided detection of mantle cell lymphoma on F-FDG PET/CT using a deep learning convolutional neural network. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 260-270.	1.0	2
3597	Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110564.	0.8	3
3598	Artificial Intelligence in Lymphoma PET Imaging. <i>PET Clinics</i> , 2022, 17, 145-174.	1.5	23
3599	Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis. <i>BMC Cancer</i> , 2021, 21, 1255.	1.1	3
3600	Surgery and Chemotherapy versus Chemotherapy Only in Older Persons with Primary Intestinal Diffuse Large B-Cell Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 8831-8839.	0.9	2
3601	CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study. <i>Leukemia and Lymphoma</i> , 2022, 63, 468-472.	0.6	10
3602	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. <i>Cancer Medicine</i> , 2022, 11, 61-73.	1.3	4
3603	Prognostic significance of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in patients with primary T cell lymphomas. <i>Nuclear Medicine Communications</i> , 2022, 43, 186-192.	0.5	0
3604	Assessment of Early Therapy Response of Non-Hodgkin's and Hodgkin's Lymphoma Using Mode Ultrasound and Dynamic Contrast-Enhanced Ultrasound. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 2033-2040.	0.8	2
3605	The Use of PET in Evaluating the Efficacy of Immunotherapy in Oncology. , 2022, , 471-493.		0
3606	Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 1999-2010.	0.6	17
3607	Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents. <i>Leukemia and Lymphoma</i> , 2022, 63, 813-820.	0.6	5
3608	Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. <i>Blood</i> , 2022, 140, 419-437.	0.6	58
3609	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. <i>Blood Advances</i> , 2022, 6, 920-930.	2.5	16
3610	The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma. <i>Scientific Reports</i> , 2022, 12, 36.	1.6	7

#	ARTICLE	IF	CITATIONS
3611	Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 797028.	1.3	8
3612	Clinicopathological characteristics and treatment outcomes of cutaneous extranodal natural killer/T-cell lymphoma: a retrospective study in China. <i>Translational Cancer Research</i> , 2020, 9, 6096-6106.	0.4	1
3613	Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL). <i>Annals of Hematology</i> , 2022, 101, 789.	0.8	0
3614	Serum Albumin Levels Strongly Predict Survival Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab-Combined Chemotherapy. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 0, , .	0.3	1
3615	PET imaging of hematological neoplasia. , 2022, , .		0
3616	A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 1058-1069.	0.6	3
3617	Matching design for augmenting the control arm of a randomized controlled trial using real-world data. <i>Journal of Biopharmaceutical Statistics</i> , 2022, 32, 124-140.	0.4	7
3618	Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter Follidela Study. <i>Cancers</i> , 2022, 14, 654.	1.7	3
3619	Radiomics Features of the Spleen as Surrogates for CT-Based Lymphoma Diagnosis and Subtype Differentiation. <i>Cancers</i> , 2022, 14, 713.	1.7	15
3620	Exploring the Interobserver Agreement in Computer-Aided Radiologic Tumor Measurement and Evaluation of Tumor Response. <i>Frontiers in Oncology</i> , 2021, 11, 691638.	1.3	0
3621	Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome. <i>Frontiers in Pharmacology</i> , 2022, 13, 788824.	1.6	1
3622	Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study. <i>Oncologist</i> , 2022, 27, 532-e542.	1.9	3
3623	Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 2536-2547.	2.5	8
3624	Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of ¹²⁵ I-2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-8.	0.7	0
3625	Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>EJHaem</i> , 2022, 3, 139-153.	0.4	4
3626	Artificial Intelligence Analysis of Gene Expression Predicted the Overall Survival of Mantle Cell Lymphoma and a Large Pan-Cancer Series. <i>Healthcare (Switzerland)</i> , 2022, 10, 155.	1.0	19
3627	Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 796270.	1.3	4
3628	Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 1091-1101.	0.8	11

#	ARTICLE	IF	CITATIONS
3629	Longitudinal CT Imaging to Explore the Predictive Power of 3D Radiomic Tumour Heterogeneity in Precise Imaging of Mantle Cell Lymphoma (MCL). <i>Cancers</i> , 2022, 14, 393.	1.7	4
3630	Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination. <i>Frontiers in Oncology</i> , 2022, 12, 796738.	1.3	2
3631	Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. <i>British Journal of Haematology</i> , 2022, 197, 212-222.	1.2	6
3632	Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma. <i>HemaSphere</i> , 2022, 6, e675.	1.2	0
3633	Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors. <i>Scientific Reports</i> , 2022, 12, 1753.	1.6	4
3634	Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2022, 62, 91-98.	0.3	1
3635	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	0.8	160
3636	Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India. <i>Frontiers in Oncology</i> , 2021, 11, 799948.	1.3	5
3637	The outcome of watchful waiting in patients with previously treated follicular lymphoma. <i>Cancer Medicine</i> , 2022, 11, 2106-2116.	1.3	4
3638	Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, 402-409.	0.4	2
3639	A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogeneic PBSCT. <i>International Journal of Hematology</i> , 2022, , 1.	0.7	0
3640	Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study. <i>Hematological Oncology</i> , 2022, 40, 637-644.	0.8	12
3641	Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit. <i>Haematologica</i> , 2022, 107, 1214-1217.	1.7	5
3642	The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2022, 33, 288-298.	0.6	99
3643	Axicabtagene CiloleuceL as Second-Line Therapy for Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 640-654.	13.9	586
3646	Clinical Features and Prognostic Significance of NOTCH1 Mutations in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 746577.	1.3	8
3647	Prognostic Role of the Expression of Latent-Membrane Protein 1 of Epstein-Barr Virus in Classical Hodgkin Lymphoma. <i>Viruses</i> , 2021, 13, 2523.	1.5	6
3649	Thoracic Imaging Manifestations of Treated Lymphomas. <i>Journal of Thoracic Imaging</i> , 2022, 37, 67-79.	0.8	0

#	ARTICLE	IF	CITATIONS
3650	Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial. <i>HemaSphere</i> , 2022, 6, e699.	1.2	9
3651	Phase Ib study of avadomide (CCâ€122) in combination with rituximab in patients with relapsed/refractory diffuse large Bâ€cell lymphoma and follicular lymphoma. <i>EJHaem</i> , 2022, 3, 394-405.	0.4	7
3652	Dual-Layer Spectral Detector CT in Comparison with FDG-PET/CT for the Assessment of Lymphoma Activity. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2022, 194, 747-754.	0.7	3
3653	A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2022, 11, 9.	2.0	2
3654	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. <i>Blood Advances</i> , 2022, 6, 1232-1242.	2.5	14
3655	Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. <i>Leukemia and Lymphoma</i> , 2022, , 1-9.	0.6	2
3656	A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib. <i>Advances in Therapy</i> , 2022, 39, 1678-1696.	1.3	5
3657	Ofatumumab plus HyperCVAD/HDâ€MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. <i>Cancer</i> , 2022, 128, 1595-1604.	2.0	2
3658	Interpretation of 2-[18F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors. <i>European Radiology</i> , 2022, , 1.	2.3	2
3659	Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma. <i>Blood Advances</i> , 2022, 6, 5659-5667.	2.5	3
3660	HIVâ€associated plasmablastic lymphoma: A singleâ€centre 12â€year experience in Kwaâ€Zulu Natal, South Africa. <i>HIV Medicine</i> , 2022, , .	1.0	2
3661	CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase. <i>Frontiers in Immunology</i> , 2022, 13, 829366.	2.2	1
3662	Relapse in patients with limitedâ€stage ocular adnexal lymphoma treated by chemoimmunotherapy: Extended followâ€up of a phase 2 study. <i>Cancer Medicine</i> , 2022, , .	1.3	4
3663	Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group. <i>Cancers</i> , 2022, 14, 1761.	1.7	0
3664	Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. <i>Npj Precision Oncology</i> , 2022, 6, 13.	2.3	18
3665	Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2022, 101, 979-989.	0.8	4
3666	Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 80.	7.1	8
3667	Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. <i>Leukemia</i> , 2022, 36, 1361-1370.	3.3	5

#	ARTICLE	IF	CITATIONS
3668	Possibility of PET/CT in Patients TM with Extranodal Diffuse Large B-Cell Lymphoma of Stomach at Different Treatment Stages. <i>Journal of Oncology Diagnostic Radiology and Radiotherapy</i> , 2022, 5, 37-45.	0.1	0
3669	Odronektamab, a human CD20 TM –CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. <i>Lancet Haematology</i> , 2022, 9, e327-e339.	2.2	98
3670	Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation TM ineligible relapsed and refractory diffuse large B TM cell lymphoma. <i>British Journal of Haematology</i> , 2022, , .	1.2	1
3671	A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1017-1020.	1.3	4
3672	Finding a consensus on time TM to TM event endpoints definitions in marginal zone lymphoma: A Delphi method. <i>Hematological Oncology</i> , 2022, 40, 1086-1089.	0.8	0
3673	A phase ^{II} trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre ^{GOAL} trial. <i>British Journal of Haematology</i> , 2022, 198, 482-491.	1.2	8
3674	Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma. <i>Medicina (Lithuania)</i> , 2022, 58, 48.	0.8	2
3675	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 821-833.	0.6	8
3676	Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment. <i>Cancers</i> , 2022, 14, 141.	1.7	8
3677	Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study. <i>Annals of Translational Medicine</i> , 2021, 9, 1769-1769.	0.7	2
3678	Treatment of adult Burkitt lymphoma with the CALGB 1002 protocol: a single center experience in Jordan. <i>Blood Research</i> , 2021, 56, 279-284.	0.5	1
3679	Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1149-1154.	2.8	3
3680	Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1302-1313.	0.6	9
3681	90Y-ibritumomab tiuxetan in B-cell non-Hodgkin lymphomas: Real-world data from the United Arab Emirates. <i>Advances in Radiation Oncology</i> , 2021, , 100882.	0.6	0
3683	Kikuchi Disease Masquerading as a T-Cell Lymphoma. <i>AJSP Review and Reports</i> , 2022, 27, 80-83.	0.0	0
3684	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. <i>Journal of Hematology and Oncology</i> , 2022, 15, 36.	6.9	17
3685	Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial. <i>BMC Cancer</i> , 2022, 22, 403.	1.1	1
3686	Efficacy and safety of allogeneic hematopoietic stem cell transplant in adults with hemophagocytic lymphohistiocytosis: a systematic review of literature. <i>Bone Marrow Transplantation</i> , 2022, 57, 866-873.	1.3	3

#	ARTICLE	IF	CITATIONS
3687	Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma. <i>Hematology</i> , 2022, 27, 404-411.	0.7	3
3688	International staging and response criteria for lymphomas. , 0, , 277-285.		0
3689	Treatment approach to diffuse large B-cell lymphomas. , 0, , 286-307.		0
3690	Hodgkin lymphoma: epidemiology, diagnosis, and treatment. , 0, , 367-403.		1
3698	Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant. <i>Leukemia and Lymphoma</i> , 2022, 63, 2444-2452.	0.6	2
3699	Interim PET-CT in the management of diffuse large B-cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 397-401.	0.9	26
3701	Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. <i>Blood Advances</i> , 2022, 6, 5550-5555.	2.5	17
3704	Immunohistochemical expression of CD-10, BCL-6 and MUM-1 antibodies and immediate clinical response in patients of diffuse large B-cell lymphomas after six cycles of chemotherapy. <i>Journal of the College of Physicians and Surgeons–Pakistan: JCPSP</i> , 2014, 24, 722-7.	0.2	0
3706	A Phase I trial of talazoparib in patients with advanced hematologic malignancies. <i>International Journal of Hematologic Oncology</i> , 2021, 10, IJH35.	0.7	0
3738	To determine the prognostic significance of 18-fluorodeoxyglucose positron emission tomography/computed tomography scan-derived parameters (total lesion glycolysis and metabolic) Tj ETQq1 1 0.784314 rgBT /Overload <i>Journal of Nuclear Medicine</i> . 2020, 35, 100.	0.1	1
3739	The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is a novel prognostic factor for patients with diffuse large B-cell lymphoma. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 725.	0.3	4
3740	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. <i>In Vivo</i> , 2022, 36, 1302-1315.	0.6	2
3741	Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT. <i>Blood Research</i> , 2022, 57, S75-S78.	0.5	6
3742	FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma“Are We Hitting the Target?. <i>Molecular Imaging and Biology</i> , 2022, 24, 807-817.	1.3	3
3743	Utility and limitations of metabolic parameters in head and neck cancer: finding a practical segmentation method. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, , 1.	0.8	1
3744	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.	3.3	47
3745	Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study. <i>Cancer Medicine</i> , 2022, 11, 3602-3611.	1.3	2
3746	Long-Term Clinical Outcomes in Treatment-Naïve Patients With Orbital Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Single-Center Study. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
3747	Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, 888250.	2.2	5
3748	End of induction positron emission tomography complete response (PET- \leq CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma. <i>British Journal of Haematology</i> , 2022, 198, 333-337.	1.2	2
3749	The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis. <i>Kidney International</i> , 2022, 102, 382-394.	2.6	6
3750	Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era. <i>International Journal of Hematology</i> , 2022, , 1.	0.7	1
3751	Long-Term Outcomes and Safety Trends of Autologous Stem-Cell Transplantation in Non-Hodgkin Lymphoma: A Report From A Tertiary Care Center in India. <i>JCO Global Oncology</i> , 2022, 8, e2100383.	0.8	1
3752	Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma. <i>Cancer Research Communications</i> , 2022, 2, 307-315.	0.7	2
3753	gBOIN- \leq ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials. <i>Biometrical Journal</i> , 2022, 64, 1178-1191.	0.6	11
3754	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	2.8	1
3755	Monitoring Gastrointestinal Tumor Response to Therapy. , 2015, , 2295-2305.		0
3756	Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma. <i>Blood Advances</i> , 2022, 6, 5811-5820.	2.5	2
3757	Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments. <i>Critical Reviews in Oncology/Hematology</i> , 2022, , 103711.	2.0	1
3758	The role of surveillance computed tomography in patients with follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210959.	1.1	1
3760	Enhancement of the International prognostic index with β 2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
3761	Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients. <i>Cancers</i> , 2022, 14, 2532.	1.7	1
3762	Machine Learning Models for the Diagnosis and Prognosis Prediction of High-Grade B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3
3763	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience. <i>Cancers</i> , 2022, 14, 2673.	1.7	4
3764	Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial. <i>Blood Advances</i> , 0, , .	2.5	0
3765	Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 487.e1-487.e7.	0.6	4

#	ARTICLE	IF	CITATIONS
3766	Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 581.e1-581.e8.	0.6	61
3767	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 2482-2494.	13.9	83
3769	Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma. <i>JAMA Oncology</i> , 2022, 8, 1035.	3.4	21
3770	Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
3771	High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
3772	Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. , 2022, 10, e004984.		28
3773	Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study. <i>Leukemia and Lymphoma</i> , 2022, 63, 2597-2603.	0.6	1
3774	Factors Associated with Discontinuation of Statin Therapy in Patients with Lymphoma Aged 80 Years and Older: A Retrospective Single-Institute Study. <i>Drugs - Real World Outcomes</i> , 0, , .	0.7	0
3775	Clinicopathologic Characteristics Associated with Prognosis in Ocular Extranodal Marginal Zone B Cell Lymphoma. <i>Medicina (Lithuania)</i> , 2022, 58, 818.	0.8	0
3776	¹⁸ F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1925-1932.	2.8	18
3777	Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. <i>Leukemia and Lymphoma</i> , 2022, 63, 2276-2289.	0.6	3
3778	Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis. <i>Hematology</i> , 2022, 27, 757-764.	0.7	2
3779	Synchronous multiple primary tumors in patients with malignant lymphoma: a retrospective study. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
3780	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 4003-4017.	3.2	15
3781	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. <i>Journal of Clinical Oncology</i> , 2023, 41, 336-342.	0.8	9
3782	The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	0.7	3
3783	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2022, 387, 310-320.	13.9	98
3784	Statistical handling of death events in the analysis of time to progression: A review of oncology journals. <i>Contemporary Clinical Trials</i> , 2022, 119, 106858.	0.8	1

#	ARTICLE	IF	CITATIONS
3785	Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma. <i>Clinical Pharmacology in Drug Development</i> , 0, , .	0.8	0
3786	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 1055-1065.	5.1	119
3787	Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma. <i>Annals of Hematology</i> , 2022, 101, 2021-2034.	0.8	2
3788	Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. <i>Blood Advances</i> , 2022, 6, 4773-4781.	2.5	7
3789	A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma. <i>Cancer Research Communications</i> , 2022, 2, 795-805.	0.7	11
3790	Pirarubicin-based intensive chemotherapy followed by consolidative high-dose chemotherapies for peripheral T-cell lymphomas: A noncomparative phase 2 study. <i>Hematological Oncology</i> , 2022, 40, 1094-1096.	0.8	0
3791	Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. <i>Clinical Cancer Research</i> , 2022, 28, 3658-3668.	3.2	5
3792	Impact of relative dose intensity of R-CCOP regimen in elderly patients with diffuse large B-cell lymphoma in China. <i>Journal of the Formosan Medical Association</i> , 2022, , .	0.8	1
3793	A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 83-95.	1.1	1
3794	Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2 "Technical"). <i>Journal of Nuclear Medicine</i> , 2023, 64, 239-243.	2.8	2
3795	Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1 "Clinical"). <i>Journal of Nuclear Medicine</i> , 2023, 64, 102-108.	2.8	14
3796	Assessing Response to Therapy. , 2023, , 28-38.		0
3797	Hematologic Malignancy: The Lymphomas. , 2023, , 529-554.		0
3799	Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study. <i>Annals of Hematology</i> , 0, , .	0.8	0
3800	Long-term survival outcomes of patients with primary ocular adnexal <sc>MALT</sc> lymphoma: A large single-center cohort study. <i>Cancer Medicine</i> , 2023, 12, 2514-2523.	1.3	0
3801	Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4633-4653.	1.1	4
3802	Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. <i>Oncologist</i> , 2022, 27, 864-873.	1.9	8
3803	Clinical characteristics and treatment of NK/T-cell lymphoma-associated HLH. <i>Annals of Hematology</i> , 2022, 101, 2289-2296.	0.8	3

#	ARTICLE	IF	CITATIONS
3804	Dual epigenetic agents plus rituximab+gemcitabine+oxaliplatin as salvage treatment in relapsed/refractory diffuse large B-cell lymphoma patients failure of salvage chemotherapy. <i>Hematological Oncology</i> , 2022, 40, 914-921.	0.8	1
3805	Multimodal deep learning model on interim [18F]FDG PET/CT for predicting primary treatment failure in diffuse large B-cell lymphoma. <i>European Radiology</i> , 2023, 33, 77-88.	2.3	4
3806	Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
3807	Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1719-1720.	1.3	1
3808	Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic lymphoma. <i>Pediatric Blood and Cancer</i> , 2022, 69, .	0.8	6
3809	Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design. <i>Leukemia and Lymphoma</i> , 2022, 63, 2889-2896.	0.6	1
3810	Patient characteristics and outcome of CD20-positive HIV-associated lymphoma: a single-center KwaZulu-Natal, South African hospital 12-year retrospective review. <i>Journal of the Egyptian National Cancer Institute</i> , 2022, 34, .	0.6	3
3811	Long-term treatment outcome of Castleman's disease: A real-world experience. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3812	Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study. <i>EJHaem</i> , 2022, 3, 1316-1320.	0.4	0
3813	Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2023, 200, 54-63.	1.2	2
3814	Multidimensional modeling of solid tumor proliferation following drug treatment: Toward computational prognosis as a tool to support oncology. , 2022, , 435-454.		0
3815	Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2022, , 431-474.		0
3816	A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 5995-6004.	2.5	10
3817	Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
3818	CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211100.	0.4	0
3819	Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study. <i>International Journal of Hematology</i> , 2023, 117, 100-109.	0.7	1
3820	Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival. <i>HemaSphere</i> , 2022, 6, e781.	1.2	4
3821	Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
3822	Clinicopathologic characteristics, outcomes, and prognostic factors of angioimmunoblastic Tâ€cell lymphoma in China. <i>Cancer Medicine</i> , 2023, 12, 3987-3998.	1.3	3
3823	Improving outcomes for high-risk DLBCL: a pilot study looking at the role of fractionated cyclophosphamide with RCHOP chemo-immunotherapy (SCUBA-1 trial). <i>Indian Journal of Hematology and Blood Transfusion</i> , 0, , .	0.3	0
3824	DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e30620.	0.4	0
3826	Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantationâ€A Phase I Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 5378.	1.0	1
3827	Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. <i>Nature Medicine</i> , 2022, 28, 1848-1859.	15.2	79
3828	The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy. <i>PLoS ONE</i> , 2022, 17, e0273839.	1.1	1
3829	Ocular adnexal lymphoma: Subtypeâ€specific clinical and genetic features. <i>Acta Ophthalmologica</i> , 2022, 100, 3-37.	0.6	2
3830	Genetic and phenotypic characterisation of <scp>HIV</scp>-associated aggressive Bâ€cell <scp>nonâ€Hodgkin</scp> lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications. <i>Histopathology</i> , 2022, 81, 826-840.	1.6	4
3831	Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A realâ€world case series. <i>Dermatologic Therapy</i> , 2022, 35, .	0.8	3
3832	Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
3833	Biomedical impact of the expression of HOX locus-associated LncRNAs HOTAIR and HOTTIP in diffuse large B cell lymphoma. , 2022, 34, 201112.		1
3834	The Role of 18FDG-PET/CT in Malignant Lymphomas Clinical Implications. , 2022, , 109-151.		0
3835	Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2023, 7, 1488-1495.	2.5	7
3836	Meta-Analysis of the Testâ€Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response. <i>Clinical Cancer Research</i> , 2023, 29, 143-153.	3.2	1
3837	Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 34.e1-34.e7.	0.6	3
3838	Positron Emission Tomographyâ€Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance). <i>Journal of Clinical Oncology</i> , 2023, 41, 1023-1034.	0.8	9
3840	Molecular remission is an independent predictor of progressionâ€free survival in patients with WaldenstrÅm macroglobulinemia treated with chemoâ€immunotherapy: Results from the FIL_BIOWM study. <i>Hematological Oncology</i> , 2023, 41, 574-577.	0.8	1
3841	Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5

#	ARTICLE	IF	CITATIONS
3842	Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study. <i>Acta Oncologica</i> , 2022, 61, 1332-1338.	0.8	1
3843	Association between genetic variants and the risk of nivolumab-induced immune-related adverse events. <i>Pharmacogenomics</i> , 2022, 23, 887-901.	0.6	5
3844	Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018). <i>Journal of Hematology</i> , 2023, 1, 3-11.		4
3845	Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma. <i>Cytotherapy</i> , 2022, , .	0.3	0
3846	Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels. <i>Cancers</i> , 2022, 14, 5318.	1.7	10
3847	Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL. <i>Clinical Cancer Research</i> , 2023, 29, 742-753.	3.2	11
3848	Phase II trial of a novel chemotherapy regimen CVP (cyclophosphamide, Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 mg) associated lymphomas. <i>British Journal of Haematology</i> , 2023, 200, 429-439.	1.2	0
3849	Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	19
3850	A systematic review of contemporary phase I trials in patients with lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 180, 103860.	2.0	1
3851	Identification of prognostic factors in classic Hodgkin lymphoma by integrating whole slide imaging and next generation sequencing. <i>Molecular Omics</i> , 2022, 18, 1015-1028.	1.4	2
3852	Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in Europe. <i>EJHaem</i> , 0, , .	0.4	0
3853	Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of MYC target genes and poor clinical outcome following R-CHOP therapy. <i>Leukemia and Lymphoma</i> , 2023, 64, 119-129.	0.6	0
3854	Modeling Patient-Specific CAR-T Cell Dynamics: Multiphasic Kinetics via Phenotypic Differentiation. <i>Cancers</i> , 2022, 14, 5576.	1.7	4
3855	Immunophenotypic transformation in relapsed/refractory mantle cell lymphoma treated with human anti-CD5 chimeric antigen receptor T cells: A Case Report. <i>Journal of Hematology</i> , 0, 1, .		1
3856	Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System. <i>JCO Global Oncology</i> , 2022, , .	0.8	2
3857	PET/CT in Hodgkin Lymphoma: An Update. <i>Seminars in Nuclear Medicine</i> , 2023, 53, 303-319.	2.5	8
3858	Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma. <i>Annals of Hematology</i> , 0, , .	0.8	2
3859	Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy. <i>HemaSphere</i> , 2022, 6, e798.	1.2	4

#	ARTICLE	IF	CITATIONS
3860	T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
3861	Carfilzomib combined with rituximab, ifosfamide, carboplatin, and Acetoposide for relapsed or refractory DLBCL. <i>Blood Advances</i> , 2023, 7, 1146-1155.	2.5	3
3862	First-line antibiotic treatment in patients with localized extragastric mucosa-associated lymphoid tissue lymphoma. <i>EJHaem</i> , 0, .	0.4	0
3863	Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 154-167.	1.3	3
3864	Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas. <i>Oncotarget</i> , 2022, 13, 1237-1244.	0.8	1
3865	Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2023, 10, e14-e23.	2.2	16
3866	A randomized, placebo-controlled phase 3 trial of the PI3K γ inhibitor leniolisib for activated PI3K γ syndrome. <i>Blood</i> , 2023, 141, 971-983.	0.6	31
3867	A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis. <i>International Journal of Hematology</i> , 0, .	0.7	0
3868	Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma. <i>Journal of Comparative Effectiveness Research</i> , 2023, 12, .	0.6	1
3869	Bridging to Transplant in Diffuse Large B Cell Lymphoma. <i>European Medical Journal Hematology</i> , 0, , 91-99.	0.0	1
3870	CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Cancer Discovery</i> , 2023, 13, 580-597.	7.7	18
3871	Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
3872	Influence of the methodological aspects of the dichotomization of total metabolic tumor volume measured through baseline fluorine-18 fluorodeoxyglucose PET on survival prediction in lymphoma. <i>Nuclear Medicine Communications</i> , 2023, 44, 74-80.	0.5	1
3873	Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 7162.	1.0	5
3874	Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial. <i>Hematological Oncology</i> , 2023, 41, 415-423.	0.8	0
3875	High-intensity chemotherapy improved the prognosis of patients with high-grade B-cell lymphoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
3876	Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 176.e1-176.e8.	0.6	0
3877	Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study. <i>Hematological Oncology</i> , 2023, 41, 396-406.	0.8	1

#	ARTICLE	IF	CITATIONS
3878	Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas. <i>Journal of Clinical Oncology</i> , 2023, 41, 1684-1694.	0.8	24
3879	IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma. <i>Haematologica</i> , 2023, 108, 1671-1675.	1.7	2
3880	Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies. <i>Trials</i> , 2023, 24, .	0.7	3
3881	Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor. <i>Journal of Clinical Medicine</i> , 2023, 12, 618.	1.0	0
3882	Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2023, 98, 464-471.	2.0	4
3883	Radiologic assessment of tumor response to immunotherapy and its complications. , 2023, , 239-261.		0
3884	Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study. <i>Blood Advances</i> , 2023, 7, 4903-4912.	2.5	5
3885	Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). <i>Oncotarget</i> , 2023, 14, 57-70.	0.8	1
3886	Novel CD19-specific $\hat{3}/\hat{1}$ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	5
3887	Clinical outcomes in patients relapsed/refractory after $\hat{2}$ prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis. <i>BMC Cancer</i> , 2023, 23, .	1.1	6
3888	Perspectives on the Treatment of Mantle Cell Lymphoma and Follicular Lymphoma in 2015 and Beyond. <i>European Medical Journal Hematology</i> , 0, , 54-64.	0.0	0
3889	Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study. <i>Innovation(China)</i> , 2023, 4, 100426.	5.2	2
3890	FDG PET/CT-based Response Assessment in Malignancies. <i>Radiographics</i> , 2023, 43, .	1.4	8
3891	Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. <i>Blood Advances</i> , 2023, 7, 2008-2017.	2.5	12
3893	Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution. <i>Chinese Medical Journal</i> , 2023, 136, 167-175.	0.9	1
3894	Prediction of miRNA-disease associations by neural network-based deep matrix factorization. <i>Methods</i> , 2023, 212, 1-9.	1.9	4
3895	Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study. <i>Lancet Oncology</i> , The, 2023, 24, 252-261.	5.1	12
3896	Myeloid and Lymphoid Disorders in Geriatric Patients. <i>Practical Issues in Geriatrics</i> , 2023, , 427-444.	0.3	0

#	ARTICLE	IF	CITATIONS
3897	Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance. <i>British Journal of Haematology</i> , 2023, 201, 865-873.	1.2	3
3898	Multisystem Imaging Recommendations/Guidelines: In the Pursuit of Precision Oncology. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2023, 44, 002-025.	0.1	2
3899	Prognostic value of PET / CT and CT in T-cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients. <i>British Journal of Haematology</i> , 2023, 201, .	1.2	0
3900	Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients. <i>Haematologica</i> , 0, , .	1.7	0
3901	Benefits of plerixafor for mobilization of peripheral blood stem cells prior to autologous transplantation: a dual-center retrospective cohort study. <i>Cytotherapy</i> , 2023, 25, 773-781.	0.3	1
3902	Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL. <i>Clinical and Translational Science</i> , 2023, 16, 1134-1148.	1.5	8
3903	Use of obinutuzumab in therapy of patients with newly diagnosed follicular lymphoma. Experience of the Oncohematology Division of the Clinical Hospital "Lapino", 2023, 3, 53-60.		0
3904	Dose-adjusted EPOCH and rituximab (DA-EPOCH) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem). <i>European Journal of Haematology</i> , 0, , .	1.1	1
3905	Application of the Central Nervous System International Prognostic Index (CNS-IPI) score in daily practice: a retrospective analysis apart from the clinical trial at two centers in Brazil. <i>Hematology, Transfusion and Cell Therapy</i> , 2023, , .	0.1	0
3906	Four-dimensional quantitative analysis using FDG-PET in clinical oncology. <i>Japanese Journal of Radiology</i> , 2023, 41, 831-842.	1.0	4
3907	Biology-Guided Radiation Therapy. <i>Surgical Oncology Clinics of North America</i> , 2023, 32, 553-568.	0.6	1
3908	Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis. <i>HemaSphere</i> , 2023, 7, e860.	1.2	1
3909	Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study. <i>Cancer Research and Treatment</i> , 0, , .	1.3	0
3910	Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2023, 29, 1894-1905.	3.2	12
3911	Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>HemaSphere</i> , 2023, 7, e837.	1.2	3
3912	Decoding the molecular heterogeneity of pediatric monomorphic post-solid organ transplant lymphoproliferative disorders. <i>Blood</i> , 2023, 142, 434-445.	0.6	3
3913	Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study. <i>Oncologist</i> , 2023, 28, e756-e764.	1.9	0
3914	Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the FIL MCL0208 trial. <i>Blood Advances</i> , 0, , .	2.5	0

#	ARTICLE	IF	CITATIONS
3915	Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2023, 7, 4926-4935.	2.5	12
3916	Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. <i>Seminars in Hematology</i> , 2023, 60, 97-106.	1.8	7
3936	Mediastinal Lymphoproliferative Disorders. , 2023, , 221-296.		0
3961	Quantitative PET-based biomarkers in lymphoma: getting ready for primetime. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 640-657.	12.5	3
3964	Stem Cell Transplant for B Cell Non-Hodgkin Lymphoma. , 2023, , 283-334.		0
4002	TO MARKET, TO MARKETâ€“2022: MACROMOLECULAR THERAPEUTICS. <i>Medicinal Chemistry Reviews</i> , 0, , 713-798.	0.1	0
4024	Hematologic Cancers. , 2023, , 441-511.		0